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1. INTRODUCTION 
Hospital and community-acquired infections associated to antibiotic resistance have become a 
major public concern at a time when antibacterial drug discovery efforts are declining, and the need 
for effective treatments against new multi-drug resistant pathogens is desperately increasing.
1
 
Recent studies estimate that at least 2 million people acquire serious infections in which bacteria 
are resistant to antibiotics
2,3
 and more than 23,000 people die as a direct result of resistant bacterial 
infections in the United States of America (USA) each year.
4
 This number is probably higher since 
deaths attributed to other diseases (e.g., chronic obstructive pulmonary disease, human 
immunodeficiency virus and cancer) for which a bacterial infection is the terminal cause are not 
included.
5
 In addition, antibacterial resistant infections cost more than 20 billion dollars to the USA 
healthcare system per year due to prolonged hospitalizations and costlier treatments compared to 
infections susceptible to antibiotics. 
1.1. Antibacterial Drug Discovery 
Antibacterial chemotherapy has its origin in the late 19
th
 century with the discoveries performed 
by renowned scientists such as Robert Koch or Louis Pasteur and the search of Paul Ehrlich for a 
“magic bullet” able to selectively kill bacterial cells, which was a turning point in human history.
6
 
However, it was not until the discovery of sulfonamides as a chemical therapy and natural -lactam 
antibiotics in the 1930s when it gave rise to the modern age of antibacterials in which rapid 
treatment of patients with previously mortal bacterial infections was possible (Figure 1). Over the 
next 40 years (1930-1970), now seen as the ‘‘golden era’’ of antibiotic research, the majority of 
antibiotic drug classes in use today were discovered.
7
 Nonetheless, after this period, all newly 
approved antibiotics, except the topical drug mupirocin developed in 1985,
8
 were based on 
medicinal chemistry programs rediscovering existing treatments with modified versions of already 
known scaffolds rather than novel chemical entities. This led to a period known as “innovation gap”, 
when we dug our own grave and bacteria easily acquired resistance to all marketed antibiotics, 
even before the antibacterials were commercialized. Since 2000, the situation has improved and 
five new classes of antibiotics have been approved by the Food and Drug Administration (FDA). 
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Figure 1. Innovation gap between 1962 and 2000 and antibiotic resistance. 
Thus, linezolid, daptomycin, and the topical retapamulin were marketed in the first decade of the 
21
st
 century (Figure 2).
9
 More recently, fidaxomicin -a macrocyclic fermentation product with a 
narrow spectrum for pathogenic Clostridium difficile- has been approved, and bedaquiline, a 
diarylquinoline developed by Janssen that specifically inhibits mycobacterial adenosine 5’-
triphosphate synthase interfering with the bacterial energy metabolism, has also been marketed. 
This compound was fast tracked through clinical trials for the treatment of tuberculosis thanks to its 
combination with at least three drugs active against the patient’s tuberculosis isolate.
10,11
 However, 
it is worth mentioning that none of these derivatives, except bedaquiline, are truly novel antibiotics, 
having been discovered decades ago and rescued from failed campaigns. More importantly, all 
these new agents have a Gram-positive spectrum whereas Gram-negative therapies are urgently 
needed. 
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Figure 2. New antibiotics approved by the FDA since 2000. 
In order to solve this global bacterial threat, pharmaceutical industry, prompted by the bacterial 
genome discovery in 1995, focused on the development of synthetic analogues and high tech 
approaches based on genomics, combinatorial chemistry, huge high-throughput screening (HTS) 
campaigns and rational design. However, the disappointing results led to an antibacterial crisis 
where only four big Pharma remain investigating in the field: AstraZeneca, Novartis, 
GlaxoSmithKline, and Sanofi-Aventis.
12
 This crisis was caused by different reasons that have been 
deeply discussed.
2,13-15
 First, HTS has shown to be four- to five-fold less productive than for other 
therapeutic targets, which has been mainly related to a wrong selection of the HTS libraries. 
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Noteworthy, most HTS campaigns use bacteria cultures that are kept under favorable growth 
conditions and hits found in such conditions may result in less active or even inactive in metabolic 
resting bacteria or in vivo models of chronic infections.
16
  
Moreover, clinical trials with antibacterials are conducted in patients with drug-susceptible 
infections whereas antibiotics for resistant pathogens are desperately needed. All this is happening 
at a time when the FDA regulations are enforced and reaching phase I clinical trials is more difficult 
than ever. Last but not least, the return in investment is quite modest owing to short term treatment 
for acute infections and low drug pricing if compared to other therapeutic areas. Consequently, a 
large number of big pharmaceutical companies has left antibacterial research. Contrary, small 
companies and biotechs seem to see an opportunity in this situation and are filling the gap rescuing 
medicinal chemistry programs and clinical trials that have been abandoned by large companies.
17
 
In order to solve the antibiotic drug discovery decline, several strategies have been 
proposed.
2,6,15,18
 Most antibacterials were discovered at a time when few molecular and mechanism 
pathways were known and target based-programs have not been very successful. Therefore, more 
phenotypic rather than target based HTS and screenings in which bacterial penetration rules are 
reformulated should be implemented. In addition, driving HTS in metabolic resting stages bacteria 
emerges as a promising hit-discovery strategy. 
Regarding the antibacterial drug discovery process itself, it presents unique challenges due to 
the differences between eukaryote host cells and the target bacteria cells. Indeed, finding a hit is 
just the beginning in a therapeutic area where one single compound must inhibit different Gram-
positive and Gram-negative pathogens all with different molecular targets, permeability and 
metabolic pathways. Therefore, factors as bacterial cell penetration and efflux, metabolism and 
elimination, together with bacteria resistance must be seriously taken into consideration.
19
 With 
respect to permeability, bacterial cell wall of Gram-positive bacteria is very different from Gram-
negative in terms of structure and physical properties. Gram-negative antibacterials usually enter 
the cell through porins in the outer membrane followed by diffusion across cytoplasmatic 
membrane, and therefore are usually more hydrophilic, with limited molecular weight and high 
charge density compounds at physiological pH. Contrary, Gram-positive bacteria possess only a 
cytoplasmatic membrane, so bigger and more lipophilic agents are required to cross it by diffusion. 
As if all this was not enough, higher doses of antibiotics are needed in order to achieve 
effectiveness when compared to other drugs due to poor penetration. At these high doses, 
acceptable side effects and good pharmacokinetic properties must be demonstrated to allow 
competitive and convenient dosing profile.
15
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However, it is undisputed that the biggest problem in this area is the antimicrobial resistance, in 
which not only hospital but also community acquired resistances to almost every new antibiotic 
have been developed. As a result, we are entering a post-antibiotic era with limited treatment 
options for multiple bacterial infections, highlighting the urgent need for novel approaches.
20,21
  
1.2. Antibacterial Targets and Resistance 
Currently, commercial antibiotics inhibit a small number of targets which are involved in the 
synthesis of (i) the cell wall, (ii) proteins, (iii) folate or (iv) nucleic acids (Figure 3). Although there 
are more than fifteen different antibacterial mechanisms of action, none of them has escaped from 
bacterial resistance. Methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide resistant 
enterococci (GRE) are examples of Gram-positive bacteria that have already shown resistance to 
the last arsenal of new marketed antibiotics such as daptomycin and linezolid.
22,23
 The situation is 
even more concerning for Gram-negative bacteria, where no new drug candidates are currently in 
advanced clinical development stages and multi-resistant strains have developed very effective 
ways to deal with the newest broad spectrum therapies.
2,24
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Figure 3. Antibiotics and their antibacterial targets.
15
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Although antibiotic resistance is not a new concept, the number of multidrug resistant pathogens 
-also colloquially known as “superbugs”-, the geographic spread and the different resistant 
mechanisms in single organisms are unprecedented and mounting.
25
 In this sense, genetic 
resistance firstly arises from a chromosomal mutation followed by clonal spread or by acquisition of 
an antibiotic resistance gene that can be transfer from one bacterium to another through different 
routes such as plasmids, bacteriophages, naked DNA or transposons.
26
 Additionally, many different 
mechanisms of antibiotic resistance have been described (Figure 4). Some target the antibiotic 
itself by (a) enzymatic degradation or modification, as for example -lactamases demolish 
penicillins or cephalosporins. Bacteria can also (b) develop bypass pathways, (c) alter or (d) 
overexpress a specific intracellular target or even (e) produce new biomolecules that block the 
target. Furthermore, (f) a decrease membrane permeability or multidrug resistant (MDR) efflux 
pumps, such as the AcrAB–TolC MDR pump that effluxes linezolid, can drop dramatically the 
antibiotic intracellular concentration. 
 
Figure 4. Antibiotic resistance and tolerance mechanisms.
15
 
The use of multitarget antibiotics has proved to be very effective in avoiding resistances, and 
drug combinations have allowed the renaissance of several antibacterial therapies. For example, 
the use of clavulanic acid, a -lactamase inhibitor, in combination to amoxicillin resulted in one of 
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the most popular antibiotics: Augmentine. Other researches involved the development of hybrid 
inhibitors which combine two different merged antibiotics, or the use of antimicrobial peptides.
27,28
 
Moreover, the employment of MDR efflux pumps inhibitors, such as NorA in Gram-positive or 
AcrAB-TolC in Gram-negavive bacteria, can restore susceptibility of antibiotics by increasing their 
intracellular concentrations. 
Notably, one of the most asked question is whether nature has already discovered all useful 
antibacterial targets or if only the “low-hanging fruit” has been identified.
29
 What is unquestionable 
is that novel mode of action (MoA) agents are urgently needed to overcome the antibiotic 
resistance problem. Bacteria are prompted to develop new strategies to confront antibiotics, so a 
multi-disciplinary approach is required and it should be continuously redefined. In summary, the key 
components for maintaining effective antimicrobial chemotherapy include better use of existing 
agents, avoiding the misuse or overuse and continuous investment in new and innovative 
techniques to discover antibiotics with novel MoA.
3,30
 
In this context, the bacterial cell division protein Filamenting temperature-sensitive mutant Z 
(FtsZ), which has not been targeted yet by any commercial antibiotic, has been proposed as an 
attractive therapeutic target for the discovery of new antibacterial agents.
2,31-33
  
1.3. FtsZ and the Divisome 
Much progress towards the understanding of bacterial cell division has been made in the last 
decades. However, the molecular mechanisms and dynamics underlying this process are still 
unclear. Bacterial cytokynesis is regulated by a macromolecular machinery called the divisome, 
which consists of an assembly of FtsZ polymers around the cylindrical axis of the cell and more 
than 20 regulating proteins.
34
 FtsZ exists in the bacterial cells both as monomers or highly order 
polymers depending on whether it is bound to guanosine 5’-triphosphate (GTP) or guanosine 5’-
diphosphate (GDP) and which accessory protein is bound to it. At the earliest step of cell division, 
FtsZ is recruited from the cytoplasm to the division site and undergoes self-assembly by the head-
to-tail association of individual subunits at mid-cell creating a GTP-hydrolytic center (Figure 5A). 
Thus, the GTP-binding promotes the FtsZ polymerization and formation of protofilaments with a 
longitudinal subunit repeated. Contrary, when GTP is hydrolyzed to GDP, the protofilament gets a 
curve conformation and disintegrates. In the cell division process, these protofilaments can 
polymerize in different shaped filaments leading to a ring-like structure known as the Z-ring (Figure 
5A).
35,36
 The Z-ring is a highly dynamic structure with a half time of a few seconds and there is 
continuous exchange of FtsZ subunits between the Z-ring and the cytoplasm.
37,38
 Other bacterial 
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division proteins are then recruited to the Z-ring to regulate and form the divisome, a complex that 
finally constricts to generate the two new daughter cells (Figure 5B). 
FtsZ
BA
Z-ring
 
Figure 5. (A) FtsZ polymerization and Z-ring formation. (B) Bacterial division process. 
FtsZ polymerization is widely regulated in space and time by placing the Z-ring in a specific 
place and coordinating the assembly/disassembly balance with DNA replication to ensure an equal 
partition into two new cells at the right time.
39
 A complex regulatory network is committed to 
orchestrate this division process initiated by FtsZ (Figure 6). In this sense, FtsZ polymerization is 
closely related to Min family proteins which are responsible from placing the Z-ring at the mid cell 
when the bacteria is big enough to divide.
40
 Then, FtsA and ZipA attach FtsZ to the cell membrane 
and stabilize FtsZ polymers at the membrane. Shape factors such as SepF and FzlA have an 
important role in regulating the highly ordered polymer structure which must progressively curve in 
order to encircle the cell. Furthermore, metabolic and oxidative sensors control the bacterial division 
depending on the environment of the cell. For example, under nutritional starvation, UgtP does not 
inhibit FtsZ assembly and the divisome is form earlier leading to smaller daughter cells. Although 
FtsZ protein is highly conserved among bacteria, its regulators are less so. In this sense, ClpX 
chaperone is one of the most conserved and its protease activity is responsible from FtsZ 
degradation.
41
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Figure 6. Direct and indirect regulators of FtsZ assembly. 
From a structural point of view, FtsZ is a tubulin-like GTPase almost universally conserved 
throughout the bacteria. Several crystal structures of FtsZ from different bacteria and archaea have 
been obtained in apo form and in complex with GTP or its closest analogues, as for example 
Methanocaldococcus jannaschii
42
 (M. Jannaschii) and Mycobacterium tuberculosis (M. 
tuberculosis).
43
 The enzymatic pocket of this protein is composed of two globular sub-domains, N- 
and C-terminal regions, separated by the helix H7 as the central core helix (Figure 7).
42,44
 During 
monomer assembling at the polymerization stage, the C-terminal GTPase-activating domain of the 
upper subunit contacts the nucleotide site of the subunit below by insertion of the T7 loop into the 
nucleotide binding site and forms the catalytic pocket, what underscores the key role of the GTP-
binding site in regulating the FtsZ function. Moreover, the long cleft located between these domains 
constitutes an additional pocket, equivalent to the taxol binding site in tubulin, that has also been 
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proposed for ligand binding.
45
 Although FtsZ and tubulin have only a 20% of sequence homology, 
they show high structure similarity. Therefore, selectivity against tubulin is an important factor in the 
discovery of FtsZ inhibitors. In fact, the identification of FtsZ selective inhibitors has demonstrated 
that it is possible to bind this protein without observing unwanted side effects through tubulin.
46
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Binding site
N-terminal
domain
H7
C-terminal
domain
Long cleft
T7 loop
 
Figure 7. Crystal structure of a Bacillus subtilis FtsZ monomer bound to GTP-γS. 
Taking into account the key role of FtsZ in the bacterial division, molecules able to inhibit its 
activity will eventually avoid bacterial viability and may hold promise for the development of 
clinically efficacious antibiotics with an unexplored MoA. 
1.4. FtsZ as an Antibacterial Target 
Over the last decade, several compounds have been identified as FtsZ inhibitors perturbing the 
protein polymerization and the GTPase activity, some of them with promising antibacterial 
profile.
33,47-50
 The reported FtsZ inhibitors able to modulate the assembly or disassembly of the 
protein include natural products, compounds derived from the tubulin field, and synthetic 
compounds identified by HTS. However, the binding modes of most of them are still unknown. 
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1.4.1. Natural Products 
Historically, natural products have been one of the most prolific sources of new molecular 
entities for drug discovery and more importantly in the case of antibiotics. Interestingly, the majority 
of natural products identified as FtsZ inhibitors are structures with phenolic moieties (Figure 8). 
Among them, viriditoxin
51
 and the macrocycle chrysophaentin A
52
 stand out. They act as GTPase 
inhibitors and block protein assembly in the 10-50 µM range. Both compounds are active against 
Gram-positive bacteria pathogens such as MRSA, with minimum inhibitory concentration (MIC) 
values of 4-8 µM in the case of viriditoxin and 2-4 µM for the chrysophaentin A. Curcumin also 
showed moderate effect increasing FtsZ GTPase activity (at 10-20 µM) and it was prompted to 
phase I clinical trials at relatively high doses (8 g/day). However, its cytotoxity through the 
eukaryote homologue tubulin and poor bioavailability stopped its development.
53
 Another 
interesting natural product is the diterpenoid totarol, endowed with antibacterial activity against M. 
tuberculosis at 16 µM.
54,55
 Furthermore, a family of five structurally diverse small compounds 
identified by HTS, zantrins Z1-Z5, inhibited FtsZ GTPase activity and induced hyperstabilization or 
destabilization of FtsZ protofilaments. Among them, polyphenol derivative Z1, showed the best 
profile with antibacterial activity against Escherichia coli (E. coli) at 20 µM and MRSA at 2.5 µM.
56
 
On the other hand, the two cationic alkaloids sanguinarine and berberine have also been described 
as FtsZ inhibitors, although the latter also showed moderate effect in tubulin.
57,58
 These compounds 
share a polycyclic scaffold structurally different from the natural products above described, and 
were used as a starting point to successfully design and synthesize new inhibitors endowed with 
good antibacterial activity in MRSA and Enterococcus faecalis (E. faecalis).
59-63
 
 
Figure 8. Natural products as FtsZ inhibitors: polyphenolic compounds and cationic alkaloids. 
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1.4.2. Compounds from the Tubulin Field 
The development of FtsZ inhibitors based on the structure of taxol, the most potent tubulin 
inhibitor, has been another area of research in the identification of new antimicrobials. Hence, a 
screening of 120 taxanes allowed the identification of new inhibitors such as SB-RA-2001 with good 
antibacterial properties in Mycobacterium strains (MIC = 2.5-5 µM).
64,65
 Further modifications led to 
semisynthetic taxane SB-RA-5001 with activity against drug sensitive and drug resistant M. 
tuberculosis at 1.3-2.5 µM, targeting FtsZ without appreciable cytotoxicity (IC50 > 80 μM) (Figure 9). 
Computational analysis suggested that this inhibitor binds to FtsZ in the long cleft between the C-
terminal domain and helix H7.
64,65
 
 
Figure 9. Taxol and its most potent FtsZ inhibitor analogues. 
1.4.3. Synthetic Derivatives 
One of the main strategies to alter FtsZ polymerization is to perturb the GTPase activity of the 
protein. Therefore, a forward approach in the development of FtsZ inhibitors has been the design 
and synthesis of GTP analogues. In fact, C8-substituted GTP derivatives, such as 8-bromo-GTP, 
inhibit FtsZ polymerization while supporting tubulin assembly, confirming that selective inhibition of 
the GTP-binding site of this bacterial protein is possible without unwanted side effects in eukaryotic 
cells (Figure 10).
46
 Unfortunately, these GTP derivatives lack antibacterial activity probably due to 
their poor penetration through bacterial cell wall. On the other hand, a family of novel trisubstituted 
benzimidazoles that increase GTPase activity and disable FtsZ assembly has been developed 
through a medicinal chemistry program. Among them, compound 1b-G1 exhibited the best 
antibacterial activity in resistant strains of M. tuberculosis (MIC = 1 µM) although its binding site is 
still unknown.
66
 Another interesting synthetic inhibitor identified from a screening of a 105,000 
compound library by Prolysis Ltd company and further hit optimization process is PC170942, with 
antibacterial activity in Gram-positive bacteria [MIC = 16 µM in Bacillus subtilis (B. subtilis) and 64 
µM in Staphylococcus aureus (S. aureus)].
67
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Figure 10. Synthetic FtsZ inhibitors. 
Nonetheless, the biggest contribution to the synthetic inhibitors came from the development of 
3-methoxybenzamide (3-MBA) derivatives (Figure 11).
68
 SAR studies carried out around this 
scaffold have explored the influence of the halogens at positions 2 and 6, and the length of an alkyl 
chain in the alkoxy group, showing that fluorine atoms and a nonyl chain gave the best antibacterial 
activity (MIC = 1.7 µM in S. aureus).
69
 Then, replacement of the 3-alkoxy moiety by a variety of 
heteroarylmethoxy substituents allowed the identification of more drug-like derivatives: PC190723 
and 8j.
70,71
 These compounds have potent antistaphylococcal activity [MIC (8j) = 0.7 µM and MIC 
(PC190723) = 2.8 µM] and although 8j showed better antibacterial activity, thiazolopyridine 
PC190723 exhibited better pharmacokinetic profile due to a lower plasma protein binding. Indeed, 
this compound is the most studied FtsZ inhibitor so far.
72,73
 PC190723 is an FtsZ polymer-
stabilizing agent that modulates the flexibility and assembly of the protein, inhibits the GTPase 
activity at 10 µM and has been characterized as a potent selective bactericide. Notably, it is the first 
inhibitor shown to be efficacious in an in vivo model of bacterial infection. A dose of 30 mg/kg of 
PC190723 completely protected mice inoculated with a lethal dose of S. aureus. One of the major 
drawbacks of this compound has been its lack of activity in Gram-negative bacteria probably due to 
its inability to target E. coli FtsZ itself. In this sense, Kaul and coworkers have demonstrated very 
recently that the co-administration of PC190723 with the efflux pump inhibitor PAN restored 
antimicrobial activity in E. coli, Klebsiella pneumonia, and Acinetobacter baumannii. However, even 
under efflux pump inhibition conditions, its activity in Gram-negative strains is 8- to 16-fold lower 
than in S. aureus.
74
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Figure 11. 3-Methoxybenzamide derivatives. 
In the search of new derivatives with improved pharmacokinetic properties, two different 
prodrugs, TXY436 and TXY541 with higher aqueous solubility have shown efficacy in in vivo 
models of methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA infections, and could 
be considered as promising agents for clinical development to treat staphylococcal infections.
75,76
 
Lately, a second generation of PC190723 derivatives with better metabolic stability has been 
described. In these compounds, the thiazolopyridine was replaced by a non-fused bicyclic scaffold 
and a hydroxymethylene substituent was incorporated in the pseudobencylic position (Figure 11).
77
 
An ester prodrug based on this new scaffold showed good in vitro and in vivo pharmacokinetic with 
improved solubility enabling intravenous or oral administration at higher doses of compound (5 
mg/kg and 10 mg/kg, respectively). This prodrug displayed improved antibacterial potency, better 
resistance profile as well as efficacy in the murine thigh model of S. aureus infection for the first 
time in the case of an FtsZ inhibitor.
76,78,79
 
X-ray structure of PC190723 bound to S. aureus FtsZ showed that this compound binds to a 
narrow pocket within the deep cleft formed by the C-terminal half of the H7 helix, the T7 loop, and 
the C-terminal four-stranded -sheet, known as the PC binding pocket (Figure 12). It has been 
proposed that the interaction of the ligand in this allosteric cleft modulates the conformational 
switch that enables the assembly of the protein.
80
 Despite the relatively high number of FtsZ 
inhibitors described in the literature, it is noteworthy that PC190723
81
 and morpholino-GTP are the 
only two compounds whose binding mode to FtsZ have been revealed by X-ray crystallography. In 
fact, the X-ray structure of S. aureus FtsZ with PC190723 showed a new allosteric binding site for 
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small molecules. However, the lack of biological tools for the assessment of a binding constant for 
this newly identified druggable site hampers the possibility of carrying out HTS campaigns for this 
allosteric pocket and makes the development of a medicinal chemistry program a very challenging 
goal.  
GTP-binding site
PC-binding site
 
Figure 12. Crystal structure of S. aureus FtsZ-GDP in complex with PC190723. 
In summary, the identification of FtsZ inhibitors with antibacterial properties provide a compelling 
rational approach for the search of new agents with novel MoA, which could contribute to fight 
against the virulence and the speed in which bacteria adquire resistance to recently approved 
antibiotics, one of the biggest threat of the health system in the 21
st
 century. 
Thus, the main objective of this work is the development of new FtsZ inhibitors with antibacterial 
properties in order to validate FtsZ protein as an antibacterial target. For this purpose we have 
focused our efforts on the identification of new compounds targeting the two druggable binding 
sites: the GTP- and the PC-binding pockets (Figure 12). 
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The development of new small molecules able to replace the natural regulator GTP and to 
specifically inhibit FtsZ in order to block the bacterial cell division process involves the following 
steps: 
 Identification of hits. 
 Design, synthesis, and biological evaluation of a new series of compounds. In this evaluation 
we will consider the assessment of the FtsZ binding affinity, the antibacterial activity and 
selectivity against tubulin. 
 Further characterization of optimized inhibitors in terms of antibacterial properties against 
Gram-positive and Gram-negative pathogens, cytological profile, and mechanism of action. 
Regarding the PC-binding pocket, the interesting antibacterial properties of 3-MBA derivatives 
such as PC190723 and the lack of a methodology to assess the binding affinity against this newly 
reported binding site in FtsZ prompted us to develop fluorescent probes based on this inhibitor to 
set up a fluorescence-based binding assay for the identification of new inhibitors. In addition, these 
probes could contribute to study this long cleft that seems to play a key role in FtsZ assembly, in 
order to get a better understanding about this dynamic process. Therefore, the second goal of this 
project implies the following steps: 
 Design and synthesis of fluorescent derivatives based on PC190723. 
 Biological evaluation and fluorescent characterization of the synthesized compounds. 
 Use of the best fluorescent probes as biological tools for the study of the bacterial cell 
division process and for the identification of new FtsZ inhibitors by a fluorescence-based 
displacement assay. 
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2. RESULTS AND DISCUSSION  
Taking into account the main objectives of this thesis, we focused on the development of FtsZ 
inhibitors targeting both binding sites described for the protein (Figure 13). First, we addressed the 
development of new small molecules able to replace the natural regulator GTP, and secondly, we 
designed a series of PC190723-based fluorescent probes in order to obtain biological tools for a 
better understanding of this allosteric binding site. 
GTP-binding site PC-binding site
Medicinal 
Chemistry Program
Development of PC190723-Based
Fluorescent Probes
New Inhibitors of FtsZ as Antibacterial Agents
 
Figure 13. Dual strategy on the search of new FtsZ inhibitors. 
2.1. Development of FtsZ Inhibitors Targeting the GTP-Binding Site 
One of the main approaches in order to alter FtsZ polymerization is to perturb the GTPase 
activity of the protein with compounds able to bind the GTP-binding pocket. Despite the number of 
small molecules that interact with FtsZ and block bacterial cell division, the specificity and binding 
site on FtsZ was only established in a few cases. In fact, at the beginning of this project only C8-
substituted GTP derivatives demonstrated to selectively inhibit FtsZ at the GTP-binding site.
82
 
Therefore, our first goal was the identification and development of non-nucleotide GTP-replacing 
inhibitors of FtsZ as antibacterial agents. 
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2.1.1. Hit Identification 
In the search of new FtsZ inhibitors of the GTP-binding site, we docked our in-house library into 
the GTP-binding pocket of B. subtilis FtsZ (Bs-FtsZ) and tested the hits with the highest scores in 
the mant-GTP fluorescent anisotropy competitive assay to measure their binding affinity 
(dissociation equilibrium constant, Kd).
82
 The best molecules obtained from this screening belonged 
to a series of galloyl derivatives (Table 1), which had been previously developed in our research 
group as anticancer fatty acid synthase (FASN) inhibitors.
83
  
Table 1. FtsZ affinity and antibacterial activity of hits obtained from our in-house compound library. 
 
Compd 
Central 
Core 
Kd
a 
(µM) 
MIC (µM) 
B. Subtilis
b
 
MIC (µM)
 
MRSA USA300
c 
UCM01 
 
12 ± 4 100 >100 
UCM02 (1) 
 
2.3 ± 0.1 100 60 
UCM03 
 
3.7 ± 0.2 50 100 
UCM04 
 
10.0 ± 0.3 100 >100 
UCM05 
 
8 ± 1 100 50 
UCM06  6 ± 2 50 50 
UCM07 
 
29 >400 >100 
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UCM08 
 
86 >200 >100 
UCM09  84 >200 >100 
UCM10 
 
33 >400 >100 
UCM11 
 
58 >500 >100 
UCM12 
 
94 >400 >100 
UCM13 
 
53 >200 >100 
UCM14 
 
11 >100 >100 
UCM15 (2) 
 
0.8 ± 0.1 40 50 
UCM16 
 
3.3 >100 >100 
UCM17 
 
5.4 100 100 
 a
Affinity constant values determined in B. subtilis FtsZ are the mean ± SEM. 
b
B. subtilis 168 
cells. 
c
MRSA USA300, S. aureus community acquired methicillin-resistant ATCC Nr: BAA-1556 
(Institute Pasteur, France)  
All these compounds share a general structure of two gallate subunits bound to a central core of 
differently substituted naphthalene, biphenyl, phenyl, or cyclohexane rings as well as an ethylene 
spacer. Among them, hits UCM02 (1) and UCM15 (2), containing a naphthalene and a biphenyl 
system as central scaffolds respectively, showed the highest affinities for Bs-FtsZ (Kd = 2.3 and 0.8 
µM, respectively) and moderate antibacterial activity in B. subtilis (MIC = 100 and 40 µM, 
respectively) and represent the first non-nucleotide synthetic molecules that effectively compete 
with GTP for binding to FtsZ (Figure 14).
84
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Figure 14. Hits identified from our in-house library. 
Molecular dynamics (MD) simulations predicted that one of the galloyl rings of compound 1 
replaces the interactions made by the phosphates of the nucleotide whereas the central core of the 
naphthalene and the other galloyl system overlap with the nucleobase of the GTP (Figure 15A). 
Further biological studies showed that hit 1 competitively inhibits the GTP-binding and perturbs 
normal assembly of the protein, impairing the localization of FtsZ into the Z-ring (Figure 15B). 
Indeed, this inhibitor induces filamentation of B. subtilis cells and finally blocks bacterial cell division 
(Figure 15C).
84
 
These findings provided a compelling rationale for the development of non-nucleotide 
derivatives targeting the GTP-binding site as antibacterial agents and prompted us to carry out a 
deeper chemical exploration around these compounds, in order to obtain FtsZ inhibitors with 
improved antibacterial properties and to gain further insight into their mechanism of action on 
bacterial cells. Therefore, in this thesis, starting from inhibitors 1 and 2, we focused our efforts on 
the development of new small molecules that replace the natural regulator GTP and block the 
bacterial cell division process by specifically inhibiting FtsZ.  
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Control Hit 1
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C
A
 
Figure 15. (A) Representative snapshot of MD simulation for the binding mode of hit 1 (green) superimposed 
with the GDP-bound crystallographic structure (grey). (B) B. subtilis cells SU570, in which the wild type ftsZ 
gene is replaced by ftsZ-gfp, were incubated during 1 h with hit 1 (40 µM) and visualized by fluorescent 
microscopy. (C) In vitro effects of hit 1 (50 µM) on B. subtilis 168 cells after 2 h of culture observed by phase-
contrast microscopy. Scale bars, 10 µm. 
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2.1.2. Design, Synthesis, and Biological Evaluation of a New Series of Compounds 
In order to carry out a structure-affinity-activity analysis around hits 1 and 2, we focused our 
attention on two subunits susceptible to structural modifications: the galloyl rings and the ester 
bonds used as spacers. Variations in the central core were discarded since derivatives of our in-
house library bearing other scaffolds displayed less affinity and/or antibacterial activity than the 1,3-
naphthyl or 3,5-biphenyl counterparts (see Table 1). The structure of compound 1 was used as a 
starting point for chemical modifications. Thus, to study the influence of the hydroxy groups of the 
phenyl rings, we first considered the reduction of the number of these groups as well as their 
substitution pattern and their replacement by other substituents such as methoxy or chlorine, while 
keeping constant other parts of the molecule (3-30). In addition, monoester derivatives of hit 1 (31 
and 32) were synthesized in order to study the influence of both phenyl rings in the binding to FtsZ 
and to explore the activity of possible metabolites of hit 1. Moreover, compounds in which the ester 
groups were replaced by other spacers such as amides, sulfonamides and double bonds were 
contemplated (33-36). After the biological evaluation of this series, the best modifications obtained 
for hit 1 were applied to biphenyl derivative 2 and compounds having a lower number of hydroxy 
groups (37-42), monoesters (43-46) and non-ester derivatives (47-50) were synthesized (Figure 
16). 
 
Figure 16. Design of compounds 3-50 based on hits 1 and 2. 
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2.1.2.1. Series I: Naphthalene Derivatives 
 Design, Synthesis, FtsZ Affinity, and Antibacterial Activity 
Following the proposed structural design, in a first stage, we explored the influence of the galloyl 
rings in the naphthalene derivative 1. Therefore, compounds 3-30 that arise from modifications of 
the hydroxy groups of the phenyl rings together with monoesters 31 and 32 were synthesized 
(Figure 17). 
 
Figure 17. Designed naphthyl derivatives 3-32 targeting the GTP-binding site. 
Target ester derivatives 3-30 were synthesized by esterification reactions of 1,3-
dihydroxynaphthalene and the corresponding benzoyl chlorides 52a-h. Thus, the proper 
(poly)hydroxybenzoic acids were initially transformed into protected benzoic acids 51a-f using tert-
butyldimethylsilyl (TBS) chloride in dimethylformamide (DMF) under microwave (MW) irradiation or 
conventional heating, followed by selective cleavage of the resulting silyl esters with acetic acid 
(Scheme 1). Both reactions were carried out in gram scale with good yields. Then, just before 
setting up the esterification reaction, carboxylic acids 51a-f, and commercially available 3,4-
dichlorobenzoic and 3,4,5-trimethoxybenzoic acids were treated with oxalyl chloride and catalytic 
DMF in toluene to give benzoyl chlorides 52a-h. 
 
Scheme 1. Reagents and conditions: (a) (i) TBS-Cl, DIPEA, DMF, MW 100 ºC, 20 min or TBS-Cl, imidazole, 
DMF, rt, 18 h; (ii) CH3CO2H, THF, rt, 3 h, 74-81%; (b) oxalyl chloride, DMF, toluene, 50 ºC, 1 h, quantitative. 
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Protected diesters 53-58 and final compound 3, with identical substitution at the 1 and 3 
positions of the naphthalene core, were readily prepared by esterification reaction of commercially 
available 1,3-dihydroxynaphthalene with an excess (4 equiv) of the corresponding benzoyl 
chlorides 52a-f,h in the presence of triethylamine as a base and dichloromethane (DCM) as solvent 
(Scheme 2). Then, TBS deprotection of the intermediate diesters 53-58 by treatment with 
hydrofluoride acid-pyridine (HF·Py) complex in tetrahydrofuran (THF) gave desired compounds 1, 
4-8. Due to the high excess of acid chlorides 52a-f,h employed in the esterification step, the 
corresponding acid anhydrides were obtained in some cases as by-products, which hampered the 
purification of the diesters and led to moderate yields. 
 
Scheme 2. Reagents and conditions: (a) Et3N, DCM, rt, 18 h, 54-71%; (b) HF·Py, pyridine, THF, rt, 15 min, 
26-88%.
 
For those compounds where 1,3-dihydroxynaphthalene was esterified with different benzoyl 
systems (9-30), the synthesis involved sequential monoesterification reactions (Scheme 3). Thus, 
the stoichiometry of the reaction of 1,3-dihydroxynaphthalene and benzoyl chlorides 52a,c,d was 
adjusted to 4 equiv of 1,3-dihydroxynaphthalene and 1 equiv of acid chloride to yield the 
corresponding monoesters 59-64. In each case, the mixture of the two possible acylated products 
was separated by column chromatography and each monoester was subjected to a second 
esterification reaction with the corresponding acid chlorides 52b-h (2 equiv) to afford the protected 
diesters 65-86, which yielded the final compound 9-30 after removal of the TBS groups under 
standard conditions. 
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Scheme 3. Reagents and conditions: (a) 52a,c, or d (0.25 equiv), Et3N, DCM, rt, 18 h, 22-38%; (b) 52b-h (2 
equiv), Et3N, DCM, rt, 18 h, 24-92%; (c) HF·Py, pyridine, THF, rt, 15 min, 15-92%. 
Next, monoester derivatives 31 and 32 were synthesized by TBS-deprotection of intermediates 
59 and 62, respectively (Scheme 4).  
 
Scheme 4. Reagents and conditions: (a) HF·Py, pyridine, THF, rt, 15 min, 78 and 93%. 
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The synthesized compounds 3-32 were then evaluated using the mant-GTP fluorescence 
anisotropy competitive assay
82
 to measure their binding affinities (Kd) for Bs-FtsZ (Table 2). All 
synthesized compounds, with the exception of the hexamethoxy derivative 3, were able to displace 
mant-GTP, showing better affinity values (Kd = 0.7-2.2 µM) than the initial hit 1 (Kd = 2.3 µM). In the 
case of compound 3, the loss of affinity (Kd > 300 µM) can be explained by the absence of free 
hydroxy groups, as the affinity was recovered when one of the original galloyl rings is kept 
(compounds 9 and 10, Kd = 1.5 and 1.6 µM, respectively). In general, the reduction in the number 
of hydroxy groups on both phenyl rings improves the binding affinity and the best Kd values 
corresponded to derivatives having four or less hydroxy groups (compounds 24, 28 and 29, Kd = 
0.7-0.8 µM). However, the substitution pattern of the phenyl rings did not exert a significant effect 
on the affinity for FtsZ. The introduction of chlorine atoms proved to be critically important for the 
affinity, being compounds 7, 19, 20, and 25 among the best inhibitors (Kd = 0.8-0.9 µM). Moreover, 
the combination of hydroxy and chlorine substituents in the same phenyl ring also demonstrated to 
be favorable for the affinity, whereas compounds with only chlorine subtituents in one of the 
benzoyl rings displayed less affinity (e.g. 20: Kd = 0.9 µM vs 22: Kd = 2.0 µM). In addition, the 
removal of one phenyl ring proved that both hydroxyphenyl rings are important for the the binding to 
FtsZ, being monoesters 31, 32 the weakest inhibitors (Kd = 26-33 µM). 
The antibacterial activity of compounds 3-32 against B. subtilis and the clinically isolated MRSA 
USA300 −as a representative strain of community acquired resistant Gram-positive bacteria− was 
also assessed (Table 2). In general, all compounds showed better antibacterial activity against B. 
subtilis than the initial hit 1, with the exception of derivatives with methoxy substituents 3, 9, and 10 
and monoesters 31 and 32 [e.g. 1: MIC (B. subtilis) = 100 µM vs 3 and 31: MIC (B. subtilis) >200 
µM]. Nonetheless, the relationship between the antibacterial activity in this strain and the number or 
position of the hydroxy groups remains unclear. Noteworthy, the antibacterial activity in B. subtilis 
(MIC) follows the same trend as the FtsZ affinity (Kd) within this series, which supports the role of 
this target in the antibacterial activity exerted by these naphthyl derivatives. Regarding the activity 
in MRSA, compounds bearing a galloyl subunit (9-22) exhibited poor antibacterial activity whereas 
the reduction in the number of hydroxy groups seems to be favorable in terms of potency. Thus, 
derivatives 6-8 and 25-30 with three or two hydroxy groups showed MIC values in MRSA ≤ 10 µM. 
In fact, the most potent derivatives were those with only two hydroxy groups [compounds 8, 29 and 
30: MIC (MRSA) = 5 µM]. Moreover, the replacement of any hydroxy group by chlorine led to a 
remarkable improvement in the activity, reaching values of 10 µM in the case of analogues 7 and 
25 [7: MIC (MRSA) = 10 µM vs 4: MIC (MRSA) > 100 µM; 25: MIC (MRSA) = 10 µM vs 24: MIC 
(MRSA) = 50 µM]. As observed in B. subtilis, the antibacterial activity of monoesters 31 and 32 in 
MRSA was also reduced when compared with their corresponding diesters 1, suggesting that both 
polyhydroxyphenyl subunits are required for FtsZ binding and antibacterial activity. 
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Table 2. FtsZ affinity and antibacterial activity of naphthalene esters 1, 3-32. 
 
Compd R
1
 R
2
 R
3
 R
4
 R
5
 R
6
 
Kd
a 
(µM) 
Bs-FtsZ 
MIC
 
(µM) 
B. Subtilis
b 
MIC
 
(µM) 
MRSA
c 
1 OH OH OH OH OH OH 2.3 ± 0.1 100 60 
3 OCH3 OCH3 OCH3 OCH3 OCH3 OCH3 >300 >200 >100 
4 OH OH H OH OH H 1.96 ± 0.04 50 >100 
5 OH H OH OH H OH 1.6 ± 0.1 25 10 
6 OH H H OH H H 1.5 ± 0.1 15 10 
7 Cl OH H Cl OH H 0.8 ± 0.1 15 10 
8 H OH H H OH H 1.72 ± 0.02 5 5 
9 OCH3 OCH3 OCH3 OH OH OH 1.5 ± 0.2 100 100 
10 OH OH OH OCH3 OCH3 OCH3 1.6 ± 0.3 100 100 
11 OH OH OH OH OH H 1.45 ± 0.03 50 100 
12 OH OH OH OH H OH 1.3 ± 0.1 50 100 
13 OH OH H OH OH OH 1.2 ± 0.1 25 100 
14 OH H OH OH OH OH 1.4 ± 0.2 50 100 
15 OH OH OH OH H H 2.0 ± 0.1 50 100 
16 OH OH OH H OH H 1.5 ± 0.1 50 100 
17 OH H H OH OH OH 1.3 ± 0.1 50 100 
18 H OH H OH OH OH 2.0 ± 0.1 >50 100 
19 OH OH OH Cl OH H 0.9 ± 0.2 25 50 
20 Cl OH H OH OH OH 0.9 ± 0.1 50 50 
21 OH OH OH Cl Cl H 1.1 ± 0.1 >15 24 
22 Cl Cl H OH OH OH 2.0 ± 0.1 >15 24 
23 OH OH H OH H OH 0.9 ± 0.1 >50 50 
24 OH H OH OH OH H 0.7 ± 0.2 25 50 
25 OH H OH Cl OH H 0.8 ± 0.1 25 10 
26 OH H OH OH H H 1.5 ± 0.1 20 10 
27 OH H OH H OH H 2.2 ± 0.1 >50 8 
28 OH H H OH OH H 0.7 ± 0.2 20 10 
29 OH H H H OH H 0.8 ± 0.2 5 5 
30 H OH H OH H H 1.5 ± 0.1 5 5 
31 OH OH OH - - - 26 ± 9 >200 >100 
32 - - - OH OH OH 33 ± 10 200 >100 
a
The values are the mean ± SEM. 
b
B. subtilis 168 cells. 
c
S. aureus community acquired methicillin 
resistant ATCC Nr: BAA-1556 (Institute Pasteur, France) MRSA USA300. 
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In order to analyze the influence of the spacer between the naphthalene central core and the 
polyhydroxyphenyl rings, derivatives 33-36 in which the ester linkers were replaced by amides, 
sulfonamides or alkene moieties were synthesized (Figure 18). As an initial exploration of this 
replacement and considering the synthetic viability, we synthesized derivatives of initial hit 1 and 
compound 7, as an example of high FtsZ affinity (Kd = 0.8 µM) and good antibacterial activity [MIC 
(MRSA) = 10 µM] inhibitor. 
 
Figure 18. Spacer exploration in the naphthalene series: compounds 33-36. 
Synthesis of amides 33 and 35 -derived from compounds 1 and 7, respectively- is outlined in 
Scheme 5. First, catalytic hydrogenation of commercially available 1,3-dinitronaphthalene afforded 
1,3-diaminonaphthalene (87). This diamine was then treated with benzoyl chlorides 52a or 52f to 
give the final compounds 33 and 35, after deprotection of the hydroxy groups with the HF·Py 
complex. In turn, sulfonamide 36 was synthesized by sulfonylation reaction of diamine 87 with 3-
chloro-4-methoxybenzenesulfonyl chloride (90) under standard basic conditions, followed by 
cleavage of the methoxy groups of intermediate 91 with boron tribromide in DCM. 
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Scheme 5. Reagents and conditions: (a) H2, 10% Pd/C, MeOH, rt, 3.5 h, 60%; (b) 52a or f (4 equiv), Et3N, 
DCM, rt, 18 h, 33-36%; (c) HF·Py, pyridine, THF, rt, 15 min, 75-78%; (d) ClSO3H, CHCl3, 0 ºC to rt, 16 h, 61%; 
(e) pyridine, DCM, rt, 18 h, 48%; (f) BBr3, DCM, rt, 18 h, 38%. 
Finally, alkene (1E,3E)-34 was synthesized by Wittig reaction of the triphenylphosphonium salt 
93 and aldehyde 95, followed by Pd(0)-catalyzed deprotection of the allyl ethers using 1,3-
dimethylbarbituric acid (DMBA) (Scheme 6). Thus, phosphonium salt 93 was prepared by radical 
bromination of 1,3-dimethylnaphthalene in the presence of N-bromosuccinimide (NBS) and 2,2’-
azobisisobutyronitrile (AIBN), and subsequent reaction of the resulting dibromo derivative 92 with 
triphenylphosphine in xylene under reflux. Aldehyde 95 was obtained by O-allylation of methyl 
3,4,5-trihydroxybenzoate and further reduction of ester 94 with sodium bis(2-
methoxyethoxy)aluminumhydride (Red-Al®). Diene 96 was obtained as a mixture of (1E,3E) and 
(1E,3Z) isomers that could be separated by chromatography and fully characterized. However, 
deprotection of both isomers gave final product (1E,3E)-34 by isomerization of the doble bond in 
the presence of Pd. 
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Scheme 6. Reagents and conditions: (a) NBS, AIBN, CCl4, 90 ºC, 16 h, 73%; (b) Ph3P, xylene, reflux, 72 h, 
96%; (c) CH2=CHCH2Br, K2CO3, DMF, 65 ºC, 4 h, 99%; (d) Red-Al®, KOt-Bu, pyrrolidine, THF, 0 ºC, 10 min, 
78%; (e) n-BuLi, THF, -78 ºC to rt, 18 h, (1E,3E) 30% and (1E,3Z) 18%; (f) DMBA, Pd(PPh3)4, DCM/MeOH, rt, 
1 h, 19%. 
Regarding the influence of the spacer between the naphthalene central core and the 
polyhydroxyphenyl subunits, the replacement of the esters by amides, sulfonamides or alquenes 
(33-36) did not provide an improvement in terms of binding affinity for FtsZ nor antibacterial activity 
in the pathogenic bacteria MRSA when compared to their parent compounds 1 and 7, and only 
amide 35 showed modest affinity for FtsZ (Kd = 3.1 µM) and antibacterial activity [MIC (B. subtilis) = 
25 µM, MIC (MRSA) = 50 µM] (Table 3). 
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Table 3. FtsZ affinity and antibacterial activity of compounds 33-36. 
 
Compd Spacer R
1
 R
2
 R
3
 
Kd
a 
(µM) 
Bs-FtsZ 
MIC (µM) 
B. subtilis
b
 
MIC (µM ) 
MRSA
c
 
1 OCO OH OH OH 2.3 ± 0.1 100 50 
33 NHCO OH OH OH 25.0 ± 0.2 >50 >100 
34 CH=CH OH OH OH 8 ± 1 >20 >100 
7 OCO Cl  OH H 0.8 ± 0.1 15 10 
35 NHCO Cl  OH H 3.1 ± 0.5 25 50 
36 NHSO2 Cl  OH H 21.3 ± 0.2 >200 >100 
a
The values are the mean ± SEM. 
b
B. subtilis 168 cells. 
c
S. aureus community acquired methicillin 
resistant ATCC Nr: BAA-1556 (Institute Pasteur, France) MRSA USA300. 
 Selectivity versus Tubulin 
Taken together the results obtained with compounds 3-36, the new identified high-affinity 
inhibitors 6, 7, 19-21, 23-26, and 28-30 (Kd ≤ 1.5 µM) endowed with good antibacterial activity (MIC 
in B. subtilis and MRSA ≤ 50 µM) were selected to assess their FtsZ selectivity, since effective 
antibacterial compounds targeting FtsZ should avoid unwanted interactions with its closest 
eukaryotic structural homolog tubulin (Figure 19A). Thus, sedimentation assays were used to 
determine the effect of the compounds on FtsZ and tubulin assembly. These polymer pelleting 
experiments were made by sedimenting the FtsZ or tubulin polymers formed under well-controlled 
assembly conditions in the presence of increasing concentrations of the selected compound, GTP 
or GDP, and quantifying them after loading the pellets and supernatants with a time lag into 
polyacrylamide gel electrophoresis (Figure 19B). It is noteworthy to mention that these assays were 
performed at the maximal concentrations of the compounds permitted by their average solubility in 
the presence of each protein: 25 µM for FtsZ or 100 µM for tubulin. The inhibition percentage was 
determined after substracting the negative control (GDP) and it was expressed relative to the 
maximal polymerization induced by GTP with regeneration system (RS) by the following equation: 
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FtsZ or Tubulin Inhibition % = 100 ∗  1 −  
 %𝑝𝑒𝑙𝑙𝑒𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 − %𝑝𝑒𝑙𝑙𝑒𝑡 𝐺𝐷𝑃 
 %𝑝𝑒𝑙𝑙𝑒𝑡 𝐺𝑇𝑃 − %𝑝𝑒𝑙𝑙𝑒𝑡 𝐺𝐷𝑃 
   
 
Notwithstanding the higher sensitivity of the tubulin inhibition test compared to FtsZ inhibition 
assay, compounds 6, 20, 21, 26, and 30 do not inhibit tubulin polymerization, whereas 19, 23, 24, 
and 29 are weak tubulin inhibitors (<25%) and derivatives 7, 25, and 28 as well as hit 1 cross-inhibit 
tubulin assembly (>40%). Therefore, the reduction of hydroxy groups, not only seems to be critical 
in terms of FtsZ affinity and antibacterial activity but also for selectivity, being hit 1 (R
1-6 
= OH) the 
most potent tubulin inhibitor, whereas compounds 6 and 26 with only two or three hydroxy groups 
are the most selective. Interestingly, all derivatives that cross-inhibit tubulin assembly (7, 25, and 
28) shared a 4-hydroxybenzoyl group at position 3 of the naphthalene. 
Thus, compounds 6 and 26 are the most potent FtsZ inhibitors, showing 46% inhibition at 25 µM 
and displaying high selectivity against tubulin (0-1% tubulin inhibition at 100 µM). Their selective 
inhibition of FtsZ vs tubulin assembly is exemplified at different concentrations (5-50 µM) in Figure 
19B. These inhibitors are able to reduce the percentage of Bs-FtsZ polymers with respect to the 
control (in the presence of GTP) in a concentration dependent manner, and prove that it is possible 
to selectively inhibit FtsZ assembly with synthetic GTP-replacing compounds that are inactive on 
tubulin polymerization. 
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Figure 19. (A) Percentage of FtsZ (25 µM of compound) and tubulin (100 µM of compound) inhibition. (B) 
Effect of increasing concentrations of compounds 6 and 26 on the assembly of Bs-FtsZ (9 µM) and tubulin (15 
µM). FtsZ assembly was performed with GTP regeneration system (RS). Podophyllotoxin (PODO, 50 µM) was 
employed as a control microtubule inhibitor in the tubulin polymerization assay. 
In summary, comparing these optimized compounds with the initial hit 1, we can infer that the 
hydroxy groups of the galloyl rings can be successfully reduced to obtain simpler and improved 
derivatives such as 6, 26 and 29, which combine good FtsZ inhibition, antibacterial activity and 
selectivity against tubulin.  
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2.1.2.2. Series II: Biphenyl Derivatives 
 Design, Synthesis, FtsZ Affinity, and Antibacterial Activity  
Considering that the reduction of hydroxy groups in the naphthalene series turned into more 
active and selective compounds, derivatives 37-42 bearing four or less hydroxy groups were 
considered in the study of the 3,5-biphenyl system as central core (Figure 20). In addition, 
monoesters 43-46 and compounds 47-50 with different spacers between the biphenyl central core 
and the polyhydroxyphenyl rings were also studied. In this series, replacement of hydroxy 
substituents by chlorine atoms was discarded due to the low FtsZ inhibition and/or the tubulin 
cross-inhibition observed in the naphthalene series for this modification. 
 
Figure 20. Designed biphenyl derivatives 37-50 targeting the GTP-binding site. 
Symmetric diesters 2, 40, and 42 were synthesized by esterification of biphenyl-3,5-diol (97) 
with an excess of the corresponding benzoyl chlorides (52a,d,e), followed by TBS deprotection of 
silyl ethers 98-100 (Scheme 7). Diol 97 was prepared by MW-assisted Suzuki cross-coupling of 3,5-
dimethoxyphenylbromide and phenylboronic acid, and subsequent methoxy deprotection with BBr3. 
For non-symmetric biphenyl derivatives (37-39 and 41), the synthesis involved sequential 
monoesterification reactions with the appropriated benzoyl chlorides. Thus, reaction of diol 97 with 
0.25 equiv of benzoyl chlorides 52b-e yielded the corresponding monoesters 101-104, which were 
used in a second esterification step with 2 equiv of acid chlorides 52c,d to afford the desired final 
compounds 37-39 and 41 after removal of TBS groups under standard conditions. In addition, 
intermediates 101-104 were deprotected to afford the desired monoesters 43-46. 
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Scheme 7. Reagents and conditions: (a) (i) PhB(OH)2, Pd(PPh3)4, Na2CO3, toluene/H2O, MW, 150 ºC, 30 min, 
75%; (ii) BBr3, DCM, rt, 18 h, 97%; (b) 52a,d or e (4 equiv), Et3N, DCM, rt, 18 h, 64-87%; (c) HF·Py, pyridine, 
THF, rt, 15 min, 28-96%; (d) 52b-e (0.25 equiv), Et3N, DCM, rt, 18 h, 46-69%; (e) 52c or d (2 equiv), Et3N, 
DCM, rt, 18 h, 34-89%. 
Regarding the spacer modifications, synthesis of compound 47, in which the ester spacers were 
removed, was accomplished by transformation of diol 97 into the corresponding triflate, followed by 
Suzuki cross-coupling reaction under MW irradiation with 3-methoxyphenylboronic acid, and further 
methoxy deprotection of intermediate 110 with BBr3 (Scheme 8). Amide 48 and sulfonamide 49 
were synthesized from biphenyl-3,5-diamine 112. First, Suzuki cross-coupling reaction under MW 
irradiation of 1-bromo-3,5-dinitrobenzene with phenylboronic acid and further catalytic reduction of 
biphenyl-3,5-dinitro (111) in anhydrous THF in the H-Cube hydrogenation system afforded 
biphenyl-3,5-diamine (112), that was transformed in situ into the corresponding amide 48 or 
sulfonamide 49, due to its low chemical stability. Thus, benzoyl chloride 52d or commercial 3-
methoxybenzenesulfonyl chloride and Et3N were added to the freshly hydrogenated solution of 
diamine 112 in THF to give the final compounds 48 and 49, after TBS deprotection of diamide 
intermediate 113 with the HF·Py complex or methoxy deprotection of disulfonamide 114 with BBr3. 
Finally, retroamide 50 which contains a reverse amide group, was synthesized by Suzuki coupling 
of dimethyl-5-bromoisophthalate with phenylboronic acid, followed by ester hydrolysis and further 
Results and Discussion 
- 40 - 
transformation into the corresponding acid chloride 116, whose condensation with (3-{[tert-
butyl(dimethyl)silyl]oxy}phenyl)amine (117) followed by TBS deprotection afforded compound 50. 
 
Scheme 8. Reagents and conditions: (a) trifluoromethanesulfonic anhydride, Et3N, DCM, rt, 2.5 h, 99%; (b) 3-
methoxyphenylboronic acid, Pd(PPh3)4, Na2CO3, toluene/EtOH/H2O, MW, 150 ºC, 15 min, 75%; (c) BBr3, 
DCM, rt, 3 h, 21-94%; (d) PhB(OH)2, Pd(PPh3)4, Na2CO3, toluene/H2O, MW, 150 ºC, 30 min, 83-90%; (e) H2, 
10% Pd/C, H-Cube reactor, THF, rt, 99%; (f) 52d or 3-methoxybenzenesulfonyl chloride, Et3N, THF, rt, 18 h, 
20-45%; (g) HF·Py, pyridine, THF, rt, 15 min, 66-89%; (h) NaOH, H2O, THF, reflux, 1.5 h, 85%; (i) SOCl2, THF, 
reflux, 3 h, 99%; (j) TBS-Cl, imidazole, 18 h, rt, 48%; (k) Et3N, THF, rt, 18 h, 89%. 
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Assessment of the binding affinities for Bs-FtsZ by the mant-GTP competitive assay showed 
that all biphenyl derivatives 37-50 were able to displace the nucleotide with higher affinity values 
than their naphthalene analogues (Table 2 and 4), confirming that the scaffold of 3,5-biphenyl is 
more favorable as central core than the 3,5-naphthyl system [e.g. Kd (8) = 1.72 µM vs Kd (42) = 0.4 
µM]. Among them, diesters 37-42 and compound 47 showed better affinity values (Kd = 0.4-0.6 µM) 
than initial hit 2 (Kd = 0.8 µM) (Table 4). In general, the tendency observed in the naphthalene 
derivatives is repeated in this second series. Thus, the reduction in the number of hydroxy groups 
of both phenyl rings improves the binding affinity for the GTP-binding site of FtsZ [Kd (37-42) = 0.4-
0.6 µM]. Although 1 or 2 hydroxy groups in each phenyl ring seems to be the optimal number of 
these substituents for FtsZ affinity, their position still did not exert a significant effect. This may be 
due to the flexibility of the FtsZ nucleotide binding loops. Removal of one of the 
polyhydroxybenzoate rings in the biphenyl derivatives demonstrated once again that both subunits 
are important for the binding, since monoesters 43-46 have ten-fold reduced affinity (Kd = 3.3-5.3 
µM). The biological evaluation of non-ester analogues 47-50 showed that they keep micromolar 
affinity for FtsZ (Kd = 0.5-8.3 µM) and proves that modifications in the spacers of this new identified 
chemotype are tolerated. Notably, derivative 47 maintains the high FtsZ affinity of its parent 
compound 40 [Kd (47) = Kd (40) = 0.5 µM]. 
In order to assess their antibacterial activity, compounds 37-50 were tested against B. subtilis 
and MRSA USA300 (Table 4). In general, diesters 37-42 showed MIC values in the micromolar 
range and the reduction in the number of hydroxy groups was also favorable in terms of potency, 
as previously observed for FtsZ affinity. In fact, the most potent derivatives were 39-42 with only 
two or three hydroxy groups [MIC (MRSA) = 5-7 µM]. On the other hand, removal of one of the 
polyhydroxybenzoyl subunits led to a reduction in the antibacterial potency [e.g. MIC (MRSA, 40, 
42) = 5-7 µM vs MIC (MRSA, 45, 46) = 50 µM]. Antibacterial evaluation of non-esters 47-50 showed 
that they also exert antimicrobial activity [MIC (B.subtilis) = 5-50 µM, MIC (MRSA) = 3-50 µM]. 
Interestingly, submicromolar high-affinity compound 47 displays the best antibacterial activity 
against MRSA (MIC = 3 µM) within analyzed compounds.  
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Table 4. FtsZ affinity and antibacterial activity of compounds 2, 37-50. 
 
Compd R
1
 R
2
 R
3
 R
4
 R
5
 R
6
 
Kd
a 
(µM) 
Bs-FtsZ 
MIC (µM) 
B. Subtilis
b
 
MIC (µM) 
MRSA
c
 
2 OH OH OH OH OH OH 0.8 ± 0.1 40 50 
37 OH OH H OH H OH 0.4 ± 0.1 15 50 
38 OH OH H OH H H 0.4 ± 0.1 15 50 
39 OH H OH OH H H 0.5 ± 0.1 5 5 
40 OH H H OH H H 0.5 ± 0.1 5 7 
41 OH H H H OH H 0.6 ± 0.1 10 5 
42 H OH H H OH H 0.4 ± 0.1 2.5 5 
43 OH OH H - - - 5.3 ± 1.0 75 50 
44 OH H OH - - - 5.3 ± 1.0 50 50 
45 OH H H - - - 3.8 ± 0.8 50 50 
46 H OH H - - - 3.3 ± 0.6 50 50 
0 
 
Compd Spacer 
Kd
a 
(µM) 
Bs-FtsZ 
MIC (µM) 
B. Subtilis
b
 
MIC (µM) 
MRSA
c
 
47 - 0.5 ± 0.1 5 3 
48 NHCO 4.3 ± 1.0 25 50 
49 NHSO2 4.8 ± 0.5 50 50 
50 CONH 8.3 ± 1.4 50 50 
a
The values are the mean ± SEM. 
b
B. subtilis 168 cells. 
c
S. aureus community acquired 
methicillin resistant ATCC Nr: BAA-1556 (Institute Pasteur, France) MRSA USA300. 
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 Selectivity versus Tubulin 
Next, we studied the effects on FtsZ polymerization and tubulin assembly of high-affinity 
inhibitors 37-42 (Kd ≤ 0.6 µM), compound 45, as a monoester example, and non-ester analogues 
47-50 (Figure 21A). In general, all derivatives were found to inhibit the GTP-induced assembly of 
FtsZ more effectively than their parent compound 2 in this in vitro assay, being 45, 47-50 the most 
potent compounds with inhibition percentages higher than 50% at 25 μM. Interestingly, biphenyl 
derivatives showed higher FtsZ inhibition and better selectivity against tubulin polymerization than 
the naphthene analogues. In fact, only 39, 45 and 49 showed significant inhibition of tubulin 
assembly at 100 µM.  
 
Figure 21. (A) Percentage of FtsZ and tubulin inhibition at 25 and 100 µM of compound respectively. (B) Effect 
of increasing concentrations of compounds 40, 45, and 48 on the assembly of Bs-FtsZ (9 µM) and tubulin (15 
µM). FtsZ assembly was performed with GTP regeneration system (RS). PODO (50 µM) was employed as a 
control microtubule inhibitor in the tubulin polymerization assay. 
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The inhibition of FtsZ vs tubulin assembly is also exemplified at increasing concentrations of the 
three structurally diverse compounds 40, 45 and 48 (Figure 21B). Thus, it can be observed how 
derivatives 40 and 48 inhibit to different extent FtsZ assembly at 5-50 μM range (Figure 21A), 
whereas they lack any significant effect on tubulin assembly up to 50 µM (Figure 21B).  
Comparing these optimized compounds with the initial hit 2, we can infer that the hydroxy 
groups of the galloyl rings can be also reduced to obtain simpler and improved biphenyl derivatives 
such as 40-42, and the ester spacer can be successfully removed (compound 47) or replaced by 
an amide (compound 48). These compounds, together with naphthyl derivatives 6, 26 and 29 could 
be considered as antibacterial candidates that combine good FtsZ inhibition, antibacterial activity 
and selectivity against tubulin.  
2.1.3. Further Characterization of Optimized Inhibitors in Terms of Antibacterial Properties, 
Cytological Profile, and Mechanism of Action 
 Antibacterial Activity in a Panel of Pathogenic Bacteria 
Taken together the results obtained with compounds 1-50, the new identified high-affinity 
inhibitors 6, 26, 29, and 40-42 (Kd ≤ 1.5 µM) endowed with good antibacterial activity (MIC in B. 
subtilis and MRSA ≤ 20 µM) and selectivity against tubulin, together with monoester 45 and non-
ester analogues 47 and 48, were selected for further studies. Hits 1 and 2 were also included for 
comparative purpose. First, their microbiological profile on a broader panel of antibiotic-resistant 
Gram-positive and Gram-negative pathogenic bacteria was assessed (Table 5). 
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Table 5. Antibacterial activity pathogenic bacteria of selected compounds. 
 
Compound 
Kd
a 
FtsZ 
(µM) 
MIC (μM) 
MRSA Mu50
b
 
E. 
faecalis
c
 
L. 
monoc.
d
 
P. 
aerug.
e E. coli
f 
1 2.3 ± 0.1 80 >100 50 100 >100 
6 1.5 ± 0.1 10 50 50 >100 >100 
26 1.5 ± 0.1 10 50 10 >100 >100 
29 0.8 ± 0.2 5 50 5 >100 >100 
2 0.8 ± 0.1 50 >100 50 50 50 
40 0.5 ± 0.1 7 50 7 >50 >100 
41 0.6 ± 0.3 5 50 5 >50 >100 
42 0.4 ± 0.1 5 50 5 >50 >100 
45 3.8 ± 0.8 50 50 50 >50 >100 
47 0.5 ± 0.1 3 >100 5 >50 >100 
48 4.3 ± 1.0 50 >100 50 >50 >100 
a
The values are the mean ± SEM. 
b
Methicillin, ampicillin and kanamycin resistant Mu50/ATCC 
700699 (Institute Pasteur, France). 
c
Enterococcus faecalis, gentamicin and vancomycin 
resistant V583 ATCC700802 (sequenced strain). 
d
Listeria monocytogenes, EGDe (sequenced 
strain). 
e
Pseudomonas aeruginosa, imipenem resistant PAO1 (sequenced strain). 
f
Escherichia 
coli, UTI89 from cystitis infection (sequenced strain). 
In general, all tested compounds inhibited the growth of Gram-positive resistant pathogenic 
bacteria such as MRSA (MIC = 3-50 µM) and Listeria monocytogenes (L. monoc., MIC = 5-50 µM), 
being derivatives 6, 26, 29, 40-42, and 45 also able to inhibit E. faecalis growth at 50 µM. 
Regarding Gram-negative bacteria, although initial biphenyl hit 2 showed moderate activity in 
Results and Discussion 
- 46 - 
resistant Pseudomonas aeruginosa (P. aerug., MIC = 50 µM) and E. coli (MIC = 50 µM), none of its 
derivatives affected the growth of Gram-negative pathogens at the assayed concentration (100 
µM), which indicates that removal of hydroxy groups was detrimental for the antibacterial activity 
against these strains. 
With the aim of determining whether the new identified inhibitors were stable in the whole 
bacteria assay, stability of representative compounds 40, 47, and 48 in bacterial culture of B. 
subtilis was assessed and they were not appreciably hydrolyzed after 18 h (90% remaining 
compound quantified by HPLC). 
 Cytological Profile and Mode of Action 
In order to identify the most effective bacterial division blockers among the selected compounds, 
we examined their effects on the cell division of wild type B. subtilis 168 and on the FtsZ subcellular 
localization in B. subtilis SU570, a strain that has FtsZ fused to a green fluorescent protein (FtsZ-
GFP) as the only FtsZ protein.  
Cytological profiling of the nucleoid, membrane shape and membrane permeability by 
fluorescence microscopy has been recently shown to uniquely distinguish the mode of action of 
antibiotics targeting the major types of bacterial biosynthetic pathways (DNA, RNA, protein, 
peptidoglycan and lipid) and subclasses among them, which permits to identify the mode of action 
of new antibiotics.
85,86
 Following this trend, we have characterized the cellular effects of our most 
effective FtsZ inhibitors (29, 40 and 41) and the structurally representative compounds 45, 47, and 
48. Cells of wild type B. subtilis 168 exposed to each of these compounds were longer than control 
cells (Figure 22). Among them, derivative 40 exhibited the clearest effect as bacterial division 
blocker. The phenotype of cells treated with biphenyl 40 (4 µM) consisted of the longest filamentous 
undivided cells. Long filaments were also observed with the amide linker analogue 48 (12 µM) and 
weaker effects were found with 41 (5 µM) and monoester 45 (25 µM) as well as with the naphthyl 
compound 29 (5 µM). 
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Figure 22. Cell division effect of FtsZ inhibitors. (A) B. subtilis 168 incubated during 3 h with FtsZ inhibitors 29 
(5 µM), 40 (4 µM), 41 (5 µM), 45 (25 µM), and 48 (12 µM) and observed by phase contrast microscopy. (B) B. 
subtilis 168 cell length. Scale bar: 10 µm. 
Interestingly, compound 47 inhibited bacterial viability without showing a clear effect on the Z-
ring, which could suggest an alternative mechanism of action.  
Moreover, each of these compounds impaired the normal assembly of FtsZ-GFP into the mid-
cell Z-ring prior to division of B. subtilis SU570 at concentrations near their MIC values, further 
supporting FtsZ targeting. The observed effects consisted of a reduction in the proportion of cells 
with normal Z-rings at division sites with respect to controls and FtsZ delocalization into 
characteristic punctuate foci along the bacterial cells in less than 1 h (Figure 23). Z-rings along the 
filamented cells were very frequently observed abnormally close to each other with compounds 29, 
40, 41, and 48. FtsZ-GFP foci were more abundant in cells treated with compounds 29 and 40, and 
by contrast, fewer Z-rings and foci were observed in cells treated with compound 45. 
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Figure 23. Effect of FtsZ inhibitors on FtsZ subcellular localization. Cells of B. subtilis SU570 (FtsZ-GFP) were 
incubated during 1 h with 29 (5 µM), 40 (3 µM), 41 (2 µM), 45 (25 µM), and 48 (12 µM). FtsZ-GFP membrane 
stained with FM4-64 and DNA stained with DAPI were visualized through their corresponding channels with a 
fluorescence microscope. Scale bar: 10 µm. 
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The impairment of the cell division ring was also reflected in an abnormal nucleoid morphology. 
Thus, cells treated with the FtsZ inhibitors 29, 40, 41, 45, and 48 showed nucleoids with a 
fragmenting appearance, in contrast with the control cells (Figure 23, DAPI column). In many 
cases, the regions of the nucleoid constriction corresponded with Z-rings or FtsZ foci, whereas in 
other zones FtsZ-GFP accumulation was not observed, which could match with previous division 
sites where the Z-ring has already disappeared. Membranes were visualized in the same B. subtilis 
SU570 cells treated with the vital stain FM4-64. In this case, and in addition to the plasma 
membrane marking the cell contour and division septa, frequent extra membrane accumulations 
and patches were observed, some of them coinciding with FtsZ foci. These observations suggest 
that these FtsZ inhibitors induce abortive division sites and plasma membrane lesions. These 
effects are similar to those reported for the most studied bacterial cell division inhibitor 
PC190723,
72,73,87
 which targets another FtsZ binding site.
81
 PC190723 (22 µM), when compared 
with inhibitor 40, also induced the formation of membrane patches that overlap with the 
characteristic FtsZ foci along the undivided cellular filaments (Figure 24).  
PC190723
28
FtsZ-GFP FM4-64 DAPIFtsZ-GFP FM4-64 DAPI
PC190723
40
 
Figure 24. Cells of B. subtilis SU570 were incubated with PC190723 (22 µM, 1 h) or 40 (3 µM, 3 h). FtsZ-GFP, 
membrane stained with FM4-64 and DNA stained with DAPI were visualized. Membrane patches were 
observed in both, cells treated with PC190723 and with 40. Insets show the magnification image of a specific 
region of the cell containing membrane patches. Scale bar: 10 µm. 
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All together, these studies show that, with the exception of the high affinity derivative 47 that 
seems to exert the inhibition of the bacterial cell division through a different mechanism, the 
majority of the compounds under study inhibit bacterial cell division by disrupting FtsZ assembly 
and impairment of the Z-ring. Among them, derivative 40 stands out as the most effective bacterial 
cell division inhibitor. 
In summary, in the first part of this thesis we have reported a series of new compounds targeting 
the GTP-binding site of FtsZ (3-50) starting from hits 1 and 2 obtained from the screening of our in-
house library. Assessment of their Kd values, as a measure of the direct interaction of these 
derivatives with the GTP-binding site of FtsZ from B. subtilis, along with their in vitro antibacterial 
activity against a panel of pathogenic bacteria and selectivity towards tubulin, has allowed us to 
identify potent and selective FtsZ inhibitors. The cytological effects of these new GTP-replacing 
FtsZ inhibitors mainly consist of Z-ring impairment and FtsZ delocalization into punctuate foci, 
which presumably lead to the observed inhibition of cell division. These studies led to the 
identification of biphenyl derivative 40 as the most effective FtsZ inhibitor and bacterial cell division 
blocker, with a Kd value in B. subtilis FtsZ of 0.5 µM, good antibacterial activity in Gram-positive 
pathogenic bacteria [MIC (MRSA) = 5 µM] and selectivity vs tubulin, followed by the naphthyl 
derivative 29. Promising biphenyl fragment 45 and amide 48 also emerge as more effective FtsZ 
inhibitors than the initial hits 1 and 2. Overall, these inhibitors contribute to expand the scarce 
number of GTP-mimetics available and provide a compelling rationale for the development of 
antibacterial agents with novel modes of action (Figure 25). 
 
Figure 25. New FtsZ inhibitors targeting the GTP-binding site. 
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2.2. Development of Fluorescent Probes for the PC190723 Binding Site of FtsZ 
Among the FtsZ inhibitors described so far, PC190723 is the most studied compound and its co-
crystalization with FtsZ has allowed the identification of a long cleft as a new allosteric druggable 
site in the protein. In addition, its analogue 8j has also been characterized as a potent FtsZ 
inhibitor, with higher FtsZ affinity and antibacterial activity.
71,72 
However, the lack of a binding assay 
to assess the affinity of small molecules for this long cleft makes difficult the development of new 
FtsZ inhibitors addressing this new binding site. Indeed, only phenotypic experiments such as 
polymer pelleting assays have been used in order to identify new inhibitors. Therefore, fluorescent 
derivatives of PC/8j could be used as valuable tools to set up a fluorescence-based assay for the 
identification of FtsZ inhibitors by screening libraries of compounds against this newly identified 
binding site. 
2.2.1. Design, Synthesis and Characterization of Fluorescent Compounds 
An extensive SAR of benzamide derivatives perfomed by Prolisis
70,71
 has shown that the 3-
methoxybenzamide is the minimal structural feature for the molecular recognition by FtsZ. 
Therefore, we have designed fluorescent derivatives based on PC/8j that contain the benzamide 
subunit following two different approaches: (i) attachment of a fluorophore to the structure of 8j 
through a rigid linker, such as an alkyne moiety, or a flexible aliphatic chain (119-122), and (ii) 
substitution of the heterocyclic subunit of PC/8j by a fluorescent tag (123-125). With respect to the 
fluorescent tag, we selected small fluorophores such as nitrobenzoxadiazole (NBD), a coumarin 
derivative, and dansyl (Figure 26). 
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Figure 26. Initial design of PC190723/8j-based fluorescent probes. 
Since the fluorescent assays will need a non-fluorescent substrate able to replace the 
fluorescent probe to confirm the interaction with the PC-binding site, we selected PC190723 for this 
purpose and carried out its synthesis following the synthetic route previously described in the 
literature (Scheme 9).
71
 Thus, conversion of commercially available 2,6-difluoro-3-methoxybenzoic 
acid into its corresponding amide 126, followed by methoxy deprotection with BBr3 afforded 2,6-
difluoro-3-hydroxybenzamide (127) in gram scale. On the other hand, the synthesis of the 
heterocyclic subunit started with the transformation of commercial 5-chloro-3-nitropyridin-2-ol into 
the bromo derivative 128, followed by reduction of the nitro group to afford 3-aminopyridine 129 that 
was then condensed with benzyloxyacetyl chloride to give amide 130. Intermediate 130 was 
cyclized with Lawesson’s reagent and the obtained benzylether 131 was deprotected and 
transformed into bromo derivative 133 by reaction of the resulting alcohol 132 with NBS. Finally, 
Williamson alkylation of phenol 127 with 133 afforded PC190723. 
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Scheme 9. Reagents and conditions: (a) i) SOCl2, toluene, reflux, 5 h, quantitative; ii) NH4OH, THF, rt, 16 h, 
80%; (b) BBr3, DCM, rt, 3 days, 79 %; (c) PBr3, toluene/DMF, 130 ºC, 3 h, 42%; (d) SnCl2·H2O, HCl, Et2O, 50 
ºC, 30 min, 98%; (e) benzyloxyacetyl chloride, Et3N, DCM, rt, 14 h, 80 %; (f) Lawesson’s reagent, toluene, 120 
ºC, 3 h, 79%; (g) BBr3, DCM, rt, 2 h, 88%; (h) NBS, Ph3P, DCM, rt, 2.5 h, 68%; (i) K2CO3, NaI, DMF, rt, 16 h, 
33%. 
Regarding the first series of derivatives 119-122, in which the fluorophores were attached to 8j 
by an alkyne or aliphatic chain, their synthesis was conceived by functionalization of 8j with an 
alkynyl amine and subsequent nucleophylic substitution reaction with the corresponding 
fluorophore (dansyl, coumarin or NBD) (Figure 27). Hydrogenation of the triple bond present in 
these derivatives will afford compounds bearing a more flexible aliphatic chain as spacer. 
 
Figure 27. Compounds 119-122. 
Thus, synthesis of propargylic amine 138 was carried out starting from commercial 5-bromo-2-
methyl-1,3-benzothiazole. Its bromination with NBS and AIBN in CCl4 followed by nucleophilic 
substitution of the bromo derivative 134 with hydroxybenzamide 127 gave the bromo aromatic 
intermediate 135 (Scheme 10).
71
 Then, Sonogashira coupling of 135 with protected propargylamine 
136 was carried out under thermal conditions using PdCl2(PPh3)2 as catalyst to obtain the 
corresponding coupling product 137 in 58% yield. This yield was improved by the use of Pd(PPh3)4 
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and MW irradiation, affording the protected amine 137 in 86%, which was deprotected to obtain the 
intermediate amine 138. Coupling of 138 with the three different fluorophores properly 
functionalized: dansyl chloride, 7-(diethylaminocoumarin)-3-carboxylic acid and 4-chloro-7-
nitrobenzofurazan (Cl-NBD) yielded dansyl and coumarin derivatives 119 and 120, respectively. 
Unfortunately, the low conversion (<5%) of the reaction of 138 with Cl-NBD did not allow the 
isolation of the desired NBD derivative (Scheme 10). 
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Scheme 10. Reagents and conditions: (a) NBS, AIBN, CCl4, 90 ºC, 3 h, 13%; (b) 127, K2CO3, DMF, rt, 16 h, 
82%; (c) Pd(PPh3)4, CuI, Et3N, DMF, MW, 100 ºC, 45 min, 86%; (d) NH4OH, MeOH, rt, 17 h, 99%; (e) Et3N, 
DCM/DMF, rt, 24 h, 28%; (f) PyBroP®, DIPEA, DMF, rt, 4 h, 5%; (g) Et3N, DCM/DMF, rt, 24 h. 
Therefore, for the synthesis of the NBD derivative we considered the possibility of synthesizing 
the NBD fluorophore functionalized with a terminal alkyne in order to perform a Sonogashira 
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coupling with the scaffold of 8j. Thus, alkyne 139 was synthesized by reaction of propargylamine 
with Cl-NBD in the presence of Et3N in gram scale, but the Sonogashira reation with bromo 
derivative 135 did not give the corresponding desired product (Scheme 11). Instead, 4-amino-NBD 
was mainly isolated from the reaction crude, as the result of the propargyl cleavage in 139 
promoted by the palladium catalyst. In an attempt to avoid this spontaneous cleavage, we proposed 
the synthesis of an NBD derivative with an additional methylene group in the alkyl chain. Hence, 
alkyne 140 was obtained from 3-butyn-1-amine and Cl-NBD in the presence of DIPEA and then 
coupled with bromo derivative 135 to afford NBD-functionalized compound 121 in 77% yield 
(Scheme 12). 
 
Scheme 11. Reagents and conditions: (a) Et3N, MeCN, rt, 2 h, 35%; (b) Pd(PPh3)4, CuI, Et3N, DMF, MW, 100 
ºC, 1 h. 
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Scheme 12. Reagents and conditions: (a) DIPEA, MeOH, rt, 15 h, 77%; (b) Pd(PPh3)4, CuI, Et3N, DMF, MW, 
100 ºC, 1 h, 41%. 
To study the influence of a more flexible chain, alkyne 137 was hydrogenated to afford aliphatic 
amide 141 in the presence of Raney-Ni as a catalyst. It is noteworthy that although the 
hydrogenation took place in low yield (22%), this catalyst allowed us to obtain the desired product 
141 since the use of palladium promotes the cleavage of the molecule through the pseudobencylic 
position to yield the corresponding hydroxybenzamide. Finally, coupling of the deprotected amine 
142 with dansyl chloride afforded the desired product 122 (Scheme 13). 
Scheme 13. Reagents and conditions: (a) H2, Ra-Ni, THF/MeOH, rt, 3 h, 22%; (b) NH4OH, MeOH, rt, 17 h, 
99%; (c) Et3N, DCM/DMF, rt, 24 h, 26%. 
With respect to derivatives 123-125, in which the heterocyclic subunit of PC was replaced by a 
fluorescent tag, an ethyl chain was chosen as spacer between the benzamide moiety and the 
fluorophore. These new probes were synthesized by reaction of the corresponding alkyl amine and 
the fluorophores. Thus, Mitsunobu reaction of phenol 127 with hydroxyethylphthalimide followed by 
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removal of the protecting group with hydrazine afforded amine 144, which was further treated with 
the different fluorophores to give fluorescent derivatives 123-125 (Scheme 14).  
 
Scheme 14. Reagents and conditions: (a) N-(2-hydroxyethyl)phthalimide, DEAD, Ph3P, THF, reflux, 24 h, 
67%; (b) N2H4·H2O, EtOH, reflux, 2 h, 67%; (c) Et3N, DCM/DMF, rt, 24 h, 8%; (d) PyBroP®, DIPEA, DMF, rt, 4 
h, 27%; (e) Et3N, DMF, rt, 20 h, 13%. 
Once all fluorescent compounds were synthesized, we assessed their fluorescent properties in 
order to evaluate their potential as chemical probes. In theory, a good candidate for a FtsZ 
fluorescent probe based on PC190723 should show a significant modification in the emission 
fluorescence spectrum [wavelength (λ) and/or emission intensity (Iem)] or in the fluorescence 
anisotropy values (r) in the presence of the protein, that could be then restored to the initial values 
by displacement with the parent compound PC190723. Therefore, fluorescence emission spectra 
and anisotropy of compounds 119-125 (10 µM) were first registered employing an excitation 
wavelength corresponding to the maximum absortion of each compound in Hepes buffer at pH 6.8 
and 25 ºC. Then, Bs-FtsZ (10 µM) in Hepes buffer, the slowly hydrolizable GTP analogue GMPCPP 
(0.1 mM) and MgCl2 (10 mM) were subsequently added to set up the polymerization conditions. 
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Finally, PC190723 or 8j (10 µM) was added in order to displace and revert the possible effect of the 
fluorescent probes.  
In general, fluorescence emission spectra of these probes did not show significant changes 
under FtsZ polymerization conditions as it is exemplified in Figure 28 for compound 125. 
wavelength (nm)
500 550 600 650 700 750
fl
u
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
u
)
0.0
5.0e+6
1.0e+7
1.5e+7
01+buffer 
01+buffer+BsZ
01+buffer+BsZ+GMPCPP
01+buffer+BsZ+GMPCPP+MgCl2
01+buffer+BsZ+GMPCPP+MgCl2+PC
01+buffer+BsZ+GMPCPP+MgCl2+8J
125 + Buf fer
125 + Buf fer  BsFtsZ
125 + Buf fer  BsFtsZ + GMPCPP
125 + Buf fer  BsFtsZ + GMPCPP + MgCl2
125 + Buf fer  BsFtsZ + GMPCPP + MgCl2 + PC
125 + Buf fer  BsFtsZ + GMPCPP + MgCl2 + 8j
F
lu
o
re
s
c
e
n
c
e
in
te
n
s
it
y
(a
.u
.)
 
Figure 28. Emission spectra of compound 125 at λexc = 474 nm. 
Regarding the anisotropy values, derivatives 119 and 120 did not undergo any significant 
variation after addition of the protein, nucleotide and MgCl2, when compared with their basal values 
[e.g. 119 (alone): r = 0.083 vs 119 (under FtsZ polymerization): r = 0.084) (Table 7). Compounds 
121 and 122 presented a high basal anisotropy which suggests the aggretation of these 
compounds in buffer solution (Table 7) [e.g. 121: r = 0.130 vs 122: r = 0.154]. 
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Table 7. Anisotropy (r) values of fluorescent derivatives 119-122. 
 
Conditions 119 120 121 122 
Compound (10 µM) 0.083 0.017 0.130 0.154 
+ Bs-FtsZ (10 µM) 0.085 0.017 0.203 0.164 
+ GMPCPP (0.1 mM) 0.086 0.016 0.246 0.171 
+ MgCl2 (10 mM) 0.084 0.022 0.248 0.188 
+ PC190723 (10 µM) 0.079 0.032 0.328 0.158 
The fluorescent assays of compounds 123-125, in which the heteroaromatic subunit of PC/8j 
was replaced by a fluorophore, showed no significant changes in their emission spectra under 
polymerization conditions. However, fluorescence anisotropy of NBD derivative 125 was increased 
when MgCl2 was added (highlighted in red in Table 8) and the polymerization was initiated (basal: r 
= 0.035; polymerization: r = 0.086). This effect was reverted after addition of PC190723 (r = 0.036, 
highlighted in blue), which indicates that this fluorescent compound binds to the protein at the same 
binding site that its parent compound (Table 8). In addition, anisotropy changes were not observed 
in control experiments without protein, confirming that the specific binding of the compound to FtsZ 
is responsible for the changes in anisotropy. 
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Table 8. Anisotropy values (r) of fluorescent derivatives 123-125. 
 
 123 124 125 
Compound (10 µM) 0.012 0.125 0.026 
+ Bs-FtsZ (10 µM) 0.036 0.133 0.034 
+ GMPCPP (0.1 mM) 0.049 0.139 0.035 
+ MgCl2 (10 mM) 0.115 0.149 0.086  
+ PC190723 (10 µM) 0.151 0.106 0.036 
Compound + GMPCPP 0.012 0.100 0.026 
Compound + MgCl2 0.036 0.120 0.034 
Compound + PC190723 0.049 0.110 0.035 
Mixture without Bs-FtsZ 0.115 0.140 0.038 
Taking into account the positive results obtained with derivative 125, we selected this compound 
to study the influence of the spacer between the difluorobenzamide and the fluorophore by 
increasing the length of the alkyl chain (145-147). Moreover, bearing in mind that 2,6-difluoro-3-
nonyloxybenzamide is a potent inhibitor of FtsZ,
69
 we considered that the introduction of an 
aliphatic chain in the spacer of 125 could increase FtsZ affinity. Thus, compound 148, having an 
octyl chain in the linker, was also synthesized. 
At this point, fluorophores for super-resolution microscopy such as 4-(and-5)-
carboxytetramethylrhodamine (TAMRA) and ATTO 565 were also taken into account.
88
 Super-
resolution imaging with available small organic fluorophores remains challenging. New fluorescent 
probes bearing photoswichable fluorophores with high intensity contrast between on and off states, 
together with high extinction coefficients and quantum yields are needed to visualize dynamic 
processes in living cells. In this sense, we conceived the synthesis of compounds based on PC/8j 
(149-150) functionalized with TAMRA and ATTO 565 in order to obtain probes with optimized 
fluorescent properties for the study of the bacterial division process (Figure 29). 
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Figure 29. Design of new fluorescent probes 145-150 based on compound 125. 
Regarding the spacer modifications of 125, Williamson alkylation of phenol 127 with different N-
protected bromo aliphatic alkylamines afforded derivatives 151, 152 and 155. These intermediate 
amines were deprotected and coupled with Cl-NBD to afford the desired final compounds 145-147 
(Scheme 15). 
 
Scheme 15. Reagents and conditions: (a) N-(3-bromopropyl)-, N-(4-bromobutyl)phthalimide, or 6-bromo-N-
Boc-1-hexanamine, K2CO3, NaI, DMF, rt, 16 h, 57-87%; (b) N2H4·H2O, EtOH, reflux, 2 h, 55-64%; (c) Cl-NBD, 
DIPEA, DMF, rt, 16 h, 4-11%; (d) TFA, DCM, rt, 1 h, 99%. 
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For the synthesis of 148, dibromoderivative 157 was obtained by treatment of tert-butyl 
carbamate with bromine in the presence of potassium carbonate at room temperature (Scheme 
16).
89
 Then, addition of 157 to 1-decene in an anti-Markovnikov fashion, followed by reduction with 
aqueous Na2SO3 afforded the desired bromo intermediate 158. Finally, Williamson alkylation of 
phenol 127 with 158, subsequent Boc removal and reaction of the resulting amine 160 with Cl-NBD 
gave final compound 148. 
 
Scheme 16. Reagents and conditions: (a) Br2, K2CO3, H2O, rt, 2 h, 79%; (b) i) 1-decene, DCM, reflux, 3 h; ii) 
12% aq. Na2SO3, 5-10 ºC, 15 min, 56%; (c) K2CO3, NaI, DMF, rt, 16 h, 23%; (d) TFA, DCM, rt, 1 h, 99%; (e) 
Cl-NBD, Et3N, DMF, rt, 16 h, 11%. 
The TAMRA and ATTO 565 fluorescent derivatives 149 and 150 were synthesized by reaction 
of amine 144 with the N-hydroxysuccinimide (NHS) esters of the corresponding fluorophore under 
basic conditions (Scheme 17). 
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Scheme 17. Reagents and conditions: (a) Et3N, DMF, rt, 4 h, 66, 99%. 
Finally, methylamino-NBD 161 was considered as a negative control in order to discard possible 
interactions of the fluorophore with FtsZ. This compound was synthesized by reaction of 
methylamine hydrochloride with Cl-NBD in MeOH (Scheme 18).
90
 
 
Scheme 18. Reagents and conditions: (a) i) CH3NH2·HCl, MeOH, 75 ºC, 30 min; ii) 0.75 M aq. NaHCO3, 0 ºC, 
1 h, 66%. 
In order to evaluate these new synthesized fluorescent derivatives 145-150, fluorescence 
emission spectra and anisotropy spectra were registered in the previously described experimental 
conditions. Once again, there were no significant fluorescence changes in the emission spectra (λ, 
Iem) of the analized compounds under polymerization conditions. However, anisotropy of NBD 
derivatives 145-147 was increased in the presence of FtsZ, the nucleotide and MgCl2, and the initial 
values were restored by displacement with inhibitor PC190723 (Table 9, 125 was included for 
comparison). In the case of probe 148, it showed the highest increase in the anisotropy under 
polymerization conditions but this value was not reverted when PC190723 was added. This last 
result suggests that this compound could be aggregated in the presence of the protein due to the 
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long hydrophobic chain or might exhibit a high affinity binding, and therefore it was not considered 
as a useful fluorescent probe for a FtsZ displacement assay. Regarding TAMRA and ATTO-565 
derivatives 149 and 150, no anisotropy changes were observed under polymerization conditions. 
Finally, as it was expected, control compound 161 did not exhibit any change in the fluorescence 
emission spectrum nor in anisotropy and could be used as a negative control. 
Table 9. Anisotropy values (r) of fluorescent derivatives 125, 145-150 and 161. 
 
 125 145 146 147 148 149 150 161 
Compound (10 µM) 0.026 0.038 0.032 0.030 0.045 0.030 0.019 0.014 
+ Bs-FtsZ (10 µM) 0.034 0.042 0.035 0.042 0.130 0.031 0.025 0.016 
+ GMPCPP (0.1 mM) 0.035 0.040 0.039 0.042 0.186 0.030 0.022 0.017 
+ MgCl2 (10 mM) 0.086 0.078 0.078 0.127 0.317 0.032 0.025 0.017 
+ PC190723 (10 µM) 0.036 0.057 0.046 0.067 0.324 0.030 0.023 0.019 
+ PC190723* 0.026 0.046 0.032 0.046 0.322 0.030 0.019 - 
Compound + GMPCPP 0.034 0.038 0.028 0.038 0.053 0.029 0.019 - 
Compound + MgCl2 0.035 0.033 0.027 0.033 0.054 0.030 0.020 - 
Compound + PC190723 0.038 0.032 0.028 0.032 0.052 0.030 0.020 - 
Mixture without Bs-FtsZ 0.026 0.035 0.027 0.035 0.052 - - - 
* Additional 10 µM of PC190723 was added. Final concentration of 20 µM. 
In summary, NBD derivatives 125, 145-147 stand out as useful fluorescent probes since they 
showed significant changes in the anisotropy values under FtsZ polymerization conditions. 
Therefore, they were selected for further biological evaluation. 
2.2.2. Biological Evaluation of Selected Fluorescent Compounds 
First, the effect of the new synthesized probes 125, 145-147 in the FtsZ polymerization process 
was determined by polymer pelleting assay, showing that these derivatives alter the FtsZ 
polymerization in a concentration depending manner. Compounds 125, 145 and 146 act as FtsZ 
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stabilizing agents like their parent compound PC190723, increasing the pellet percentage with 
respect to the control. This stabilizing effect is exemplified in Figure 30 for compounds 125 and 146. 
Contrary, derivative 147, in which the alkyl chain was elongated to six methylene units, reduces 
the pellet percentage of FtsZ with respect to the control, acting as an inhibitor of the polymerization 
instead of stabilizing the protofilaments. Polymer pelleting assay also showed that derivative 148 
was able to stabilize FtsZ polymers at lower concentrations than derivative 125. As it is shown in 
Figure 30, compound 148 increased the polymer concentration up to 91% at 10 µM whereas 
derivative 125 only exhibited 77% of pellet at the same concentration. 
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Figure 30. Polymer pelleting assays in the presence of 125, 146-148. 
Therefore, the best candidates to be used as fluorescent probes to set up a displacement 
binding assay against the PC-binding site would be the NBD derivatives 125 and 145-147. In order 
to evaluate the potential of these probes, displacement anisotropy curves were performed. Starting 
from a solution of polymerized FtsZ (5 µM) in the presence of GMPCPP (0.1 mM), MgCl2 (10 mM) 
and the corresponding fluorescent probe (5 µM), increasing concentrations of the inhibitor 
PC190723 were subsequently added until the anisotropy recovered the basal value of the free 
compound (Figure 31). As it is shown in the graph, anisotropy values decreased with the increasing 
concentrations of PC190723 in all cases, confirming the suitability of these NBD derivatives as 
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fluorescent probes. Although the biggest difference between the bound and unbound state was 
observed with derivative 147, this inhibitor had shown a different phenotytic pattern in the polymer 
pelleting assay. In addition, compound 145 exibited the lower anisotropy difference between the 
bound and unbound state. Therefore, derivatives 125 and 146 were selected to carry out a 
fluorescence-based displacement assay to screen a library of already described FtsZ inhibitors that 
do not target the GTP-binding site and a series of hits from a commercial library that has already 
been docked to the PC-binding pocket. This assay is currently on going in the laboratory and it will 
allow the assessment of the binding constants for the PC-binding site and therefore the possibility 
of performing an HTS in order to identify new FtsZ inhibitors targeting this allosteric binding site. 
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Figure 31. Displacement curves of fluorescent probes 125 and 145-147 by PC190723. 
Finally, in order to confirm whether selected fluorescent probes would enable the visualization of 
FtsZ in cells, allowing the monitorization of the division process, we carried out in vivo studies of the 
probes at different concentrations with B. subtilis cells. Interestingly, probes 125 and 145-147 at 
concentrations lower than 50 µM were able to stain FtsZ protein in B. subtilis without affecting 
bacterial cell division process (Figure 32A). The fluorescence disappears by addition of PC190723 
(25 µM) and consequent displacement of the fluorescent probes, which demonstrates the specificity 
of the staining (Figure 32B). Moreover, at higher concentration (200 µM) the probes enabled not 
only to label the cells but also to alter FtsZ polymerization (Figure 32C). As a negative control, 
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fluorescence was not observed with NBD derivative 161 and cells were not affected by this 
compound. 
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Figure 32. In vivo studies of fluorescent probes 125 and 145-147 in B. subtilis. (A) Labeling of FtsZ with the 
probes at 50 µM and visualization by fluorescent microscopy. (B) To assess specificity, cells were labeled 
under previous conditions and PC190723 (25 µM) was then added. (C) Fluorescent filamentous cells were 
observed at 200 µM of compound. 
In summary, in the second part of this project we have developed the fluorescent probes 125, 
and 145-147 which represent, to the best of our knowledge, the first probes targeting the new 
binding site identified for PC190723. These compounds can be used depending on their 
concentration for the visualization of the bacterial cell division and to study the role of FtsZ in this 
process, or as biological tools for the screening and identification of new hits for the PC-binding 
site, which will allow the discovery of new allosteric inhibitors of FtsZ.  
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3. CONCLUSIONS 
 
The present work was aimed at the search of small molecules targeting FtsZ protein as 
antibacterial agents. To achieve this goal our efforts have being focused on the two druggable 
binding sites identified for the protein: i) the orthosteric GTP-binding pocket and ii) the allosteric PC-
binding site.  
Concerning the GTP-binding site, we have developed a series of compounds able to replace the 
natural regulator GTP and to specifically inhibit FtsZ. These inhibitors perturb protein assembly and 
block bacterial cytokinesis. Furthermore, they display high antibacterial activity against multidrug-
resistant Gram-positive pathogenic bacteria. Among them, biphenyl 40 stands out as the most 
promising FtsZ inhibitor, with good affinity (Kd = 0.5 µM) and antibacterial activity [MIC (MRSA) = 7 
μM], and selectivity against tubulin. This compound together with 29, 45, and 48, acts as an 
effective FtsZ assembly modifier and leads to filamentous undivided cells, finally disrupting bacterial 
viability. 
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Regarding the PC-binding site, we have developed the first fluorescent derivatives of PC190723 
as chemical probes for the study of FtsZ. Among synthesized compounds, NBD derivatives 125, 
145-147 have been used to set up a fluorescence-based displacement assay that will allow the 
identification of new allosteric inhibitors of FtsZ. These compounds have demonstrated to be 
valuable tools for the in vivo labeling of FtsZ. 
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Overall, the new non-nucleotide GTP-replacing compounds synthesized in this work contribute 
to expand the scarce number of GTP mimetics available and provide a compelling rationale for the 
development of antibacterial agents with novel modes of action. Moreover, we described the first 
small molecule fluorescent probes for the visualization of the Z-ring targeting the allosteric PC-
binding site. These probes should provide key insights towards the understanding of the role of 
FtsZ in the bacterial division process. 
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4.  EXPERIMENTAL PART 
4.1. Chemistry 
Unless stated otherwise, starting materials, reagents and solvents were purchased as high-
grade commercial products from Sigma-Aldrich, ABCR, Acros, Lancaster, Invitrogen, ATTO-TEC or 
Scharlab and were used without further purification. Tetrahydrofuran (THF) and dichloromethane 
(DCM) were either distilled from sodium benzophenone ketyl and calcium hydride respectively, or 
dried using a Pure Solv
TM
 Micro 100 Liter solvent purification system. Triethylamine and pyridine 
were dried over potassium hydroxide and distilled before using. Analitical thin-layer 
chromatography (TLC) was run on Merck silica gel plates (Kieselgel 60 F-254) with detection by UV 
light (254 nm), ninhydrin solution, or 10% phosphomolybdic acid solution in EtOH. Flash 
chromatography was performed on a Varian 971-FP flash purification system using silica gel 
cartridges (Varian, particle size 50 μm). All compounds were obtained as oils, except for those 
whose melting points (mp) are indicated, which were solids. Mp (uncorrected) were determined on 
a Stuart Scientific electrothermal apparatus. Infrared (IR) spectra were measured on a Shimadzu-
8300 or Bruker Tensor 27 instrument equipped with a Specac ATR accessory of 5200-650 cm
-1
 
transmission range; frequencies (ν) are expressed in cm
-1
. Nuclear magnetic resonance (NMR) 
spectra were recorded on a Bruker Avance III 700 MHz (
1
H, 700 MHz; 
13
C, 175 MHz), Bruker 
Avance 500 MHz (
1
H, 500 MHz; 
13
C, 125 MHz) or Bruker DPX 300 MHz (
1
H, 300 MHz; 
13
C, 75 
MHz) instrument at room temperature at the Universidad Complutense de Madrid (UCM) NMR core 
facility. Chemical shifts (δ) are expressed in parts per million relative to internal tetramethylsilane; 
coupling constants (J) are in hertz (Hz). The following abbreviations are used to describe peak 
patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintet), m (multiplet), br 
(broad), app (apparent). 2D NMR experiments (heteronuclear multiple quantum correlation [HMQC] 
and heteronuclear multiple bond correlation [HMBC]) of representative compounds were carried out 
to assign protons and carbons of the new structures and the following abbreviations have been 
used for the peak assignment: gal. (gallic acid), eud. (eudesmic acid), prot. (protocatechuic acid), α-
res. (α-resorcylic acid), m-sal. (m-salicylic acid), p-sal. (p-salicylic acid), Clbenz. (3-chloro-4-
hydroxybenzoic acid), Cl2benz. (3,4-dichlorobenzoic acid), naph. (naphthalene), biph. (biphenyl), 
coum. (coumarin), DS (dansyl), NBD (nitrobenzoxadiazole) and pht. (phthalimide) (see Figure 33). 
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Mass spectrometry (MS) was carried out on a Bruker LC-Esquire spectrometer in electrospray 
ionization (ESI) mode at the UCM’s mass spectrometry core faciliy. High performance liquid 
chromatography coupled to mass spectrometry (HPLC-MS) analysis was performed using an 
Agilent 1200LC-MSD VL instrument. LC separation was achieved with an Zorbax Eclipse XDB-C18 
column (5 µm, 4.6 mm x 150 mm) for naphthalene derivatives and a Zorbax SB-C3 column (5 µm, 
2.1 mm x 50 mm) for biphenyl derivatives, both together with a guard column (5 µm, 4.6 mm x 12.5 
mm). The gradient mobile phases consisted of A (95:5 water/MeOH) and B (5:95 water/MeOH) with 
0.1% ammonium hydroxide and 0.1% formic acid as the solvent modifiers. MS analysis was 
performed with an ESI source. The capillary voltage was set to 3.0 kV and the fragmentor voltage 
was set at 72 eV. The drying gas temperature was 350 ºC, the drying gas flow was 10 L/min, and 
the nebulizer pressure was 20 psi. Spectra were acquired in positive or negative ionization mode 
from 100 to 1200 m/z and in UV-mode at four different wavelengths (210, 230, 254, and 280 nm). 
Elemental analyses (C, H, N, S) were obtained on a LECO CHNS-932 apparatus at the UCM and 
the Universidad Autónoma de Madrid analysis services and were within ±0.5% of the theoretical 
values, confirming a purity of at least 95% of all tested compounds.  
 
Figure 33. Common names used for the peak assignment. 
4.1.1. Synthesis of Intermediates 51a-f, 52a-h, and 97 
General Procedure for the Synthesis of Carboxylic Acids 51a-f. Method A: A mixture of 
the corresponding carboxylic acid (1 equiv), imidazole (2.4 equiv/hydroxy group) and tert-
butyldimethylsilyl (TBS) chloride (1.4 equiv/hydroxy group) was dissolved in anhydrous DMF (3.4 
mL/mmol acid) under an argon atmosphere. The reaction mixture was stirred overnight at room 
temperature. Method B: A mixture of the corresponding carboxylic acid (1 equiv), DIPEA (3 equiv), 
and TBS-Cl (1.4 equiv/hydroxy group) was dissolved in anhydrous DMF (2.0 mL/mmol acid) under 
an argon atmosphere. The reaction mixture was heated in the microwave at 100 ºC for 20 min.  
For both methods, a 1 M aqueous solution of H3PO4 was added to the reaction mixture and it 
was extracted with hexane. The organic layer was washed with saturated aqueous solutions of 
NaHCO3 and NaCl, dried (Na2SO4) and the solvent was evaporated under reduced pressure. The 
residue was dried under high vacuum to obtain the corresponding silyl esters as colourless oils 
which were used in the next step without further purification.  
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Silyl esters were treated with water (3.0 mL/mmol), AcOH (9.0 mL/mmol) and THF (6.0 
mL/mmol) and stirred for 3 h at room temperature. The reaction mixture was extracted with DCM, 
and the organic phase was washed with water and saturated aqueous solutions of NaHCO3 and 
NaCl, and dried (Na2SO4). The solvent was evaporated under reduced pressure. The resulting oil 
was purified by chromatography using DCM as eluent to afford pure 51a-f. 
 
3,4,5-Tris{[tert-butyl(dimethyl)silyl]oxy}benzoic acid (51a). Obtained from galic acid (3.0 g, 
18 mmol) by method A in 84% yield. mp 238-239 ºC (Lit.
91
 223-224 C); IR (ATR)  3461 (OH), 
1697 (C=O), 1575 (Ar), 1078 (C-O); 
1
H NMR (300 MHz, CDCl3)  0.17 (s, 6H, (CH3)2Si), 0.27 (s, 
12H, 2(CH3)2Si), 0.97 (s, 18H, 2(CH3)3CSi), 1.02 (s, 9H, (CH3)3CSi), 7.31 (s, 2H, H2, H6); 
13
C NMR 
(75 MHz, CDCl3)  −3.8 ((CH3)2Si), −3.5 (2(CH3)2Si), 17.8 ((CH3)3CSi), 18.0 (2(CH3)3CSi), 26.2 
(3(CH3)3CSi), 116.2 (C2H, C6H), 121.2 (C1), 144.2 (C-O), 148.2 (2C-O), 172.2 (C=O). The 
spectroscopic data are in agreement with those previously described.
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3,4-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoic acid (51b). Obtained from protocatechuic 
acid (4.0 g, 26 mmol) by method B in 81% yield. mp 154-157 ºC; IR (ATR)  1690 (C=O), 1598 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.23 (s, 6H, (CH3)2Si), 0.24 (s, 6H, (CH3)2Si), 0.99 (s, 9H, (CH3)3CSi), 
1.00 (s, 9H, (CH3)3CSi), 6.87 (d, J = 8.3, 1H, H5), 7.57 (d, J = 2.0, 1H, H2), 7.61 (dd, J = 8.3, 2.2, 
1H, H6); 
13
C NMR (75 MHz, CDCl3)  −4.1, −4.0 (2(CH3)2Si), 18.5 (2(CH3)3CSi), 25.9 (2(CH3)3CSi), 
120.6, 122.5 (2CH), 122.8 (C1), 124.5 (CH), 146.8, 152.5 (2C-O), 172.0 (C=O); ESI-MS 406.1 
(M+Na)
+
. 
 
 
Experimental part 
- 78 - 
 
3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoic acid (51c). Obtained from α-resorcilic acid 
(2.1 g, 14 mmol) by method A in 76% yield. mp 188-192 ºC; IR (ATR)  1692 (C=O), 1593 (Ar), 
1171 (C-O); 
1
H NMR (300 MHz, CDCl3)  0.25 (s, 12H, 2(CH3)2Si), 1.01 (s, 18H, 2(CH3)3CSi), 6.63 
(d, J = 2.3, 1H, H4), 7.17 (d, J = 2.3, 2H, H2, H6); 
13
C NMR (75 MHz, CDCl3)  −4.3 (2(CH3)2Si), 18.8 
(2(CH3)3CSi), 25.9 (2(CH3)3CSi), 115.4 (C2H, C6H), 114.4 (C4H), 133.4 (C1), 157.5 (2C-O), 167.1 
(C=O). The spectroscopic data are in agreement with those previously described.
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3-{[tert-Butyl(dimethyl)silyl]oxy}benzoic acid (51d). Obtained from m-salicylic acid (3.0 g, 
22 mmol) by method B in 67% yield. mp 96-97 ºC; IR (ATR)  1685 (CO), 1581, 1471 (Ar); 
1
H NMR 
(300 MHz, CDCl3)  0.22 (s, 6H, (CH3)2Si), 1.00 (s, 9H, (CH3)3CSi), 7.09 (ddd, J = 8.1, 2.6, 1.1 Hz, 
1H, H4), 7.33 (t, J = 7.9 Hz, 1H, H5), 7.57 (dd, J = 2.5, 1.5 Hz, 1H, H2), 7.72 (dt , J = 7.8, 1.3 Hz, 1H, 
H6); 
13
C NMR (75 MHz, CDCl3)  −4.3 ((CH3)2Si), 18.4 ((CH3)3CSi), 25.8 ((CH3)3CSi), 121.6, 123.4, 
125.9, 129.7 (4CH), 130.7 (C1), 155.9 (C-O), 172.1 (C=O); ESI-MS 250.8 (M−H)
−
. The 
spectroscopic data are in agreement with those previously described.
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4-{[tert-Butyl(dimethyl)silyl]oxy}benzoic acid (51e). Obtained from p-salicylic acid (3.0 g, 
22 mmol) by method B in 74% yield. mp 108-111 ºC; IR (ATR)  1675 (C=O), 1597, 1510, 1422 
(Ar); 
1
H NMR (300 MHz, CDCl3)  0.24 (s, 6H, (CH3)2Si), 0.99 (s, 9H, (CH3)3CSi), 6.89 (d, J = 8.7 
Hz, 2H, H3, H5), 8.02 (d, J = 8.7 Hz, 2H, H2, H6); 
13
C NMR (75 MHz, CDCl3)  −4.2 ((CH3)2Si), 18.4 
((CH3)3CSi), 25.7 ((CH3)3CSi), 120.1 (C3H, C5H), 122.4 (C1), 132.5 (C2H, C6H), 161.0 (C-O), 172.2 
(C=O); ESI-MS 250.8 (M−H)
−
. The spectroscopic data are in agreement with those previously 
described.
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4-{[tert-Butyl(dimethyl)silyl]oxy}-3-chlorobenzoic acid (51f). Obtained from 3-chloro-4-
hydroxybenzoic acid (5.0 g, 29 mmol) by method A in 74% yield. mp 106-107 ºC; IR (ATR)  1693 
(C=O), 1596 (Ar); 
1
H NMR (300 MHz, CDCl3) 0.27 (s, 6H, (CH3)2Si), 1.04 (s, 9H, (CH3)3CSi), 6.93 
(d, J = 8.5, 1H, H5), 7.90 (dd, J = 8.5, 2.2, 1H, H6), 8.13 (d, J = 2.1, 1H, H2); 
13
C NMR (75 MHz, 
CDCl3)  −4.2 ((CH3)2Si), 18.5 ((CH3)3CSi), 25.7 ((CH3)3CSi), 120.3 (CH), 123.2, 126.1 (C1,C3), 
130.3, 132.8 (2CH), 156.8 (C-O), 170.9 (C=O); ESI-MS 309.0 (M+Na)
+
. 
General Procedure for the Synthesis of Acid Chlorides 52a-h. To a solution of the 
corresponding carboxylic acid 51a-f, commercial 3,4-dichlorobenzoic acid or 3,4,5-
trimethoxybenzoic acid (1 equiv) and a catalytic amount of anhydrous DMF in dry toluene (1 
mL/mmol) under an argon atmosphere, oxalyl chloride (1.5 equiv) was added dropwise. The 
reaction mixture was stirred at 50 ºC for 1 h. Once at room temperature, the mixture was decanted 
and the solvent was evaporated under reduced pressure to afford the corresponding acid chloride 
in quantitative yield as a solid that was used in the next step without further purification. 
The following acid chlorides were synthesized: 
3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy}benzoyl chloride (52a) 
3,4-bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl chloride (52b) 
3,5-bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl chloride (52c) 
3-{[tert-butyl(dimethyl)silyl]oxy}benzoyl chloride (52d) 
4-{[tert-butyl(dimethyl)silyl]oxy}benzoyl chloride (52e) 
4-{[tert-butyl(dimethyl)silyl]oxy}-3-chlorobenzoyl chloride (52f) 
3,4-dichlorobenzoyl chloride (52g) 
3,4,5-trimethoxybenzoyl chloride (52h) 
 
Biphenyl-3,5-diol (97). The reaction was performed in batches of 500 mg of starting material. 
A suspension of 3,5-dimethoxyphenylbromide (500 mg, 2.3 mmol), phenylboronic acid (337 mg, 2.8 
mmol), Na2CO3 (732 mg, 6.9 mmol) and Pd(PPh3)4 (133 mg, 0.12 mmol) in a 5:3 mixture of toluene 
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and water (16 mL) under an argon atmosphere was heated at 150 ºC in the microwave for 30 min. 
Afterward, the reaction mixture was extracted with ethyl acetate and the organic phase was dried 
(Na2SO4) and concentrated under reduced pressure. The crude was purified by chromatography 
(from hexane to DCM) to afford 3,5-dimethoxybiphenyl in 75% yield, which was used in the next 
step without further purification. Rf (hexane/DCM, 1:1) 0.57; mp 62-64 ºC; IR (ATR)  1598, 1462 
(Ar).; 
1
H NMR (300 MHz, CDCl3)  3.75 (s, 6H, 2CH3O), 6.39 (t, J = 2.3 Hz ,1H, H4), 6.65 (d, J = 2.3 
Hz, 2H, H2, H6), 7.26 (t, J = 7.2 Hz, 1H, H4’), 7.30-7.37 (m, 2H, H3’, H5’), 7.47-7.51 (m, 2H, H2’, H6’); 
13
C NMR (75 MHz, CDCl3)  55.5 (2CH3), 99.4 (C4H), 105.6 (C2H, C6H), 127.3 (C2’H, C6’H), 127.7 
(C4’H), 128.8 (C3’H, C5’H), 141.3, 143.6 (2Cbiph.), 161.2 (2C-OH); ESI-MS 215.1 (M+H)
+
. 
3,5-Dimethoxybiphenyl (730 mg, 3.1 mmol) was dissolved in anhydrous DCM (14 mL) under 
an argon atmosphere and BBr3 (0.8 mL, 8.2 mmol) was added dropwise at -20 ºC. The mixture was 
then warmed up to room temperature and stirred overnight. Then, the reaction was quenched with 
1 M HCl (0.8 mL) at 0 ºC and extracted with ethyl acetate (3 x 10 mL). The organic layers were 
dried (Na2SO4) and concentrated under reduced pressure, and the crude was purified by 
chromatography (from DCM to DCM/MeOH, 95:5) to afford intermediate 97 in 97% yield. Rf 
(DCM/MeOH, 98:2) 0.41; mp 157-159 ºC; IR (ATR)  3379 (OH), 1609, 1481, 1434 (Ar); 
1
H NMR 
(300 MHz, acetone-d6)  6.28 (t, J = 2.2, 1H, H4), 6.53 (d, J = 2.2, 2H, H2, H6), 7.23 (t, J = 7.2, 1H, 
H4’), 7.29-7.35 (m, 2H, H3’, H5’), 7.44-7.49 (m, 2H, H2’, H6’), 8.27 (br s, 2H, 2OH); 
13
C NMR (75 MHz, 
acetone-d6)  102.6 (C4H), 106.4 (C2H, C6H), 127.6 (C2’H, C6’H), 128.2 (C4’H), 129.6 (C3’H, C5’H), 
142.1, 144.1 (2Cbiph.), 159.8 (2C-OH); ESI-MS 187.1 (M+H)
+
. 
4.1.2 Synthesis of 1-32 and 37-46 
General Procedure for the Synthesis of Final Compound 3 and Protected Diesters 53-58 
and 98-100. To a solution of 1,3-dihydroxynaphthalene or 97 (1 equiv) and triethylamine (4 equiv) 
in anhydrous DCM (10 mL/mmol acid chloride 52) under an argon atmosphere, a solution of the 
corresponding acid chloride 52a-f,h (4 equiv) in anhydrous DCM (2 mL/mmol) was added dropwise 
and the reaction mixture was stirred at room temperature overnight. Then, the mixture was washed 
with a saturated aqueous solution of NaHCO3 and with water. The organic layer was dried 
(Na2SO4) and the solvent was evaporated under reduced pressure. The crude was purified by 
chromatography (from hexane to DCM) to afford final compound 3 or the corresponding diesters 
53-58 and 98-100.  
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Naphthalene-1,3-diyl bis(3,4,5-trimethoxybenzoate) (3). Obtained from 1,3-
dihydroxynaphthalene (87 mg, 0.54 mmol) and acid chloride 52h (500 mg, 2.2 mmol) in 69% yield. 
Rf (DCM) 0.20; mp 139-140 ºC; IR (ATR)  1735 (C=O), 1590, 1503, 1460 (Ar); 
1
H NMR (300 MHz, 
CDCl3)  3.96 (s, 6H, 2CH3), 3.97 (s, 3H, CH3), 3.98 (s, 6H, 2CH3), 3.99 (s, 3H, CH3), 7.34 (d, J = 
2.2, 1H, CHnaph.), 7.48-7.60 (m, 6H, 2CHnaph., 4CHeud.), 7.68 (d, J = 2.0, 1H, CHnaph.), 7.90 (d, J = 7.7, 
1H, CHnaph.), 7.95 (d, J = 8.1, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  56.5 (2CH3), 56.6 (2CH3), 
61.1, 61.2 (2CH3), 107.7 (2CHeud.), 107.8 (2CHeud.), 114.6, 117.2, 121.6 (3CHnaph.), 124.0, 124.3 
(2Ceud.), 125.5 (Cnaph.), 126.5, 127.5, 128.1 (3CHnaph.), 134.6 (Cnaph.), 135.2, 143.2 (2C-Oeud.), 147.7, 
148.1 (2C-Onaph.), 153.3 (2C-Oeud.), 153.4 (2C-Oeud.), 164.7, 164.9 (2C=O); ESI-MS 566.2 (M+NH4)
+
; 
elemental analysis (calcd., found for C30H28O10): C (65.69, 65.40), H, (5.15, 5.12). 
 
Naphthalene-1,3-diyl bis(3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy}benzoate) (53). Obtained 
from 1,3-dihydroxynaphthalene (71 mg, 0.44 mmol) and acid chloride 52a (935 mg, 1.8 mmol) in 
71% yield. Rf (hexane/DCM, 6:4) 0.41; mp 198-200 ºC; IR (ATR)  1740 (C=O), 1577 (Ar), 1088 (C-
O); 
1
H NMR (300 MHz, CDCl3) 0.19 (s, 6H, (CH3)2Si para), 0.21 (s, 6H, 2(CH3)2Si para), 0.28 (s, 
12H, 2(CH3)2Si meta), 0.29 (s, 12H, 2(CH3)2Si meta), 0.98 (s, 18H, 2(CH3)3CSi meta), 0.99 (s, 18H, 
2(CH3)3CSi meta), 1.02 (s, 9H, (CH3)3CSi para), 1.04 (s, 9H, (CH3)3CSi para), 7.40 (d, J = 2.3, 1H, 
CHnaph.), 7.42 (s, 2H, 2CHgal.), 7.45-7.49 (m, 4H, 2CHgal., 2CHnaph.), 7.63 (d, J = 2.0, 1H, CHnaph.), 
7.85-7.90 (m, 1H, CHnaph.), 7.97-8.01 (m, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −3.6 ((CH3)2Si 
para), −3.7 ((CH3)2Si para), −3.7 (4(CH3)2Si meta), 18.5 (2(CH3)3CSi), 18.8 (2(CH3)3CSi), 18.9 
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(2(CH3)3CSi), 26.1 (2(CH3)3CSi para), 26.2 (4(CH3)3CSi meta), 114.4 (CHnaph.), 116.1 (4CHgal.), 
116.6 (CHnaph.), 120.8, 121.0 (2Cgal.), 121.5 (CHnaph.), 125.3 (Cnaph.), 126.0, 127.1, 127.8 (3CHnaph.), 
134.3 (Cnaph.), 144.1, 144.2 (2Cgal.), 147.5, 148.1 (2C-Onaph.), 148.7, 148.8 (4C-Ogal.), 164.4, 164.8 
(2C=O). 
 
Naphthalene-1,3-diyl bis(3,4-bis{[tert-butyl(dimethyl)silyl]oxy}benzoate) (54). Obtained 
from 1,3-dihydroxynaphthalene (58 mg, 0.36 mmol) and acid chloride 52b (520 mg, 1.3 mmol) in 
63% yield. Rf (hexane/DCM, 1:1) 0.56; mp 131-133 ºC; IR (ATR) 1737 (C=O), 1599 (Ar); 
1
H NMR 
(300 MHz, CDCl3) 0.26 (s, 6H, (CH3)2Si), 0.27 (s, 12H, 2(CH3)2Si), 0.28 (s, 6H, (CH3)2Si), 1.02 (s, 
18H, 2(CH3)3CSi), 1.02 (s, 9H, (CH3)3CSi), 1.03 (s, 9H, (CH3)3CSi), 6.96 (d, J = 8.4, 1H, H5), 6.97 
(d, J = 8.4, 1H, H5), 7.36 (d, J = 2.2, 1H, CHnaph.), 7.42-7.60 (m, 2H, 2CHnaph.), 7.64 (d, J = 1.7, 1H, 
H2), 7.70 (d, J = 2.2, 1H, H2), 7.75 (dd, J = 8.4, 2.2, 1H, H6), 7.79 (d, J = 8.4, 1H, H6), 7.81-7.92 (m, 
2H, 2CHnaph.), 7.97 (d, J = 7.7, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −4.1 (2(CH3)2Si), −4.0 
(2(CH3)2Si), 18.5 (2(CH3)3CSi), 18.6 (2(CH3)3CSi), 25.9 (4(CH3)3CSi), 114.5, 116.7 (2CHnaph.), 
120.7, 120.8 (2CHprot.), 121.6 (CHnaph.), 122.1, 122.4 (2Cprot.), 122.8 (2CHprot.), 124.4, 124.6 
(2CHprot.), 125.3 (Cnaph.), 126.1, 127.2, 127.9 (3CHnaph.), 134.4 (Cnaph.), 147.0, 147.1 (2C-Oprot.), 
147.6, 148.1 (2C-Onaph.), 152.5, 152.7 (2C-Oprot.), 164.5, 164.8 (2C=O); ESI-MS 911.5 (M+Na)
+
. 
 
Naphthalene-1,3-diyl bis(3,5-bis{[tert-butyl(dimethyl)silyl]oxy}benzoate) (55). Obtained 
from 1,3-dihydroxynaphthalene (21 mg, 0.13 mmol) and acid chloride 52c (210 mg, 0.52 mmol) in 
55% yield. Rf (hexane/DCM, 1:1) 0.56; mp 131-133 ºC; IR (ATR)  1745 (C=O), 1590 (Ar); 
1
H NMR 
(300 MHz, CDCl3)  0.24 (s, 12H, 2(CH3)2Si), 0.25 (s, 12H, 2(CH3)2Si), 1.00 (s, 18H, 2(CH3)3CSi), 
1.01 (s, 18H, 2(CH3)3CSi), 6.61 (t, J = 2.3, 1H, H4), 6.65 (t, J = 2.3, 1H, H4), 7.31 (d, J = 2.3, 2H, H2, 
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H6), 7.37 (t, J = 2.2, 1H, CHnaph.), 7.40 (d, J = 2.3, 2H, H2, H6), 7.47-7.58 (m, 2H, 2CHnaph.), 7.67 (d, 
J = 2.0, 1H, CHnaph.), 7.88 (d, J = 7.4, 1H, CHnaph.), 7.95 (d, J = 7.8, 1H, CHnaph.); 
13
C NMR (75 MHz, 
CDCl3) –4.0 (4(CH3)2Si), 18.6 (4(CH3)3CSi), 26.1 (4(CH3)3CSi), 114.7 (CHnaph.), 115.5 (2CHα-res.), 
115.6 (2CHα-res.), 117.3, 118.1 (2CHnaph.), 121.9 (2CHα-res.), 125.6 (Cnaph.), 126.6, 127.7, 128.3 
(3CHnaph.), 131.1, 131.3 (2Cα-res.), 134.7 (Cnaph.), 147.8, 148.3 (2C-Onaph.), 157.3 (2C-Oα-res.), 157.8 
(2C-Oα-res.), 164.9, 165.2 (2C=O); ESI-MS 911.4 (M+Na)
+
. 
  
Naphthalene-1,3-diyl bis(3-{[tert-butyl(dimethyl)silyl]oxy}benzoate) (56). Obtained from 
1,3-dihydroxynaphthalene (60 mg, 0.37 mmol) and acid chloride 52d (410 mg, 1.5 mmol) as an oil 
in 61% yield. Rf (hexane/DCM, 2:8) 0.91; IR (ATR)  1744 (C=O), 1593, 1480 (Ar); 
1
H NMR (300 
MHz, CDCl3)  0.26 (s, 6H, (CH3)2Si), 0.27 (s, 6H, (CH3)2Si), 1.01 (s, 9H, (CH3)3CSi), 1.02 (s, 9H, 
(CH3)3CSi), 7.13 (ddd, J = 8.1, 2.5, 0.9, 1H, H4), 7.17 (ddd, J = 8.1, 2.5, 0.9, 1H, H4), 7.39 (d, J = 
1.8, 1H, CHnaph.), 7.40 (t, J = 7.9, 1H, H5), 7.43 (t, J = 7.9, 1H, H5), 7.48-7.59 (m, 2H, 2CHnaph.), 
7.68-7.69 (m, 2H, H2, CHnaph.), 7.77 (app t, J = 2.0, 1H, H2), 7.85 (dt, J = 7.9, 1.3, 1H, H6), 7.89 (d, J 
= 7.5, 1H, CHnaph.), 7.92-7.99 (m, 2H, H6, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −4.2 (2(CH3)2Si), 
18.4 (2(CH3)3CSi), 25.8 (2(CH3)3CSi), 114.5, 117.0 (2CHnaph.), 121.6, 121.7, 121.8 (2CHm-sal., 
CHnaph.), 123.4, 123.5 (2CHm-sal.), 125.4 (Cnaph.), 125.8, 126.0 (2CHm-sal.), 126.4, 127.4, 128.1 
(3CHnaph.), 129.8, 130.0 (2CHm-sal.), 130.6, 130.8 (2Cm-sal.), 134.5 (Cnaph.), 147.6, 148.1 (2C-Onaph.), 
156.1, 156.2 (2C-Om-sal.), 164.7, 165.0 (2C=O); ESI-MS 651.4 (M+Na)
+
. 
 
Naphthalene-1,3-diyl bis(4-{[tert-butyl(dimethyl)silyl]oxy}benzoate) (57). Obtained from 
1,3-dihydroxynaphthalene (67 mg, 0.42 mmol) and acid chloride 52e (450 mg, 1.7 mmol) as an oil 
in 58% yield. Rf (hexane/DCM, 2:8) 0.58; IR (ATR)  1738 (C=O), 1636, 1509 (Ar); 
1
H NMR (300 
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MHz, CDCl3)  0.27 (s, 6H, (CH3)2Si), 0.29 (s, 6H, (CH3)2Si), 1.01 (s, 9H, (CH3)3CSi), 1.02 (s, 9H, 
(CH3)3CSi), 6.95 (d, J = 8.8, 2H, H3, H5), 6.99 (d, J = 8.8, 2H, H3, H5), 7.35 (d, J = 2.2, 1H, CHnaph.), 
7.46-7.56 (m, 2H, 2CHnaph.), 7.65 (d, J = 2.0, 1H, CHnaph.), 7.87 (d, J = 7.4, 1H, CHnaph.), 7.96 (d, J = 
8.0, 1H, CHnaph.), 8.14 (d, J = 8.8, 2H, H2, H6), 8.23 (d, J = 8.8, 2H, H2, H6); 
13
C NMR (75 MHz, 
CDCl3)  −4.2 (2(CH3)2Si), 18.4 (2(CH3)3CSi), 25.8 (2(CH3)3CSi), 114.6, 116.9 (2CHnaph.), 120.3 
(2CHp-sal.), 120.4 (2CHp-sal.), 121.7 (Cp-sal.), 122.1 (CHnaph.), 122.4 (Cp-sal.), 125.4 (Cnaph.), 126.2, 
127.3, 128.0 (3CHnaph.), 132.5 (2CHp-sal.), 132.6 (2CHp-sal.), 134.5 (Cnaph.), 147.7, 148.2 (2C-Onaph.), 
161.0, 161.1 (2C-Op-sal.), 164.7, 164.9 (2C=O); ESI-MS 626.8 (M−H)
−
. 
 
Naphthalene-1,3-diyl bis(4-{[tert-butyl(dimethyl)silyl]oxy}-3-chlorobenzoate) (58). Obtained 
from 1,3-dihydroxynaphthalene (66 mg, 0.41 mmol) and acid chloride 52f (500 mg, 1.6 mmol) in 
54% yield. Rf (hexane/DCM, 1:1) 0.50; mp 69-72 ºC; IR (ATR)  1741 (C=O), 1594, 1500 (Ar); 
1
H 
NMR (300 MHz, CDCl3)  0.30 (s, 6H, (CH3)2Si), 0.32 (s, 6H, (CH3)2Si), 1.06 (s, 9H, (CH3)3CSi), 
1.07 (s, 9H, (CH3)3CSi), 6.99 (d, J = 8.5, 1H, H5), 7.03 (d, J = 8.5, 1H, H5), 7.34 (d, J = 2.1, 1H, 
CHnaph.), 7.47-7.58 (m, 2H, CHnaph.), 7.66 (d, J = 2.2, 1H, CHnaph.), 7.88 (d, J = 7.5, 1H, CHnaph.), 7.94 
(d, J = 8.1, 1H, CHnaph.), 8.03 (dd, J = 8.5, 2.2, 1H, H6), 8.11 (dd, J = 8.5, 2.2, 1H, H6), 8.26 (d, J = 
2.2, 1H, H2), 8.34 (d, J = 2.2, 1H, H2); 
13
C NMR (75 MHz, CDCl3)  −4.2, −4.1 (2(CH3)2Si), 18.5 
(2(CH3)3CSi), 25.7 (2(CH3)3CSi), 114.4, 117.0 (2CHnaph.), 120.4, 120.5 (2CHClbenz.), 121.6 (CHnaph.), 
123.0, 123.3 (2CClbenz.), 125.3 (Cnaph.), 126.3 (2CClbenz.), 126.4, 127.5, 128.1 (3CHnaph.), 130.3, 130.4, 
132.7, 132.8 (4CHClbenz.), 134.5 (Cnaph.), 147.5, 147.9 (2C-Onaph.), 156.7, 156.9 (2C-OClbenz.), 163.7, 
163.9 (2C=O); ESI-MS 580.8 (M−TBS)
−
. 
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Biphenyl-3,5-diyl bis(3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy}benzoate (98). Obtained from 
97 (102 mg, 0.55 mmol) and acid chloride 52a (1.2 g, 2.2 mmol) as an oil in 87% yield. Rf 
(hexane/DCM, 1:1) 0.74; IR (ATR)  1739 (C=O), 1578, 1487, 1428 (Ar); 
1
H NMR (300 MHz, 
CDCl3)  0.17 (s, 12H, 2(CH3)2Si para), 0.26 (s, 24H, 4(CH3)2Si meta), 0.97 (s, 36H, 4(CH3)3CSi 
meta), 1.01 (s, 18H, 2(CH3)3CSi para), 7.11 (t, J = 2.1, 1H, C4H), 7.34 (d, J = 2.1, 2H, H2, H6), 7.36-
7.38 (m, 5H, 4CHgal., H4’), 7.61 (t, J = 7.2, 2H, H3’, H5’), 7.61 (d, J = 6.9, 2H, H2’, H6’); 
13
C NMR (75 
MHz, CDCl3)  −3.7 (2(CH3)2Si para), −3.5 (4(CH3)2Si meta), 18.7 (2(CH3)3CSi para), 19.0 
(4(CH3)3CSi meta), 26.2 (2(CH3)3CSi para), 26.3 (4(CH3)3CSi meta), 114.8 (C4H), 116.3 (4CHgal.), 
118.1 (C2H, C6H), 121.0 (2Cgal.), 127.4 (C2’H, C6’H), 128.1 (C4’H), 129.0 (C3’H, C5’H), 139.7, 143.5 
(2Cbiph.), 144.2 (2C-Obiph.), 148.8 (4C-Ogal.), 152.0 (2C-Ogal.), 164.8 (2C=O); ESI-MS 1198.5 
(M+Na)
+
.
 
 
Biphenyl-3,5-diyl bis(3-{[tert-butyl(dimethyl)silyl]oxy}benzoate) (99). Obtained from 97 (50 
mg, 0.27 mmol) and acid chloride 52d (292 mg, 1.1 mmol) as an oil in 77% yield. Rf (DCM) 0.92; IR 
(ATR)  1743 (CO), 1593, 1482, 1463, 1439 (Ar), 1282 (CO); 
1
H NMR (300 MHz, CDCl3)  0.26 
(s, 12H, 2(CH3)2Si), 1.02 (s, 18H, 2(CH3)3CSi), 7.13 (ddd, J = 8.1, 2.5, 0.9, 2H, 2H4’’), 7.18 (t, J = 
2.1, 1H, H4), 7.36-7.42 (m, 5H, H2, H6, H4’, 2H5’’), 7.45 (t, J = 7.2, 2H, H3’, H5’), 7.63 (d, J = 7.0, 2H, 
H2’, H6’), 7.67 (t, J = 2.0, 2H, 2H2’’), 7.83 (dt, J = 7.8, 1.3, 2H, 2H6’’); 
13
C NMR (75 MHz, CDCl3)  
−4.3 (2(CH3)2Si), 18.4 (2(CH3)3CSi), 25.8 (2(CH3)3CSi), 114.6 (C4H), 118.2 (C2H, C6H), 121.7 
(2CHm-sal.), 123.4 (2CHm-sal.), 125.9 (2CHm-sal.), 127.4 (C2’H, C6’H), 128.2 (C4’H), 129.0 (C3’H, C5’H), 
129.8 (2CHm-sal.), 130.7 (2Cm-sal.), 139.6, 143.7 (2Cbiph.), 151.8 (2C-Obiph.), 156.1 (2C-Om-sal.), 164.8 
(2C=O); ESI-MS 418.9 [M−(C13H19O2Si)]
−
. 
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Biphenyl-3,5-diyl bis(4-{[tert-butyl(dimethyl)silyl]oxy}benzoate) (100). Obtained from 97 
(60 mg, 0.32 mmol) and acid chloride 52e (350 mg, 1.3 mmol) as an oil in 64% yield. Rf 
(hexane/DCM, 6:4) 0.26; IR (ATR)  1732 (C=O), 1601, 1509 (Ar), 1264 (C-O); 
1
H NMR (300 MHz, 
CDCl3)  0.26 (s, 12H, 2(CH3)2Si), 1.01 (s, 18H, 2(CH3)3CSi), 6.93 (d, J = 8.6, 4H, 2H3’’, 2H5’’), 7.13 
(t, J = 2.0, 1H, H4), 7.32-7.49 (m, 5H, H2, H6, H3’, H4’, H5’), 7.61 (d, J = 7.1, 2H, H2’, H6’), 8.11 (d, J = 
8.6, 4H, 2H2’’, 2H6’’); 
13
C NMR (75 MHz, CDCl3)  −4.2 (2(CH3)2Si), 18.4 (2(CH3)3CSi), 25.7 
(2(CH3)3CSi), 114.8 (C4H), 118.1 (C2H, C6H), 120.3 (4CHp-sal.), 122.3 (2Cp-sal.), 127.4 (C2’H, C6’H), 
128.1 (C4’H), 129.0 (C3’H, C5’H), 132.5 (4CHp-sal.), 141.3, 144.0 (2Cbiph.), 151.8 (4C-O), 159.2 
(2C=O); ESI-MS 677.2 (M+Na)
+
.
 
General Procedure for the Synthesis of Protected Monoesters 59-64 and 101-104. To a 
solution of 1,3-dihydroxynaphthalene or 97 (4 equiv) and triethylamine (4 equiv) in anhydrous DCM 
(10 mL/mmol acid chloride 52) under an argon atmosphere, a solution of the corresponding acid 
chloride 52a,c,d (1 equiv) in anhydrous DCM (2 mL/mmol) was added dropwise. The reaction 
mixture was stirred at room temperature overnight. Then, the mixture was washed with a saturated 
aqueous solution of NaHCO3 and with water, the organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. The crude was purified by chromatography (from hexane to 
DCM) to afford the corresponding monoesters 59-64 or 101-104. 
3-Hydroxy-1-naphthyl 3,4,5-tris{[(tert-butyl(dimethyl)silyl]oxy}benzoate (59) and 4-
hydroxy-2-naphthyl 3,4,5-tris{[(tert-butyl(dimethyl)silyl]oxy}benzoate (62). Obtained from 1,3-
dihydroxynaphthalene (625 mg, 3.9 mmol) and acid chloride 52a (500 mg, 0.94 mmol). 
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59: 33% yield; Rf (hexane/DCM, 2:8) 0.51; mp 158-160 ºC; IR (ATR)  3398 (OH), 1736 
(C=O), 1577, 1490, 1428 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.22 (s, 6H, (CH3)2Si para), 0.30 (s, 
12H, 2(CH3)2Si meta), 1.00 (s, 18H, 2(CH3)3CSi meta), 1.05 (s, 9H, (CH3)3CSi para), 6.89 (d, J = 
2.1, 1H, CHnaph.), 7.06 (d, J = 2.3, 1H, CHnaph.), 7.26-7.35 (m, 1H, CHnaph.), 7.37-7.43 (m, 1H, 
CHnaph.), 7.53-7.55 (m, 3H, 2CHgal., CHnaph.), 7.85 (d, J = 8.3, 1H, CHnaph.); 
13
C NMR (75 MHz, 
CDCl3) –3.8 ((CH3)2Si para), –3.6 (2(CH3)2Si meta), 18.6 ((CH3)3CSi para), 18.9 (2(CH3)3CSi 
meta), 26.2 (3(CH3)3CSi), 107.9, 111.1 (2CHnaph.), 116.3 (2CHgal.), 120.7 (Cgal.), 121.2 (CHnaph.), 
122.4 (Cnaph.), 123.9, 126.6, 127.0 (3CHnaph.), 135.3 (Cnaph.), 144.4, 147.7 (2C-Onaph.), 148.9 (2C-Ogal. 
meta), 153.4 (C-Ogal. para), 165.2 (C=O); ESI-MS 653.0 (M−H)
−
. 
 
62: 38% yield; Rf (hexane/DCM, 2:8) 0.20; mp 169-170 ºC; IR (ATR)  3381 (OH), 1741 
(C=O), 1581, 1488, 1429 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.22 (s, 6H, (CH3)2Si para), 0.31 (s, 
12H, 2(CH3)2Si meta), 1.00 (s, 18H, 2(CH3)3CSi meta), 1.06 (s, 9H, (CH3)3CSi para), 6.73 (d, J = 
2.0, 1H, CHnaph.), 6.96 (s, 1H, OH), 7.23 (d, J = 1.9, 1H, CHnaph.), 7.27-7.34 (m, 1H, CHnaph.), 7.44-
7.49 (m, 3H, 2CHgal., CHnaph.), 7.50 (d, J = 8.2, 1H, CHnaph.), 7.89 (d, J = 8.3, 1H, CHnaph.); 
13
C NMR 
(75 MHz, CDCl3)  −3.4 ((CH3)2Si para), −3.1 (2(CH3)2Si meta), 19.0 ((CH3)3CSi para), 19.3 
(2(CH3)3CSi meta), 26.5 ((CH3)3CSi para), 26.6 (2(CH3)3CSi meta), 104.9, 110.9 (2CHnaph.), 116.6 
(2CHgal.), 121.3 (Cgal.), 122.5 (CHnaph.), 123.5 (Cnaph.), 125.0, 127.4, 127.6 (3CHnaph.), 134.9 (Cnaph.), 
144.8 149.0 (2C-Onaph.), 149.2 (2C-Ogal. meta), 153.7 (C-Ogal. para), 166.6 (C=O); ESI-MS 653.3 
(M−H)
−
. 
3-Hydroxy-1-naphthyl 3,5-bis{[tert-butyl(dimethyl)silyl]oxy}benzoate (60) and 4-hydroxy-2-
naphthyl 3,5-bis{[tert-butyl(dimethyl)silyl]oxy}benzoate (63). Obtained from 1,3-
dihydroxynaphthalene (1.6 g, 10 mmol) and acid chloride 52c (1.0 g, 2.5 mmol). 
 
60: 24% yield; Rf (DCM) 0.42; mp 123-124 ºC; IR (ATR)  3391 (OH), 1713 (C=O), 1588 (Ar); 
1
H 
NMR (300 MHz, CDCl3)  0.29 (s, 12H, 2(CH3)2Si), 1.04 (s, 18H, 2(CH3)3CSi), 6.70 (t, J = 2.2, 1H, 
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CH4), 6.89 (d, J = 2.2, 1H, CHnaph.), 7.03 (d, J = 2.2, 1H, CHnaph.), 7.29-7.43 (m, 2H, 2CHnaph.), 7.45 
(d, J = 2.4, 2H, H2, H6), 7.45 (d, J = 8.1, 1H, CHnaph.), 7.54 (d, J = 8.1, 1H, CHnaph.); 
13
C NMR (75 
MHz, CDCl3)  −3.9 (2(CH3)2Si), 18.7 (2(CH3)3CSi), 26.1 (2(CH3)3CSi), 108.6, 111.6 (2CHnaph.), 
115.7 (2CHα-res.), 118.4 (CHα-res.), 121.5 (CHnaph.), 122.5 (Cnaph.), 124.3, 127.1, 127.4 (3CHnaph.), 
131.1 (Cα-res.), 135.7 (Cnaph.), 147.9, 153.9 (2C-Onaph.), 157.4 (2C-Oα-res.), 165.9 (C=O); ESI-MS 
547.3 (M+Na)
+
. 
 
63: 22% yield; Rf (DCM) 0.59; mp 133-134 ºC; IR (ATR)  3417 (OH), 1717 (C=O), 1589, 1471 (Ar); 
1
H NMR (300 MHz, CDCl3) 0.23 (s, 12H, 2(CH3)2Si), 0.99 (s, 18H, 2(CH3)3CSi), 6.63 (t, J = 2.3, 
1H, H4), 7.17 (d, J = 1.9, 1H, CHnaph.), 7.19-7.24 (m, 2H, 2CHnaph.), 7.35 (d, J = 2.3, 2H, H2, H6), 
7.38-7.40 (m, 1H, CHnaph.), 7.67 (d, J = 8.2, 1H, CHnaph.), 7.78 (d, J = 8.4, 1H, CHnaph.); 
13
C NMR (75 
MHz, CDCl3)  −3.9 (2(CH3)2Si), 18.7 (2(CH3)3CSi), 26.2 (2(CH3)3CSi), 104.7, 110.9 (2CHnaph.), 
115.7 (2CHα-res.), 118.3 (CHα-res.), 122.6 (CHnaph.), 123.7 (Cnaph.), 125.1, 127.5, 127.6 (3CHnaph.), 
131.4 (Cα-res.), 134.9 (Cnaph.), 148.7, 154.0 (2C-Onaph.), 157.8 (2C-Oα-res.), 166.9 (C=O); ESI-MS 
547.3 (M+Na)
+
. 
3-Hydroxy-1-naphthyl 3-{[tert-butyl(dimethyl)silyl]oxy}benzoate (61) and 4-hydroxy-2-
naphthyl 3-{[tert-butyl(dimethyl)silyl]oxy}benzoate (64) Obtained from 1,3-
dihydroxynaphthalene (2.8 g, 18 mmol) and acid chloride 52d (1.2 g, 4.4 mmol) as oils. 
 
61: 27% yield; Rf (hexane/DCM, 2:8) 0.21; IR (ATR)  3406 (OH), 1731 (C=O), 1594, 1478 
(Ar); 
1
H NMR (300 MHz, CDCl3)  0.27 (s, 6H, (CH3)2Si), 1.03 (s, 9H, (CH3)3CSi), 5.67 (br s, 1H 
OH), 6.95 (d, J = 2.2, 1H, CHnaph.), 7.03 (d, J = 2.3, 1H, CHnaph.), 7.18 (ddd, J = 8.1, 2.5, 1.0, 1H, 
H4), 7.32 (ddd, J = 8.1, 6.8, 1.2, 1H, CHnaph.), 7.39-7.47 (m, 2H, CHnaph., H5), 7.59 (d, J = 8.2, 1H, 
CHnaph.), 7.78 (t, J = 2.0, 1H, H2), 7.82 (d, J = 8.4, 1H, CHnaph.), 7.95 (dt, J = 7.8, 1.3, 1H, H6); 
13
C 
NMR (75 MHz, CDCl3)  −4.2 ((CH3)2Si), 18.4 ((CH3)3CSi), 25.8 ((CH3)3CSi), 108.3, 111.1, 121.3 
(3CHnaph.), 121.9 (CHm-sal.), 122.4 (Cnaph.), 123.5 (CHm-sal.), 124.2 (CHnaph.), 126.1 (CHm-sal.), 126.8, 
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127.2 (2CHnaph.), 130.0 (CHm-sal.), 130.5 (Cm-sal.), 135.4 (Cnaph.), 147.7, 153.3 (2C-Onaph.), 156.2 (C-
Om-sal.), 165.5 (C=O); ESI-MS 393.0 (M−H)
−
. 
 
64: 26% yield; Rf (hexane/DCM, 2:8) 0.40; IR (ATR)  3387 (OH), 1712 (C=O), 1590, 1480 
(Ar); 
1
H NMR (300 MHz, CDCl3)  0.25 (s, 6H, (CH3)2Si), 1.02 (s, 9H, (CH3)3CSi), 6.34 (br s, 1H, 
OH), 6.69 (d, J = 2.1, 1H, CHnaph.), 7.14 (ddd, J = 8.1, 2.5, 0.9, 1H, H4), 7.24 (d, J = 1.9, 1H, 
CHnaph.), 7.35 (ddd, J = 8.3, 6.9, 1.2, 1H, CHnaph.), 7.40 (t, J = 8.0, 1H, H5), 7.47 (ddd, J = 8.2, 6.9, 
1.2, 1H, CHnaph.), 7.70 (t, J = 2.0, 1H, H2), 7.75 (d, J = 8.2, 1H, CHnaph.), 7.86 (dt, J = 7.8, 1.3, 1H, 
H6), 7.93 (d, J = 8.3, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −4.3 ((CH3)2Si), 18.4 ((CH3)3CSi), 
25.8 ((CH3)3CSi), 104.5, 111.1 (2CHnaph.), 121.8 (CHm-sal.), 122.1 (CHnaph.), 123.1 (Cnaph.), 123.5 
(CHm-sal.), 125.0 (CHnaph.), 125.9 (CHm-sal.), 127.3, 127.5 (2CHnaph.), 129.8 (CHm-sal.), 130.8 (Cm-sal.), 
134.7 (Cnaph.), 148.5, 153.2 (2C-Onaph.), 156.1 (C-Om-sal.), 166.1 (C=O); ESI-MS 393.0 (M−H)
−
. 
 
5-Hydroxybiphenyl-3-yl 3,4-bis{[tert-butyl(dimethyl)silyl]oxy}benzoate (101). Obtained 
from 97 (901 mg, 4.8 mmol) and acid chloride 52b (481 mg, 1.2 mmol) as an oil in 47% yield. Rf 
(DCM) 0.78; IR (ATR)  3404 (OH), 1707 (C=O), 1511, 1466, 1421 (Ar), 1301 (C-O); 
1
H NMR (300 
MHz, CDCl3)  0.24 (s, 6H, (CH3)2Si), 0.26 (s, 6H, (CH3)2Si), 1.01 (s, 18H, 2(CH3)3CSi), 5.32 (s, 1H, 
OH), 6.70 (t, J = 2.1, 1H, H4), 6.92 (d, J = 8.4, 1H, H5’’), 6.94 (t, J = 1.7, 1H, H6), 7.00 (t, J = 1.7, 1H, 
H2), 7.32-7.44 (m, 3H, H3’, H4’, H5’), 7.56 (d, J = 7.0, 2H, H2’, H6’), 7.67 (d, J = 2.1, 1H, H2’’), 7.72 (dd, 
J = 8.4, 2.2, 1H, H6’’); 
13
C NMR (75 MHz, CDCl3)  −3.9, −4.0 (2(CH3)2Si), 18.6, 18.7 (2(CH3)3CSi), 
25.9, 26.0 (2(CH3)3CSi), 108.5 (C4H), 112.3 (C6H), 112.6 (C2H), 120.8 (C5’’H), 122.3 (Cprot.), 123.0 
(C2’’H), 124.7 (C6’’H), 127.2 (C2’H, C6’H), 127.8 (C4’H), 128.8 (C3’H, C5’H), 140.2, 143.8 (2Cbiph.), 
147.1, 152.1 (2C-Oprot.), 152.8 (C-Obiph.), 157.3 (C-OH), 165.8 (C=O); ESI-MS 573.2 (M+Na)
+
. 
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5-Hydroxybiphenyl-3-yl 3,5-bis{[tert-butyl(dimethyl)silyl]oxy}benzoate (102). Obtained 
from 97 (126 mg, 0.68 mmol) and acid chloride 52c (68 mg, 0.17 mmol) as an oil in 69% yield. Rf 
(DCM) 0.71; IR (ATR) 3410 (OH), 1714 (C=O), 1449, 1336 (Ar), 1170 (C-O); 
1
H NMR (300 MHz, 
CDCl3)  0.24 (s, 12H, 2(CH3)2Si), 1.00 (s, 18H, 2(CH3)3CSi), 5.40 (s, 1H, OH), 6.61 (t, J = 2.3, 1H, 
H4’’), 6.70 (t, J = 2.1, 1H, H4), 6.95 (t, J = 1.8, 1H, H6), 7.01 (t, J = 1.7, 1H, H2), 7.29 (d, J = 2.3, 2H, 
H2’’, H6’’), 7.32-7.44 (m, 3H, H3’, H4’, H5’), 7.55 (dd, J = 8.2, 1.3, 2H, H2’, H6’); 
13
C NMR (75 MHz, 
CDCl3)  −4.2 (2(CH3)2Si), 18.4 (2(CH3)3CSi), 25.8 (2(CH3)3CSi), 108.3 (C4H), 112.1 (C6H), 113.1 
(C2H), 115.3 (2CHα-res.), 117.8 (CHα-res.), 127.3 (C2’H, C6’H), 128.0 (C4’H), 128.9 (C3’H, C5’H), 131.2 
(Cα-res.), 140.1, 144.0 (2Cbiph.), 152.2 (C-Obiph.), 156.8 (C-OH), 156.9 (2C-Oα-res.), 165.1 (C=O); ESI-
MS 549.2 (M−H)
−
. 
 
5-Hydroxybiphenyl-3-yl 3-{[tert-butyl(dimethyl)silyl]oxy}benzoate (103). Obtained from 97 
(701 mg, 3.8 mmol) and acid chloride 52d (255mg, 0.94 mmol) as an oil in 46% yield. Rf (DCM) 
0.20; IR (ATR) 3407 (OH), 1713 (C=O), 1596, 1483, 1435 (Ar), 1285 (C-O); 
1
H NMR (300 MHz, 
CDCl3)  0.25 (s, 6H, (CH3)2Si), 1.02 (s, 9H, (CH3)3CSi), 6.69 (t, J = 2.2, 1H, H4), 6.93 (t, J = 1.9, 
1H, H6), 7.00 (t, J = 1.7, 1H, H2), 7.14 (ddd, J = 8.1, 2.5, 0.9, 1H, H4’’), 7.30-7.43 (m, 4H, H3’, H4’, H5’, 
H5’’), 7.53 (dd, J = 8.1, 1.4, 2H, H2’, H6’), 7.67 (t, J = 2.0, 1H, H2’’), 7.83 (dt, J = 7.7, 1.4, 1H, H6’’); 
13
C 
NMR (75 MHz, CDCl3)  −4.3 ((CH3)2Si), 18.3 ((CH3)3CSi), 25.8 ((CH3)3CSi), 108.3 (C4H), 112.3 
(C6H), 112.7 (C2H), 121.7 (CHm-sal.), 123.4 (CHm-sal.), 125.9 (CHm-sal.), 127.2 (C2’H, C6’H), 127.9 
(C4’H), 128.9 (C3’H, C5’H), 129.8 (CHm-sal.), 130.7 (Cm-sal.), 140.0, 143.9 (2Cbiph.), 152.0 (C-Obiph.), 
156.0 (C-Om-sal.), 157.0 (C-OH), 165.7 (C=O); ESI-MS 418.9 (M−H)
−
. 
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5-Hydroxybiphenyl-3-yl 4-{[tert-butyl(dimethyl)silyl]oxy}benzoate (104). Obtained from 97 
(566 mg, 3.0 mmol) and 4-{[tert-butyl(dimethyl)silyl]oxy}benzoyl chloride 52e (206 mg, 0.76 mmol) 
as an oil in 52% yield. Rf (DCM) 0.21; IR (ATR)  3450 (OH), 1732 (C=O), 1601, 1509 (Ar), 1263 
(C-O); 
1
H NMR (300 MHz, CDCl3)  0.26 (s, 6H, (CH3)2Si), 1.01 (s, 9H, (CH3)3CSi), 6.70 (t, J = 2.1, 
1H, H4), 6.91-6.96 (m, 3H, H6, H3’’, H5’’), 7.00 (t, J = 1.7, 1H, H2), 7.32-7.37 (m, 1H, H4’), 7.42 (t, J = 
7.2, 2H, H3’, H5’), 7.56 (d, J = 6.9, 2H, H2’, H6’), 8.11 (d, J = 8.7, 2H, H2’’,H6’’); 
13
C NMR (75 MHz, 
CDCl3)  −4.2 ((CH3)2Si), 18.4 ((CH3)3CSi), 25.7 ((CH3)3CSi), 108.4 (C4H), 112.0 (C6H), 113.2 
(C2H), 120.3 (2CHp-sal.), 122.4 (Cp-sal.), 127.3 (C2’H, C6’H), 127.9 (C4’H), 128.9 (C3’H, C5’H), 132.5 
(2CHp-sal.), 140.1, 143.9 (2Cbiph.), 152.3 (C-O), 156.8 (2C-O), 161.0 (C=O); ESI-MS 418.9 (M−H)
−
. 
General Procedure for the Synthesis of Protected Diesters 65-86 and 105-108. To a 
solution of monoester 59-64 or 101-104 (1 equiv) and triethylamine (2 equiv) in anhydrous DCM (10 
mL/mmol acid chloride 52) under an argon atmosphere, a solution of the corresponding acid 
chloride 52b-h (2 equiv) in anhydrous DCM (2 mL/mmol) was added dropwise and the reaction 
mixture was stirred at room temperature overnight. Then, the mixture was washed with a saturated 
aqueous solution of NaHCO3 and with water, and the organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. The crude was purified by chromatography (from hexane to 
DCM) to afford the title diesters 65-86 or 105-108. 
 
4-[(3,4,5-Trimethoxybenzoyl)oxy]-2-naphthyl 3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy} 
benzoate (65). Obtained from monoester 62 (200 mg, 0.31 mmol) and acid chloride 52h (140 mg, 
0.62 mmol) in 91% yield. Rf (hexane/DCM, 2:8) 0.30; mp 167-169 ºC; IR (ATR)  1734 (C=O), 
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1585, 1495, 1466 (Ar); 
1
H NMR (300 MHz, CDCl3) 0.18 (s, 6H, (CH3)2Si para), 0.27 (s, 12H, 
2(CH3)2Si meta), 0.97 (s, 18H, 2(CH3)3CSi meta), 0.99 (s, 9H, (CH3)3CSi para), 3.97 (s, 6H, 2CH3O 
meta), 3.98 (s, 3H, CH3O para), 7.33 (d, J = 2.1, 1H, CHnaph.), 7.41 (s, 2H, 2CHgal.), 7.45-7.56 (m, 
2H, 2CHnaph.), 7.57 (s, 2H, 2CHeud.), 7.66 (d, J = 2.0, 1H, CHnaph.), 7.87-7.92 (m, 2H, 2CHnaph.); 
13
C 
NMR (75 MHz, CDCl3)  −3.7 ((CH3)2Si para), −3.5 (2(CH3)2Si meta), 18.7 ((CH3)3CSi para), 19.0 
(2(CH3)3CSi meta), 26.3 ((CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 56.5 (2CH3O meta), 61.2 (CH3O 
para), 107.8 (2CHeud.), 114.7 (CHnaph.), 116.3 (2CHgal.), 117.1 (CHnaph.), 121.0 (Cgal.), 121.6 (CHnaph.), 
124.1, 125.3 (Ceud., Cnaph.), 126.3, 127.4, 128.1 (3CHnaph.), 134.6 (Cnaph.), 143.3, 144.3 (2C-Onaph.), 
147.6, 148.3 (2C-O para), 148.9 (2C-Ogal. meta), 153.4 (2C-Oeud. meta), 164.7, 164.9 (2C=O); ESI-
MS 847.0 (M−H)
−
. 
 
3-[(3,4,5-Trimethoxybenzoyl)oxy]-1-naphthyl 3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy} 
benzoate (66). Obtained from monoester 59 (95 mg, 0.15 mmol) and acid chloride 52h (67 mg, 
0.29 mmol) in 82% yield. Rf (hexane/DCM, 2:8) 0.44; mp 197-198 ºC; IR (ATR)  1735 (C=O), 
1598, 1495, 1464 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.19 (s, 6H, (CH3)2Si para), 0.29 (s, 12H, 
2(CH3)2Si meta), 0.98 (s, 18H, 2(CH3)3CSi meta), 1.02 (s, 9H, (CH3)3CSi para), 3.95 (s, 6H, 2CH3O 
meta), 3.96 (s, 3H, CH3O para), 7.40 (d, J = 2.1, 1H, CHnaph.), 7.49 (s, 2H, 2CHgal./eud.), 7.50 (s, 2H, 
2CHgal./eud.), 7.51-7.58 (m, 2H, 2CHnaph.), 7.64 (d, J = 1.9, 1H, CHnaph.), 7.88 (d, J = 7.4, 1H, CHnaph.), 
8.02 (d, J = 8.0, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −3.7 ((CH3)2Si para), −3.4 (2(CH3)2Si 
meta), 18.7 ((CH3)3CSi para), 19.0 (2(CH3)3CSi meta), 26.3 ((CH3)3CSi para), 26.4 (2(CH3)3CSi 
meta), 56.5 (2CH3O meta), 61.2 (CH3O para), 107.8 (2CHeud.), 114.4 (CHnaph.), 116.3 (2CHgal.), 
116.8 (CHnaph.), 120.8 (Cgal.), 121.7 (CHnaph.), 124.4, 125.5 (Ceud., Cnaph.), 126.3, 127.4, 128.0 
(3CHnaph.), 134.5 (Cnaph.), 143.3, 144.3 (2C-Onaph.), 147.8, 148.1 (2C-O para), 149.0 (2C-Oeud. meta), 
153.3 (2C-Ogal. meta), 164.6, 164.9 (2C=O); ESI-MS 847.0 (M−H)
−
. 
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3-[(3,4-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3,4,5-tris{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (67). Obtained from monoester 59 (490 mg, 0.75 mmol) and acid 
chloride 52b (670 mg, 1.7 mmol) as an oil in 82% yield. Rf (hexane/DCM, 3:7) 0.37; 
1
H NMR (300 
MHz, CDCl3)  0.27 (s, 6H, (CH3)2Si), 0.35 (s, 12H, 2(CH3)2Si), 0,36 (s, 12H, 2(CH3)2Si), 1.06 (s, 
18H, 2(CH3)3CSi), 1.10 (s, 27H, 3(CH3)3CSi), 7.05 (d, J = 8.4, 1H, H5), 7.47 (d, J = 2.1, 1H, CHnaph.), 
7.52-7.58 (m, 3H, 2CHgal., CHnaph.), 7.71 (d, J = 1.8, 1H, CHnaph.), 7.89-7.95 (m, 4H, 2CHnaph., H2, 
H6), 8.05 (d, J = 7.8, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −4.1 ((CH3)2Si), −4.0 (2(CH3)2Si), 
−3.9 ((CH3)2Si), −3.6 ((CH3)2Si), 18.4 (2(CH3)3CSi), 18.5 ((CH3)3CSi), 18.8 (2(CH3)3CSi), 25.8 
((CH3)3CSi), 25.9 (2(CH3)3CSi), 26.1 ((CH3)3CSi), 26.2 ((CH3)3CSi), 114.4 (CHnaph.), 116.1 (2CHgal.), 
116.6 (CHnaph.), 120.7 (CHprot.), 121.0 (Cgal.), 121.5 (CHnaph.), 122.1 (Cprot.), 122.8, 124.5 (2CHprot.), 
125.2 (Cnaph.), 126.0, 127.1, 127.8 (3CHnaph.), 134.3 (Cnaph.), 144.0 (C-Ogal. para), 147.0 (C-Oprot.), 
147.5, 148.1 (2C-Onaph.), 148.6 (2C-Ogal. meta), 152.6 (C-Oprot.), 164.3, 164.6 (2C=O); ESI-MS 
1041.6 (M+Na)
+
. 
 
3-[(3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3,4,5-tris{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (68). Obtained from monoester 59 (190 mg, 0.29 mmol) and acid 
chloride 52c (230 mg, 0.58 mmol) in 90% yield. Rf (hexane/DCM, 4:6) 0.35; mp 67-71 ºC; IR (ATR) 
 1743 (C=O), 1588 (Ar); 
1
H NMR (300 MHz, CDCl3) 0.21 (s, 6H, (CH3)2Si), 0.25 (s, 12H, 
2(CH3)2Si), 0.29 (s, 12H, 2(CH3)2Si), 0.99 (s, 18H, 2(CH3)3CSi), 1.02 (s, 18H, 2(CH3)3CSi), 1.04 (s, 
9H, (CH3)3CSi), 6.62 (t, J = 2.3, 1H, H4), 7.32 (d, J = 2.3, 2H, H2, H6), 7.41 (d, J = 2.1, 1H, CHnaph.), 
7.48-7.58 (m, 4H, 2CHnaph., 2CHgal.), 7.65 (d, J = 1.8, 1H, CHnaph.), 7.88 (d, J = 7.4, 1H, CHnaph.), 
8.01 (d, J = 7.8, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3) −4.4 ((CH3)2Si para), −3.8 (2(CH3)2Si 
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meta), −3.6 (2(CH3)2Si meta), 18.3 ((CH3)3CSi para), 18.6 (2(CH3)3CSi meta), 18.9 (2(CH3)3CSi 
meta), 25.7 ((CH3)3CSi para), 26.1 (2(CH3)3CSi meta), 26.2 (2(CH3)3CSi meta), 114.3 (CHnaph.), 
115.2 (2CHα-res.), 116.2 (2CHgal.), 116.2, 117.7 (2CHnaph.), 120.7 (Cgal.), 121.5 (CHα-res.), 125.4 
(Cnaph.), 126.1, 127.2, 127.9 (3CHnaph.), 131.0 (Cα-res.), 134.3 (Cnaph.), 144.3 (C-Ogal. para), 147.6, 
148.0 (2C-Onaph.), 148.8 (2C-Ogal. meta), 156.8 (2C-Oα-res.), 164.4, 164.8 (2C=O); ESI-MS 1041.6 
(M+Na)
+
. 
 
4-[(3,4-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 3,4,5-tris{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (69). Obtained from monoester 62 (490 mg, 0.75 mmol) and acid 
chloride 52b (670 mg, 1.7 mmol) as an oil in 92% yield. Rf (hexane/DCM, 4:6) 0.39; 
1
H NMR (300 
MHz, CDCl3)  0.25 (s, 6H, (CH3)2Si), 0.30 (s, 6H, (CH3)2Si), 0.31 (s, 6H, (CH3)2Si), 0.33 (s, 12H, 
2(CH3)2Si), 1.03 (s, 18H, 2(CH3)3CSi), 1.05 (s, 9H, (CH3)3CSi), 1.06 (s, 9H, (CH3)3CSi), 1.08 (s, 9H, 
(CH3)3CSi), 6.98 (d, J = 8.4, 1H, H5), 7.46 (d, J = 2.1, 1H, CHnaph.), 7.49-7.59 (m, 4H, 2CHgal., 
2CHnaph.), 7.67 (d, J = 2.1, 1H, CHnaph.), 7.76 (d, J = 2.1, 1H, H2), 7.81 (dd, J = 8.3, 2.0, 1H, H6), 
7.89 (dd, J = 7.1, 1.7, 1H, CHnaph.), 8.04 (d, J = 7.5, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −3.6 
((CH3)2Si), −3.5 ((CH3)2Si), −3.3 ((CH3)2Si), −3.1 (2(CH3)2Si), 18.9 ((CH3)3CSi), 19.0 (2(CH3)3CSi), 
19.3 (2(CH3)3CSi), 26.1 ((CH3)3CSi), 26.3 ((CH3)3CSi), 26.4 ((CH3)3CSi), 26.6 ((CH3)3CSi), 26.7 
((CH3)3CSi), 114.9 (CHnaph.), 116.6 (2CHgal.), 117.1 (CHnaph.), 121.1 (CHprot.), 121.2 (Cgal.), 121.9 
(CHnaph.), 122.8 (Cprot.), 123.3, 124.9 (2CHprot.), 125.7 (Cnaph.), 126.5, 127.6, 128.3 (3CHnaph.), 134.8 
(Cnaph.), 144.7 (C-Ogal. para), 147.4 (C-Oprot.), 147.9, 148.5 (2C-Onaph.), 149.2 (2C-Ogal. meta), 152.9 
(C-Oprot.), 164.8, 165.2 (2C=O); ESI-MS 1041.6 (M+Na)
+
. 
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4-[(3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 3,4,5-tris{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (70). Obtained from monoester 62 (190 mg, 0.29 mmol) and acid 
chloride 52c (230 mg, 0.58 mmol) in 91% yield. Rf (hexane/DCM, 4:6) 0.41; mp 149-151 ºC; IR 
(ATR)  1743 (C=O), 1588 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.19 (s, 6H, (CH3)2Si para), 0.27 (s, 
12H, 2(CH3)2Si meta), 0.28 (s, 12H, 2(CH3)2Si meta), 0.98 (s, 9H, (CH3)3CSi para), 1.01 (s, 18H, 
2(CH3)3CSi meta), 1.02 (s, 18H, 2(CH3)3CSi meta), 6.66 (t, J = 2.3, 1H, H4), 7.37 (d, J = 2.1, 1H, 
CHnaph.), 7.41 (d, J = 2.3, 2H, H2, H6), 7.42 (s, 2H, 2CHgal.), 7.47-7.57 (m, 2H, 2CHnaph.), 7.65 (d, J = 
1.8, 1H, CHnaph.), 7.88 (d, J = 7.4, 1H, CHnaph.), 7.95 (d, J = 7.9, 1H, CHnaph.); 
13
C NMR (75 MHz, 
CDCl3)  −4.3 ((CH3)2Si para), −3.8 (2(CH3)2Si meta), −3.6 (2(CH3)2Si meta), 15.2 ((CH3)3CSi para, 
2(CH3)3CSi meta), 16.0 (2(CH3)3CSi meta), 25.7 ((CH3)3CSi para), 26.1 (2(CH3)3CSi meta), 26.4 
(2(CH3)3CSi meta), 114.5 (CHnaph.), 115.2 (2CHα-res.), 116.2 (2CHgal.), 116.9, 117.8 (2CHnaph.), 121.0 
(Cgal.), 121.5 (CHα-res.), 125.2 (Cnaph.), 126.2, 127.2, 127.9 (3CHnaph.), 130.8 (Cα-res.), 134.4 (Cnaph.), 
144.1 (C-Ogal. para), 147.4, 148.2 (2C-Onaph.), 148.7 (2C-Ogal. meta), 156.9 (2C-Oα-res.), 164.5, 164.8 
(2C=O); ESI-MS 1041.6 (M+Na)
+
. 
 
3-[(3-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3,4,5-tris{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (71). Obtained from monoester 59 (200 mg, 0.31 mmol) and acid 
chloride 52d (210 mg, 0.76 mmol) as an oil in 44% yield. Rf (hexane/DCM, 1:1) 0.40; IR (ATR)  
1741 (C=O), 1581, 1485 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.20 (s, 6H, (CH3)2Si para), 0.25 (s, 6H, 
(CH3)2Si meta), 0.29 (s, 12H, 2(CH3)2Si meta), 0.98 (s, 18H, 2(CH3)3CSi meta), 1.02 (s, 9H, 
(CH3)3CSi meta/para), 1.03 (s, 9H, (CH3)3CSi meta/para), 7.13 (ddd, J = 8.0, 2.5, 1.0, 1H, H4), 7.39 
(t, J = 7.9, 1H, H5), 7.41 (d, J = 2.0, 1H, CHnaph.), 7.47-7.58 (m, 4H, 2CHgal., 2CHnaph.), 7.65 (d, J = 
2.0, 1H, CHnaph.), 7.68 (t, J = 2.0, 1H, H2), 7.84 (dt, J = 7.9, 1.3, 1H, H6), 7.88 (dd, J = 7.9, 1.3, 1H, 
CHnaph.), 8.01 (dd, J = 8.0, 1.3, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −4.3 ((CH3)2Si meta), −3.7 
((CH3)2Si para), −3.5 (2(CH3)2Si meta), 18.4 ((CH3)3CSi meta), 18.7 ((CH3)3CSi para), 19.0 
(2(CH3)3CSi meta), 25.8 ((CH3)3CSi meta), 26.3 ((CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 114.4 
(CHnaph.), 116.3 (2CHgal.), 116.7 (CHnaph.), 120.8 (Cgal.), 121.7 (CHm-sal.), 121.9 (CHnaph.), 123.4 (CHm-
sal.), 125.5 (Cnaph.), 125.8 (CHm-sal.), 126.6, 127.4, 128.0 (3CHnaph.), 129.8 (CHm-sal.), 130.8 (Cm-sal.), 
134.4 (Cnaph.), 144.4 (C-Ogal. para), 147.7, 148.0 (2C-Onaph.), 148.9 (2C-Ogal. meta), 156.1 (C-Om-sal.), 
164.5, 165.1 (2C=O); ESI-MS 911.5 (M+Na)
+
. 
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3-[(4-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3,4,5-tris{[tert-
butyl(dimethyl)silyl]oxy} benzoate (72). Obtained from monoester 59 (200 mg, 0.31 mmol) and 
acid chloride 52e (210 mg, 0.76 mmol) as an oil in 55% yield. Rf (hexane/DCM, 1:1) 0.87; IR (ATR) 
 1740 (C=O), 1601, 1501 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.19 (s, 6H, (CH3)2Si para), 0.27 (s, 
6H, (CH3)2Si para), 0.28 (s, 12H, 2(CH3)2Si meta), 0.98 (s, 18H, 2(CH3)3CSi meta), 1.01 (s, 9H, 
(CH3)3CSi para), 1.03 (s, 9H, (CH3)3CSi para), 6.94 (d, J = 8.7, 2H, H3, H5), 7.40 (d, J = 2.2, 1H, 
CHnaph.), 7.43-7.58 (m, 2H, 2CHnaph.), 7.49 (s, 2H, 2CHgal.), 7.63 (d, J = 2.3, 1H, CHnaph.), 7.87 (d, J = 
7.4, 1H, CHnaph.), 8.00 (d, J = 7.9, 1H, CHnaph.), 8.13 (d, J = 8.7, 2H, H2, H6); 
13
C NMR (75 MHz, 
CDCl3)  −4.2, −3.7 (2(CH3)2Si para), −3.4 (2(CH3)2Si meta), 18.4, 18.7 (2(CH3)3CSi para), 19.0 
(2(CH3)3CSi meta), 25.8, 26.3 (2(CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 114.5 (CHnaph.), 116.3 
(2CHgal.), 116.8 (CHnaph.), 120.3 (2CHp-sal.), 120.9 (Cgal.), 121.6 (CHnaph.), 122.4 (Cp-sal.), 125.4 
(Cnaph.), 126.2, 127.3, 128.0 (3CHnaph.), 132.5 (2CHp-sal.), 134.5 (Cnaph.), 144.4 (C-Ogal. para), 147.7, 
148.2 (2C-Onaph.), 148.9 (2C-Ogal. meta), 161.0 (C-Op-sal.), 164.5, 165.0 (2C=O); ESI-MS 911.5 
(M+Na)
+
. 
 
4-[(3-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 3,4,5-tris{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (73). Obtained from monoester 62 (100 mg, 0.15 mmol) and acid 
chloride 52d (83 mg, 0.30 mmol) as an oil in 66% yield. Rf (hexane/DCM, 1:1) 0.47; IR (ATR)  
1790 (C=O), 1582, 1484 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.18 (s, 6H, (CH3)2Si para), 0.26 (s, 6H, 
(CH3)2Si meta), 0.27 (s, 12H, 2(CH3)2Si meta), 0.97 (s, 18H, 2(CH3)3CSi meta), 1.01 (s, 9H, 
(CH3)3CSi meta/para), 1.02 (s, 9H, (CH3)3CSi meta/para), 7.17 (ddd, J = 8.1, 2.5, 1.0, 1H, H4), 7.37 
(d, J = 2.1, 1H, CHnaph.), 7.41 (s, 2H, 2CHgal.), 7.43 (t, J = 8.0, 1H, H5), 7.45-7.57 (m, 2H, 2CHnaph.), 
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7.65 (d, J = 1.9, 1H, CHnaph.), 7.76 (t, J = 2.0, 1H, H2), 7.88 (d, J = 8.0, 1H, CHnaph.), 7.93 (dt, J = 
7.8, 1.3, 1H, H6), 7.95 (d, J = 8.0, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −4.2 ((CH3)2Si meta), 
−3.7 ((CH3)2Si para), −3.5 (2(CH3)2Si meta), 18.4 ((CH3)3CSi meta), 18.7 ((CH3)3CSi para), 19.0 
(2(CH3)3CSi meta), 25.8 ((CH3)3CSi meta), 26.4 ((CH3)3CSi para), 26.5 (2(CH3)3CSi meta), 114.6 
(CHnaph.), 116.3 (2CHgal.), 117.0 (CHnaph.), 121.0 (Cgal.), 121.5 (CHm-sal.), 121.7, 123.4 (CHm-sal., 
CHnaph.), 125.2 (Cnaph.), 125.9 (CHm-sal.), 126.2, 127.4, 128.0 (3CHnaph.), 130.0 (CHm-sal.), 130.6 (Cm-
sal.), 134.5 (Cnaph.), 144.3 (C-Ogal. para), 147.5, 148.3 (2C-Onaph.), 148.8 (2C-Ogal. meta), 156.2 (C-
Om-sal.), 164.8, 164.9 (2C=O); ESI-MS 911.5 (M+Na)
+
. 
 
4-[(4-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 3,4,5-tris{[tert-butyl 
(dimethyl)silyl]oxy} benzoate (74). Obtained from monoester 62 (100 mg, 0.15 mmol) and acid 
chloride 52e (83 mg, 0.30 mmol) as an oil in 71% yield. Rf (hexane/DCM, 2:8) 0.88; IR (ATR)  
1741 (C=O), 1601, 1477 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.17 (s, 6H, (CH3)2Si para), 0.27 (s, 
12H, 2(CH3)2Si meta), 0.29 (s, 6H, (CH3)2Si para), 0.97 (s, 18H, 2(CH3)3CSi meta), 1.02 (s, 9H, 
(CH3)3CSi para), 1.03 (s, 9H, (CH3)3CSi para), 6.98 (d, J = 8.8, 2H, H3, H5), 7.34 (d, J = 2.2, 1H, 
CHnaph.), 7.41 (s, 2H, 2CHgal.), 7.43-7.58 (m, 2H, 2CHnaph.), 7.64 (d, J = 1.9, 1H, CHnaph.), 7.87 (d, J = 
8.6, 1H, CHnaph.), 7.95 (d, J = 8.0, 1H, CHnaph.), 8.22 (d, J = 8.8, 2H, H2, H6); 
13
C NMR (75 MHz, 
CDCl3)  −4.2, −3.7 (2(CH3)2Si para), −3.5 (2(CH3)2Si meta), 18.4, 18.7 (2(CH3)3CSi para), 19.0 
(2(CH3)3CSi meta), 25.8, 26.3 (2(CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 114.6 (CHnaph.), 116.3 
(2CHgal.), 116.9 (CHnaph.), 120.4 (2CHp-sal.), 121.1 (Cgal.), 121.7 (Cp-sal.), 122.1 (CHnaph.), 125.4 
(Cnaph.), 126.2, 127.3, 128.0 (3CHnaph.), 132.6 (2CHp-sal.), 134.5 (Cnaph.), 144.2 (C-Ogal. para), 147.7, 
148.3 (2C-Onaph.), 148.8 (2C-Ogal. meta), 161.2 (C-Op-sal.), 164.8, 164.9 (2C=O); ESI-MS 911.4 
(M+Na)
+
. 
Experimental part 
- 98 - 
 
3-[(4-{[tert-Butyl(dimethyl)silyl]oxy}-3-chlorobenzoyl)oxy]-1-naphthyl 3,4,5-tris{[tert-
butyl(dimethyl)silyl] oxy}benzoate (75). Obtained from monoester 59 (200 mg, 0.31 mmol) and 
acid chloride 52f (190 mg, 0.61 mmol) in 58% yield. Rf (hexane/DCM, 2:8) 0.72; mp 135-136 ºC; IR 
(ATR)  1741 (C=O), 1586, 1493 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.21 (s, 6H, (CH3)2Si para), 
0.30 (s, 12H, 2(CH3)2Si meta), 0.31 (s, 6H, (CH3)2Si para), 0.99 (s, 18H, 2(CH3)3CSi meta), 1.04 (s, 
9H, (CH3)3CSi para), 1.07 (s, 9H, (CH3)3CSi para), 7.00 (d, J = 8.5, 1H, H5), 7.41 (d, J = 2.1, 1H, 
CHnaph.), 7.47-7.59 (s, 4H, 2CHnaph., 2CHgal.), 7.65 (d, J = 1.5, 1H, CHnaph.), 7.88 (d, J = 8.0, 1H, 
CHnaph.), 7.99-8.06 (m, 2H, CHnaph., H6), 8.27 (d, J = 2.1, 1H, H2); 
13
C NMR (75 MHz, CDCl3)  −4.1, 
−3.7 (2(CH3)2Si para), −3.4 (2(CH3)2Si meta), 18.5, 18.7 (2(CH3)3CSi para), 19.0 (2(CH3)3CSi 
meta), 25.7, 26.3 (2(CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 114.3 (CHnaph.), 116.3 (2CHgal.), 116.7 
(CHnaph.), 120.4 (CHClbenz.), 120.8 (Cgal.), 121.7 (CHnaph.), 123.3 (CClbenz.), 125.5 (Cnaph.), 126.3 
(CHnaph., CClbenz.), 127.4, 128.0 (2CHnaph.), 130.3, 132.8 (2CHClbenz.), 134.4 (Cnaph.), 144.4 (C-Ogal. 
para), 147.7, 147.9 (2C-Onaph.), 148.9 (2C-Ogal. meta), 156.7 (C-OClbenz.), 164.0, 164.5 (2C=O); ESI-
MS 945.3 (M+Na)
+
. 
 
4-[(4-{[tert-Butyl(dimethyl)silyl]oxy}-3-chlorobenzoyl)oxy]-2-naphthyl 3,4,5-tris{[tert-
butyl(dimethyl)silyl] oxy}benzoate (76). Obtained from monoester 62 (200 mg, 0.31 mmol) and 
acid chloride 52f (190 mg, 0.61 mmol) in 57% yield. Rf (hexane/DCM, 2:8) 0.92; mp 76-78 ºC; IR 
(ATR)  1742 (C=O), 1586, 1491 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.18 (s, 6H, (CH3)2Si para), 
0.28 (s, 12H, 2(CH3)2Si meta), 0.32 (s, 6H, (CH3)2Si para), 0.98 (s, 18H, 2(CH3)3CSi meta), 1.02 (s, 
9H, (CH3)3CSi para), 1.08 (s, 9H, (CH3)3CSi para), 7.03 (d, J = 8.5, 1H, H5), 7.34 (d, J = 2.1, 1H, 
CHnaph.), 7.41 (s, 2H, 2CHgal.), 7.46-7.57 (m, 2H, 2CHnaph.), 7.66 (d, J = 1.6, 1H, CHnaph.), 7.88 (d, J = 
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7.9, 1H, CHnaph.), 7.92 (d, J = 7.8, 1H, CHnaph.), 8.11 (dd, J = 8.5, 2.2, 1H, H6), 8.34 (d, J = 2.1, 1H, 
H2); 
13
C NMR (75 MHz, CDCl3)  −4.1, −3.7 (2(CH3)2Si para), −3.5 (2(CH3)2Si meta), 18.6, 18.7 
(2(CH3)3CSi para), 19.0 (2(CH3)3CSi meta), 25.7, 26.3 (2(CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 
114.6 (CHnaph.), 116.3 (2CHgal.), 117.1 (CHnaph.), 120.5 (CHClbenz.), 121.1 (Cgal.), 121.6 (CHnaph.), 
123.0 (CClbenz.), 125.2 (Cnaph.), 126.3 (CHnaph.), 126.4 (CClbenz.), 127.4, 128.1 (2CHnaph.), 130.4, 132.8 
(2CHClbenz.), 134.5 (Cnaph.), 144.3 (C-Ogal. para), 147.4, 148.2 (2C-Onaph.), 148.8 (2C-Ogal. meta), 
156.9 (C-OClbenz.), 163.8, 164.9 (2C=O); ESI-MS 807.1 (M−TBS)
−
. 
 
3-[(3,4-Dichlorobenzoyl)oxy]-1-naphthyl 3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy} 
benzoate (77). Obtained from monoester 59 (325 mg, 0.50 mmol) and acid chloride 52g (208 mg, 
0.99 mmol) in 48% yield. Rf (hexane/DCM, 1:1) 0.53; mp 162-164 ºC; IR (ATR)  1743 (C=O), 
1578, 1486 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.20 (s, 6H, (CH3)2Si para), 0.29 (s, 12H, 2(CH3)2Si 
meta), 0.98 (s, 18H, 2(CH3)3CSi meta), 1.03 (s, 9H, (CH3)3CSi para), 7.41 (d, J = 2.1, 1H, CHnaph.), 
7.50-7.59 (m, 4H, 2CHnaph., 2CHgal.), 7.62 (d, J = 8.4, 1H, H5), 7.65 (d, J = 1.8, 1H, CHnaph.), 7.88 (d, 
J = 7.5, 1H, CHnaph.), 7.98-8.07 (m, 2H, CHnaph., H6), 8.32 (d, J = 1.9, 1H, H2); 
13
C NMR (75 MHz, 
CDCl3) −3.7 ((CH3)2Si para), −3.4 (2(CH3)2Si meta), 18.7 ((CH3)3CSi para), 19.0 (2(CH3)3CSi 
meta), 26.3 ((CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 114.0 (CHnaph.), 116.3 (2CHgal.), 116.6 
(CHnaph.), 120.7 (Cgal.), 121.7 (CHnaph.), 125.6 (Cnaph.), 126.5, 127.6, 128.1 (3CHnaph.), 129.4 (CCl2benz., 
CHCl2benz.), 131.0, 132.2 (2CHCl2benz.), 133.5 (CCl2benz.), 134.4 (Cnaph.), 138.7 (CCl2benz.), 144.5 (C-Ogal. 
para), 147.6, 147.8 (2C-Onaph.), 149.0 (2C-Ogal. meta), 163.4, 164.5 (2C=O). 
 
4-[(3,4-Dichlorobenzoyl)oxy]-2-naphthyl 3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy} 
benzoate (78). Obtained from monoester 62 (305 mg, 0.47 mmol) and acid chloride 52g (195 mg, 
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0.93 mmol) in 74% yield. Rf (hexane/DCM, 1:1) 0.60; mp 63-65 ºC; IR (ATR)  1744 (C=O), 1578, 
1485 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.17 (s, 6H, (CH3)2Si para), 0.27 (s, 12H, 2(CH3)2Si meta), 
0.97 (s, 18H, 2(CH3)3CSi meta), 1.01 (s, 9H, (CH3)3CSi para), 7.35 (d, J = 2.2, 1H, CHnaph.), 7.40 (s, 
2H, 2CHgal.), 7.48-7.58 (m, 2H, 2CHnaph.), 7.66 (d, J = 8.4, 1H, H5), 7.67 (d, J = 2.2, 1H, CHnaph.), 
7.86-7.90 (m, 2H, 2CHnaph.), 8.14 (dd, J = 8.4, 2.0, 1H, H6), 8.40 (d, J = 1.9, 1H, H2); 
13
C NMR (75 
MHz, CDCl3)  −3.7 ((CH3)2Si para), −3.5 (2(CH3)2Si meta), 18.7 ((CH3)3CSi para), 19.0 
(2(CH3)3CSi meta), 26.3 ((CH3)3CSi para), 26.4 (2(CH3)3CSi meta), 114.6 (CHnaph.), 116.3 (2CHgal.), 
117.4 (CHnaph.), 121.0 (Cgal.), 121.3 (CHnaph.), 125.0 (Cnaph.), 126.5, 127.5, 128.2 (3CHnaph.), 129.1 
(CCl2benz.), 129.5, 131.1, 132.3 (3CHCl2benz.), 133.7 (CCl2benz.), 134.5 (Cnaph.), 138.9 (CCl2benz.), 144.4 
(C-Ogal. para), 147.1, 148.2 (2C-Onaph.), 148.9 (2C-Ogal. meta), 163.2, 164.9 (2C=O); ESI-MS 677.4 
((M−COC6H3Cl2)+Na)
+
. 
 
3-[(3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3,4-bis{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (79). Obtained from monoester 63 (400 mg, 0.76 mmol) and acid 
chloride 52b (670 mg, 1.7 mmol) as an oil in 85% yield. Rf (hexane/DCM, 3:7) 0.43; 
1
H NMR (300 
MHz, CDCl3) 0.33 (s, 12H, 2(CH3)2Si), 0.36 (s, 12H, 2(CH3)2Si), 1.09 (s, 18H, 2(CH3)3CSi meta), 
1.10 (s, 9H, (CH3)3CSi para/meta), 1.11 (s, 9H, (CH3)3CSi para/meta), 6.73 (t, J = 2.3, 1H, H4'), 7.06 
(d, J = 8.4, 1H, H5), 7.45 (d, J = 2.1, 2H, H2', H6'), 7,50 (d, J = 2.1, 1H, CHnaph.), 7.51-7.60 (m, 2H, 
2CHnaph.), 7.73 (d, J = 1.8, 1H, CHnaph.), 7.91-7.97 (m, 3H, H2, H6, CHnaph.), 8.08 (d, J = 7.8, 1H, 
CHnaph.); 
13
C NMR (75 MHz, CDCl3)  −4.4 ((CH3)2Si para/meta), −4.2 ((CH3)2Si para/meta), −4.1 
(2(CH3)2Si meta), 18.1 ((CH3)3CSi para), 18.4 (3(CH3)3CSi meta), 25.6 ((CH3)3CSi para/meta), 25.8 
((CH3)3CSi para/meta), 25.9 (2(CH3)3CSi meta), 114.2 (CHnaph.), 115.0 (2CHα-res.), 116.5 (CHnaph.), 
117.5 (CHα-res.), 120.7 (CHprot.), 121.4 (Cprot.), 122.0 (CHnaph.), 122.7, 124.5 (2CHprot.), 125.3 (Cnaph.), 
126.1, 127.2, 127.8 (3CHnaph.), 130.9 (Cα-res.), 134.2 (Cnaph.), 147.0, 147.5, 147.8 (2C-Onaph., C-Oprot.), 
152.6, (C-Oprot.), 156.7 (2C-Oα-res.), 164.2, 164.6 (2C=O); ESI-MS 911.4 (M+Na)
+
. 
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4-[(3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 3,4-bis{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (80). Obtained from monoester 60 (400 mg, 0.76 mmol) and acid 
chloride 52b (670 mg, 1.7 mmol) as an oil in 86% yield. Rf (hexane/DCM, 3:7) 0.34; 
1
H NMR (300 
MHz, CDCl3)  0.27 (s, 18H, 3(CH3)2Si meta), 0.28 (s, 6H, (CH3)2Si para), 1.03 (s, 36H, 4(CH3)3CSi 
para,meta), 6.67 (t, J = 2.4, 1H, H4’), 6.95 (d, J = 8.4, 1H, H5), 7.38 (d, J = 2.1, 2H, H2’, H6’), 7.42 (d, 
J = 2.1, 1H, CHnaph.), 7.48-7.58 (m, 2H, 2CHnaph.), 7.66 (d, J = 2.1, 1H, CHnaph.), 7.72 (d, J = 2.1, 1H, 
H2), 7.77 (dd, J = 8.4, 2.1, 1H, H6), 7.88 (d, J = 7.8, 1H, CHnaph.), 7.97 (d, J = 7.8, 1H, CHnaph.); 
13
C 
NMR (75 MHz, CDCl3)  −4.4 (2(CH3)2Si meta), −4.1 ((CH3)2Si para/meta), −4.0 ((CH3)2Si 
para/meta), 18.2 (2(CH3)3CSi meta), 18.4 ((CH3)3CSi para/meta), 18.5 ((CH3)3CSi meta/para), 25.6 
(2(CH3)3CSi meta), 25.8 ((CH3)3CSi para/meta), 25.9 ((CH3)3CSi para/meta), 114.4 (CHnaph.), 115.1 
(2CHα-res.), 116.8 (CHnaph.), 117.8 (CHα-res.), 120.6 (CHprot.), 121.4 (CHnaph.), 122.3 (Cprot.), 122.7, 
124.4 (2CHprot.), 125.1 (Cnaph.), 126.1, 127.2, 127.9 (3CHnaph.), 130.7 (Cα-res.), 134.3 (Cnaph.), 146.9, 
147.3, 148.0 (2C-Onaph., C-Oprot.), 152.5 (C-Oprot.), 156.9 (2C-Oα-res.), 164.4, 164.7 (2C=O); ESI-MS 
889.4 (M+H)
+
. 
 
 
4-[(3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 4-{[tert-butyl 
(dimethyl)silyl]oxy}-3-chlorobenzoate (81). Obtained from monoester 60 (150 mg, 0.29 mmol) 
and acid chloride 52f (175 mg, 0.57 mmol) in 24% yield. Rf (DCM) 0.77; mp 65-67 ºC; IR (ATR)  
1739 (C=O), 1592, 1448 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.26 (s, 12H, 2(CH3)2Si meta), 0.31 (s, 
6H, (CH3)2Si para), 1.02 (s, 18H, 2(CH3)3CSi meta), 1.07 (s, 9H, (CH3)3CSi para), 6.66 (t, J = 2.3, 
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1H, H4’), 6.99 (d, J = 8.5, 1H, H5), 7.37 (d, J = 2.2, 1H, CHnaph.), 7.41 (d, J = 2.3, 2H, H2’, H6’), 7.46-
7.57 (m, 2H, 2CHnaph.), 7.66 (d, J = 2.0, 1H, CHnaph.), 7.88 (d, J = 7.7, 1H, CHnaph.), 7.96 (d, J = 8.0, 
1H, CHnaph.), 8.03 (dd, J = 8.5, 2.2, 1H, H6), 8.26 (d, J = 2.2, 1H, H2); 
13
C NMR (75 MHz, CDCl3)  
−4.2 (2(CH3)2Si meta), −4.1 ((CH3)2Si para), 18.4 (2(CH3)3CSi meta), 18.6 ((CH3)3CSi para), 25.7 
((CH3)3CSi para), 25.8 (2(CH3)3CSi meta), 114.4 (CHnaph.), 115.3 (2CHα-res.), 116.9 (CHnaph.), 118.0 
(CHα-res.), 120.4 (CHClbenz.), 121.6 (CHnaph.), 123.2 (Cα-res.), 125.4 (CClbenz.), 126.3 (Cnaph.), 126.4, 
127.5, 128.1 (3CHnaph.), 130.3 (CHClbenz.), 130.8 (CClBenz.), 132.8 (CHClbenz.), 134.5 (Cnaph.), 147.6, 
147.9 (2C-Onaph.), 156.8 (C-OClbenz.), 157.1 (2C-Oα-res.), 163.9, 164.6 (2C=O); ESI-MS 816.4 
(M+Na)
+
. 
 
3-[(3-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3,5-bis{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (82). Obtained from monoester 60 (200 mg, 0.38 mmol) and acid 
chloride 52d (210 mg, 0.76 mmol) as an oil in 70% yield. Rf (Hexane/DCM, 1:1) 0.46; IR (ATR)  
1744 (C=O), 1591, 1447 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.25 (s, 6H, (CH3)2Si), 0.26 (s, 12H, 
2(CH3)2Si), 1.01 (s, 27H, 3(CH3)3CSi), 6.65 (t, J = 2.3, 1H, H4), 7.13 (ddd, J = 8.1, 2.5, 1.0, 1H, H4'), 
7.36-7.42 (m, 4H, CHnaph., H5', H2, H6), 7.48-7.58 (m, 2H, 2CHnaph.), 7.67-7.69 (m, 2H, CHnaph., H2'), 
7.84 (dt, J =7.7, 1.3, 1H, H6'), 7.89 (d, J = 7.8, 1H, CHnaph.), 7.96 (d, J = 7.9, 1H, CHnaph.); 
13
C NMR 
(75 MHz, CDCl3)  −4.3 ((CH3)2Si), −4.2 (2(CH3)2Si), 18.4 (3(CH3)3CSi), 25.8 (3(CH3)3CSi), 114.5 
(CHnaph.), 115.3 (2CHα-res.), 117.0 (CHnaph.), 118.0 (CHα-res.), 121.6, 121.7 (CHm-sal., CHnaph.), 123.4 
(CHm-sal.), 125.4 (Cnaph.), 125.8 (CHm-sal.), 126.4, 127.4, 128.1 (3CHnaph.), 129.8 (CHm-sal.), 130.7, 
130.8 (Cα-res., Cm-sal.), 134.5 (Cnaph.), 147.6, 148.0 (2C-Onaph.), 156.1 (C-Om-sal.), 157.0 (2C-Oα-res.), 
164.6, 165.0 (2C=O); ESI-MS 781.0 (M+Na)
+
. 
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3-[(4-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3,5-bis{[tert-
butyl(dimethyl)silyl]oxy} benzoate (83). Obtained from monoester 60 (200 mg, 0.38 mmol) and 
acid chloride (52e, 210 mg, 0.76 mmol) in 62% yield. Rf (hexane/DCM, 1:1) 0.42; mp 128-129 ºC; 
IR (ATR)  1742 (C=O), 1595, 1453 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.26 (s, 12H, 2(CH3)2Si 
meta), 0.27 (s, 6H, (CH3)2Si para), 1.01 (s, 27H, 3(CH3)3CSi), 6.66 (t, J = 2.3, 1H, H4), 6.95 (d, J = 
8.8, 2H, H3', H5'), 7.37 (d, J = 2.2, 1H, CHnaph.), 7.40 (d, J = 2.2, 2H, H2, H6), 7.47-7.58 (m, 2H, 
2CHnaph.), 7.66 (d, J = 2.0, 1H, CHnaph.), 7.88 (d, J = 7.9, 1H, CHnaph.), 7.95 (d, J = 7.9, 1H, CHnaph.), 
8.14 (d, J = 8.8, 2H, H2', H6'); 
13
C NMR (75 MHz, CDCl3)  −4.3 (2(CH3)2Si meta), -4.2 ((CH3)2Si 
para), 18.3 (2(CH3)3CSi meta), 18.4 ((CH3)3CSi para), 25.7 ((CH3)3CSi para), 25.8 (2(CH3)3CSi 
meta), 114.6 (CHnaph.), 115.3 (2CHα-res.), 117.0 (CHnaph.), 118.0 (CHα-res.), 120.3 (2CHp-sal.), 121.6 
(CHnaph.), 122.3 (Cp-sal.), 125.3 (Cnaph.), 126.3, 127.4, 128.0 (3CHnaph.), 130.8 (Cα-res.), 132.5 (2CHp-
sal.), 134.5 (Cnaph.), 147.5, 148.1 (2C-Onaph.), 157.0 (2C-Oα-res.), 161.0 (C-Op-sal.), 164.6, 165.0 
(2C=O); ESI-MS 781.0 (M+Na)
+
. 
 
4-[(3-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 3,4-bis{[tert-butyl 
(dimethyl)silyl]oxy} benzoate (84). Obtained from monoester 61 (150 mg, 0.38 mmol) and acid 
chloride 52b (305 mg, 0.76 mmol) as an oil in 43% yield. Rf (hexane/DCM, 1:1) 0.40; IR (ATR)  
1739 (C=O), 1594, 1511 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.26 (s, 6H, (CH3)2Si), 0.27 (s, 6H, 
(CH3)2Si), 0.28 (s, 6H, (CH3)2Si), 1.02 (s, 27H, 3(CH3)3CSi), 6.94 (d, J = 8.4, 1H, H5), 7.17 (dd, J = 
8.1, 2.6, 1H, H4’), 7.37 (d, J = 2.1, 1H, CHnaph.), 7.43 (t, J = 7.9, 1H, H5’), 7.46-7.58 (m, 2H, 
2CHnaph.), 7.66 (d, J = 2.0, 1H, CHnaph.), 7.71 (d, J = 2.1, 1H, H2), 7.74-7.79 (m, 2H, H2’, H6), 7.88 (d, 
J = 7.7, 1H, CHnaph.), 7.92-7.97 (m, 2H, CHnaph., H6’); 
13
C NMR (75 MHz, CDCl3)  −4.3, −4.0, −3.9 
(3(CH3)2Si), 18.4, 18.6, 18.7 (3(CH3)3CSi), 25.8, 26.0, 26.1 (3(CH3)3CSi), 114.6, 117.1 (2CHnaph.), 
120.8 (CHprot.), 121.6 (CHnaph.), 121.8 (CHm-sal.), 122.5 (Cprot.), 122.9, 123.5 (CHm-sal., CHprot.), 124.6 
(CHprot.), 125.3 (Cnaph.), 126.0 (CHm-sal.), 126.3, 127.4, 128.1 (3CHnaph.), 130.0 (CHm-sal.), 130.5 (Cm-
sal.), 134.5 (Cnaph.), 147.1 (C-Oprot.), 147.5, 148.2 (2C-Onaph.), 152.6 (C-Oprot.), 156.2 (C-Om-sal.), 164.8, 
164.9 (2C=O); ESI-MS 781.0 (M+Na)
+
. 
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3-[(4-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-1-naphthyl 3-{[tert-
butyl(dimethyl)silyl]oxy}benzoate (85). Obtained from monoester 61 (150 mg, 0.38 mmol) and 
acid chloride 52e (210 mg, 0.76 mmol) as an oil in 84% yield. Rf (hexane/DCM, 1:1) 0.38; IR (ATR) 
1740 (C=O), 1599, 1507 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.26 (s, 6H, (CH3)2Si meta), 0.27 (s, 
6H, (CH3)2Si para), 1.02 (s, 9H, (CH3)3CSi), 1.03 (s, 9H, (CH3)3CSi), 6.95 (d, J = 8.8, 2H, H3', H5'), 
7.17 (ddd, J = 8.1, 2.5, 1.0, 1H, H4), 7.38 (d, J = 2.2, 1H, CHnaph.), 7.43 (t, J = 7.9, 1H, H5), 7.47-
7.58 (m, 2H, 2CHnaph.), 7.66 (d, J = 2.0, 1H, CHnaph.), 7.77 (app t, J = 2.0, 1H, H2), 7.88 (d, J = 7.8, 
1H, CHnaph.), 7.92-7.98 (m, 2H, CHnaph., H6), 8.15 (d, J = 8.8, 2H, H2', H6'); 
13
C NMR (75 MHz, CDCl3) 
 −4.3 ((CH3)2Si), −4.2 ((CH3)2Si), 18.3 ((CH3)3CSi), 18.4 ((CH3)3CSi), 25.7 ((CH3)3CSi), 25.8 
((CH3)3CSi), 114.6, 117.0 (2CHnaph.), 120.3 (2CHp-sal.), 121.6, 121.8 (CHnaph., CHm-sal.), 122.3 (Cp-sal.), 
123.5 (CHm-sal.), 125.3 (Cnaph.), 126.0 (CHm-sal.), 126.3, 127.4, 128.1 (3CHnaph.), 130.0 (CHm-sal.), 
130.6 (Cm-sal.), 132.5 (2CHp-sal.), 134.5 (Cnaph.), 147.5, 148.1 (2C-Onaph.), 156.2 (C-Om-sal.), 161.0 (C-
Op-sal.), 164.7, 164.9 (2C=O); ESI-MS 651.0 (M+Na)
+
. 
 
4-[(4-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]-2-naphthyl 3-{[tert-butyl(dimethyl) 
silyl]oxy}benzoate (86). Obtained from monoester 64 (150 mg, 0.38 mmol) and acid chloride 52e 
(210 mg, 0.76 mmol) as an oil in 85% yield. Rf (hexane/DCM, 1:1) 0.38; IR (ATR)  1741 (C=O), 
1599, 1509 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.25 (s, 6H, (CH3)2Si), 0.29 (s, 6H, (CH3)2Si), 1.01 (s, 
9H, (CH3)3CSi), 1.02 (s, 9H, (CH3)3CSi), 6.99 (d, J = 8.7, 2H, H3’, H5’), 7.13 (ddd, J = 8.1, 2.5, 0.9, 
1H, H4), 7.36-7.41 (m, 2H, CHnaph., H5), 7.46-7.57 (m, 2H, 2CHnaph.), 7.67-7.69 (m, 2H, CHnaph., H2), 
7.83-7.89 (m, 2H, CHnaph., H6), 7.97 (d, J = 8.1, 1H, CHnaph.), 8.23 (d, J = 8.7, 2H, H2’, H6’); 
13
C NMR 
(75 MHz, CDCl3)  −4.3 ((CH3)2Si), −4.2 ((CH3)2Si), 18.3 ((CH3)3CSi), 18.4 ((CH3)3CSi), 25.7 
((CH3)3CSi), 25.8 ((CH3)3CSi), 114.5, 116.9 (2CHnaph.), 120.1 (CHm-sal.), 120.4 (2CHp-sal.), 121.7 
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(CHnaph.), 122.1 (Cp-sal.), 123.4 (CHm-sal.), 125.5 (Cnaph.), 125.8 (CHm-sal.), 126.3, 127.4, 128.1 
(3CHnaph.), 129.8 (CHm-sal.), 130.8 (Cm-sal.), 132.6 (2CHp-sal.), 134.5 (Cnaph.), 147.7, 148.0 (2C-Onaph.), 
156.1 (C-Om-sal.), 161.2 (C-Op-sal.), 164.7, 165.0 (2C=O); ESI-MS 651.0 (M+Na)
+
. 
 
5-[(3,5-Bis{[tert-butyl(dimethyl)silyl]oxy}benzoyl)oxy]biphenyl-3-yl 3,4-bis{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (105). Obtained from monoester 101 (168 mg, 0.31 mmol) and acid 
chloride 52c (245 mg, 0.61 mmol) as an oil in 34% yield. Rf (hexane/DCM, 6:4) 0.74; IR (ATR)  
1743 (C=O), 1591, 1447 (Ar), 1198, 1169 (C-O); 
1
H NMR (300 MHz, CDCl3)  0.23 (s, 12H, 
2(CH3)2Si meta), 0.24 (s, 6H, (CH3)2Si meta/para), 0.26 (s, 6H, (CH3)2Si meta/para), 1.00 (s, 18H, 
2(CH3)3CSi meta), 1.01 (s, 18H, 2(CH3)3CSi meta, para), 6.60 (t, J = 2.2, 1H, H4’’’), 6.92 (d, J = 8.4, 
1H, H5’’), 7.13 (t, J = 2.1, 1H, H4), 7.28 (d, J = 2.2, 2H, H2’’’, H6’’’), 7.36 (d, J = 2.1, 2H, H2, H6), 7.39-
7.46 (m, 3H, H3’, H4’, H5’), 7.61 (d, J = 7.1, 2H, H2’, H6’), 7.67 (d, J = 2.1, 1H, H2’’), 7.72 (dd, J = 8.4, 
2.2, 1H, H6’’); 
13
C NMR (75 MHz, CDCl3)  −4.2 (2(CH3)2Si), −4.0, −3.9 (2(CH3)2Si), 18.2 
(2(CH3)3CSi), 18.4, 18.5 (2(CH3)3CSi), 25.8 (2(CH3)3CSi), 26.0, 26.1 (2(CH3)3CSi), 114.7 (C4H), 
115.5 (2CHα-res.), 117.8, 118.0, 118.3 (C2H, C6H, CHα-res.), 120.8 (CHprot.), 122.4 (Cprot.), 122.9, 124.6 
(2CHprot ), 127.4 (C2’H, C6’H), 128.1 (C4’H), 129.0 (C3’H, C5’H), 131.0 (Cα-res.), 139.6, 143.6 (2Cbiph.), 
147.1, 151.8, 152.0, 152.9 (2C-Oprot., 2C-Obiph.), 156.9 (2C-Oα-res.), 164.7 (2C=O); ESI-MS 934.4 
(M+Na)
+
. 
 
5-[(3-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]biphenyl-3-yl 3,4-bis{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (106). Obtained from monoester 101 (256 mg, 0.47 mmol) and acid 
chloride 52d (252 mg, 0.93 mmol) as an oil in 89% yield. Rf (hexane/DCM, 9:1) 0.14; IR (ATR)  
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1740 (C=O), 1510, 1465, 1440, 1418 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.27, 0.28, 0.29 (s, 18H, 
3(CH3)2Si), 1.03 (s, 18H, 2(CH3)3CSi meta), 1.04 (s, 9H, (CH3)3CSi para), 6.95 (d, J = 8.4, 1H, H4’’’), 
7.14 (ddd, J = 8.2, 2.4, 0.8, 1H, H5’’), 7.18 (t, J = 2.0, 1H, H4), 7.36-7.48 (m, 6H, H2, H6, H3’, H4’, H5’, 
H5’’’), 7.64 (d, J = 7.1, 2H, H2’, H6’), 7.69 (t, J = 1.9, 1H, H2’’’), 7.72 (d, J = 1.9, 1H, H2’’), 7.77 (dd, J = 
8.4, 2.1, 1H, H6’’), 7.85 (d, J = 7.8, 1H, H6’’’); 
13
C NMR (75 MHz, CDCl3)  −4.3, −4.0, −3.9 
(3(CH3)2Si), 18.4, 18.6, 18.7 (3(CH3)3CSi), 25.8, 26.0, 26.1 (3(CH3)3CSi), 114.7 (C4H), 118.0, 118.2 
(C2H, C6H), 120.8 (CHprot.),121.7 (CHm-sal.), 122.4 (Cprot.), 122.9 (CHprot.), 123.4 (CHm-sal.), 124.5 
(CHprot.), 125.8 (CHm-sal.), 127.4 (C2’H, C6’H), 128.2 (C4’H), 129.0 (C3’H, C5’H), 129.8 (CHm-sal.), 130.8 
(Cm-sal.), 139.7, 143.7 (2Cbiph.), 147.1, 151.8, 152.0, 152.7 (2C-Oprot., 2C-Obiph.), 156.1 (C-Om-sal.), 
164.6, 164.8 (2C=O); ESI-MS 807.4 (M+Na)
+
. 
 
5-[(3-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]biphenyl-3-yl 3,5-bis{[tert-butyl 
(dimethyl)silyl]oxy}benzoate (107). Obtained from monoester 103 (101 mg, 0.24 mmol) and acid 
chloride 52c (193 mg, 0.48 mmol) as an oil in 61% yield. Rf (hexane/DCM, 6:4) 0.28; 
1
H NMR (300 
MHz, CDCl3)  0.24 (s, 12H, 2(CH3)2Si), 0.25 (s, 6H, (CH3)2Si), 1.00 (s, 18H, 2(CH3)3CSi), 1.01 (s, 
9H, (CH3)3CSi), 6.61 (t, J = 2.3, 1H, H4’’), 7.12 (ddd, J = 8.2, 2.5, 1.0, 1H, H4’’’), 7.16 (t, J = 2.1, 1H, 
H4), 7.30 (d, J = 2.3, 2H, H2’’, H6’’), 7.33-7.41 (m, 4H, H2, H6, H4’, H5’’’), 7.45 (t, J = 7.2, 2H, H3’, H5’), 
7.62 (d, J = 6.9, 2H, H2’, H6’), 7.66 (t, J = 2.0, 1H, H2’’’), 7.82 (dt, J = 7.8, 1.3, 1H, H6’’’); 
13
C NMR (75 
MHz, CDCl3)  −4.3 (3(CH3)2Si), 18.4 (3(CH3)3CSi), 25.8 (3(CH3)3CSi), 114.6 (C4H), 115.3 (2CHα-
res.), 117.8, 118.1, 118.2 (C2H, C6H, CHα-res.), 121.7 (CHm-sal.), 123.4, 125.9 (2CHm-sal.), 127.4 (C2’H, 
C6’H), 128.2 (C4’H), 129.0 (CHα-res., CHm-sal.), 129.8 (CHm-sal.), 130.7, 131.0 (Cα-res., Cm-sal.), 139.6, 
143.7 (2Cbiph.), 151.8 (2C-Obiph.), 156.1 (C-Om-sal.), 156.9 (2C-Oα-res.), 164.7, 164.8 (2C=O); ESI-MS 
807.4 (M+Na)
+
. 
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5-[(4-{[tert-Butyl(dimethyl)silyl]oxy}benzoyl)oxy]biphenyl-3-yl 3-{[tert-butyl(dimethyl) 
silyl]oxy}benzoate (108). Obtained from monoester 104 (110 mg, 0.26 mmol) and acid chloride 
52d (142 mg, 0.52 mmol) as an oil in 61% yield. Rf (hexane/DCM, 1:1) 0.45; IR (ATR)  1739 
(C=O), 1600, 1508 (Ar), 1281, 1256 (C-O); 
1
H NMR (300 MHz, CDCl3)  0.25 (s, 6H, (CH3)2Si), 
0.27 (s, 6H, (CH3)2Si), 1.01 (s, 9H, (CH3)3CSi), 1.02 (s, 9H, (CH3)3CSi), 6.95 (d, J = 8.8, 2H, H3’’’, 
H5’’’), 7.13 (ddd, J = 8.1, 2.5, 0.9, 1H, H4’’), 7.16 (t, J = 2.1, 1H, H4), 7.34-7.42 (m, 4H, H2, H6, H4’, 
H5’’), 7.45 (t, J = 7.2, 2H, H3’, H5’), 7.62 (d, J = 7.1, 2H, H2’, H6’), 7.67 (t, J = 2.0, 1H, H2’’), 7.83 (dt, J 
= 7.8, 1.3, 1H, H6’’), 8.13 (d, J = 8.7, 2H, H2’’’, H6’’’); 
13
C NMR (75 MHz, CDCl3)  −4.3, −4.2 
(2(CH3)2Si), 18.3, 18.4 (2(CH3)3CSi), 25.7, 25.8 (2(CH3)3CSi), 114.7 (C4H), 118.0, 118.2 (C2H, 
C6H), 120.3 (2CHp-sal.),121.7 (CHm-sal.), 122.3 (Cp-sal.), 123.4, 125.8 (2CHm-sal.), 127.4 (C3’H, C5’H), 
128.2 (C4’H), 129.0 (C2’H, C6’H), 129.8 (CHm-sal.), 130.7 (Cm-sal.), 132.5 (2CHp-sal.), 139.6, 143.7 
(2Cbiph.), 151.8, 151.9 (2C-Obiph.), 156.1 (C-Op-sal.), 161.0 (C-Om-sal.), 164.7, 164.8 (2C=O); ESI-MS 
677.3 (M+Na)
+
. 
General Procedure for the Synthesis of Final Compounds 1, 2, 4-32 and 37-46. To a 
solution of the corresponding TBS derivative 53-59, 62, 65-86 or 98-108 in a mixture of pyridine 
(0.96 mL/mmol of TBS group) and anhydrous THF (2 mL/mmol of TBS group) under an argon 
atmosphere, HF·pyridine complex (0.96 mL/mmol of TBS group) was added and the reaction 
mixture was stirred at room temperature. After the disappearance of the starting material (TLC 
analysis, approx. 15 min), the reaction was diluted with water (50 mL) and the mixture was 
extracted with ethyl acetate. The organic layer was washed with a saturated aqueous solution of 
CuSO4, water and dried (Na2SO4). The solvent was evaporated under reduced pressure and the 
resulting solid was recrystallized from DCM/MeOH or purified by chromatography (from DCM to 
DCM/MeOH, 95:5; Rf is specified) to afford the corresponding pure final compound. 
 
Naphthalene-1,3-diyl bis(3,4,5-trihydroxybenzoate) (1). Obtained from silyl ether 53 (300 
mg, 0.39 mmol) in 65% yield. mp 163-164 ºC (Lit.
95
 163-164 ºC); IR (ATR)  3385 (OH), 1709 
(C=O), 1608 (Ar); 
1
H NMR (300 MHz, CD3OD) 7.18-7.27 (m, 3H, 2CHgal., CHnaph.), 7.34 (s, 2H, 
2CHgal.), 7.45-7.65 (m, 3H, 3CHnaph.), 7.88-7.96 (m, 2H, 2CHnaph.); 
13
C NMR (75 MHz, CD3OD)  
109.7, 109.8 (4CHgal.), 114.7, 116.8 (2CHnaph.), 119.1, 119.4 (2Cgal.), 121.4 (CHnaph.), 125.6 (Cnaph.), 
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126.3, 127.4, 128.0 (3CHnaph.), 134.8 (Cnaph.), 139.7, 139.9 (2C-Ogal.), 145.8, 145.9 (4C-Ogal.), 148.1, 
148.6 (2C-Onaph.), 165.7, 165.9 (2C=O); ESI-MS 462.7 (M–H)
–
. The spectroscopic data are in 
agreement with those previously described.
95
 
 
Biphenyl-3,5-diyl bis(3,4,5-trihydroxybenzoate) (2). Obtained from silyl ether 98 (626 mg, 
0.53 mmol) in 28% yield. mp 205-207 ºC; Rf (hexane/ethyl acetate/acetic acid, 7:3:0.01) 0.40; IR 
(ATR)  3356 (OH), 1692 (C=O), 1612, 1536, 1454 (Ar), 1195 (C-O); 
1
H NMR (300 MHz, acetone-
d6)  7.21 (s, 1H, H4), 7.31 (s, 4H, 4CHgal.), 7.40 (t, J = 7.3, 1H, H4’), 7.47-7.52 (m, 4H, H2, H6, H3’, 
H5’), 7.74-7.78 (m, 2H, H2’, H6’), 8.32 (br s, 1H, OH), 8.46 (br s, 4H, 4OH), 8.54 (br s, 1H, OH); 
13
C 
NMR (75 MHz, acetone-d6) 110.5 (4CHgal.), 115.9 (C4H), 118.5 (C2H, C6H), 120.6 (2Cgal.), 127.8 
(C2’H, C6’H), 129.0 (C4’H), 129.9 (C3’H, C5’H), 139.7 (2C-Obiph.), 140.1, 143.8 (2Cbiph.), 146.3 (4C-
Ogal.), 153.2 (2C-Ogal.), 165.2 (2C=O); ESI-MS 488.7 (M–H)
–
; elemental analysis (calcd., found for 
C26H18O10·3H2O): C (57.36, 57.76), H (4.44, 4.20). 
 
Naphthalene-1,3-diyl bis(3,4-dihydroxybenzoate) (4). Obtained from silyl ether 54 (168 mg, 
0.39 mmol) in 26% yield. mp 79-81 ºC; IR (ATR)  3423 (OH), 1712 (C=O), 1603 (Ar); 
1
H NMR (300 
MHz, CD3OD) 6.90 (d, J = 8.2, 1H, H5), 6.94 (d, J = 8.3, 1H, H5'), 7.29 d (d, J = 2.1, 1H, CHnaph.), 
7.50-7.75 (m, 7H, 3CHnaph., H2, H6, H2', H6'), 7.89-7.97 (m, 2H, 2CHnaph.); 
13
C NMR (75 MHz, 
CD3OD)  115.8 (CHnaph.), 116.2, 116.4 (2CHprot.), 117.9 (CHnaph.), 118.0 (2CHprot.), 121.3, 121.6 
(2Cprot.), 122.4 (CHnaph.), 124.6, 124.7 (2CHprot.), 126.6 (Cnaph.), 127.4, 128.4, 129.0 (3CHnaph.), 135.8 
(Cnaph.), 146.5, 146.7 (2C-Oprot.), 149.1, 149.6 (2C-Onaph.), 152.7, 152.9 (2C-Oprot.), 166.6, 166.7 
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(2C=O); ESI-MS 454.9 (M+Na)
+
; elemental analysis (calcd., found for C24H16O8·2H2O): C (61.54, 
61.19), H (4.30, 4.03). 
 
Naphthalene-1,3-diyl bis(3,5-dihydroxybenzoate) (5). Obtained from silyl ether 55 (140 mg, 
0.32 mmol) in 52% yield. mp 167-169 ºC; IR (ATR)  3386 (OH), 1710 (C=O), 1603 (Ar); 
1
H NMR 
(300 MHz, CD3OD)  6.58 (t, J = 2.3, 1H, H4), 6.62 (t, J = 2.3, 1H, H4'), 7.15 (d, J = 2.3, 2H, H2, H6), 
7.23 (d, J = 2.4, 2H, H2', H6'), 7.34 (d, J = 2.2, 1H, CHnaph.), 7.54-7.60 (m, 2H, 2CHnaph.), 7.71 (d, J = 
2.0, 1H, CHnaph.), 7.90-7.99 (m, 2H, 2CHnaph.); 
13
C NMR (75 MHz, CD3OD) 109.0 (2CHα-res.), 109.3 
(4CHα-res.), 115.4, 117.9, 122.2 (3CHnaph.), 126.4 (Cnaph.), 127.4, 128.4, 128.9 (3CHnaph.), 131.7, 
132.1 (2Cα-res.), 135.7 (Cnaph.), 148.8, 149.3 (2C-Onaph.), 160.0 (2C-Oα-res.), 160.1 (2C-Oα-res.), 166.3, 
166.5 (2C=O); ESI-MS 454.8 (M+Na)
+
; elemental analysis (calcd., found for C24H16O8·3/2H2O): C 
(62.75, 62.25), H (4.17, 4.02). 
 
Naphthalene-1,3-diyl bis(3-hydroxybenzoate) (6). Obtained from silyl ether 56 (187 mg, 
0.30 mmol) in 75% yield. Rf (DCM/MeOH, 95:5) 0.33; mp 91-93 ºC; IR (ATR)  3410 (OH), 1720 
(C=O), 1595, 1492 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.21 (ddd, J = 8.6, 2.5, 1.0, 1H, H4), 7.25 
(ddd, J = 8.6, 2.5, 1.0, 1H, H4'), 7.45 (t, J = 8.0, 1H, H5), 7.49 (t, J = 8.0, 1H, CH5'), 7.54 (d, J = 2.3, 
1H, CHnaph.), 7.56-7.67 (m, 2H, 2CHnaph.), 7.70 (app t, J = 2.0, 1H, H2), 7.74 (dt, J = 7.7, 1.2 1H, H6), 
7.78 (app t, J = 2.0, 1H, H2'), 7.81-7.84 (m, 2H, H6', CHnaph.), 7.99-8.06 (m, 2H, 2CHnaph.), 8.95 (br s, 
2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  115.8 (CHnaph.), 117.3, 117.4 (2CHm-sal.), 117.9 
(CHnaph.), 121.9 (CHm-sal.), 122.1 (2CHm-sal.), 122.1 (CHm-sal.), 122.3 (CHnaph.), 126.2 (Cnaph.), 127.4, 
128.4, 128.8 (3CHnaph.), 130.9, 131.1 (2CHm-sal.), 131.3, 131.6 (2Cm-sal.), 135.3 (Cnaph.), 148.6, 149.2 
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(2C-Onaph.), 158.6, 158.7 (2C-Om-sal.), 165.3, 165.5 (2C=O); ESI-MS 399.0 (M−H)
−
; elemental 
analysis (calcd., found for C24H16O6·1/2H2O): C (70.41, 70.54), H (4.19, 4.23). 
 
Naphthalene-1,3-diyl bis(3-chloro-4-hydroxybenzoate) (7). Obtained from silyl ether 58 
(153 mg, 0.13 mmol) in 88% yield. Rf (DCM) 0.14; mp 217-219 ºC; IR (ATR) 3371 (OH), 1728 
(C=O), 1595, 1505 (Ar); 
1
H NMR (300 MHz, acetone-d6) 7.22 (d, J = 8.5, 1H, H5), 7.26 (d, J = 8.6, 
1H H5'), 7.50 (d, J = 2.1, 1H, CHnaph.), 7.55-7.66 (m, 2H, 2CHnaph.), 7.81 (d, J = 2.0, 1H, CHnaph.), 
7.98-8.07 (m, 3H, 2CHnaph., H6), 8.14 (dd, J = 8.6, 2.1, 1H, H6'), 8.20 (d, J = 2.1, 1H, H2), 8.28 (d, J = 
2.1, 1H, H2'), 8.59 (s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6) 115.7, 117.6, 117.7, 117.8 
(2CHnaph., 2CHClbenz.), 121.5, 121.7 (2CClbenz.), 122.3 (CHnaph.), 122.4, 122.7 (2CClbenz.), 126.2 (Cnaph.), 
127.3, 128.3, 128.8 (3CHnaph.), 131.5, 131.6, 133.0, 133.1 (4CHClbenz.), 135.3 (Cnaph.), 148.5, 149.1 
(2C-Onaph.), 158.9, 159.0 (2C-OClbenz.), 164.2, 164.3 (2C=O); ESI-MS 467.0 (M−H)
−
; elemental 
analysis (calcd., found for C24H14 Cl2O6·1/2H2O): C (60.67, 60.27), H (3.61, 3.16). 
 
Naphthalene-1,3-diyl bis(4-hydroxybenzoate) (8). Obtained from silyl ether 57 (120 mg, 
0.19 mmol) in 86% yield. Rf (DCM/MeOH, 95:5) 0.38; mp 269-270 ºC (decomposed); IR (ATR)  
3369 (OH), 1708 (C=O), 1600, 1513 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.03 (d, J = 8.8, 2H, H3, 
H5), 7.08 (d, J = 8.8, 2H, H3', H5'), 7.46 (d, J = 2.2, 1H, CHnaph.), 7.53-7.65 (m, 2H, 2CHnaph.), 7.78 (d, 
J = 2.0, 1H, CHnaph.), 7.98 (d, J = 8.2, 1H, CHnaph.), 8.02 (d, J = 7.4, 1H, CHnaph.), 8.12 (d, J = 8.8, 
2H, H2, H6), 8.21 (d, J = 8.8, 2H, H2', H6'), 9.45 (br s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  
115.9 (CHnaph.), 116.4 (2CHp-sal.), 116.5 (2CHp-sal.), 117.6 (CHnaph.), 121.1, 121.4 (2Cp-sal.), 122.3 
(CHnaph.), 126.2 (Cnaph.), 127.1, 128.2, 128.7 (3CHnaph.), 133.3 (2CHp-sal.), 133.4 (2CHp-sal.), 135.3 
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(Cnaph.), 148.7, 149.3 (2C-Onaph.), 163.4, 163.6 (2C-Op-sal.), 165.1, 165.2 (2C=O); ESI-MS 398.5 
(M−H)
−
; elemental analysis (calcd., found for C24H16O6·1/4H2O): C (71.19, 71.24), H (4.11, 4.24). 
 
4-[(3,4,5-Trimethoxybenzoyl)oxy]-2-naphthyl 3,4,5-trihydroxybenzoate (9). Obtained from 
silyl ether 65 (240 mg, 0.28 mmol) in 32% yield. Rf (DCM/ethyl acetate, 1:1) 0.65; mp 104-105 ºC; 
IR (ATR)  3400 (OH), 1730 (C=O), 1596, 1505, 1460 (Ar); 
1
H NMR (300 MHz, acetone-d6)  3.88 
(s, 3H, CH3 para), 3.96 (s, 6H, 2CH3 meta), 7.34 (s, 2H, 2CHgal.), 7.45 (d, J = 2.2, 1H, CHnaph.), 7.52-
7.67 (m, 4H, 2CHnaph., 2CHeud.), 7.77 (d, J = 2.0, 1H, CHnaph.), 7.97 (d, J = 8.2, 1H, CHnaph.), 8.02 (d, 
J = 7.7, 1H, CHnaph.); 
13
C NMR (75 MHz, acetone-d6)  56.8 (2CH3 meta), 60.8 (CH3 para), 108.6 
(2CHeud.), 110.6 (2CHgal.), 115.9, 117.8 (2CHnaph.), 120.7 (Cgal.), 122.4 (CHnaph.), 124.8 (Cnaph.), 126.1 
(Ceud.), 127.2, 128.2, 128.8 (3CHnaph.), 135.3 (Cnaph.), 139.7 (C-Oeud. para), 144.3 (C-Ogal. para), 
146.3 (2C-Oeud. meta), 148.6, 149.4 (2C-Onaph.), 154.5 (2C-Ogal. meta) , 165.1, 165.4 (2C=O); ESI-
MS 505.0 (M−H)
−
; elemental analysis (calcd., found for C27H22O10·1/2H2O): C (62.91, 62.57), H 
(4.50, 4.84). 
 
3-[(3,4,5-Trimethoxybenzoyl)oxy]-1-naphthyl 3,4,5-trihydroxybenzoate (10). Obtained 
from silyl ether 66 (101 mg, 0.12 mmol) in 58% yield. Rf (DCM/ethyl acetate, 1:1) 0.60; mp 172-173 
ºC; IR (ATR)  3390 (OH), 1728 (C=O), 1599, 1460 (Ar); 
1
H NMR (300 MHz, acetone-d6)  3.85 (s, 
3H, CH3 para), 3.95 (s, 6H, 2CH3 meta), 7.42 (s, 2H, 2CHgal.), 7.45 (d, J = 2.2, 1H, CHnaph.), 7.54 (s, 
2H, 2CHeud.), 7.55-7.67 (m, 2H, 2CHnaph.), 7.78 (d, J = 1.9, 1H, CHnaph.), 7.99 (dd, J = 8.2, 1.4, 1H, 
Experimental part 
- 112 - 
CHnaph.), 8.03 (dd, J = 8.2, 1.1, 1H, CHnaph.), 8.37 (br s, 1H, OH para), 8.48 (br s, 2H, 2OH meta); 
13
C NMR (75 MHz, acetone-d6)  56.7 (2CH3 meta), 60.8 (CH3 para), 108.4 (2CHgal.), 110.6 
(2CHeud.), 115.7, 117.6 (2CHnaph.), 120.3 (Ceud.), 122.3 (CHnaph.), 125.1 (Cnaph.), 126.3 (Cgal.), 127.2, 
128.3, 128.8 (3CHnaph.), 135.3 (Cnaph.), 144.2 (2C-O para), 146.4 (2C-O meta), 148.8, 149.2 (2C-
Onaph.), 154.4 (2C-O meta), 165.1, 165.2 (2C=O); ESI-MS 505.1 (M−H)
−
; elemental analysis (calcd., 
found for C27H22O10·1/2H2O): C (62.91, 62.57), H (4.50, 4.70). 
 
3-[(3,4-Dihydroxybenzoyl)oxy]-1-naphthyl 3,4,5-trihydroxybenzoate (11). Obtained from 
silyl ether 67 (143 mg, 0.32 mmol) in 83% yield. mp 148 ºC (decomposed); IR (ATR)  3324 (OH), 
1703 (C=O), 1607 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.05 (d, J = 8.8, 1H, H5), 7.33 (s, 2H, 
2CHgal.), 7.43 (d, J = 2.2, 1H, CHnaph.), 7.51-7.67 (m, 2H, 2CHnaph.), 7.75 (d, J = 2.0, 1H, CHnaph.), 
7.66-7.81 (m, 2H, H2, H6), 7.92-8.06 (m, 2H, 2CHnaph.), 8.32 (br s, 1H, OH), 8.45 (br s, 2H, 2OH), 
8.61 (br s, 1H, OH), 8.95 (br s, 1H, OH); 
13
C NMR (75 MHz, acetone-d6)  110.6 (2CHgal.), 115.9, 
116.3, 117.6, 117.8 (2CHnaph., 2CHprot.), 120.7 (Cgal.), 121.5 (Cprot.), 122.3 (CHnaph.), 124.5 (CHprot.), 
126.2 (Cnaph.), 127.1, 128.2, 128.8 (3CHnaph.), 135.3 (Cnaph.), 139.8 (C-Ogal. para), 146.1(2C-Ogal. 
meta), 146.3 (C-Oprot.), 148.8, 149.5 (2C-Onaph.), 152.0 (C-Oprot.), 165.2, 165.4 (2C=O); ESI-MS 
447.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O9·3/2H2O): C (60.63, 60.30), H (4.03, 
4.05). 
 
3-[(3,5-Dihydroxybenzoyl)oxy]-1-naphthyl 3,4,5-trihydroxybenzoate (12). Obtained from 
silyl ether 68 (160 mg, 0.36 mmol) in 91% yield. mp 175-177 ºC; IR (ATR)  3367 (OH), 1698 
(C=O), 1605 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.73 (t, J = 2.3, 1H, H4), 7.30 (d, J = 2.3, 1H, 
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CHnaph.), 7.33 (s, 2H, 2CHgal.), 7.47 (d, J = 2.3, 1H, CHnaph.), 7.56-7.65 (m, 2H, 2CHnaph.), 7.77 (d, J = 
2.0, 2H, H2, H6), 7.97 (d, J = 7.8, 1H, CHnaph.), 8.03 (d, J = 7.8, 1H, CHnaph.), 8.31 (br s, 1H, OH), 
8.43 (br s, 2H, 2OH), 8.81 (br s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  108.8 (CHα-res.), 109.2 
(2CHα-res.), 110.6 (2CHgal.), 115.7, 117.5 (2CHnaph.), 120.4 (Cgal.), 122.3 (CHnaph.), 126.3 (Cnaph.), 
127.2, 128.2, 128.8 (3CHnaph.), 132.2 (Cα-res.), 135.3 (Cnaph.), 139.8 (C-Ogal. para), 146.4 (2C-Ogal. 
meta), 148.8, 149.2 (2C-Onaph.), 159.7 (2C-Oα-res.), 165.4 (2C=O); ESI-MS 447.1 (M−H)
−
; elemental 
analysis (calcd., found for C24H16O9·2H2O): C (59.51, 59.36), H (4.16, 3.98). 
 
4-[(3,4-Dihydroxybenzoyl)oxy]-2-naphthyl 3,4,5-trihydroxybenzoate (13). Obtained from 
silyl ether 69 (240 mg, 0.54 mmol) in 78% yield. mp 140 ºC (decomposed); IR (ATR)  3401 (OH), 
1709 (C=O), 1606 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.02 (d, J = 8.7, 1H, H5), 7.42 (s, 2H, 
2CHgal.), 7.43 (d, J = 2.2, 1H, CHnaph.), 7.57-7.63 (m, 2H, 2CHnaph.), 7.68-7.71 (m, 2H, H2, H6), 7.76 
(d, J = 2.0, 1H, CHnaph.), 7.97 (d, J = 7.9, 1H, CHnaph.), 8.02 (d, J = 7.3, 1H, CHnaph.), 8.33 (br s, 1H, 
OH), 8.47 (br s, 2H, OH), 8.52 (br s, 1H, OH), 8.87 (br s, 1H, OH); 
13
C NMR (75 MHz, acetone-d6)  
110.7 (2CHgal.), 115.9, 116.2, 117.7, 117.8 (2CHnaph., 2CHprot.), 120.4 (Cgal.), 121.8 (Cprot.), 122.3 
(CHnaph.), 124.3 (CHprot.), 126.2 (Cnaph.), 127.1, 128.2, 128.8 (3CHnaph.), 135.3 (Cnaph.), 140.0 (C-Ogal. 
para), 146.3 (2C-Ogal. meta), 146.5 (C-Oprot.), 148.8, 149.4 (2C-Onaph.), 151.8 (C-Oprot.), 165.2, 165.3 
(2C=O); ESI-MS 447.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O9·H2O): C (61.81, 
61.42), H (3.89, 3.80). 
 
4-[(3,5-Dihydroxybenzoyl)oxy]-2-naphthyl 3,4,5-trihydroxybenzoate (14). Obtained from 
silyl ether 70 (121 mg, 0.27 mmol) in 84% yield. mp 176-178 ºC; IR (ATR)  3464 (OH), 1695 
(C=O), 1605 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.73 (t, J = 2.3, 1H, H4), 7.31 (d, J = 2.3, 2H, 
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H2, H6), 7.34 (s, 2H, 2CHgal.), 7.47 (d, J = 2.1, 1H, CHnaph.), 7.55-7.65 (m, 2H, 2CHnaph.), 7.76 (d, J = 
1.9, 1H, CHnaph.), 7.96- 8.04 (m, 2H, 2CHnaph.), 8.26 (br s, 1H, OH), 8.39 (br s, 2H, OH), 8.78 (br s, 
2H, OH); 
13
C NMR (75 MHz, acetone-d6)  109.1 (CHα-res.), 109.4 (2CHα-res.), 110.6 (2CHgal.), 115.9, 
117.8 (2CHnaph.), 120.7 (Cgal.), 122.2 (CHnaph.), 126.0 (Cnaph.), 127.2, 128.3, 128.8 (3CHnaph.), 131.9 
(Cα-res.), 135.4 (Cnaph.), 139.8 (C-Ogal. para), 146.3 (2C-Ogal. meta), 148.5, 149.4 (2C-Onaph.), 159.9 
(2C-Oα-res.), 165.3, 165.4 (2C=O); ESI-MS 447.0 (M−H)
−
; elemental analysis (calcd., found for 
C24H16O9·3/2 H2O): C (60.63, 60.56), H (4.03, 3.93). 
 
3-[(3-Hydroxybenzoyl)oxy]-1-naphthyl 3,4,5-trihydroxybenzoate (15). Obtained from silyl 
ether 71 (119 mg, 0.13 mmol) in 28% yield. Rf (DCM/MeOH, 95:5) 0.33; mp 117-119 ºC; IR (ATR)  
3005 (OH), 1713 (C=O); 
1
H NMR (300 MHz, acetone-d6)  7.21 (ddd, J = 8.1, 2.6, 1.0, 1H, H4), 
7.42-7.48 (m, 4H, 2CHgal., CHnaph., H5), 7.55-7.66 (m, 2H, 2CHnaph.), 7.69 (dd, J = 2.2, 1.6, 1H, H2), 
7.73 (dt, J = 7.7, 1.3, 1H, H6), 7.80 (d, J = 2.0, 1H, CHnaph.), 7.99 (d, J = 8.2, 1H, CHnaph.), 8.03 (d, J 
= 8.2, 1H, CHnaph.), 8.59 (br s, 4H, 4OH); 
13
C NMR (75 MHz, acetone-d6)  110.6 (2CHgal.), 115.7 
(CHnaph.), 117.3, 117.6 (CHnaph., CHm-sal.), 120.3 (Cgal.), 121.8, 122.1, 122.3 (CHnaph., 2CHm-sal.), 126.3 
(Cnaph.), 127.2, 128.3, 128.8 (3CHnaph.), 130.9 (CHm-sal.), 131.6 (Cm-sal.), 135.3 (Cnaph.), 139.9 (C-Ogal. 
para), 146.4 (2C-Ogal. meta), 148.8, 149.2 (2C-Onaph.), 158.6 (C-Om-sal.), 165.2, 165.4 (2C=O); ESI-
MS 431.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O8·H2O): C (64.00, 64.02), H (4.03, 
4.18). 
 
3-[(4-Hydroxybenzoyl)oxy]-1-naphthyl 3,4,5-trihydroxybenzoate (16). Obtained from silyl 
ether 72 (149 mg, 0.17 mmol) in 53% yield. Rf (DCM/MeOH, 95:5) 0.18; mp 134 ºC (decomposed); 
IR (ATR)  3330 (OH), 1712 (C=O), 1607, 1513 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.03 (d, J = 
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8.8, 2H, H3, H5), 7.42 (s, 2H, 2CHgal.), 7.45 (d, J = 2.2, 1H, CHnaph.), 7.54-7.65 (m, 2H, 2CHnaph.), 
7.77 (d, J = 2.1, 1H, CHnaph.), 7.97 (d, J = 7.8, 1H, CHnaph.), 8.01 (d, J = 7.8, 1H, CHnaph.), 8.12 (d, J 
= 8.8, 2H, H2, H6), 8.49 (br s, 4H, 4OH);
 13
C NMR (75 MHz, acetone-d6)  110.6 (2CHp-sal.), 115.8 
(CHnaph.), 116.4 (2CHgal.), 117.6 (CHnaph.), 120.3 (Cgal.), 121.4 (Cp-sal.), 122.3 (CHnaph.), 126.2 (Cnaph.), 
127.1, 128.2, 128.7 (3CHnaph.), 133.3 (2CHp-sal.), 135.3 (Cnaph.), 139.9 (C-Ogal. para), 146.4 (2C-Ogal. 
meta), 148.7, 149.4 (2C-Onaph.), 150.6 (C-Op-sal.), 163.4, 165.2 (2C=O); ESI-MS 431.0 (M−H)
−
; 
elemental analysis (calcd., found for C24H16O8·2/3H2O): C (64.87, 64.92), H (3.83, 4.06). 
 
4-[(3-Hydroxybenzoyl)oxy]-2-naphthyl 3,4,5-trihydroxybenzoate (17). Obtained from silyl 
ether 73 (81 mg, 0.09 mmol) in 15% yield. Rf (DCM/MeOH, 95:5) 0.24; mp 128-130 ºC; IR (ATR)  
3005 (OH), 1713 (C=O); 
1
H NMR (300 MHz, acetone-d6)  7.25 (ddd, J = 8.1, 2.6, 1.0, 1H, H4), 7.33 
(s, 2H, 2CHgal.), 7.48 (d, J = 2.1, 1H, CHnaph.), 7.49 (t, J = 8.0, 1H, H5), 7.55-7.66 (m, 2H, 2CHnaph.), 
7.76-7.78 (m, 2H, CHnaph., H2), 7.82 (dt, J = 7.7, 1.3, 1H, H6), 7.98 (dd, J = 8.1, 1.1, 1H, CHnaph.), 
8.03 (dd, J = 8.1, 1.1, 1H, CHnaph.), 8.66 (br s, 4H, 4OH); 
13
C NMR (75 MHz, acetone-d6)  110.6 
(2CHgal.), 115.9 (CHnaph.), 117.4, 117.9 (CHm-sal., CHnaph.), 120.8 (Cgal.), 122.1, 122.2, 122.3 (CHnaph., 
2CHm-sal.), 126.0 (Cnaph.), 127.2, 128.3, 128.8 (3CHnaph.), 131.1 (CHm-sal.), 131.4 (Cm-sal.), 135.4 
(Cnaph.), 139.8 (C-Ogal. para), 146.3 (2C-Ogal. meta), 148.5, 149.4 (2C-Onaph.), 158.7 (C-Om-sal.), 
165.3, 165.4 (2C=O); ESI-MS 431.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O8·H2O): C 
(64.00, 64.24), H (4.03, 4.07). 
 
4-[(4-Hydroxybenzoyl)oxy]-2-naphthyl 3,4,5-trihydroxybenzoate (18). Obtained from silyl 
ether 74 (60 mg, 0.07 mmol) in 69% yield. Rf (DCM/MeOH, 95:5) 0.60; mp 146-148 ºC; IR (ATR)  
3352 (OH), 1730 (C=O), 1607, 1514 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.07 (d, J = 8.6, 2H, H3, 
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H5), 7.33 (s, 2H, 2CHgal.), 7.44 (d, J = 2.2, 1H, CHnaph.), 7.53-7.65 (m, 2H, 2CHnaph.), 7.75 (d, J = 2.0, 
1H, CHnaph.), 7.98 (d, J = 8.7, 1H, CHnaph.), 8.02 (d, J = 7.7, 1H, CHnaph.), 8.21 (d, J = 8.8, 2H, H2, 
H6), 8.29 (br s, 1H, OH), 8.40 (br s, 2H, 2OH), 9.43 (br s, 1H, OH); 
13
C NMR (75 MHz, acetone-d6)  
110.5 (2CHp-sal.), 115.9 (CHnaph.), 116.6 (2CHgal.), 117.6 (CHnaph.), 120.7 (Cgal.), 121.1 (Cp-sal.), 122.3 
(CHnaph.), 126.2 (Cnaph.), 127.1, 128.2, 128.7 (3CHnaph.), 133.4 (2CHp-sal.), 135.3 (Cnaph.), 139.7 (C-
Ogal. para), 146.3 (2C-Ogal. meta), 148.7, 149.4 (2C-Onaph.), 160.3 (C-Op-sal.), 163.6, 165.4 (2C=O); 
ESI-MS 431.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O8·H2O): C (64.00, 64.12), H 
(4.03, 4.13). 
 
3-[(3-Chloro-4-hydroxybenzoyl)oxy]-1-naphthyl 3,4,5-trihydroxybenzoate (19). Obtained 
from silyl ether 75 (162 mg, 0.18 mmol) in 50% yield. Rf (DCM/MeOH, 95:5) 0.23; mp 138-139 ºC; 
IR (ATR)  3398 (OH), 1725 (C=O), 1603, 1504 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.22 (d, J = 
8.5, 1H, H5), 7.42 (s, 2H, 2CHgal.), 7.47 (d, J = 2.2, 1H, CHnaph.), 7.55-7.65 (m, 2H, 2CHnaph.), 7.79 
(d, J = 2.0, 1H, CHnaph.), 7.96-8.03 (m, 2H, 2CHnaph.), 8.05 (dd, J = 8.6, 2.1, 1H, H6), 8.20 (d, J = 2.1, 
1H, H2), 8.56 (br s, 4H, 4OH); 
13
C NMR (75 MHz, acetone-d6)  110.6 (2CHgal.), 115.7 (CHnaph.), 
117.5, 117.6 (CHClbenz., CHnaph.), 120.3, 121.5 (Cgal., CClbenz.), 122.3 (CHnaph.), 122.7 (CClbenz.), 126.3 
(Cnaph.), 127.2, 128.2, 128.8 (3CHnaph.), 131.4, 133.0 (2CHClbenz.), 135.2 (Cnaph.), 139.9 (C-Ogal. para), 
146.4 (2C-Ogal. meta), 148.8, 149.1 (2C-Onaph.), 158.9 (C-OClbenz.), 164.3, 165.2 (2C=O); ESI-MS 
465.0 (M−H)
−
; elemental analysis (calcd., found for C24H15ClO8·H2O): C (59.45, 59.80), H (3.53, 
3.65). 
 
4-[(3-Chloro-4-hydroxybenzoyl)oxy]-2-naphthyl 3,4,5-trihydroxybenzoate (20). Obtained 
from silyl ether 76 (162 mg, 0.18 mmol) in 57% yield. Rf (DCM/MeOH, 95:5) 0.25; mp 143-145 ºC; 
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IR (ATR)  3383 (OH), 1721 (C=O), 1609, 1512 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.26 (d, J = 
8.4, 1H, H5), 7.33 (s, 2H, 2CHgal.), 7.46 (d, J = 2.2, 1H, CHnaph.), 7.54-7.65 (m, 2H, 2CHnaph.), 7.77 
(d, J = 1.8, 1H, CHnaph.), 7.99 (d, J = 8.2, 1H, CHnaph.), 8.02 (d, J = 7.5, 1H, CHnaph.), 8.15 (dd, J = 
8.5, 2.1, 1H, H6), 8.28 (d, J = 2.1, 1H, H2), 8.41 (br s, 4H, 4OH); 
13
C NMR (75 MHz, acetone-d6)  
110.5 (2CHgal.), 115.9 (CHnaph.), 117.7, 117.8 (CHClbenz., CHnaph.), 120.7, 121.7 (Cgal., CClbenz.), 122.3 
(CHnaph.), 122.5 (CClbenz.), 126.1 (Cnaph.), 127.2, 128.3, 128.8 (3CHnaph.), 131.6, 133.1 (2CHClbenz.), 
135.3 (Cnaph.), 140.3 (C-Ogal. para), 146.3 (2C-Ogal. meta), 148.5, 149.4 (2C-Onaph.), 159.0 (C-
OClbenz.), 164.2, 165.4 (2C=O); ESI-MS 465.0 (M−H)
−
; elemental analysis (calcd., found for 
C24H15ClO8·H2O): C (59.45, 59.56), H (3.53, 3.60). 
 
 
3-[(3,4-Dichlorobenzoyl)oxy]-1-naphthyl 3,4,5-trihydroxybenzoate (21). Obtained from silyl 
ether 77 (198 mg, 0.24 mmol) in 84% yield. mp 218-220 ºC; IR (ATR)  3393 (OH), 1735 (C=O), 
1614, 1537 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.42 (s, 2H, 2CHgal.), 7.50-7.52 (m, 1H, CHnaph.), 
7.58-7.67 (m, 2H, 2CHnaph.), 7.84-7.87 (m, 2H, CHnaph., H5), 7.96-8.05 (m, 2H, 2CHnaph.), 8.19 (d, J = 
8.4, 1H, H6), 8.37-8.38 (m, 1H, H2), 8.49 (br s, 3H, 3OH); 
13
C NMR (75 MHz, acetone-d6)  110.6 
(2CHgal.), 115.4, 117.5 (2CHnaph.), 120.3 (Cgal.), 122.4 (CHnaph.), 126.5 (Cnaph.), 127.4, 128.4, 128.8 
(3CHnaph.), 130.6 (CHCl2benz.), 130.9 (CCl2benz.), 132.1, 132.7 (2CHCl2benz.), 133.5 (CCl2benz.), 135.2 
(Cnaph.), 138.5 (CCl2benz.), 146.4 (2C-Ogal. meta), 148.9 (2C-Onaph.), 149.0 (C-Ogal. para), 163.8, 165.2 
(2C=O); ESI-MS 483.0 (M−H)
−
; elemental analysis (calcd., found for C24H14Cl2O7·3/2H2O): C 
(56.27, 56.00), H (3.34, 3.01). 
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4-[(3,4-Dichlorobenzoyl)oxy]-2-naphthyl 3,4,5-trihydroxybenzoate (22). Obtained from silyl 
ether 78 (266 mg, 0.32 mmol) in 86% yield. mp 249-251 ºC; IR (ATR)  3373 (OH), 1734 (C=O), 
1609, 1512 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.16 (s, 2H, 2CHgal.), 7.55-7.67 (m, 3H, 
3CHnaph.), 7.83 (s, 1H, CHnaph.), 7.92-7.97 (m, 2H, CHnaph., H5), 8.05 (d, J = 8.0, 1H, CHnaph.), 8.21 (d, 
J = 8.4, 1H, H6), 8.43 (s, 1H, H2), 9.23 (br s, 1H, OH para), 9.48 (br s, 2H, 2OH meta); 
13
C NMR (75 
MHz, acetone-d6)  109.2 (2CHgal.), 115.1, 117.4 (2CHnaph.), 117.9 (Cgal.), 121.3 (CHnaph.), 124.3 
(Cnaph.), 126.7, 127.6, 127.8 (3CHnaph.), 129.1 (CCl2benz.), 130.0, 131.5, 131.7 (3CHCl2benz.), 132.1 
(CCl2benz.), 133.9 (Cnaph.), 137.3 (CCl2benz.), 145.8 (2C-Ogal. meta), 146.7 (2C-Onaph.), 147.9 (C-Ogal. 
para), 162.9, 164.6 (2C=O); ESI-MS 483.0 (M−H)
−
; elemental analysis (calcd., found for 
C24H14Cl2O7·H2O): C (57.28, 56.99), H (3.20, 3.02). 
 
 
3-[(3,5-Dihydroxybenzoyl)oxy]-1-naphthyl 3,4-dihydroxybenzoate (23). Obtained from silyl 
ether 79 (167 mg, 0.39 mmol) in 85% yield. mp 252 ºC (decomposed); IR (ATR)  3310 (OH), 1741 
(C=O), 1699, 1605 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.60 (t, J = 2.3, 1H, H4'), 6.88 (d, J = 8.6, 
1H, H5), 7.17 (d, J = 2.3, 2H, H2', H6'), 7.35 (d, J = 2.2, 1H, CHnaph.), 7.40-7.53 (m, 2H, 2CHnaph.), 
7.54-7.57 (m, 2H, H2, H6), 7.65 (d, J = 2.2, 1H, CHnaph.), 7.75-7.87 (m, 1H, CHnaph.), 7.87-7.93 (m, 
1H, CHnaph.); 
13
C NMR (75 MHz, acetone-d6)  109.0 (CHα-res.), 109.3 (2CHα-res.), 115.9, 116.1, 
117.7, 117.8 (2CHnaph., 2CHprot.), 121.8 (Cprot.), 122.2 (CHnaph.), 124.4 (CHprot.), 126.0 (Cnaph.), 127.2, 
128.3, 128.8 (3CHnaph.), 131.9 (Cα-res.), 135.3 (Cnaph.), 145.9 (C-Oprot.), 148.5, 149.4 (2C-Onaph.), 
151.7 (C-Oprot.), 159.9 (2C-Oα-res.), 165.3 (2C=O); ESI-MS 431.0 (M−H)
−
; elemental analysis (calcd., 
found for C24H16O8·2H2O): C (61.54, 61.57), H (4.30, 4.03). 
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4-[(3,5-Dihydroxybenzoyl)oxy]-2-naphthyl 3,4-dihydroxybenzoate (24). Obtained from silyl 
ether 80 (187 mg, 0.43 mmol) in 92% yield. mp 254 ºC (decomposed); IR (ATR)  3315 (OH), 1702 
(C=O), 1605 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.70 (t, J = 2.1, 1H, H4’), 7.06 (d, J = 8.7, 1H, 
H5), 7.22 (d, J = 2.1, 2H, H2’, H6'), 7.47 (d, J = 2.1, 1H, CHnaph.), 7.55-7.65 (m, 2H, 2CHnaph.), 7.77-
7.80 (m, 3H, H2, H6, CHnaph.), 7.98 (d, J = 8.1, 1H, CHnaph.), 8.02 (d, J = 7.5, 1H, CHnaph.), 8.60 (br s, 
1H, OH), 8.78 (br s, 2H, 2OH), 8.95 (br s, 1H, OH);
 13
C-NMR (75 MHz, acetone-d6)  108.4 (CHα-
res.), 108.8 (2CHα-res.), 115.2, 116.8, 117.1, 117.3 (2CHnaph., 2CHprot.), 120.9 (Cprot.), 121.9 (CHnaph.), 
124.0 (CHprot.), 125.8 (Cnaph.), 126.7, 127.8, 128.3 (3CHnaph.), 131.7 (Cα-res.), 134.8 (Cnaph.), 145.6 (C-
Oprot.), 148.3, 148.7 (2C-Onaph.), 151.5 (C-Oprot.), 159.9 (2C-Oα-res.), 164.6, 164.9 (2C=O); ESI-MS 
431.0 (M−H)
–
; elemental analysis (calcd., found for C24H16O8·H2O): C (62.88, 62.45), H (3.96, 4.02).  
 
4-[(3,5-Dihydroxybenzoyl)oxy]-2-naphthyl 3-chloro-4-hydroxybenzoate (25). Obtained 
from silyl ether 81 (55 mg, 0.07 mmol) in 90% yield. Rf (DCM) 0.20; mp 228-229 ºC; IR (ATR)  
3434 (OH), 1693 (C=O), 1465 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.73 (t, J = 2.2, 1H, H4’), 7.22 
(d, J = 8.5, 1H, H5), 7.30 (d, J = 2.2, 2H, H2’, H6’), 7.51 (d, J = 2.2, 1H, CHnaph.), 7.61 (tt, J = 8.3, 3.4, 
2H, 2CHnaph.), 7.81 (d, J = 2.0, 1H, CHnaph.), 7.98 (d, J = 8.3, 1H, CHnaph.), 8.02-8.08 (m, 2H, CHnaph., 
H6), 8.21 (d, J = 2.1, 1H, H2), 9.00 (br s, 3H, 3OH); 
13
C NMR (75 MHz, acetone-d6)  109.0 (CHα-
res.), 109.3 (2CHα-res.), 115.7 (CHnaph.), 117.6, 117.8 (CHClbenz, CHnaph.), 121.5 (CClbenz), 122.2 
(CHnaph.), 122.7 (CClbenz.), 126.1 (Cnaph.), 127.3, 128.3, 128.8 (3CHnaph.), 131.5 (CHClbenz), 131.8 (Cα-
res.), 133.0 (CHClbenz.), 135.3 (Cnaph.), 148.5, 149.1 (2C-Onaph.), 158.9 (C-OClbenz.), 159.8 (2C-Oα-res.), 
164.3, 165.2 (2C=O); ESI-MS 449.0 (M−H)
−
; elemental analysis (calcd., found for 
C24H15ClO7·1/2H2O): C (62.69, 63.08), H (3.51, 4.00). 
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3-[(3-Hydroxybenzoyl)oxy]-1-naphthyl 3,5-dihydroxybenzoate (26). Obtained from silyl 
ether 82 (203 mg, 0.27 mmol) in 82% yield. Rf (DCM/MeOH, 95:5) 0.51; mp 118-121 ºC; IR (ATR)  
3392 (OH), 1731 (C=O), 1602, 1453 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.74 (t, J = 2.2, 1H, H4), 
7.21 (ddd, J = 8.2, 2.5, 0.9, 1H, H4'), 7.31 (d, J = 2.3, 2H, H2, H6), 7.45 (t, J = 7.9, 1H, H5'), 7.52 (d, J 
= 2.2, 1H, CHnaph.), 7.57-7.65 (m, 2H, 2CHnaph.), 7.69 (app t, J = 2.0, 1H, H2'), 7.73 (dt, J = 7.8, 1.2, 
1H, H6'), 7.82 (d, J = 2.0, 1H, CHnaph.), 7.99 (d, J = 7.5, 1H, CHnaph.), 8.03 (d, J = 7.5, 1H, CHnaph.), 
8.84 (br s, 3H, 3OH); 
13
C NMR (75 MHz, acetone-d6)  109.0 (CHα-res.), 109.3 (2CHα-res.), 115.7 
(CHnaph.), 117.3, 117.8 (CHm-sal., CHnaph.), 121.8, 122.0, 122.2 (2CHm-sal., CHnaph.), 126.1 (Cnaph.), 
127.3, 128.3, 128.8 (3CHnaph.), 130.8 (CHm-sal.), 131.6, 131.8 (Cα-res., Cm-sal.), 135.3 (Cnaph.), 148.5, 
149.1 (2C-Onaph.), 158.5 (C-Om-sal.), 159.8 (2C-Oα-res.), 165.2, 165.4 (2C=O); ESI-MS 415.0 (M−H)
−
; 
elemental analysis (calcd., found for C24H16O7·3/2H2O): C (65.01, 65.37), H (4.32, 4.27). 
 
3-[(4-Hydroxybenzoyl)oxy]-1-naphthyl 3,5-dihydroxybenzoate (27). Obtained from silyl 
ether 83 (175 mg, 0.23 mmol) in 71% yield. Rf (DCM/MeOH, 95:5) 0.30; mp 208 ºC; IR (ATR)  
3386 (OH), 1713 (C=O), 1603, 1511 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.73 (t, J = 2.3, 1H, H4), 
7.03 (d, J = 8.8, 2H, H3', H5'), 7.31 (d, J = 2.3, 2H, H2, H6), 7.49 (d, J = 2.2, 1H, CHnaph.), 7.55-7.67 
(m, 2H, 2CHnaph.), 7.79 (d, J = 2.1, 1H, CHnaph.), 7.99 (dd, J = 7.9, 1.1, 1H, CHnaph.), 8.03 (d, J = 7.4, 
1H, CHnaph.), 8.12 (d, J = 8.8, 2H, H2', H6'), 9.01 (br s, 3H, 3OH); 
13
C NMR (75 MHz, acetone-d6) 
109.0 (CHα-res.), 109.3 (2CHα-res.), 115.9 (CHnaph.), 116.4 (2CHp-sal.), 117.8 (CHnaph.), 121.3 (Cp-sal.), 
122.2 (CHnaph.), 126.0 (Cnaph.), 127.2, 128.3, 128.8 (3CHnaph.), 131.8 (Cα-res.), 133.3 (2CHp-sal.), 135.3 
(Cnaph.), 148.5, 149.3 (2C-Onaph.), 159.8 (2C-Oα-res.), 163.5 (C-Op-sal.), 165.2, 165.3 (2C=O); ESI-MS 
415.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O7·3/2H2O): C (65.01, 65.08), H (4.32, 
4.24). 
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4-[(3-Hydroxybenzoyl)oxy]-2-naphthyl 3,4-dihydroxybenzoate (28). Obtained from silyl 
ether 84 (175 mg, 0.23 mmol) in 63% yield. Rf (DCM/MeOH, 95:5) 0.60; mp 99-102 ºC; IR (ATR)  
3386 (OH), 1732 (C=O), 1600, 1499 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.01 (d, J = 8.8, 1H, 
H5), 7.25 (ddd, J = 8.2, 2.5, 0.9, 1H, H4’), 7.47-7.52 (m, 2H, CHnaph., H5’), 7.55-7.64 (m, 2H, 
2CHnaph.), 7.67-7.71 (m, 2H, H2, H6), 7.77 (app t, J = 2.0, 1H, H2’), 7.79 (d, J = 2.1, 1H, CHnaph.), 7.82 
(dt, J = 7.7, 1.3, 1H, H6’), 7.99 (d, J = 8.0, 1H, CHnaph.), 8.03 (d, J = 8.0, 1H, CHnaph.), 8.80 (br s, 3H, 
3OH); 
13
C NMR (75 MHz, acetone-d6)  115.9 (CHnaph.), 116.1 (CHprot.), 117.4, 117.7, 117.9 
(CHnaph., CHm-sal., CHprot.), 121.7 (Cprot.), 122.0, 122.2 (CHnaph., 2CHm-sal.), 124.3 (CHprot.), 126.0 
(Cnaph.), 127.2, 128.3, 128.8 (3CHnaph.), 131.0 (CHm-sal.), 131.3 (Cm-sal.), 135.3 (Cnaph.), 145.9 (C-
Oprot.), 148.5, 149.4 (2C-Onaph.), 151.8 (C-Oprot.), 158.7 (C-Om-sal.), 165.2, 165.3 (2C=O); ESI-MS 
415.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O7·H2O): C (66.36, 66.58), H (4.18, 4.15). 
 
3-[(4-Hydroxybenzoyl)oxy]-1-naphthyl 3-hydroxybenzoate (29). Obtained from silyl ether 
85 (202 mg, 0.32 mmol) in 51% yield. Rf (DCM/MeOH, 95:5) 0.45; mp 209 ºC; IR (ATR)  3383 
(OH), 1711 (C=O), 1599, 1512 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.03 (d, J = 8.8, 2H, H3', H5'), 
7.25 (ddd, J = 8.2, 2.5, 0.8, 1H, H4), 7.50 (t, J = 7.9, 1H, H5), 7.51 (d, J = 2.2, 1H, CHnaph.), 7.55-
7.67 (m, 2H, 2CHnaph.), 7.76-7.84 (m, 3H, H2, H6, CHnaph.), 7.99 (d, J = 8.1, 1H, CHnaph.), 8.03 (d, J = 
7.7, 1H, CHnaph.), 8.13 (d, J = 8.8, 2H, H2', H6'), 9.14 (br s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6) 
 115.9 (CHnaph.), 116.4 (2CHp-sal.), 117.4, 117.9 (CHm-sal., CHnaph.), 121.4 (Cp-sal.), 122.0, 122.1, 
122.2 (CHnaph., 2CHm-sal.), 126.0 (Cnaph.), 127.2, 128.3, 128.8 (3CHnaph.), 131.0 (CHm-sal.), 131.3 (Cm-
sal.), 133.3 (2CHp-sal.), 135.3 (Cnaph.), 148.5, 149.3 (2C-Onaph.), 158.7 (C-Om-sal.), 163.4 (C-Op-sal.), 
165.2, 165.3 (2C=O); ESI-MS 399.0 (M−H)
−
; elemental analysis (calcd., found for C24H16O6·H2O): C 
(69.33, 68.90), H (4.11, 4.34). 
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4-[(4-Hydroxybenzoyl)oxy]-2-naphthyl 3-hydroxybenzoate (30). Obtained from silyl ether 
86 (188 mg, 0.30 mmol) in 45% yield. Rf (DCM/MeOH, 95:5) 0.50; mp 195-196 ºC; IR (ATR)  3369 
(OH), 1729 (C=O), 1701, 1598, 1512 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.08 (d, J = 8.8, 2H, 
H3’, H5’), 7.21 (ddd, J = 8.1, 2.5, 0.9, 1H, H4), 7.45 (t, J = 7.9, 1H, H5), 7.50 (d, J = 2.2, 1H, CHnaph.), 
7.55-7.66 (m, 2H, 2CHnaph.), 7.68-7.70 (m, 1H, H2), 7.73 (dt, J = 7.7, 1.3, 1H, H6), 7.81 (d, J = 2.0, 
1H, CHnaph.), 7.99 (d, J = 8.2, 1H, CHnaph.), 8.03 (d, J = 7.5, 1H, CHnaph.), 8.21 (d, J = 8.8, 2H, H2’, 
H6’), 9.17 (br s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  115.7 (CHnaph.), 116.6 (2CHp-sal.), 117.3, 
117.6 (CHm-sal., CHnaph.), 121.1 (Cp-sal.), 121.8, 122.1, 122.4 (CHnaph., 2CHm-sal.), 126.3 (Cnaph.), 127.2, 
128.3, 128.8 (3CHnaph.), 130.9 (CHm-sal.), 131.6 (Cm-sal.), 133.4 (2CHp-sal.), 135.2 (Cnaph.), 148.7, 149.2 
(2C-Onaph.), 158.6 (C-Om-sal.), 163.6 (C-Op-sal.), 165.1, 165.4 (2C=O); ESI-MS 399.0 (M−H)
−
; 
elemental analysis (calcd., found for C24H16O6·1/3H2O): C (70.93, 71.13), H (4.13, 4.35). 
 
3-Hydroxy-1-naphthyl 3,4,5-trihydroxybenzoate (31). Obtained from silyl ether 59 (143 mg, 
0.22 mmol) in 78% yield. Rf (DCM/MeOH, 9:1) 0.36; mp 168-170 ºC (decomposed); IR (ATR)  
3361 (OH), 1703 (C=O), 1611 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.09 (d, J = 2.3, 1H, CHnaph.), 
7.17 (d, J = 2.3, 1H, CHnaph.), 7.28-7.34 (m, 1H, CHnaph.), 7.40 (s, 2H, 2CHgal.), 7.41-7.47 (m, 1H, 
CHnaph.), 7.75 (d, J = 8.3, 1H, CHnaph.), 7.80 (d, J = 8.3, 1H, CHnaph.), 8.25 (br s, 1H, OH), 8.38 (br s, 
2H, 2OH), 8.83 (br s, 1H, OH); 
13
C NMR (75 MHz, acetone-d6)  107.9 (CHnaph.), 110.6 (2CHgal.), 
112.3 (CHnaph.), 120.7 (Cgal.), 122.2 (CHnaph.), 123.1 (Cnaph.), 124.3, 127.3, 127.7 (3CHnaph.), 136.5 
(Cnaph.), 139.7 (C-Ogal. para), 146.4 (2C-Ogal. meta), 149.2, 156.0 (2C-Onaph.), 165.3 (C=O); ESI-MS 
311.1 (M–H)
–
; elemental analysis (calcd., found for C17H12O6·H2O): C (61.82, 62.02), H, (4.27, 
4.31). 
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4-Hydroxy-2-naphthyl 3,4,5-trihydroxybenzoate (32). Obtained from silyl ether 62 (230 mg, 
0.35 mmol) in 93% yield. Rf (DCM/MeOH, 9:1) 0.47; mp 188-190 ºC (decomposed); IR (ATR) 
3369 (OH), 1701 (C=O), 1613 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.83 (d, J = 2.1, 1H, 
CHnaph.), 7.24 (d, J = 2.0, 1H, CHnaph.), 7.30 (s, 2H, 2CHgal.), 7.42-7.54 (m, 2H, 2CHnaph.), 7.83 (d, J = 
7.5, 1H, CHnaph.), 8.20 (br s, 1H, OH), 8.24 (d, J = 8.2, 1H, CHAr), 8.32 (br s, 2H, 2OH), 9.35 (br s, 
1H, OH); 
13
C NMR (75 MHz, acetone-d6)  105.1 (CHnaph.), 110.5 (2CHgal.), 110.9 (CHnaph.), 121.1 
(Cgal.), 123.1 (CHnaph.), 124.1 (Cnaph.), 125.2, 127.9, 128.2 (3CHnaph.), 135.7 (Cnaph.), 139.5 (C-Ogal. 
para), 143.3 (2C-Ogal. meta), 150.4, 155.0 (2C-Onaph.), 165.5 (C=O); ESI-MS 311.1 (M–H)
–
; 
elemental analysis (calcd., found for C17H12O6·1/2H2O): C (63.55, 63.46), H, (4.08, 4.00). 
 
5-[(3,5-Dihydroxybenzoyl)oxy]biphenyl-3-yl 3,4-dihydroxybenzoate (37). Obtained from 
silyl ether 105 (75 mg, 0.08 mmol) in 83% yield. Rf (DCM/MeOH, 95:5) 0.27; mp 92-94 ºC; IR (ATR) 
3378 (OH), 1708 (C=O), 1601, 1451 (Ar), 1207 (C-O); 
1
H NMR (300 MHz, acetone-d6)  6.69 (t, J 
= 2.2, 1H, H4’’’), 7.00 (d, J = 8.6, 1H, H5’’), 7.20 (d, J = 2.2, 2H, H2’’’, H6’’’), 7.25 (t, J = 2.1, 1H, H4), 
7.38-7.52 (m, 3H, H3’, H4’, H5’), 7.53 (d, J = 2.0, 2H, H2, H6), 7.65-7.68 (m, 2H, H2’’, H6’’), 7.76 (d, J = 
7.2, 2H, H2’, H6’), 8.75 (br s, 4H, 4OH); 
13
C NMR (75 MHz, acetone-d6)  108.9 (CHα-res.), 109.3 
(2CHα-res.), 115.8 (C4H), 116.1, 117.8 (2CHprot.), 118.5, 118.8 (C2H, C6H), 121.8 (Cprot.), 124.3 
(CHprot.), 127.9 (C2’H, C6’H), 129.0 (C4’H), 129.9 (C3’H, C5’H), 132.2 (Cα-res.), 140.1, 143.9 (2Cbiph.), 
145.9, 151.8, 153.0, 153.3 (2C-Oprot., 2C-Obiph.), 159.7 (2C-Oα-res.), 165.1, 165.3 (2C=O); ESI-MS 
457.0 (M–H)
–
; elemental analysis (calcd., found for C26H18O8·H2O): C (64.33, 64.33), H, (4.36, 
4.55). 
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5-[(3-Hydroxybenzoyl)oxy]biphenyl-3-yl 3,4-dihydroxybenzoate (38). Obtained from silyl 
ether 106 (166 mg, 0.21 mmol) in 54% yield. Rf (DCM/MeOH, 95:5) 0.45; mp 110-112 ºC; IR (ATR) 
3390 (OH), 1708 (C=O), 1603, 1451 (Ar), 1290, 1206 (C-O); 
1
H NMR (300 MHz, acetone-d6)  
7.00 (d, J = 8.7, 1H, H4’’’), 7.20 (ddd, J = 8.1, 2.5, 0.8, 1H, H5’’), 7.27 (t, J = 2.0, 1H, H4), 7.39-7.56 
(m, 6H, H2, H6, H3’, H4’, H5’, H5’’’), 7.65-7.72 (m, 4H, H2’’, H6’’, H2’’’, H6’’’), 7.77 (d, J = 7.4, 2H, H2’, H6’), 
8.77 (br s, 3H, 3OH); 
13
C NMR (75 MHz, acetone-d6)  115.9 (C4H), 116.1 (CHprot.), 117.4 (CHm-sal.), 
117.8 (CHprot.), 118.5, 118.8 (C2H, C6H), 121.7 (Cprot.), 121.8, 122.1 (2CHm-sal.), 124.4 (CHprot.), 127.9 
(C2’H, C6’H), 129.0 (C4’H), 129.9 (C3’H, C5’H), 130.8 (CHm-sal.), 131.7 (Cm-sal.), 140.1, 143.9 (2Cbiph.), 
145.9, 151.7, 153.0, 153.3 (2C-Oprot., 2C-Obiph.), 158.6 (C-Om-sal.), 165.1, 165.3 (2C=O); ESI-MS 
441.1 (M–H)
–
; elemental analysis (calcd., found for C26H18O7·2/3H2O): C (68.72, 69.06), H, (4.29, 
4.78). 
 
5-[(3-Hydroxybenzoyl)oxy]biphenyl-3-yl 3,5-dihydroxybenzoate (39). Obtained from silyl 
ether 107 (71 mg, 0.09 mmol) in 95% yield. Rf (DCM/MeOH, 95:5) 0.44; mp 93-94 ºC; IR (ATR) 
3406 (OH), 1713 (C=O), 1601, 1454 (Ar), 1208 (C-O); 
1
H NMR (300 MHz, acetone-d6)  6.69 (t, J 
= 2.3, 1H, H4’’), 7.17-7.23 (m, 3H, H2’’, H6’’, H4’’’), 7.30 (t, J = 2.1, 1H, H4), 7.44 (t, J = 7.8, 2H, H4’, 
H5’’’), 7.50 (t, J = 7.3, 2H, H3’, H5’), 7.56-7.59 (m, 2H, H2, H6), 7.67 (t, J = 2.0, 1H, H2’’’), 7.71 (dt, J = 
7.8, 1.3, 1H, H6’’’), 7.77 (d, J = 7.1, 2H, H2’, H6’), 8.81 (br s, 3H, 3OH); 
13
C NMR (75 MHz, acetone-
d6)  108.8 (CHα-res.), 109.2 (2CHα-res.), 115.8 (C4H), 117.3 (CHm-sal.), 118.7 (C2H, C6H), 121.8 (CHm-
sal.), 122.1 (CHm-sal.), 127.8 (C2’H, C6’H), 129.1 (C4’H), 129.9 (C3’H, C5’H), 130.8 (CHm-sal.), 131.6, 
132.2 (Cm-sal, Cα-res.), 139.9, 144.0 (2Cbiph.), 153.0 (2C-Obiph.), 158.6 (C-Om-sal.), 159.7 (2C-Oα-res.), 
165.3 (2C=O); ESI-MS 440.7 (M–H)
–
; elemental analysis (calcd., found for C26H18O7·1/2H2O): C 
(69.18, 69.00), H, (4.24, 4.60). 
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Biphenyl-3,5-diyl bis(3-hydroxybenzoate) (40). Obtained from silyl ether 99 (58 mg, 0.09 
mmol) in 56% yield. Rf (DCM/MeOH, 95:5) 0.92; mp 95-96 ºC; IR (ATR) 3434 (OH), 1701 (C=O), 
1464, 1364 (Ar), 1214, 1181 (C-O); 
1
H NMR (300 MHz, acetone-d6)  7.20 (ddd, J = 8.1, 2.5, 0.9, 
2H, 2H4’’), 7.32 (t, J = 2.1, 1H, H4), 7.39-7.47 (m, 3H, H4’, 2H5’’), 7.51 (t, J = 7.3, 2H, H3’, H5’), 7.58 (t, 
J = 2.1, 2H, H2, H6), 7.67 (t, J = 1.9, 2H, 2H2’’), 7.71 (dt, J = 7.7, 1.3, 2H, 2H6’’), 7.77 (d, J = 7.1, 2H, 
H2’, H6’), 8.86 (br s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  115.8 (C4H), 117.3 (C2H, C6H), 
118.7 (2CHm-sal.), 121.8 (2CHm-sal.), 122.1 (2CHm-sal.), 127.8 (C2’H, C6’H), 129.1 (C4’H), 129.9 (C3’H, 
C5’H), 130.8 (2CHm-sal.), 131.6 (2Cm-sal.), 139.9, 144.0 (2Cbiph.), 153.0 (2C-Obiph.), 158.6 (2C-Om-sal.), 
165.3 (2C=O); ESI-MS 424.7 (M–H)
–
; elemental analysis (calcd., found for C26H18O6·1/2H2O): C 
(71.72, 72.18), H, (4.40, 4.81). 
 
5-[(4-Hydroxybenzoyl)oxy]biphenyl-3-yl 3-hydroxybenzoate (41). Obtained from silyl ether 
108 (104 mg, 0.16 mmol) in 77% yield. Rf (DCM/MeOH, 95:5) 0.48; mp 74-75 ºC; IR (ATR) 3392 
(OH), 1707 (C=O), 1597, 1483 (Ar), 1283, 1264 (C-O); 
1
H NMR (300 MHz, acetone-d6)  7.03 (d, J 
= 8.8, 2H, H3’’’, H5’’’), 7.20 (ddd, J = 8.1, 2.5, 1.0, 1H, H4’’), 7.28 (t, J = 2.1, 1H, H4), 7.37-7.54 (m, 4H, 
H3’, H4’, H5’, H5’’), 7.56 (t, J = 1.9, 2H, H2, H6), 7.67 (t, J = 2.0, 1H, H2’’), 7.71 (dt, J = 7.7, 1.3, 1H, 
H6’’), 7.76 (d, J = 7.1, 2H, H2’, H6’), 8.10 (d, J = 8.8, 2H, H2’’’, H6’’’), 9.09 (br s, 2H, 2OH); 
13
C NMR 
(75 MHz, acetone-d6)  115.9 (C4H), 116.4 (2CHp-sal.), 117.3, 118.5, 118.8 (C2H, C6H, CHm-sal.), 
121.4 (Cp-sal.), 121.8, 122.1 (2CHm-sal.), 127.8 (C3’H, C5’H), 129.0 (C4’H), 129.9 (C2’H, C6’H), 130.8 
(CHm-sal.), 131.6 (Cm-sal.), 133.3 (2CHp-sal.), 140.0, 143.9 (2Cbiph.), 153.0, 153.2 (2C-Obiph.), 158.5 (C-
OHp-sal.), 163.4 (C-OHm-sal.), 165.0, 165.3 (2C=O); ESI-MS 424.7 (M–H)
–
; elemental analysis (calcd., 
found for C26H18O6·1/2H2O): C (71.72, 71.29), H, (4.40, 4.76). 
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Biphenyl-3,5-diyl bis(4-hydroxybenzoate) (42). Obtained from silyl ether 100 (43 mg, 0.07 
mmol) in 96% yield. Rf (DCM/MeOH, 95:5) 0.13; mp 230 ºC (decomposed); IR (ATR) 3362 (OH), 
1704 (C=O), 1605, 1513, 1450 (Ar), 1262 (C-O); 
1
H NMR (300 MHz, acetone-d6)  7.02 (d, J = 8.8, 
4H, 2H3’’, 2H5’’), 7.25 (t, J = 2.1, 1H, H4), 7.41 (t, J = 7.3, 1H, H4’), 7.50 (t, J = 7.7, 2H, H3’, H5’), 7.53 
(d, J = 2.1, 2H, H2, H6), 7.76 (d, J = 7.2, 2H, H2’, H6’), 8.10 (d, J = 8.8, 4H, 2H2’’, 2H6’’), 9.40 (br s, 
2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  115.9 (C4H), 116.4 (4CHp-sal.), 118.6 (C2H, C6H), 121.4 
(2Cp-sal.), 127.8 (C2’H, C6’H), 129.0 (C4’H), 129.9 (C3’H, C5’H), 133.3 (4CHp-sal.), 140.1, 143.8 (2Cbiph.), 
153.1 (2C-Obiph.), 163.4 (2C-OH), 165.0 (2C=O); ESI-MS 424.9 (M–H)
–
; elemental analysis (calcd., 
found for C26H18O6·1/2H2O): C (71.72, 71.75), H, (4.40, 4.72). 
 
5-Hydroxybiphenyl-3-yl 3,4-dihydroxybenzoate (43). Obtained from silyl ether 101 (70 mg, 
0.13 mmol) in 51% yield. Rf (DCM/MeOH, 97:3) 0.21; mp 174-175 ºC; IR (ATR) 3368 (OH), 1701 
(C=O), 1608, 1523, 1447 (Ar), 1294, 1214 (C-O); 
1
H NMR (300 MHz, acetone-d6)  6.75 (t, J = 2.1, 
1H, H4), 6.99 (d, J = 8.1, 1H, H5’’), 7.02 (t, J = 1.7, 1H, H6), 7.05 (t, J = 1.7, 1H, H2), 7.36 (t, J = 7.3, 
1H, H4’), 7.45 (t, J = 7.4, 2H, H3’, H5’), 7.62-7.70 (m, 4H, H2’, H6’, H2’’, H6’’), 8.75 (br s, 3H, 3OH); 
13
C 
NMR (75 MHz, acetone-d6)  109.2 (C4H), 112.0, 112.6 (CHprot., C6H), 116.1 (C2H), 117.7 (CHprot.), 
122.1 (Cprot.), 124.2 (CHprot.), 127.7 (C2’H, C6’H), 128.6 (C4’H), 129.7 (C3’H, C5’H), 141.1, 144.0 
(2Cbiph.), 145.9, 151.5 (2C-OHprot.), 153.7 (C-Obiph.), 159.5 (C-OHbiph.), 165.2 (C=O); ESI-MS 321.0 
(M–H)
–
; elemental analysis (calcd., found for C19H14O5·H2O): C (67.05, 66.88), H, (4.74, 5.01). 
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5-Hydroxybiphenyl-3-yl 3,5-dihydroxybenzoate (44). Obtained from silyl ether 102 (65 mg, 
0.12 mmol) in 57% yield. Rf (DCM/MeOH, 95:5) 0.27; mp 200-203 ºC; IR (ATR) 3366 (OH), 1703 
(C=O), 1601, 1483, 1456, 1425, 1346 (Ar), 1225 (C-O); 
1
H NMR (300 MHz, acetone-d6)  6.67 (t, J 
= 2.2, 1H, H4’’), 6.76 (t, J = 2.0, 1H, H4), 7.04 (t, J = 1.9, 1H, H6), 7.06 (t, J = 2.0, 1H, H2), 7.17 (d, J 
= 2.2, 2H, H2’’, H6’’), 7.37 (t, J = 7.3, 1H, H4’), 7.46 (t, J = 7.4, 2H, H3’, H5’), 7.66 (d, J =7.1, 2H, H2’, 
H6’), 8.72 (br s, 2H, 2OH), 8.84 (br s, 1H, 1OH); 
13
C NMR (75 MHz, acetone-d6)  108.7 (C4’’H), 
109.1 (C4H), 109.2 (2CHα-res.), 112.2 (C2H), 112.5 (C6H), 127.7 (C2’H, C6’H), 128.6 (C4’H), 129.7 
(C3’H, C5’H), 132.5 (Cα-res.), 141.0, 144.1 (2Cbiph.), 153.6 (C-Obiph.), 159.5 (C-OHbiph.), 159.7 (2C-OHα-
res.), 165.3 (C=O); ESI-MS 321.0 (M–H)
–
; elemental analysis (calcd., found for C19H14O5·1/2H2O): C 
(69.51, 69.28), H, (4.50, 4.87). 
 
5-Hydroxybiphenyl-3-yl 3-hydroxybenzoate (45). Obtained from silyl ether 103 (82 mg, 0.20 
mmol) in 84% yield. Rf (DCM/MeOH, 95:5) 0.30; mp 62-63 ºC; IR (ATR) 3363 (OH), 1709 (C=O), 
1590, 1455 (Ar), 1286, 1205 (C-O); 
1
H NMR (300 MHz, acetone-d6)  6.78 (t, J = 2.1, 1H, H4), 7.05-
7.08 (m, 2H, H2, H6), 7.19 (ddd, J = 8.2, 2.6, 1.0, 1H, H4’’), 7.35-7.49 (m, 4H, H3’, H4’, H5’, H5’’), 7.64-
7.70 (m, 4H, H2’, H6’, H2’’, H6’’), 8.83 (br s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  109.1 (C4H), 
112.2, 112.5 (CHm-sal., C6H), 117.3 (C2H), 121.6, 122.0 (2CHm-sal.), 127.7 (C2’H, C6’H), 128.6 (C4’H), 
129.7 (C3’H, C5’H), 130.8 (CHm-sal.), 131.9 (Cm-sal.), 141.0, 144.1 (2Cbiph.), 153.5 (C-Obiph.), 158.6 (C-
OHm-sal.), 159.5 (C-OHbiph.), 165.3 (C=O); ESI-MS 304.8 (M–H)
–
; elemental analysis (calcd., found 
for C19H14O4·1/2H2O): C (72.37, 72.66), H, (4.79, 5.15). 
 
5-Hydroxybiphenyl-3-yl 4-hydroxybenzoate (46). Obtained from silyl ether 104 (32 mg, 0.08 
mmol) in 90% yield. Rf (DCM/MeOH, 95:5) 0.19; mp 55-56 ºC; IR (ATR) 3354 (OH), 1696 (C=O), 
1594, 1511, 1483, 1453 (Ar), 1263, 1164 (C-O); 
1
H NMR (300 MHz, acetone-d6)  6.76 (t, J = 2.2, 
1H, H4), 6.97-7.06 (m, 4H, H2, H6, H3’’, H5’’), 7.36 (t, J = 7.3, 1H, H4’), 7.46 (t, J = 7.4, 2H, H3’, H5’), 
7.65 (d, J = 7.1, 2H, H2’, H6’), 8.07 (d, J = 8.8, 2H, H2’’,H6’’), 8.84 (br s, 1H, OH), 9.39 (br s, 1H, OH); 
13
C NMR (75 MHz, acetone-d6)  109.2 (C4H), 112.0 (C6H), 112.6 (C2H), 116.3 (2CHp-sal.), 121.7 
(Cp-sal.), 127.7 (C2’H, C6’H), 128.6 (C4’H), 129.7 (C3’H, C5’H), 133.2 (2CHp-sal.), 141.0, 144.0 
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(2CHbiph.), 153.6 (C-Obiph.), 159.5 (C-OHbiph.), 163.3(C-OHp-sal.), 165.1 (C=O); ESI-MS 304.8 (M–H)
–
; 
elemental analysis (calcd., found for C19H14O4·4/3H2O): C (69.08, 69.35), H, (5.09, 5.26). 
4.1.3. Synthesis of 33-36 and 47-50 
 
Naphthalene-1,3-diamine (87). To a solution of 1,3-dinitronaphthalene (1.0 g, 4.6 mmol) in 
MeOH (40 mL), 10% Pd/C (100 mg) was added and the reaction was stirred in a Parr hydrogenator 
under an initial hydrogen pressure of 40 psi at room temperature for 3.5 h. The mixture was filtered 
through a short column of Celite® and the solvent was evaporated under reduced pressure. The 
crude was purified by chromatography (from DCM to DCM/MeOH, 95:5) to afford diamine 87 as an 
oil in 60% yield. Rf (DCM) 0.14; IR (ATR)  3356 (NH2), 1659, 1621 (Ar); 
1
H NMR (300 MHz, 
DMSO-d6)  4.99 (br s, 2H, NH2), 5.42 (br s, 2H, NH2), 6.11-6.12 (m, 2H, 2CH), 6.91 (t, J = 7.5, 1H, 
CH), 7.15 (t, J = 7.5, CH), 7.30 (d, J = 8.2, 1H, CH), 7.76 (d, J = 8.2, 1H, CH); 
13
C NMR (75 MHz, 
DMSO-d6)  96.5, 99.4 (2CH), 117.2 (C), 118.7, 122.1, 125.1, 125.5 (4CH), 136.2 (C), 145.1 (C-N), 
147.3 (C-N); ESI-MS 159.0 (M+H)
+
. 
General Procedure for the Synthesis of Protected Amides 88 and 89. To a solution of 87 
(1 equiv) and triethylamine (4 equiv) in anhydrous DCM (10 mL/mmol acid chloride 52) under an 
argon atmosphere, a solution of the corresponding acid chloride 52a or f (4 equiv) in anhydrous 
DCM (2.0 mL/mmol) was added dropwise. The reaction was stirred at room temperature overnight. 
Then, the crude was washed with a saturated aqueous solution of NaHCO3 and with H2O, the 
organic layer was dried (Na2SO4) and the solvent was evaporated under reduced pressure. The 
crude was purified by chromatography (from hexane to DCM) to afford protected amide 88 or 89.  
 
N,N'-Naphthalene-1,3-diylbis(3,4,5-tris{[tert-butyl(dimethyl)silyl]oxy}benzamide) (88). 
Obtained from acid chloride 52a (4.0 g, 7.6 mmol) and diamine 87 (300 mg, 1.9 mmol) in 33% yield. 
Rf (hexane/DCM, 1:1) 0.70; mp 170-172 ºC; IR (ATR)  3307 (NH), 1661 (C=O), 1572, 1477 (Ar); 
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1
H NMR (300 MHz, CDCl3)  0.17 (s, 6H, (CH3)2Si para), 0.18 (s, 6H, (CH3)2Si para), 0.26 (s, 12H, 
2(CH3)2Si meta), 0.29 (s, 12H, 2(CH3)2Si meta), 0.97 (s, 18H, 2(CH3)3CSi meta), 0.99 (s, 18H, 
2(CH3)3CSi meta), 1.01 (s, 9H, (CH3)3CSi para), 1.02 (s, 9H, (CH3)3CSi para), 7.06 (s, 2H, 2CHgal.), 
7.15 (s, 2H, 2CHgal.), 7.43-7.56 (m, 2H, 2CHnaph.), 7.75-7.83 (m, 2H, CHnaph., NH), 7.89 (dd, J = 7.8, 
1.5, 1H, CHnaph.), 8.15-8.23 (m, 2H, CHnaph. , NH), 8.48 (d, J = 1.2, 1H, CHnaph.); 
13
C NMR (75 MHz, 
CDCl3)  −3.8, −3.7 (2(CH3)2Si para), −3.5 (2(CH3)2Si meta), −3.4 (2(CH3)2Si meta), 18.6, 18.7 
(2(CH3)3CSi para), 18.9 (2(CH3)3CSi meta), 19.0 (2(CH3)3CSi meta), 26.3 ((CH3)3CSi para), 26.4 
(4(CH3)3CSi meta, (CH3)3CSi para), 113.3 (2CHgal., CHnaph.), 113.5 (2CHgal.), 114.4, 119.6 
(2CHnaph.), 123.7 (Cnaph.), 125.5 (CHnaph.), 126.8 (Cgal.), 126.9 (CHnaph.), 127.2 (Cgal.), 129.3 (CHnaph.), 
133.4, 134.9, 135.5 (3Cnaph.), 142.6, 142.7 (2C-Ogal. para), 149.1 (2C-Ogal. meta), 149.2 (2C-Ogal. 
meta), 165.1, 165.9 (2C=O); ESI-MS 1169.5 (M+Na)
+
. 
 
N,N'-Naphthalene-1,3-diylbis(4-{[tert-butyl(dimethyl)silyl]oxy}-3-chlorobenzamide) (89). 
Obtained from acid chloride 52f (700 mg, 2.3 mmol) and diamine 87 (90 mg, 0.57 mmol) in 36% 
yield. Rf (DCM) 0.34; mp 220-223 ºC; IR (ATR)  1645 (C=O), 1599, 1495 (Ar); 
1
H NMR (300 MHz, 
CDCl3)  0.26 (s, 6H, (CH3)2Si), 0.35 (s, 6H, (CH3)2Si), 1.08 (s, 9H, (CH3)3CSi), 1.13 (s, 9H, 
(CH3)3CSi), 6.72 (d, J = 8.4, 1H, H5), 6.99 (d, J = 8.4, 1H, H5'), 7.06 (t, J = 7.4, 1H, CHnaph.), 7.28-
7.40 (m, 3H, 2CHnaph., H6), 7.50 (d, J = 8.3, 1H, H6'), 7.56 (s, 1H, CHnaph.), 7.66 (s, 2H, H2, H2'), 7.83 
(d, J = 8.4, 1H, CHnaph.), 8.12 (d, J = 1.6, 1H, CHnaph.), 8.60 (s, 1H, NH), 8.67 (s, 1H, NH); 
13
C NMR 
(75 MHz, CDCl3)  −4.2, −4.1 (2(CH3)2Si), 18.5, 18.6 (2(CH3)3CSi), 25.7, 25.8 (2(CH3)3CSi), 116.7, 
118.4 (2CHnaph.), 119.9, 120.4 (2CHClbenz.), 120.8 (Cnaph.), 125.1 (CHnaph.), 125.6, 125.8 (2CClbenz.), 
126.2, 126.3, 127.1, 127.3 (2CHClbenz., 2CHnaph.), 128.0 (CClbenz.), 128.2 (CHnaph.), 128.3 (CClbenz.), 
130.0, 130.3 (2CHClbenz.), 132.0, 134.0 (2C-N), 134.9 (Cnaph.), 154.5, 155.1 (2C-OClbenz), 164.6, 165.9 
(2C=O); ESI-MS 717.2 (M+Na)
+
. 
General Procedure for the Synthesis of Final Compounds 33 and 35. To a solution of TBS 
derivative 88 or 89 in a mixture of pyridine (0.96 mL/mmol of TBS group) and THF (2.0 mL/mmol of 
TBS group), HF·pyridine complex (0.96 mL/mmol of TBS group) was added, and the reaction was 
stirred at room temperature until the disappearance of the starting material (TLC analysis, approx. 
15 min). Afterward, the mixture was diluted with water (50 mL/mmol) and extracted with ethyl 
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acetate. The organic layer was washed with a saturated aqueous solution of CuSO4 and dried 
(Na2SO4). The solvent was evaporated under reduced pressure and the crude was purified by 
chromatography (DCM/MeOH, 95:5) to afford final compound 33 or 35. 
 
N,N'-Naphthalene-1,3-diylbis(3,4,5-trihydroxybenzamide) (33). Obtained from silyl ether 88 
(188 mg, 0.16 mmol) in 78% yield. Rf (DCM/MeOH, 95:5) 0.20; mp >250 ºC (decomposed); IR 
(ATR)  3297 (NH), 1600 (C=O), 1529, 1498 (Ar); 
1
H NMR (300 MHz, methanol-d4)7.02 (s, 2H, 
2CHgal.), 7.12 (s, 2H, 2CHgal.), 7.42-7.53 (m, 2H, 2CHnaph.), 7.84-7.87 (m, 2H, 2CHnaph.), 7.92 (d, J = 
8.0, 1H, CHnaph.), 8.25 (d, J = 1.8, 1H, CHnaph.); 
13
C NMR (75 MHz methanol-d4)  108.2 (2CHgal.), 
108.4 (2CHgal.), 117.7, 120.3, 123.8 (3CHnaph.), 126.2 (Cgal.), 126.3 (CHnaph.), 126.5 (Cgal.), 127.7 
(CHnaph.), 128.3 (Cnaph.), 129.1 (CHnaph.), 135.3, 136.0, 137.4 (3Cnaph.), 138.5, 138.7 (2C-Ogal. para), 
146.8 (2C-Ogal. meta), 146.8 (2C-Ogal. meta), 169.3, 170.2 (2C=O); ESI-MS 460.7 (M−H)
−
; elemental 
analysis (calcd., found for C24H18N2O8·H2O): C (60.00, 59.97), H, (4.20, 4.02), N, (5.83, 6.06). 
 
N,N'-Naphthalene-1,3-diylbis(3-chloro-4-hydroxybenzamide) (35). Obtained from silyl ether 
89 (36 mg, 0.05 mmol) in 75% yield. Rf (DCM/MeOH, 95:5) 0.42; mp 159-162 ºC (decomposed); IR 
(ATR)  3343 (OH), 1645 (C=O), 1546, 1492 (Ar); 
1
H NMR (300 MHz, acetone-d6)  7.13 (d, J = 
8.5, 1H, H5), 7.18 (d, J = 8.6, 1H, H5'), 7.42 (ddd, J = 8.2, 6.9, 1.2, 1H, CHnaph.), 7.50 (ddd, J = 8.1, 
7.4, 0.9, 1H, CHnaph.), 7.88 (d, J = 8.0, 1H, CHnaph.), 7.94 (dd, J = 8.5, 2.2, 1H, H6), 8.02 (dd, J = 8.5, 
2.2, 1H, H6'), 8.06 (d, J = 8.5, 1H, CHnaph.), 8.12 (d, J = 2.2, 1H, H2), 8.13 (d, J = 1.8, 1H, CHnaph.), 
8.19 (d, J = 2.2, 1H, H2'), 8.50 (d, J = 1.5, 1H, CHnaph.), 9.53 (br s, 2H, 2OH), 9.61 (br s, 1H, NH), 
9.72 (br s, 1H, NH); 
13
C NMR (75 MHz, acetone-d6)  115.6, 117.2, 117.3, 118.1 (2CHnaph., 
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2CHClbenz.), 121.1, 121.2 (2CClbenz.), 123.4, 125.5 (2CHnaph.), 126.8 (Cnaph.), 127.3 (CHnaph.), 128.3, 
128.5 (2CClbenz.), 128.9 (2CHClbenz.), 129.0 (CHnaph.), 130.5, 130.7 (2CHClbenz.), 135.1, 135.5, 137.5 
(3Cnaph.), 156.9, 157.0 (2C-OClbenz.), 164.9, 165.5 (2C=O); ESI-MS 465.0 (M−H)
−
; elemental analysis 
(calcd., found for C24H16N2O4·H2O): C (59.31, 59.40), H, (3.92, 3.74), N, (5.39, 5.77). 
 
3-Chloro-4-methoxybenzenesulfonyl chloride (90).
96
 To a solution of 2-chloroanisole (9.9 
mL, 78 mmol) in chloroform (100 mL) at 0 ºC under an argon atmosphere, chlorosulfonic acid (10.5 
mL, 156 mmol) was added dropwise and the reaction was stirred at room temperature overnight. 
The reaction mixture was then poured into ice-water (150 mL) and the aqueous phase was 
extracted with chloroform (2 x 50 mL). The combined organic phases were dried (Na2SO4) and 
concentrated under reduced pressure. The crude was purified by chromatography (from hexane to 
hexane/ethyl acetate, 9:1) to afford intermediate 90 as an oil in 61% yield. Rf (DCM) 0.41; IR (ATR) 
 1579, 1489 (Ar), 1375, 1173 (SO2Cl); 
1
H NMR (300 MHz, CDCl3) 4.03 (s, 3H, CH3), 7.08 (d, J = 
8.9, 1H, H5), 7.93 (d, J = 8.8, 2.4, 1H, H6), 8.04 (d, J = 2.4, 1H, H2); 
13
C NMR (75 MHz, CDCl3)  
57.0 (CH3), 111.9 (C5H), 124.1 (C-Cl), 127.9, 129.3 (C2H, C6H), 136.5 (C-SO2), 160.5 (C-O); ESI-
MS 220.8 (MSO2H−H)
−
. The spectroscopic data are in agreement with those previously described.
96
  
 
N,N'-Naphthalene-1,3-diylbis(3-chloro-4-methoxybenzenesulfonamide) (91). To a solution 
of diamine 87 (150 mg, 0.95 mmol) and pyridine (0.31 mL, 3.8 mmol) in anhydrous DCM (20 mL) 
under an argon atmosphere, a solution of sulfonyl chloride 90 (500 mg, 1.6 mmol) in anhydrous 
DCM (8 mL) was added dropwise and the reaction was stirred at room temperature overnight. The 
crude was then washed with a saturated aqueous solution of NaHCO3 and with water, and the 
organic layer was dried (Na2SO4) and concentrated under reduced pressure. The crude was 
purified by chromatography (from DCM to DCM/MeOH, 97:3) to afford compound 91 in 48% yield. 
Rf (DCM/MeOH, 95:5) 0.68; mp 131-133 ºC; IR (ATR)  3261 (NH), 1584, 1489 (Ar), 1161 
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(SO2NH); 
1
H NMR (300 MHz, acetone-d6)  3.93 (s, 6H, 2CH3), 7.14 (d, J = 8.8, 1H, H5), 7.18 (d, J 
= 8.8, 1H, H5'), 7.34 (ddd, J = 8.2, 6.9, 1.2, 1H, CHnaph.), 7.43 (ddd, J = 8.1, 7.4, 1.0, 1H, CHnaph.), 
7.53 (s, 2H, H2, H2'), 7.62 (dd, J = 8.7, 2.2, 1H, H6), 7.73 (d, J = 2.3, 1H, CHnaph.), 7.74-7.77 (m, 2H, 
CHnaph., H6'), 7.83 (d, J = 2.3, 1H, CHnaph.), 8.00 (d, J = 8.4, 1H, CHnaph.), 9.10 (br s, 1H, NH), 9.27 
(br s, 1H, NH); 
13
C NMR (75 MHz, acetone-d6)  57.1 (2CH3), 113.1, 113.2 (2CHClbenz.), 116.1, 
117.2, 123.1 (3CHnaph.), 123.2 (2CClbenz.), 126.2 (CHnaph.), 126.8 (Cnaph.), 127.9, 128.6 (2CHnaph.), 
128.8, 128.9 (2CHClbenz.), 129.7 (2CHClbenz.), 132.9, 133.3, 134.6, 135.4, 136.0 (2CClbenz., 3Cnaph.), 
159.3, 159.4 (2C-OClbenz.); ESI-MS 564.9 (M−H)
−
. 
 
N,N'-Naphthalene-1,3-diylbis(3-chloro-4-hydroxybenzenesulfonamide) (36). To a solution 
of sulfonamide 91 (100 mg, 0.18 mmol) in anhydrous DCM (5 mL) under an argon atmosphere, 
BBr3 (0.1 mL, 1.1 mmol) was added at 0 ºC and the reaction was stirred at room temperature 
overnight. MeOH was then added dropwise to hydrolyze the remaining BBr3 and the solvent was 
removed under reduced pressure. The residue was dissolved in diethyl ether, washed with water 
and dried (Na2SO4). The solvent was evaporated under reduced pressure and the crude was 
purified by chromatography (from DCM to DCM/MeOH, 95:5) to afford the title compound 36 in 38% 
yield. Rf (DCM/MeOH, 95:5) 0.35; mp 121-122 ºC; IR (ATR)  3346 (OH, NH), 1466, 1363 (Ar), 
1180 (SO2NH); 
1
H NMR (300 MHz, CDCl3)  7.02 (d, J = 8.6, 1H, H5), 7.07 (d, J = 8.6, 1H, H5'), 
7.33 (ddd, J = 8.2, 6.9, 1.2, 1H, CHnaph.), 7.43 (ddd, J = 8.1, 7.0, 1.1, 1H, CHnaph.), 7.46 (dd, J = 8.5, 
2.3, H6), 7.50 (d, J = 2.1, 1H, CHnaph.), 7.53 (d, J = 1.9, 1H, CHnaph.), 7.60 (dd, J = 8.6, 2.2, 1H, H6'), 
7.70 (d, J = 2.2, 1H, H2), 7.75 (d, J = 8.1, 1H, CHnaph.), 7.81 (d, J = 2.3, 1H, H2'), 8.00 (d, J = 8.4, 
1H, CHnaph.), 9.03 (br s, 1H, NH), 9.23 (br s, 1H, NH), 9.83 (br s, 2H, 2OH); 
13
C NMR (75 MHz, 
CDCl3) 116.2, 117.4 (2CHnaph.), 117.5 (2CHClbenz.), 121.5 (2CClbenz.), 123.2, 126.1 (2CHnaph.), 127.0 
(Cnaph.), 127.9, 128.5 (2CHnaph.), 128.6 (2CHClbenz.), 130.1, 130.2 (2CHClbenz.), 132.3, 132.7, 134.6, 
135.4, 136.1 (2CClbenz., 3Cnaph.), 157.7, 157.8 (2C-OClbenz.); ESI-MS 537.0 (M−H)
−
; elemental 
analysis (calcd., found for C22H16Cl2N2O6S2·H2O): C (47.40, 47.35), H, (3.25, 3.42), N, (5.03, 5.05), 
S, (11.50, 11.72). 
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1,3-Bis(bromomethyl)naphthalene (92).
97
 To a solution of a 1,3-dimethylnaphthalene (3.0 
mL, 19 mmol) in anhydrous chloroform (30 mL) at 90 ºC under an argon atmosphere, NBS (8.0 g, 
45 mmol) and AIBN (31 mg, 0.19 mmol) were added. The reaction was stirred at 90 ºC overnight. 
Then, the mixture was cooled to room temperature, filtered and the solvent was evaporated under 
reduced pressure. The crude was purified by chromatography (from hexane to hexane/ethyl 
acetate, 95:5) to afford intermediate 92 in 73% yield. mp 113-115 ºC (Lit.
98
 114-116 ºC); IR (ATR)  
1508 (Ar), 783, 754 (C-Br); 
1
H NMR (300 MHz, CDCl3)  4.63 (s, 2H, CH2), 4.94 (s, 2H, CH2), 7.55 
(t, J = 7.1, 1H, CHnaph.), 7.58 (s, 1H, CHnaph.), 7.63 (t, J = 7.3, 1H, CHnaph.), 7.83 (s, 1H, CHnaph.), 7.86 
(d, J = 8.1, 1H, CHnaph.), 8.14 (d, J = 8.3, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3) 31.4, 33.7 
(2CH2), 124.0, 127.2, 127.6, 128.8, 129.3, 129.8 (6CHnaph.), 131.0, 134.2, 134.6, 135.0 (4Cnaph.); 
ESI-MS 331.9 (M+NH4)
+
. The spectroscopic data are in agreement with those previously 
described.
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[Naphthalene-1,3-diyldi(methylene)]bis[bromo(triphenyl)phosphorane] (93). A mixture of 
bromo derivative 92 (390 mg, 1.2 mmol) and Ph3P (720 mg, 2.7 mmol) in 10 mL of xylene was 
refluxed for 72 h under an argon atmosphere. The solvent was then evaporated under reduced 
pressure to afford the desired product in 96% yield. Rf (hexane) 0.31; mp 160-162 ºC; IR (ATR)  
1437 (Ar); 
1
H NMR (300 MHz, CDCl3)  5.34 (d, J = 14.7, 2H, CH2), 5.52 (d, J = 14.2, 2H, CH2), 
7.01 (t, J = 7.5, 1H, CHnaph.), 7.22 (t, J = 7.5, 1H, CHnaph.), 6.99-7.81 (m, 34H, 30CHPh, 4CHnaph.); 
13
C 
NMR (75 MHz, CDCl3)  28.1 (d, J = 47.3, CH2), 30.6 (d, J = 47.3, CH2), 116.8 (d, J = 17.7, 3CPh), 
118.0 (d, J = 18.3, 3CPh), 123.4 (CH), 124.5, 124.6, 124.7 (3Cnaph.), 126.5, 127.0 (2CH), 128.5 (d, J 
= 8.6, 4CHPh) 128.6 (d, J = 10.5, 2CHPh), 128.8 (d, J = 8.0, 2CHPh) 130.2 (d, J = 10.3, 4CHPh), 130.4 
(d, J = 10.4, 4CHPh), 131.9 (CH), 132.1 (d, J = 10.0, 2CHPh), 133.0 (Cnaph.), 133.6, 133.9 (2CH), 
134.3 (d, J = 10.0, 4CHPh), 134.4 (d, J = 9.9, 4CHPh), 135.1 (CH), 135.2 (3CH); ESI-MS 339.2 
[(M+2H)/2]
+
. 
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Methyl 3,4,5-tris(allyloxy)benzoate (94). To a suspension of methyl 3,4,5-trihydroxybenzoate 
(3.8 g, 21 mmol) and K2CO3 (26 g, 188 mmol) in anhydrous DMF (250 mL) at 65 ºC under an argon 
atmosphere, allyl bromide (7.2 mL, 83 mmol) was added dropwise and the reaction was stirred at 
65 ºC for 4 h. Afterward, ice water (1 L) was added and the aqueous phase was extracted with 
ether (4 x 250 mL). The combined organic extracts were washed with water (3 x 500 mL) and brine 
(500 mL), dried (Na2SO4) and concentrated under reduced pressure to afford intermediate 94 as an 
oil in 99% yield. The compound was used in the next step without further purification. Rf 
(hexane/ethyl acetate, 9:1) 0.41; 
1
H NMR (300 MHz, CDCl3)  3.88 (s, 3H, CH3), 4.60-4.62 (m, 6H, 
3CH2O), 5.18 (dq, J = 10.3, 1.9, 1H, CH=CHH cis para), 5.26-5.36 (m, 3H, CH=CHH trans para, 
2CH=CHH cis meta), 5.43 (dq, J = 17.3, 1.6, 2H, 2CH=CHH trans meta), 6.00-6.15 (m, 3H, 
3CH=CH2), 7.28 (s, 2H, H2, H6); ESI-MS 305.1 (M+H)
+
. The spectroscopic data are in agreement 
with those previously described.
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3,4,5-Tris(allyloxy)benzaldehyde (95). To a solution of Red-Al® (65% wt solution in toluene, 
2.0 mL, 6.6 mmol) in anhydrous THF (1.4 mL) under an argon atmosphere, a solution of pyrrolidine 
(0.57 mL, 6.9 mmol) in THF (4.2 mL) was added at -10 ºC. The reaction was stirred for 1 h at room 
temperature and KOt-Bu (74 mg, 0.66 mmol) was then added. This mixture was added dropwise to 
a solution of methyl 3,4,5-tris(allyloxy)benzoate 94 (1.0 g, 3.3 mmol) in anhydrous THF (2 mL) at 0 
ºC. The reaction mixture was stirred at this temperature for 10 min, after which a 1 M aqueous 
solution of HCl (80 mL) was slowly added. The reaction was then warmed to room temperature and 
extracted with ethyl acetate (120 mL). The organic layer was washed with water (50 mL) and with 
brine (50 mL), dried (Na2SO4) and evaporated under reduced pressure. The crude was purified by 
chromatography (hexane/ethyl acetate, 95:5) to afford aldehyde 95 as an oil in 78% yield. Rf 
(hexane/ethyl acetate, 9:1) 0.54; IR (ATR)  2870 (CHO), 1690 (C=O), 1581, 1494 (Ar); 
1
H NMR 
(300 MHz, CDCl3)  4.63-4.67 (m, 6H, 3CH2O), 5.18 (dq, J = 10.3, 1.9, 1H, CH=CHH cis para), 
5.28-5.37 (m, 3H, CH=CHH trans para, 2CH=CHH cis meta), 5.44 (dq, J = 17.3, 1.6, 2H, 
2CH=CHH trans meta), 6.00-6.15 (m, 3H, 3CH=CH2), 7.60 (s, 2H, H2, H6), 9.82 (s, 1H, CHO); 
13
C 
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NMR (75 MHz, CDCl3)  70.1 (2CH2O meta), 74.3 (CH2O para), 108.7 (C2H, C6H), 118.0 (2CH=CH2 
meta), 118.3 (CH=CH2 para), 131.8 (C-CHO), 132.9 (2CH=CH2 meta), 134.1 (CH=CH2 para), 143.4 
(C-O para), 153.1 (2C-O meta), 191.2 (CHO); ESI-MS 275.1 (M+H)
+
. The spectroscopic data are in 
agreement with those previously described.
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1,3-Bis{(E)-2-[3,4,5-tris(allyloxy)phenyl]vinyl}naphthalene (96). To a solution of 93 (710 
mg, 0.84 mmol) in anhydrous THF (30 mL) under an argon atmosphere, n-butyllithium (1.6 M 
solution in hexane, 1.6 mL, 2.4 mmol) was added dropwise within a period of 1h at -78 ºC. The 
reaction mixture was stirred at this temperature for 1 h and a solution of aldehyde 95 (600 mg, 2.2 
mmol) in anhydrous THF (10 mL) was slowly added. Then, the mixture was allowed to warm to 
room temperature and stirred for 18 h, before being quenched by addition of 2.0 mL of MeOH. The 
solvents were evaporated under reduced pressure and the crude was purified by chromatography 
(hexane/ethyl acetate, 97:3) to afford the desired (1E,3E)-96 as an oil in 30% yield as well as the 
corresponding isomer (1E,3Z)-96 in 18% yield. 
(1E,3E)-96: Rf (hexane/ethyl acetate, 95:5) 0.33; IR (ATR)  1578, 1502 (C=C, Ar); 
1
H NMR 
(300 MHz, CDCl3)  4.60 (dt, J = 4.9, 1.2, 2H, CH2O para), 4.62 (dt, J = 4.9, 1.3, 2H, CH2O para), 
4.65-4.70 (m, 8H, 4CH2O meta), 5.21 (ddt, J = 10.3, 5.1, 1.8, 2H, 2CH=CHH cis para), 5.29-5.40 
(m, 6H, 2CH=CHH trans para, 4CH=CHH cis meta), 5.41-5.44 (m, 4H, 4CH=CHH trans meta), 
6.06-6.20 (m, 6H, 6CH=CH2), 6.82 (s, 2H, H2, H6), 6.86 (s, 2H, H2, H6), 7.10 (d, J = 15.9, 1H, 
CH=CH), 7.14 (d, J = 16.3, 1H, CH=CH), 7.20 (d, J = 16.3, 1H, CH=CH), 7.48-7.54 (m, 2H, 
2CHnaph.), 7.72 (d, J = 15.9, 1H, CH=CH), 7.81 (s, 1H, CHnaph.), 7.86 (dd, J = 6.1, 3.4, 1H, CHnaph.), 
7.91 (s, 1H, CHnaph.), 8.14 (dd, J = 6.2, 3.5, 1H, CHnaph.); 
13
C NMR (75 MHz, CDCl3)  70.2 (2CH2O 
meta), 70.3 (2CH2O meta), 74.4 (2CH2O para), 106.2 (C2H, C6H), 106.4 (C2H, C6H), 117.5 
(2CH=CH2 meta), 117.6 (2CH=CH2 meta), 117.7, 117.8 (2CH=CH2 para), 121.4, 123.9, 125.4, 
126.2, 126.5, 126.6, 128.1, 128.8, 129.2 (9CH), 131.2 (C), 132.2 (CH), 133.0, 133.2 (2C), 133.5 
(2CH=CH2 meta), 133.6 (2CH=CH2 meta), 134.2, 134.6 (2C), 134.7 (2CH=CH2 para), 135.6 (C), 
138.1, 138.2 (2C-O para), 152.9 (2C-O meta), 153.0 (2C-O meta); ESI-MS 691.3 (M+Na)
+
. 
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(1E,3Z)-96: Rf (hexane/ethyl acetate, 95:5) 0.27; IR (ATR)  1582, 1502 (C=C, Ar); 
1
H NMR 
(300 MHz, CDCl3)  4.11 (dt, J = 5.0, 1.5, 4H, 2CH2O meta), 4.44 (d, J = 6.0, 2H, CH2O para), 4.58 
(d, J = 6.0, 2H, CH2O para), 4.64 (dt, J = 5.1, 1.5, 4H, 2CH2O meta), 5.04 (dq, J = 10.5, 5.4 , 2H, 
2CH=CHH cis), 5.06-5.22 (m, 4H, 2CH=CHH trans, 2CH=CHH cis), 5.24-5.37 (m, 4H, 2CH=CHH 
trans, 2CH=CHH cis), 5.45 (dq, J = 17.3, 2.3 , 2H, 2CH=CHH trans), 5.75 (ddt, J = 17.2, 10.4, 5.1, 
2H, 2CH=CH2 para), 5.94-6.19 (m, 4H, 4CH=CH2 meta), 6.34 (s, 2H, H2, H6), 6.73 (d, J = 12.2, 1H, 
CH=CH cis), 6.74 (s, 2H, H2, H6), 6.97 (d, J = 16.3, 1H, CH=CH trans), 6.98 (d, J = 11.5, 1H, 
CH=CH cis), 7.07 (d, J = 16.2, 1H, CH=CH trans), 7.39-7.51 (m, 2H, 2CHnaph.), 7.65 (s, 1H, CHnaph.), 
7.78 (s, 1H, CHnaph.), 7.84 (d, J = 7.7, 1H, CHnaph.), 7.98 (d, J = 8.1, 1H, CHnaph.); 
13
C NMR (75 MHz, 
CDCl3)  69.6 (2CH2O meta), 70.1 (2CH2O meta), 74.1, 74.3 (2CH2O para), 106.1 (C2H, C6H), 
108.6 (C2H, C6H), 117.1 (2CH=CH2 meta), 117.5 (2CH=CH2 meta), 117.6, 117.7 (2CH=CH2 para), 
123.9, 125.3, 125.9, 126.3, 126.7, 127.7, 127.9, 128.5, 129.4 (9CH), 131.1, 131.9 (2C), 132.3 (CH), 
132.9 (C), 133.3 (2CH=CH2 meta), 133.5 (2CH=CH2 meta), 134.2 (C), 134.6 (CH=CH2 para), 134.7 
(C, CH=CH2 para), 135.6 (C), 137.2, 138.0 (2C-O para), 152.1 (2C-O meta), 152.9 (2C-O meta); 
ESI-MS 691.3 (M+Na)
+
. 
 
5,5'-{Naphthalene-1,3-diylbis[(E)ethene-2,1-diyl]}dibenzene-1,2,3-triol (34). A solution of 
(1E,3E)-96 (76 mg, 0.11 mmol), N,N'-dimethylbarbituric acid (213 mg, 1.4 mmol) and Pd(PPh3)4 (39 
mg, 0.03 mmol) in a 1:1 mixture of MeOH and anhydrous DCM (2 mL) was stirred for 1 h at room 
temperature under an argon atmosphere. Afterward, the solvent was evaporated under reduced 
pressure and DCM was added. The resulting solid was filtered and purified by chromatography 
(DCM/MeOH/acetic acid, 97:3:0.1) to afford the title compound 34 in 19% yield. Rf 
(DCM/MeOH/acetic acid, 97:3:0.1) 0.36; mp >300 ºC; IR (ATR)  1551, 1516 (C=C, Ar); 
1
H NMR 
(300 MHz, acetone-d6)  6.75 (s, 2H, H2, H6), 6.81 (s, 2H, H2, H6), 7.13 (d, J = 16.3, 1H, CH=CH), 
7.15 (d, J = 15.9, 1H, CH=CH), 7.29 (d, J = 16.3, 1H, CH=CH), 7.47-7.52 (m, 2H, 2CHnaph.), 7.74 (d, 
J = 16.0, 1H, CH=CH), 7.85 (s, 1H, CHnaph.), 7.89 (dd, J = 6.4, 3.1, 1H, CHnaph.), 7.95 (br s, 6H, 
6OH), 8.06 (s, 1H, CHnaph.), 8.26 (dd, J = 6.2, 3.4, 1H, CHnaph.); 
13
C NMR (75 MHz, acetone-d6)  
106.8 (C2H, C6H), 107.3 (C2H, C6H), 121.5, 123.3, 124.6, 126.2, 126.5, 126.7, 127.0, 129.4 (8CH), 
130.0, 130.2 (2C), 130.6 (CH), 131.7 (C), 133.3 (CH), 134.2, 135.3, 136.1 (3C), 136.5 (2C-O para), 
Experimental part 
- 137 - 
146.7 (4C-O meta); ESI-MS 427.0 (M−H)
−
; elemental analysis (calcd., found for C26H20O6·H2O): C 
(68.56, 68.76), H, (5.06, 5.42).  
 
Biphenyl-3,5-diyl bis(trifluoromethanesulfonate) (109). To a solution of 97 (510 mg, 2.7 
mmol) and triethylamine (0.77 mL, 5.8 mmol) in anhydrous DCM (9 mL) under an argon 
atmosphere, trifluoromethanesulfonic anhydride (Tf2O) (1.2 mL, 6.9 mmol) was added dropwise at 
0 ºC. The mixture was then warmed to room temperature and stirred for 2.5 h. Afterward, the 
reaction was cooled to 0 ºC and ice water was added to hydrolyze the remaining Tf2O. A saturated 
aqueous solution of NaHCO3 (5 mL) was added and the mixture was extracted with DCM (3 x 10 
mL). The organic phases were dried over Na2SO4, filtered and the solvent was removed under 
reduced pressure. The crude was purified by chromatography (from hexane to hexane/ethyl 
acetate, 9:1) to afford the title compound 109 in 99% yield. Rf (hexane/ethyl acetate, 9:1) 0.57; mp 
68-69 ºC; IR (ATR)  1459, 1428 (Ar), 1213 (SO2); 
1
H NMR (300 MHz, CDCl3)  7.21 (t, J = 2.2, 1H, 
H4), 7.47-7.57 (m, 7H, 7CHAr); 
13
C NMR (75 MHz, CDCl3)  113.8 (C4H), 118.9 (q, J = 321.1, 2CF3), 
120.3 (C2H, C6H), 127.3 (C3’H, C5’H), 129.5 (C2’H, C6’H), 129.6 (C4’H), 137.3, 146.0 (2Cbiph.), 149.9 
(2C-Obiph.); ESI-MS 317.0 (M-SO2CF3−H)
−
. 
 
3,3''-Dimethoxy-5'-phenyl-1,1':3',1''-terphenyl (110). To a suspension of 109 (115 mg, 0.26 
mmol), 3-methoxyphenylboronic acid (194 mg, 1.3 mmol) and Na2CO3 (118 mg, 2.1 mmol) in a 
10:5:8 mixture of toluene, EtOH and water (5 mL) under an argon atmosphere, Pd(PPh3)4 (18 mg, 
0.02 mmol) was added and the reaction was heated at 150 ºC in the microwave for 15 min. The 
mixture was extracted with ethyl acetate and the organic phase was dried (Na2SO4) and 
concentrated under reduced pressure. The crude was purified by chromatography (from hexane to 
DCM) to afford the title compound 110 in 75% yield. Rf (hexane/ethyl acetate, 1:1) 0.53; mp 114-
116 ºC; IR (ATR)  1579, 1492, 1463, 1408 (Ar); 
1
H NMR (300 MHz, CDCl3)  3.89 (s, 6H, 2CH3O), 
6.95 (dd, J = 8.1, 2.5, 2H, H4, H4’’), 7.23 (t, J = 2.0, 2H, H2, H2’’), 7.29 (d, J = 8.0, 2H, H6, H6’’), 7.38-
7.43 (m, 3H, H3’’’, H4’’’, H5’’’), 7.49 (t, J = 7.3, 2H, H5, H5’’), 7.70 (d, J = 7.1, 2H, H2’’’, H6’’’), 7.78 (s, 3H, 
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H2’, H4’, H6’); 
13
C NMR (75 MHz, CDCl3)  55.5 (2CH3O), 113.1, 113.2, (C2H, C2’’H, C4H, C4’’H), 
120.0 (C6H, C6’’H), 125.4 (C2’H), 125.5 (C4’H, C6’H), 127.5 (C4’’’H, C6’’’H), 127.7 (C4’’’H), 129.0 (C5H, 
C5’’H), 130.0 (C3’’’H, C5’’’H), 142.4, 142.5, 142.8 (6C), 160.2 (2C-O); ESI-MS 367.1 (M+H)
+
. 
 
5'-Phenyl-1,1':3',1''-terphenyl-3,3''-diol (47). To a solution of intermediate 110 (70 mg, 0.19 
mmol) in 5 mL of anhydrous DCM, BBr3 (0.11 mL, 1.1 mmol) was added at 0 ºC under an argon 
atmosphere, and the reaction was stirred at room temperature for 3 h. Afterward, MeOH was added 
dropwise to hydrolyze the remaining BBr3 and the mixture was concentrated under reduced 
pressure. The residue was dissolved in diethyl ether, washed with water and dried (Na2SO4). The 
solvent was evaporated under reduced pressure and the crude was purified by chromatography 
(from DCM to DCM/MeOH, 95:5) to afford the title compound 47 in 94% yield. Rf (DCM/MeOH, 
95:5) 0.46; mp 270-272 ºC; IR (ATR)  3347 (OH), 1586, 1496, 1455, 1414 (Ar); 
1
H NMR (300 
MHz, acetone-d6)  6.88 (app dt, J = 7.3, 1.7, 2H, H4, H4’’), 7.26-7.27 (m, 2H, H2, H2’’), 7.29-7.36 (m, 
4H, H3’’’, H5’’’, H6, H6’’), 7.41 (t, J = 7.3, 1H, H4’’’), 7.51 (t, J = 7.5, 2H, H5, H5’’), 7.81-7.85 (m, 5H, H2’, 
H4’, H6’, H2’’’, H6’’’), 8.58 (s, 2H, 2OH); 
13
C NMR (75 MHz, acetone-d6)  114.9 (C2H, C2’’H), 115.4 
(C4H, C4’’H), 119.3 (C6H, C6’’H), 125.4 (C2’H), 125.5 (C4’H, C6’H), 128.1 (C2’’’H, C6’’’H), 128.5 (C4’’’H), 
129.8 (C5’H, C5’’H), 130.9 (C3’’’H, C5’’’H), 141.8, 143.1 (2C), 143.2, 143.3 (4C), 158.8 (2C-O); ESI-
MS 337.1 (M−H)
−
; elemental analysis (calcd., found for C24H18O2·5/4H2O): C (79.87, 79.98), H, 
(5.73, 5.23). 
 
3,5-Dinitrobiphenyl (111). A suspension of 1-bromo-3,5-dinitrobenzene (500 mg, 2.3 mmol), 
phenylboronic acid (296 mg, 2.4 mmol), Na2CO3 (644 mg, 2.4 mmol) and Pd(PPh3)4 (117 mg, 0.10 
mmol) in a 5:3 water of toluene and water (2 mL) was heated in the microwave at 150 ºC for 30 
min. The mixture was extracted with ethyl acetate and the organic phase was dried (Na2SO4) and 
concentrated under reduced pressure. The crude was purified by chromatography (from hexane to 
DCM) to afford the desired product 111 in 83% yield. Rf (hexane/ethyl acetate, 9:1) 0.57; mp 151-
153 ºC; IR (ATR)  1591, 1541, 1523, 1349 (Ar); 
1
H NMR (300 MHz, CDCl3)  7.53-7.60 (m, 3H, 
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H3’, H4’, H5’), 7.69 (dd, J = 7.9, 1.5, 2H, H2’, H6’), 8.78 (d, J = 2.0, 2H, H2, H6), 9.02 (t, J = 2.0, 1H, 
H4); 
13
C NMR (75 MHz, CDCl3)  117.2 (C4’H), 127.1 (C2H, C6H), 127.4 (C2’H, C6’H), 129.8 (C3’H, 
C5’H), 130.0 (C4’H), 136.6 (C1), 145.0 (C1’), 149.1 (2C-NO2). 
 
Biphenyl-3,5-diamine (112). A solution of dinitro derivative 111 (110 mg, 0.45 mmol) in 
anhydrous THF (10 mL) under an argon atmosphere was pumped through an H-Cube continuous-
flow hydrogenation reactor at 1 mL/min using a 10% Pd/C CatCart® cartridge, under full-H2 mode 
at room temperature. The resulting solution of diamine 112 was collected under an argon 
atmosphere protected from light to be directly used in the next reaction due to its unstability. The 
conversion into the diamino derivative was checked by TLC. 
General Procedure for the Synthesis of Protected Diamide 113 and Sulfonamide 114. To 
the solution of diamine 112 (1 equiv) in anhydrous THF previously obtained, triethylamine (4 equiv) 
was added followed by dropwise addition of a solution of acid chloride 52d or 3-
methoxybenzenesulfonyl chloride (4 equiv) in anhydrous THF (2 mL/mmol) under an argon 
atmosphere. The reaction was protected from light and stirred at room temperature overnight. 
Then, the mixture was washed with a saturated aqueous solution of NaHCO3 and with water, and 
the organic layer was dried (Na2SO4) and concentrated under reduced pressure. The crude was 
purified by chromatography using the appropriate eluent to afford the corresponding diamide 113 or 
disulfonamide 114.  
 
N,N'-Biphenyl-3,5-diylbis(3-{[tert-butyl(dimethyl)silyl]oxy}benzamide) (113). Obtained 
from diamine 112 (0.45 mmol) and acid chloride 52d (488 mg, 1.8 mmol) as an oil in 21% yield. 
Chromatography: hexane to DCM; Rf (DCM) 0.40; IR (ATR)  1652 (C=O), 1548, 1434 (Ar); 
1
H 
NMR (300 MHz, CDCl3)  0.23 (s, 12H, 2(CH3)2Si), 1.01 (s, 18H, 2(CH3)3CSi), 7.02 (ddd, J = 8.0, 
1.5, 0.9, 2H, 2H4’’), 7.30-7.44 (m, 9H, H3’, H4’, H5’, 2H2’’, 2H5’’, 2H6’’), 7.61 (d, J = 7.0, 2H, H2’, H6’), 
7.73 (d, J = 1.7, 2H, H2, H6), 8.04-8.06 (m, 3H, H4, 2NH); 
13
C NMR (75 MHz, CDCl3)  −4.3 
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(2(CH3)2Si), 18.3 (2(CH3)3CSi), 25.8 (2(CH3)3CSi), 110.7 (C4H), 115.0 (C2H, C6H), 119.3, 119.6, 
123.9 (6CHm-sal.), 127.4 (C2’H, C6’H), 127.9 (C4’H), 128.9 (C3’H, C5’H), 130.0 (2CHm-sal.), 136.4 (2Cm-
sal.), 139.1 (2C-NH), 140.4 (C1), 143.1 (C1’), 156.3 (2C-Om-sal.), 165.8 (2C=O); ESI-MS 651.3 (M−H)
−
. 
 
N,N'-Biphenyl-3,5-diylbis(3-methoxybenzenesulfonamide) (114). Obtained from 112 (0.45 
mmol) and 3-methoxybenzenesulfonyl chloride (372 mg, 1.8 mmol) in 45% yield. Chromatography: 
DCM to DCM/MeOH, 95:5; Rf (DCM/MeOH, 95:5) 0.58; mp 79-82 ºC; IR (ATR)  3253 (NH), 1483, 
1439 (Ar), 1152 (SO2); 
1
H NMR (300 MHz, C6D6)  3.16 (s, 6H, 2CH3O), 6.54 (br s, 2H, 2NH), 6.60 
(ddd, J = 8.4, 2.6, 0.8, 2H, 2H4’’), 6.63 (d, J = 2.0, 2H, 2H2’’), 6.81 (t, J = 8.0, 2H, 2H5’’), 7.05-7.20 
(m, 5H, H2’, H3’, H4’, H5’, H6’), 7.34 (t, J = 1.9, 1H, H4), 7.44 (d, J = 8.3, 2H, 2H6’’), 7.50 (t, J = 2.0, 2H, 
H2, H6); 
13
C NMR (75 MHz, CDCl3)  55.7 (2CH3O), 111.6 (C4H), 111.8 (C2H, C6H), 116.0, 119.5, 
120.1 (6CHm-sal.), 127.1 (C2’H, C6’H), 128.3 (C4’H), 129.0 (C3’H, C5’H), 130.3 (2CHm-sal.), 138.2 (2C1’’), 
139.4 (C1), 140.0 (2C-NH), 143.6 (C1’), 160.0 (2C-Om-sal.); ESI-MS 547.2 (M+Na)
+
. 
 
N,N'-Biphenyl-3,5-diylbis(3-hydroxybenzamide) (48). To a solution of amide 113 (35 mg, 
0.05 mmol) in a mixture of pyridine (0.10 mL, 0.96 mL/mmol of TBS group) and anhydrous THF (5 
mL), HF·pyridine complex (0.10 mL, 0.96 mL/mmol of TBS group) was added and the reaction was 
stirred at room temperature until complete disappearance of the starting material (TLC, approx. 15 
min). Then, the mixture was diluted with water (15 mL) and extracted with ethyl acetate. The 
organic layer was washed with a saturated aqueous solution of CuSO4 and dried (Na2SO4). The 
solvent was evaporated under reduced pressure and the crude was purified by chromatography 
(from DCM to DCM/MeOH, 95:5) to afford pure final product 48 in 66% yield. Rf (DCM/MeOH, 95:5) 
0.57; mp 95-96 ºC; IR (ATR)  3425 (OH), 1698 (C=O), 1422, 1363 (Ar); 
1
H NMR (300 MHz, 
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acetone-d6)  6.99 (dd, J = 8.1, 1.8, 2H, 2H4’’), 7.32 (t, J = 7.9, 2H, 2H5’’), 7.34-7.36 (m, 3H, 2H2’’, 
H4’), 7.40 (d, J = 7.7, 2H, 2H6’’), 7.44 (t, J = 7.7, 2H, H3’, H5’), 7.66 (d, J = 7.3, 2H, H2’, H6’), 7.77 (d, J 
= 1.6, 2H, H2, H6), 8.08 (s, 1H, H4); 
13
C NMR (75 MHz, acetone-d6)  114.1 (C4H), 115.6 (2C2’’H), 
117.1 (C2H, C6H), 119.5 (2C6’’H), 119.9 (2C4’’H), 128.1 (C2’H, C6’H), 128.7 (C4’H), 129.9 (C3’H, C5’H), 
130.7 (2C5’’H), 137.7 (2Cm-sal.), 140.7 (2C-NH), 141.9 (C1), 143.5 (C1’), 160.0 (2C-Om-sal.), 169.1 
(2C=O); ESI-MS 423.1 (M−H)
−
; elemental analysis (calcd., found for C26H20N2O4·2/3H2O): C (71.55, 
71.93), H, (4.93, 4.96), N, (6.42, 6.23). 
 
N,N'-Biphenyl-3,5-diylbis(3-hydroxybenzenesulfonamide) (49). To a solution of 
sulfonamide 114 (50 mg, 0.10 mmol) in 5 mL of anhydrous DCM, BBr3 (50 µL, 0.57 mmol) was 
added at 0 ºC under an argon atmosphere and the reaction was then stirred at room temperature 
for 3 h. Afterward, MeOH was added dropwise to hydrolyze the remaining BBr3 and the mixture was 
concentrated under reduced pressure. The crude was dissolved in diethyl ether, washed with water 
and dried (Na2SO4). The solvent was evaporated under reduced pressure and the residue was 
purified by chromatography (from DCM to DCM/MeOH, 95:5) to afford the title compound 49 in 21% 
yield. Rf (DCM/MeOH, 95:5) 0.29; mp 154-157 ºC; IR (ATR)  3249 (NH, OH), 1480, 1448 (Ar), 
1148 (SO2); 
1
H NMR (300 MHz, CD3OD)  7.05 (ddd, J = 8.1, 2.4, 0.8, 2H, 2H4’’), 7.17 (d, J = 2.0, 
2H, H2, H6), 7.25 (t, J = 2.0, 2H, H4), 7.27 (dd, J = 6.7, 1.2, 2H, 2H6’’), 7.31 (t, J = 2.0, 2H, 2H2’’), 
7.33 (t, J = 7.9, 2H, 2H5’’), 7.34-7.36 (m, 1H, H4’), 7.41-7.44 (m, 4H, H2’, H3’, H5’, H6’,), 9.01, 9.12 (br 
s, 4H, 2OH, 2NH); 
13
C NMR (75 MHz, CD3OD)  111.5 (C4H), 114.5 (2C6’’H), 115.2 (2C2’’H), 119.1 
(C2H, C6H), 120.9 (2C4’’H), 127.5 (C2’H, C6’H), 128.8 (C4’H), 129.8 (C3’H, C5’H), 131.1 (2C5’’H), 140.2 
(2Cm-sal.), 140.7 (C1), 141.8 (2C-NH), 143.5 (C1’), 158.8 (2C-OH); ESI-MS 495.0 (M−H)
−
; elemental 
analysis (calcd., found for C24H20N2O6S2·H2O): C (56.02, 55.86), H, (4.31, 4.55), N, (5.44, 5.20), S, 
(12.46, 12.60). 
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Biphenyl-3,5-dicarboxylic acid (115). A suspension of dimethyl 5-bromoisophthalate (500 
mg, 1.8 mmol), phenylboronic acid (780 mg, 6.4 mmol), Na2CO3 (970 mg, 9.2 mmol) and Pd(PPh3)4 
(106 mg, 0.09 mmol) in a 5:3 mixture of toluene and water (16 mL) under an argon atmosphere was 
heated at 150 ºC in the microwave for 30 min. The mixture was extracted with ethyl acetate and the 
organic phase was dried (Na2SO4) and evaporated under reduced pressure. The crude was purified 
by chromatography (from hexane to DCM) to afford dimethyl biphenyl-3,5-dicarboxylate in 90% 
yield. Rf (hexane/DCM, 3:7) 0.45; mp 94-96 ºC (Lit.
101
 90.9-92.4 ºC); IR (ATR)  1726 (C=O), 
1435, 1339 (Ar); 1H NMR (300 MHz, CDCl3)  3.98 (s, 6H, 2CH3O), 7.41 (t, J = 7.2, 1H, H4’), 7.49 
(t, J = 7.4, 2H, H3’, H5’), 7.66 (d, J = 7.1, 2H, H2’, H6’), 8.47 (d, J = 1.5, 2H, H2, H6), 8.66 (t, J = 1.5, 
1H, H4); 
13
C NMR (75 MHz, CDCl3)  52.6 (2CH3O), 127.3 (C2’H, C6’H), 128.4 (C4’H), 129.2 (C3’H, 
C5’H), 129.5 (C4H), 131.3 (C3, C5), 132.5 (C2H, C6H), 139.2 (C1), 142.1 (C1’), 166.4 (2CO); ESI-MS 
293.1 (M+Na)
+
. The spectroscopic data are in agreement with those previously described.
101
 
Dimethyl biphenyl-3,5-dicarboxylate (440 mg, 1.6 mmol) was dissolved in THF (20 mL), a 
solution of NaOH (1.0 g, 26 mmol) in 25 mL of water was added and the mixture was refluxed for 
1.5 h. Afterward, the organic solvent was evaporated under reduced pressure and the reaction was 
cooled to 0 ºC and acidified with concentrated HCl. The resulting precipitate was filtered, washed 
with water and dried under vacuum to obtain the title compound 115 in 85% yield. Rf (DCM) 0.05; 
mp >304 ºC (decomposed); IR (ATR)  1694 (C=O), 1461, 1431, 1406 (Ar); 
1
H NMR (300 MHz, 
DMSO-d6)  7.44 (t, J = 7.2, 1H, H4’), 7.52 (t, J = 7.3, 2H, H3’, H5’), 7.74 (d, J = 7.2, 2H, H2’, H6’), 
8.37 (d, J = 1.5, 2H, H2, H6), 8.46 (t, J = 1.4, 1H, H4); 
13
C NMR (75 MHz, DMSO-d6)  126.9 (C2’H, 
C6’H), 128.4 (C4’H), 128.8 (C4H), 129.3 (C3’H, C5’H), 131.3 (C2H, C6H), 132.1 (C3, C5), 138.4 (C1), 
141.1 (C1’), 166.5 (2CO); ESI-MS 241.1 (M−H)
−
. 
 
Biphenyl-3,5-dicarboxylic chloride (116). Thionyl chloride (0.34 ml, 4.6 mmol) was added 
dropwise to a solution of dicarboxylic acid 115 (140 mg, 0.58 mmol) in anhydrous THF (10 mL) 
under an argon atmosphere, and the mixture was refluxed for 3 h. Then it was cooled to room 
temperature and the solvent was removed under reduced pressure. Excess of thionyl chloride was 
removed by azeotropic destilation with toluene (4 x 10 mL) to afford the corresponding acid chloride 
116 in quantitative yield which was used in the next step without further purification.  
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(3-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)amine (117).
102
 To a solution of imidazole (2.0 g, 
29.3 mmol) and 3-hydroxyaniline (2.0 g, 18 mmol) in anhydrous DMF (40 mL) under an argon 
atmosphere, TBS chloride (3.6 g, 24 mmol) was added and reaction was stirred at room 
temperature overnight. Then, water (80 mL) was added and the mixture was extracted with ether (3 
x 60 mL). The combined organic extracts were washed with brine, dried (Na2SO4) and concertrated 
under reduced pressure. The crude was purified by chromatography (from hexane to DCM) to 
afford amine 117 as an oil in 48% yield. Rf (hexane/DCM, 1:1) 0.36; IR (ATR)  3379 (NH), 1493, 
1472, 1463 (Ar); 
1
H NMR (300 MHz, CDCl3)  0.21 (s, 6H, (CH3)2Si), 1.00 (s, 9H, (CH3)3CSi), 6.21 
(t, J = 2.2, 1H, H2), 6.27 (ddd, J = 8.1, 2.2, 0.8, 1H, H6), 6.30 (ddd, J = 8.1, 2.2, 0.8, 1H, H4), 7.00 (t, 
J = 8.0, 1H, H5); 
13
C NMR (75 MHz, CDCl3)  −4.3 ((CH3)2Si), 18.3 ((CH3)3CSi), 25.8 ((CH3)3CSi), 
107.2, 108.6, 110.5 (C2H, C4H, C6H), 130.1 (C5H), 147.8 (C-N), 156.8 (C-O); ESI-MS 224.1 (M+H)
+
. 
The spectroscopic data are in agreement with those previously described.
102
 
 
N,N'-Bis(3-{[tert-butyl(dimethyl)silyl]oxy}phenyl)biphenyl-3,5-dicarboxamide (118). A 
solution of 116 (150 mg, 0.54 mmol) in THF (4.4 mL) was added dropwise to a solution of amine 
117 (480 mg, 2.2 mmol) and triethylamine (0.30 mL, 2.2 mmol) in anhydrous THF (22 mL) under an 
argon atmosphere. The mixture was stirred at room temperature overnight. Afterward, the reaction 
mixture was washed with a saturated aqueous solution of NaHCO3 and water, and the organic 
phase was dried (Na2SO4), filtered and concentrated under reduced pressure. The crude was 
purified by chromatography (from hexane to DCM) to afford the title compound 118 in 89% yield. Rf 
(hexane/DCM, 8:2) 0.23; mp 218-220 ºC; IR (ATR)  3292 (OH), 1651 (C=O), 1542, 1494, 1448 
(Ar); 
1
H NMR (300 MHz, CDCl3)  0.26 (s, 12H, 2(CH3)2Si), 1.01 (s, 18H, 2(CH3)3CSi), 6.67 (ddd, J 
= 8.0, 2.3, 0.8, 2H, 2H4’’), 7.24 (t, J = 8.1, 2H, 2H5’’), 7.43-7.47 (m, 3H, H4’, 2H6’’), 7.55 (t, J = 7.4, 
2H, H3’, H5’), 7.63 (t, J = 2.1, 2H, 2H2’’), 7.81 (d, J = 7.2, 2H, H2’, H6’), 8.40 (d, J = 1.6, 2H, H2, H6), 
8.48 (t, J = 1.6, 1H, H4), 9.83 (s, 2H, NH); 
13
C NMR (75 MHz, CDCl3)  −4.2 (2(CH3)2Si), 18.8 
(2(CH3)3CSi), 26.1 (2(CH3)3CSi), 112.8 (2C2’’H), 114.0 (2C6’’H), 116.4 (2C4’’H), 126.3 (C4H), 128.1 
(C2’H, C6’H), 129.0 (C4’H), 129.6 (C3’H, C5’H), 130.0 (C2H, C6H), 130.3 (2C5’’H), 137.3 (C3, C5), 
140.4 (C1), 141.3 (2C-NH), 142.5 (C1’), 156.9 (2C-O), 165.6 (2C=O); ESI-MS 651.5 (M+H)
+
. 
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N,N'-Bis(3-hydroxyphenyl)biphenyl-3,5-dicarboxamide (50). To a solution of silyl derivative 
118 (150 mg, 0.23 mmol) in a mixture of pyridine (0.44 mL, 0.96 mL/mmol of TBS group) and 
anhydrous THF (10 mL) under an argon atmosphere, HF·pyridine complex (0.44 mL, 0.96 mL/mmol 
of TBS group) was added and the reaction mixture was stirred at room temperature. After the 
complete disappearance of the starting material (TLC, approx. 15 min), the reaction mixture was 
diluted with water (15 mL) and extracted with ethyl acetate. The organic layer was washed with a 
saturated aqueous solution of CuSO4, dried (Na2SO4) and evaporated under reduced pressure and 
the resulting solid was purified by chromatography (DCM/MeOH, 95:5) to afford final compound 50 
in 89% yield. Rf (DCM/MeOH, 95:5) 0.36; IR (ATR)  3379 (NH), 1493, 1472, 1463 (Ar); 
1
H NMR 
(300 MHz, CDCl3)  6.64 (ddd, J = 8.0, 2.3, 0.9, 2H, 2H4’’), 7.18 (t, J = 8.1, 2H, 2H5’’), 7.29 (d, J = 
8.1, 2H, 2H6’’), 7.45 (t, J = 7.3, 1H, H4’), 7.54 (t, J = 7.4, 2H, H3’, H5’), 7.58 (t, J = 2.1, 2H, 2H2’’), 7.81 
(d, J = 7.3, 2H, H2’, H6’), 8.38 (d, J = 1.6, 2H, H2, H6), 8.47 (t, J = 1.5, 1H, H4), 9.76 (s, 2H, OH); 
13
C 
NMR (75 MHz, CDCl3)  108.3 (2C2’’H), 111.9 (2C4’’H), 112.2 (2C6’’H), 126.4 (C4H), 128.1 (C2’H, 
C6’H), 129.0 (C4’H), 129.5 (C3’H, C5’H), 130.0 (C2H, C6H), 130.3 (2C5’’H), 137.4 (C3, C5), 140.4 (C1), 
141.3 (2C-NH), 142.4 (C1’), 158.7 (2C-OH), 165.7 (2C=O); ESI-MS 423.1 (M−H)
−
; elemental 
analysis (calcd., found for C26H20N2O4·5/4H2O): C (69.87, 70.02), H, (4.93, 5.07), N, (6.27, 6.01). 
4.1.4. Synthesis of PC190723 
 
2,6-Difluoro-3-hydroxybenzamide (126).
70
 To a suspension of 2,6-difluoro-3-methoxy 
benzoic acid (5.8 g, 31 mmol) in anhydrous toluene (40 mL) at room temperature under an argon 
atmosphere, thionyl chloride (3.4 mL, 46 mmol) was added dropwise and the reaction was refluxed 
for 5 h. Afterward, the reaction was cooled to room temperature and concentrated under reduced 
pressure. Then, a 28% aqueous ammonia solution (25 mL, 706 mmol) was added dropwise at 0 ºC 
and the reaction mixture was stirred at room temperature for 16 h. The solvent was evaporated 
under reduced pressure and the resulting solid was suspended in water and filtered. The collected 
solid was dried under vacuum to give intermediate 126 as a white solid (99% yield) that was used 
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without further purification. Rf (hexane/ethyl acetate, 3:7) 0.40; mp 167-169 ºC; IR (ATR)  3381, 
3183 (NH2), 1649 (C=O), 1591, 1490, 1451 (Ar); 
1
H NMR (300 MHz, acetone-d6)  3.88 (s, 3H, 
OCH3), 6.97 (app td, J = 9.0, 2.0, 1H, C5H), 7.18 (app td, J = 9.3, 5.1, 2H, C4H), 7.18 (br s, CONH2), 
7.44 (br s, 1H, CONH2); 
13
C NMR (75 MHz, acetone-d6)  57.1 (OCH3), 111.4 (dd, J = 23.1, 4.2, 
C5H), 115.1 (dd, J = 9.4, 2.8, C4H), 117.3 (t, J = 21.6, C1), 145.3 (dd, J = 11.0, 3.2, C3), 149.5 (dd, J 
= 250.1, 8.1, CF), 153.4 (dd, J = 241.6, 6.5, CF), 162.2 (CONH2); ESI-MS 188.1 (M+H)
+
. The 
spectroscopic data are in agreement with those previously described.
70
 
 
2,6-Difluoro-3-hydroxybenzamide (127).
71
 To a suspension of methoxy derivative 126 (5.8 g, 
31 mmol) in anhydrous DCM (60 mL) under an argon atmosphere, a 1 M solution of BBr3 in DCM 
(62 mL, 62 mmol) was added dropwise. The reaction was stirred 3 days at room temperature. 
Then, the solvent was evaporated under reduced pressure and the residue was dissolved in ethyl 
acetate and washed with water (100 mL). The aqueous phase was extracted with ethyl acetate (3 x 
100 mL) and the combined organic extracts were dried (Na2SO4) and concentrated under reduced 
pressure. The crude was purified by chromatography (from hexane to hexane/ethyl acetate, 3:7) to 
afford intermediate 127 in 79% yield. Rf (hexane/ethyl acetate, 2:8) 0.50; mp 123-124 ºC; IR (ATR) 
 3193 (NH2), 1666 (C=O), 1596, 1493, 1396 (Ar); 
1
H NMR (300 MHz, acetone-d6)  6.87 (app td, J 
= 8.8, 1.8, 1H, C5H), 7.01 (app td, J = 9.2, 5.4, 1H, C4H), 7.17 (br s, 1H, CONH2), 7.41 (br s, 1H, 
CONH2), 8.79 (s, 1H, OH); 
13
C NMR (75 MHz, acetone-d6)  111.7 (dd, J = 23.3, 4.0, C5H), 117.0 (t, 
J = 21.6, C1), 118.7 (dd, J = 9.1, 3.7, C4H), 142.3 (dd, J = 13.5, 3.2, C3), 148.5 (dd, J = 245.4, 7.9, 
CF), 152.6 (dd, J = 240.3, 6.2, CF), 162.4 (CONH2); ESI-MS 172.0 (M−H)
−
. The spectroscopic data 
are in agreement with those previously described.
71
 
 
2-Bromo-5-chloro-3-nitropyridine (128).
70
 To a solution of a 5-chloro-2-hydroxy-3-
nitropyridine (1.5 g, 8.6 mmol) in a mixture of anhydrous toluene (15 mL) and DMF (2.5 mL) under 
an argon atmosphere, PBr3 (1.2 mL, 13 mmol) was added dropwise and the reaction was heated at 
130 ºC for 3 h. Afterward, the mixture was cooled to room temperature, water (50 mL) was added 
and the mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were 
dried (Na2SO4) and concentrated under reduced pressure. The crude was purified by 
chromatography (from hexane to hexane/ethyl acetate, 9:1) to afford intermediate 128 in 42% yield. 
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Rf (hexane/ethyl acetate, 9:1) 0.48; 
1
H NMR (300 MHz, CDCl3)  8.14 (d, J = 2.3, 1H, CH), 8.57 (d, 
J = 2.3, 1H, CH). The spectroscopic data are in agreement with those previously described.
70
  
 
2-Bromo-5-chloropyridin-3-amine (129).
70
 To a solution of 128 (854 mg, 3.6 mmol) in Et2O 
(7 mL), a solution of SnCl2·2H2O (4.1 g, 18 mmol) in HCl (5.6 mL) was added dropwise and the 
reaction was heated at 50 ºC for 30 min. Then, the solvent was evaporated and the residue was 
dissolved in water (25 mL). A 28% aqueous ammonia solution was added until pH 10 and the 
mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated under reduced pressure. The crude was purified by chromatography 
(from hexane to hexane/ethyl acetate, 9:1) to afford intermediate 129 in 98% yield. Rf (hexane/ethyl 
acetate, 9:1) 0.31; 
1
H NMR (300 MHz, CDCl3)  7.00 (d, J = 2.2, 1H, CH), 7.75 (d, J = 2.3, 1H, CH). 
The spectroscopic data are in agreement with those previously described.
70
  
 
2-(Benzyloxy)-N-(2-bromo-5-chloropyridin-3-yl)acetamide (130).
70
 To a solution of 129 
(730 mg, 3.5 mmol) and Et3N (0.54 mL, 3.9 mmol) in anhydrous DCM (11 mL) at 0 ºC under an 
argon atmosphere, a solution of benzyloxyacetyl chloride (0.66 mL, 4.2 mmol) in anhydrous DCM 
(4 mL) was added dropwise and the reaction was stirred at room temperature for 14 h. Then, the 
mixture was concentrated under reduced pressure and the residue was purified by chromatography 
(from hexane to hexane/ethyl acetate, 9:1) to afford intermediate 130 in 80% yield. Rf (hexane/ethyl 
acetate, 9:1) 0.32; 
1
H NMR (300 MHz, CDCl3)  4.15 (s, 2H, CH2), 4.72 (s, 2H, CH2), 7.35-7.41 (s, 
5H, CHBn), 8.09 (d, J = 2.4, 1H, CH), 8.83 (d, J = 2.4, 1H, CH), 9.11 (br s, 1H, NH). The 
spectroscopic data are in agreement with those previously described.
70
 
 
2-[(Benzyloxy)methyl]-6-chloro[1,3]thiazolo[5,4-b]pyridine (131).
71
 To a solution of 130 
(1.0 g, 2.8 mmol) in anhydrous toluene (20 mL) under an argon atmosphere, Lawesson’s reagent 
(682 mg, 4.2 mmol) was added and the reaction was heated at 120 ºC for 3 h. Then, the mixture 
was concentrated under reduced pressure and the residue was purified by chromatography (from 
hexane to hexane/ethyl acetate, 9:1) to afford intermediate 131 in 79% yield. Rf (hexane/ethyl 
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acetate, 9:1) 0.50; 
1
H NMR (300 MHz, CDCl3)  4.74 (s, 2H, CH2), 4.91 (s, 2H, CH2), 7.35-7.41 (s, 
5H, CHBn), 8.19 (d, J = 2.2, 1H, CH), 8.55 (d, J = 2.2, 1H, CH). The spectroscopic data are in 
agreement with those previously described.
71
 
 
6-Chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)methanol (132).
70
 To a solution of 131 (647 mg, 2.2 
mmol) in anhydrous DCM (3 mL) at -78 ºC under an argon atmosphere, a 1 M solution of BBr3 in 
DCM (11 mL, 11 mmol) was added dropwise. The reaction was warmed to room temperature and 
stirred for 2 h. After this time, a saturated aqueous solution of NaHCO3 (25 mL) was added and the 
mixture was extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated under reduced pressure. The crude was purified by 
chromatography (from hexane to hexane/ethyl acetate, 8:2) to afford intermediate 132 in 88% yield. 
Rf (hexane/ethyl acetate, 9:1) 0.15; 
1
H NMR (300 MHz, DMSO-d6)  4.88 (d, J = 5.9, 2H, CH2), 6.46 
(t, J = 5.9, 1H, OH), 8.54 (d, J = 2.3, 1H, CH), 8.66 (d, J = 2.2, 1H, CH). The spectroscopic data are 
in agreement with those previously described.
70
  
 
2-(Bromomethyl)-6-chloro[1,3]thiazolo[5,4-b]pyridine (133).
71
 To a suspension of 132 (184 
mg, 0.92 mmol) and Ph3P (290 mg, 1.1 mmol) in anhydrous DCM (5 mL) under an argon 
atmosphere, NBS (240 mg, 1.3 mmol) was slowly added and the reaction was stirred at room 
temperature for 2.5 h. Then, a saturated aqueous solution of NaHCO3 (25 mL) was added and the 
mixture was extracted with ethyl acetate (3 x 25 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated under reduced pressure. The crude was purified by 
chromatography (from hexane to hexane/ethyl acetate, 95:5) to afford intermediate 133 in 68% 
yield. Rf (hexane/ethyl acetate, 9:1) 0.68; 
1
H NMR (300 MHz, CDCl3)  4.78 (s, 2H, CH2), 8.24 (d, J 
= 2.2, 1H, CH), 8.58 (d, J = 1.8, 1H, CH). The spectroscopic data are in agreement with those 
previously described.
70
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3-[(6-Chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)methoxy]-2,6-difluorobenzamide 
(PC190723).
71
 To a suspension of hydroxybenzamide 127 (137 mg, 0.79 mmol), NaI (136 mg, 0.91 
mmol), and K2CO3 (436 mg, 3.2 mmol) in anhydrous DMF (5 mL) under an argon atmosphere, 
bromo derivative 133 (240 mg, 0.91 mmol) was added. The reaction was stirred at room 
temperature overnight. Then, the mixture was concentrated under reduced pressure and the 
residue was purified by chromatography (hexane/ethyl acetate, from 6:4 to 1:1) to afford PC190723 
in 33% yield. Rf (hexane/ethyl acetate, 6:4) 0.52; mp 217-218 ºC (Lit.
71
 218 C);
 1
H NMR (300 MHz, 
DMSO-d6)  5.73 (s, 2H, CH2), 7.12 (app td, J = 9.1, 1.8, 1H, C5H), 7.41 (app td, J = 9.4, 5.2, 1H, 
C4H), 7.92 (br s, 1H, CONH2), 8.19 (br s, 1H, CONH2), 8.69 (d, J = 2.2, 1H, CH), 8.73 (d, J = 2.2, 
1H, CH); elemental analysis (calcd., found for C14H8ClF2N3O2S): C (47.27, 47.34), H, (2.27, 2.28), N 
(11.81, 11.59), S (9.01, 9.08). The spectroscopic data are in agreement with those previously 
described.
71
 
4.1.5. Synthesis of 119-122 
 
5-Bromo-2-(bromomethyl)-1,3-benzothiazole (134).
70
 To a solution of a 2-methyl-5-
bromobenzothiazole (5.0 g, 22 mmol) in CCl4 (90 mL), NBS (7.8 g, 44 mmol) and AIBN (750 mg, 
4.6 mmol) were added. The reaction was heated at 90 ºC for 3 h. After this time, the solvent was 
evaporated and the residue was purified by chromatography (from hexane to hexane/ethyl acetate, 
95:5) to afford bromo derivative 134 in 13% yield. Rf (hexane/ethyl acetate, 1:1) 0.12; mp 110-112 
ºC (Lit.
70
 116-117 C); IR (ATR)  1730, 1583, 1542, 1507, 1435 (Ar); 
1
H NMR (300 MHz, CDCl3)  
4.79 (s, 2H, CH2), 7.54 (dd, J = 8.6, 1.8, 1H, C6H), 7.74 (d, J = 8.6, 1H, C7H), 8.17 (d, J = 1.8, 1H, 
C4H); 
13
C NMR (75 MHz, acetone-d6)  27.0 (CH2), 120.3 (C5), 123.0 (C7H), 126.6 (C4H), 129.1 
(C6H), 135.3 (C7a), 154.2 (C3a), 168.3 (C2); ESI-MS 307.8 (M+H)
+
. The spectroscopic data are in 
agreement with those previously described.
70
 
 
3-[(5-Bromo-1,3-benzothiazol-2-yl)methoxy]-2,6-difluorobenzamide (135).
71
 To a 
suspension of 127 (532 mg, 3.1 mmol) and K2CO3 (1.3 g, 9.2 mmol) in anhydrous DMF (15 mL) 
under an argon atmosphere, bromo derivative 134 (943 mg, 3.1 mmol) was added and the reaction 
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was stirred at room temperature overnight. Then, the mixture was concentrated under reduced 
pressure and the residue was purified by chromatography (hexane/ethyl acetate, from 7:3 to 3:7) to 
afford intermediate 135 in 82% yield. Rf (hexane/ethyl acetate, 1:1) 0.25; mp 242-244 ºC; IR (ATR) 
 3373 (NH2), 1669 (C=O), 1591, 1524, 1490 (Ar); 
1
H NMR (300 MHz, DMSO-d6)  5.70 (s, 2H, 
CH2), 7.10 (app td, J = 9.0, 1.8, 1H, C5H), 7.39 (app td, J = 9.4, 5.2, 1H, C4H), 7.64 (dd, J = 8.6, 1.9 
, 1H, C6’H), 7.87 (br s, 1H, CONH2), 8.13 (d, J = 8.6, 1H, C7’H), 8.15 (br s, 1H, CONH2), 8.25 (d, J = 
1.9, 1H, C4’H); 
13
C NMR (75 MHz, DMSO-d6)  68.6 (CH2), 111.1 (dd, J = 23.4, 4.1, C5H), 116.3 
(dd, J = 9.4, 1.9, C4H), 116.8 (dd, J = 24.8, 20.3, C1), 119.2 (C5’), 124.4 (C7’H), 125.3 (C4’H), 128.3 
(C6’H), 133.7 (C7’a), 141.9 (dd, J = 11.0, 3.3, C3), 148.1 (dd, J = 248.9, 9.1, CF), 152.5 (dd, J = 
242.2, 7.1, CF), 153.7 (C3’a), 161.1 (C2’), 169.9 (CONH2); ESI-MS 400.8 (M+H)
+
. The spectroscopic 
data are in agreement with those previously described.
71
 
 
2,2,2-Trifluoro-N-prop-2-ynylacetamide (136).
103
 To a solution of propargylamine (2.0 g, 36 
mmol) in MeOH (30 mL), ethyl trifluoroacetate (4.3 mL, 36 mmol) was added dropwise and the 
reaction was stirred at room temperature overnight. Then, the solvent was evaporated under 
reduced pressure and the crude was purified by chromatography (DCM) to afford intermediate 136 
in 60% yield. Rf (DCM) 0.37; IR (ATR)  3305 (NH), 1711 (C=O) ; 
1
H NMR (300 MHz, CDCl3)  2.32 
(t, J = 2.6, 1H, CH), 4.13 (dd, J = 5.3, 2.5, 2H, CH2), 6.80 (br s, 1H, NH); 
13
C NMR (75 MHz, 
acetone-d6)  29.8 (CH2), 73.3 (CH), 77.4 (C), 115.7 (q, J = 288.0, CF3), 157.1 (q, J = 37.4, CO); 
ESI-MS 150.0 (M+H)
+
. The spectroscopic data are in agreement with those previously described.
103
 
 
2,6-Difluoro-3-[(5-{3-[(trifluoroacetyl)amino]prop-1-ynyl}-1,3-benzothiazol-2-yl) 
methoxy]benzamide (137). A suspension of bromo derivative 135 (300 mg, 0.75 mmol), alkyne 
136 (341 mg, 2.3 mmol), triethylamine (0.16 mL, 1.1 mmol), CuI (74 mg, 0.075 mmol) and 
Pd(PPh3)4 (87 mg, 0.075 mmol) in anhydrous DMF (15 mL) under an argon atmosphere was 
heated in the microwave at 100 ºC for 45 min. Then, the mixture was concentrated under reduced 
pressure and the residue was purified by chromatography (from hexane to ethyl acetate) to afford 
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intermediate 137 in 86% yield. Rf (hexane/ethyl acetate, 1:1) 0.16; mp 187-189 ºC; IR (ATR)  3301 
(NH2), 1716, 1679 (C=O), 1553, 1489, 1439 (Ar); 
1
H NMR (300 MHz, DMSO-d6)  4.32 (d, J = 5.6, 
2H, CH2NH), 5.70 (s, 2H, CH2O), 7.11 (app td, J = 8.9, 1.8, 1H, C5H), 7.39 (app td, J = 9.3, 5.2, 1H, 
C4H), 7.51 (dd, J = 8.4, 1.5, 1H, C6’H), 7.88 (br s, 1H, CONH2), 8.08 (d, J = 1.0, 1H, C4’H), 8.16-
8.18 (m, 2H, C7’H, CONH2), 10.10 (t, J = 5.3, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6) 29.4 
(CH2NH), 68.6 (CH2O), 82.1, 85.3 (C≡C), 111.1 (dd, J = 23.2, 4.0, C5H), 116.2 (d, J = 9.3, C4H), 
116.6-117.0 (m, C1, CF3), 119.9 (C5’), 123.1 (C7’H), 125.5 (C4’H), 128.3 (C6’H), 135.1 (C7’a), 141.9 
(dd, J = 11.0, 3.2, C3), 148.3 (dd, J = 248.7, 8.4, CF), 152.3 (dd, J = 242.2, 7.1, CF), 152.7 (C3’a), 
156.2 (d, J = 37.0, COCF3), 161.1 (C2’), 169.3 (CONH2); ESI-MS 469.6 (M+H)
+
. 

3-{[5-(3-Aminoprop-1-yn-1-yl)-1,3-benzothiazol-2-yl]methoxy}-2,6-difluorobenzamide 
(138). To a solution of intermediate 137 (70 mg, 0.15 mmol) in MeOH (15 mL), a 28% aqueous 
ammonia solution (10 mL, 282 mmol) was added and the reaction was stirred at room temperature 
overnight. Then, the solvent was evaporated under reduced pressure and the crude was triturated 
with Et2O to afford amine 138 (99% yield) which was used in the next step without purification. ESI-
MS 374.1 (M+H)
+
. 
 
3-({5-[3-({[5-(Dimethylamino)-1-naphthyl]sulfonyl}amino)prop-1-ynyl]-1,3-benzothiazol-2-
yl}methoxy)-2,6-difluorobenzamide (119). To a solution of the amine 138 (55 mg, 0.15 mmol) 
and triethylamine (62 µL, 0.44 mmol) in a 2:1 mixture of anhydrous DCM and DMF (3 mL) under an 
argon atmosphere, a solution of dansyl chloride (60 mg, 0.22 mmol) in anhydrous DCM (1 mL) was 
added. The reaction was stirred at room temperature for 24 h. Afterward, the solvent was 
evaporated under reduced pressure and the crude was purified by chromatography (from DCM to 
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ethyl acetate) to afford final compound 119 in 28% yield. Rf (ethyl acetate) 0.65; mp 194-196 ºC; IR 
(ATR) 1739 (C=O), 1489, 1461 (Ar);
 1
H NMR (700 MHz, DMSO-d6) 2.67 (s, 6H, 2CH3), 4.04 (d, 
J = 4.9, 2H, CH2N), 5.67 (s, 2H, CH2O), 6.79 (dd, J = 8.3, 1.4, 1H, CHDS), 7.12 (app t, J = 9.0, 1H, 
C5H), 7.21 (d, J = 7.4, 1H, CHDS), 7.27 (d, J = 0.8, 1H, C4’H), 7.38 (app td, J = 9.2, 5.1, 1H, C4H), 
7.58-7.63 (m, 2H, C6’H, CHDS), 7.90 (br s, 1H, CONH2), 7.96 (d, J = 8.3, 1H, C7’H), 8.17 (br s, 1H, 
CONH2), 8.22 (dd, J = 7.2, 1.0, 1H, CHDS), 8.32 (d, J = 8.6, 1H, CHDS), 8.36 (d, J = 8.6, 1H, CHDS), 
8.53 (t, J = 5.0, 1H, NHSO2);
 13
C NMR (175 MHz, DMSO-d6)  32.4 (CH2N), 44.9 (2CH3), 68.5 
(CH2O), 82.2, 86.3 (C≡C), 111.2 (dd, J = 25.0, 2.9, C5H), 115.0 (CHDS), 116.2 (d, J = 8.7, C4H), 
116.9 (dd, J = 25.5, 20.0, C1), 119.2 (CHDS), 119.6 (C5’), 122.6 (C7’H), 123.6 (C4’H), 124.9 (C6’H), 
127.7, 127.8, 129.0 (3CHDS), 129.4 (CDS), 129.8 (CHDS), 132.1 (C7’a), 134.7, 136.0 (2CDS), 142.3 
(dd, J = 10.8, 2.4, C3), 148.0 (dd, J = 248.8, 8.4, CF), 151.4 (CDS), 152.1 (C3’a), 152.5 (dd, J = 
243.1, 6.7, CF), 161.1 (C2’), 169.0 (CONH2); ESI-MS 607.1 (M+H)
+
; elemental analysis (calcd., 
found for C30H24F2N4O4S2): C (59.39, 59.57), H, (3.99, 4.27), N (9.27, 8.93), S (10.57, 10.77). 
 
N-(3-(2-((3-Carbamoyl-2,4-difluorophenoxy)methyl)benzo[d]thiazol-5-yl)prop-2-ynyl)-7-
(diethylamino)-2-oxo-2H-chromene-3-carboxamide (120). To a solution of amine 138 (119 mg, 
0.32 mmol), PyBroP® (268 mg, 0.57 mmol) and DIPEA (111 µL, 0.64 mmol) in anhydrous DMF (5 
mL) under an argon atmosphere, a solution of 7-diethylaminocoumarin-3-carboxylic acid (100 mg, 
0.38 mmol) in anhydrous DMF (1 mL) was added. The reaction was stirred at room temperature for 
4 h. Afterward, the solvent was evaporated under reduced pressure and the crude was purified by 
chromatography (from DCM to ethyl acetate) to afford final compound 120 in 5% yield. Rf (ethyl 
acetate) 0.70; mp 248-249 ºC; 
1
H NMR (700 MHz, DMSO-d6)  1.17 (t, J = 7.0, 6H, 2CH3), 3.50 (q, 
J = 6.9, 4H, 2CH2), 4.43 (d, J = 5.5, 2H, CH2NH), 5.71 (s, 2H, CH2O), 6.64 (d, J = 2.0, 1H, CHcoum.), 
6.83 (dd, J = 8.9, 2.1, 1H, CHcoum.), 7.13 (app t, J = 8.8, 1H, C5H), 7.40 (app td, J = 9.1, 5.1, 1H, 
C4H), 7.52 (dd, J = 8.3, 1.1, 1H, C6’H), 7.72 (d, J = 9.1, 1H, CHcoum.), 7.90 (s, 1H, CONH2), 8.08 (s, 
1H, CH4’), 8.16 (d, J = 8.4, 1H, C7’H), 8.18 (s, 1H, CONH2), 8.72 (s, 1H, CHcoum.), 9.00 (t, J = 5.5, 
1H, NH); 
13
C NMR (175 MHz, DMSO-d6)  12.3 (2CH3), 29.2 (CH2NH), 44.4 (2CH2), 68.8 (CH2O), 
81.1, 87.5 (2C≡C), 95.9 (CHcoum.), 107.7, 108.8 (2Ccoum.), 110.2 (CHcoum.), 111.1 (dd, J = 24.3, 4.2, 
C5H), 116.2 (d, J = 9.9, C4H), 117.1-117.0 (m, C1), 120.4 (C5’), 123.0 (C7’H), 125.4 (C4’H) 128.4 
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(CHcoum.), 132.0 (C6’H), 134.8 (C7’a), 141.8-142.1 (m, C3), 148.2 (CHcoum.), 149.2 (d, J = 265.5, CF), 
152.4 (d, J = 242.0, CF), 152.5 (C3’a), 152.6, 157.4 (2Ccoum.), 161.1 (CONH), 161.7 (C2’), 162.2 
(C=Ocoum.), 169.2 (CONH2); ESI-MS 617.2 (M+H)
+
; elemental analysis (calcd., found for 
C32H26F2N4O5S·3H2O): C (57.31, 57.21), H, (4.81, 4.55), N (8.35, 7.96), S (4.78, 4.58). 
 
7-Nitro-N-prop-2-yn-1-yl-2,1,3-benzoxadiazol-4-amine (139).
104
 To a solution of Cl-NBD (1.0 
g, 5.0 mmol) in anhydrous acetonitrile (40 mL) under an argon atmosphere, propargylamine (0.64 
mL, 10 mmol) was added and the reaction was stirred for 2 h at room temperature. Then, the 
solvent was evaporated under reduced pressure and the crude was purified by chromatography 
(from hexane to ethyl acetate) to afford intermediate 139 in 35% yield. mp 145-146 ºC (Lit.
104
 145-
147 ºC) 
1
H NMR (300 MHz, acetone-d6)  2.47 (t, J = 2.5, 1H, C≡CH), 4.34 (dd, J = 5.9, 2.5, 2H, 
CH2), 6.41 (d, J = 8.7, 1H, CHNBD), 8.06 (br s, 1H, NH), 8.49 (d, J = 8.6, 1H, CHNBD). The 
spectroscopic data are in agreement with those previously described.
104
 
 
N-But-3-yn-1-yl-7-nitro-2,1,3-benzoxadiazol-4-amine (140). To a solution of Cl-NBD (1.1 g, 
5.3 mmol) and DIPEA (4.8 mL, 27 mmol) in MeOH (50 mL) under an argon atmosphere, a solution 
of 1-amino-3-butyne (0.64 mL, 5.3 mmol) in MeOH (50 mL) was added and the reaction was stirred 
for 15 h at room temperature. Then, the solvent was evaporated under reduced pressure and the 
crude was purified by chromatography (from hexane to DCM) to afford intermediate 140 in 77% 
yield. Rf (DCM) 0.59; mp 134-136 ºC; IR (ATR) 3286 (NH), 1582, 1496 (Ar), 1299 (NO2);
 1
H NMR 
(300 MHz, acetone-d6) 2.50 (t, J = 2.6, 1H, C≡CH), 2.74 (td, J = 7.0, 2.7, 2H, CH2), 3.83-3.86 (m, 
CH2N), 6.54 (d, J = 8.8, 1H CHNBD), 8.28 (s, 1H, NH), 8.51 (d, J = 8.8, 1H, CHNBD); 
13
C NMR (75 
MHz, acetone-d6)  18.9 (CH2), 43.4 (CH2N), 71.9 (CH≡C), 81.6 (CH≡C), 100.2 (br s, CHNBD), 123.9 
(CNBD), 137.6 (CHNBD), 145.1(CNBD), 145.5 (2CNBD); ESI-MS 233.0 (M+H)
+
. 
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2,6-Difluoro-3-[(5-{4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]but-1-yn-1-yl}-1,3-
benzothiazol-2-yl)methoxy]benzamide (121). A suspension of bromo derivative 135 (150 mg, 
0.38 mmol), alkyne 140 (262 mg, 1.13 mmol), Pd(PPh3)4 (37 mg, 0.02 mmol), CuI (43 mg, 0.04 
mmol) and triethylamine (79 µL, 0.56 mmol) in anhydrous DMF (8 mL) under an argon atmosphere 
was heated in the microwave at 100 ºC for 1 h. Then, the mixture was concentrated under reduced 
pressure and the residue was purified by chromatography (from hexane to ethyl acetate) to afford 
final compound 121 in 41% yield. Rf (hexane/ethyl acetate, 1:1) 0.29; mp 189-192 ºC; IR (ATR)  
3405 (NH2), 1684 (C=O), 1623, 1584, 1489 (Ar); 
1
H NMR (700 MHz, DMSO-d6)  2.46-2.55 (m, 2H, 
CH2N), 2.91 (t, J = 6.7, 2H, CH2), 5.68 (s, 2H, CH2O), 6.59 (d, J = 9.0, 1H, CHNBD), 7.11 (app td, J = 
9.1, 1.7, 1H, C5H), 7.28-7.46 (m, 2H, C4H, C6’H), 7.89 (br s, 1H, CONH2), 7.97 (s, 1H, C4’H), 8.10 
(d, J = 8.4, 1H, C7’H), 8.18 (br s, 1H, CONH2), 8.52 (d, J = 8.7, 1H, CHNBD), 9.62 (br s, 1H, NHNBD); 
13
C NMR (175 MHz, DMSO-d6)  19.0 (CH2), 42.2 (CH2N), 68.6 (CH2O), 81.5, 88.1 (C≡C), 99.7 (br 
s, CHNBD), 111.1 (dd, J = 23.0, 3.8, C5H), 116.2 (d, J = 9.4, C4H), 116.6 (dd, J = 25.3, 20.3, C1), 
120.9 (C5’), 122.9 (C7’H), 125.3 (C4’H), 128.2 (C6’H), 128.7 (CNBD), 134.5 (C7’a), 137.7 (br s, CHNBD), 
141.9 (dd, J = 11.1, 3.2, C3), 144.1, 144.3, 144.4 (3CNBD), 148.0 (dd, J = 248.6, 8.2, CF), 152.4 
(C3’a), 152.5 (dd, J = 242.6, 7.7, CF), 161.1 (C2’), 169.0 (CONH2); ESI-MS 551.1 (M+H)
+
; elemental 
analysis (calcd., found for C25H16F2N6O5S): C (54.55, 54.45), H, (2.93, 3.32), N (15.27, 14.98), S 
(5.82, 5.71). 
 
2,6-Difluoro-3-[(5-{3-[(trifluoroacetyl)amino]propyl}-1,3-benzothiazol-2-yl)methoxy] 
benzamide (141). To a suspension of alkyne 137 (250 mg, 0.53 mmol) in a mixture of anhydrous 
THF (20 mL) and MeOH (40 mL) under an argon atmosphere, Raney-Ni (1 mL, slurry in water) was 
added. The reaction was stirred under hydrogen atmosphere (1 bar) at room temperature for 3 h. 
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Then, the mixture was filtered through Celite® and concentrated under reduced pressure. The 
crude was purified by chromatography (from hexane to ethyl acetate) to afford intermediate 141 in 
22% yield. Rf (hexane/ethyl acetate, 1:1) 0.16; mp 102-104 ºC; IR (ATR) 3303 (NH), 1710, 1680 
(C=O), 1489 (Ar);
 1
H NMR (300 MHz, DMSO-d6) 1.96 (qt, J = 7.5, 2H, CH2CH2CH2), 2.82 (t, J = 
7.7, 2H, CH2Ar), 3.34 (t, J = 7.2, 2H, CH2N), 5.57 (s, 2H, CH2O), 6.97 (app td, J = 8.9, 1.8, 1H, 
C5H), 7.32 (app td, J = 9.2, 5.0, 1H, C4H), 7.35 (dd, J = 8.3, 1.3, 1H, C6’H), 7.54-7.64 (m, 3H, 
CONH2, CONH), 7.84 (s, 1H, C4’H), 7.92 (d, J = 8.3, 1H, C7’H); 
13
C NMR (75 MHz, DMSO-d6)  
31.7, 33.9 (CH2CH2Ar), 40.3 (CH2NH), 70.4 (CH2O), 112.1 (dd, J = 23.7, 3.7, C5H), 117.0-117.2 (m, 
C1), 117.6 (q, J = 286.0, CF3) 118.7 (d, J = 9.2, C4H), 123.2 (C7’H), 127.8 (C4’H), 130.0 (C6’H), 133.9 
(C5’), 141.7 (C7’a), 143.8 (dd, J = 11.2, 2.4, C3), 150.7 (dd, J = 252.3, 8.2, CF), 154.2 (C3’a), 154.9 
(dd, J = 244.5, 6.6, CF), 159.0 (d, J = 36.8, COCF3), 165.0 (C2’), 169.7 (CONH2); ESI-MS 473.7 
(M+H)
+
. 
 
3-{[5-(3-Aminopropyl)-1,3-benzothiazol-2-yl]methoxy}-2,6-difluorobenzamide (142). To a 
solution of intermediate 141 (60 mg, 0.13 mmol) in MeOH (20 mL), a 28% aqueous ammonia 
solution (7.8 mL) was added and the reaction was stirred at room temperature overnight. Then, the 
solvent was evaporated under reduced pressure to afford amine 142 (99% yield) which was used 
without purification. ESI-MS 378.1 (M+H)
+
. 
 
3-({5-[3-({[5-(Dimethylamino)-1-naphthyl]sulfonyl}amino)propyl]-1,3-benzothiazol-2-
yl}methoxy)-2,6-difluorobenzamide (122). To a solution of amine 142 (50 mg, 0.13 mmol) and 
triethylamine (58 µL, 0.41 mmol) in a 2:1 mixture of anhydrous DCM and DMF (3 mL) under an 
argon atmosphere, a solution of dansyl chloride (56 mg, 0.21 mmol) in anhydrous DCM (1 mL) was 
added. The reaction was stirred at room temperature for 24 h. Afterward, the solvent was 
evaporated under reduced pressure and the crude was purified by chromatography (from DCM to 
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ethyl acetate) to afford final compound 122 in 26% yield. Rf (DCM/ethyl acetate, 1:4) 0.64; mp 185-
186 ºC; IR (ATR) 3435 (NH), 1670 (C=O), 1604, 1486, 1450 (Ar);
 1
H NMR (700 MHz, DMSO-d6)  
1.58 (qt, J = 7.2, 2H, CH2CH2CH2), 2.55 (t, J = 7.7, 2H, CH2Ar), 2.82 (s, 6H, 2CH3), 2.83 (t, J = 7.3, 
2H, CH2N), 5.66 (s, 2H, CH2O), 7.02 (dd, J = 8.2, 1.5, 1H, CHDS), 7.10 (app t, J = 9.0, 1H, C5H), 
7.26 (d, J = 7.3, 1H, CHDS), 7.38 (app td, J = 9.2, 5.1, 1H, C4H), 7.57-7.62 (m, 3H, CHDS, C4’H, 
C6’H), 7.89 (br s, 1H, CONH2), 7.92 (d, J = 8.2, 1H, C7’H), 8.01 (t, J = 5.9, 1H, NHSO2), 8.07 (dd, J 
= 7.1, 1.1, 1H, CHDS), 8.18 (br s, 1H, CONH2), 8.33 (d, J = 8.7, 1H, CHDS), 8.45 (d, J = 8.4, 1H, 
CHDS); 
13
C NMR (175 MHz, DMSO-d6)  31.1, 31.8 (CH2CH2Ar), 41.8 (CH2N), 45.1 (2CH3), 68.5 
(CH2O), 111.1 (d, J = 21.6, C5H), 115.1 (CHDS), 116.2 (d, J = 8.5, C4H), 116.8 (t, J = 23.4, C1), 
119.1 (CHDS), 122.0 (C7’H), 123.6 (C4’H), 126.2 (C6’H), 127.9 (2CHDS), 128.3 (CHDS), 129.1 (CDS, 
C5’), 129.4 (CHDS), 131.9 (C7’a), 136.1, 140.1 (2CDS), 142.0 (d, J = 9.0, C3), 148.0 (dd, J = 249.5, 
7.7, CF), 151.4 (CDS), 152.4 (d, J = 240.4, CF), 152.9 (C3a’), 161.1 (C2’), 167.4 (CONH2); ESI-MS 
611.2 (M+H)
+
; elemental analysis (calcd., found for C30H28F2N4O4S2): C (59.00, 58.71), H, (4.62, 
4.63), N (9.17, 9.17), S (10.50, 10.19). 
4.1.6. Synthesis of 123-125, 149, and 150 
 
3-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]-2,6-difluorobenzamide (143). To a 
solution of hydroxybenzamide 127 (300 mg, 1.7 mmol), N-(2-hydroxyethyl)phthalimide (480 mg, 2.5 
mmol) and Ph3P (870 mg, 3.3 mmol) in anhydrous THF (10 mL) under an argon atmosphere, 
diethyl azodicarboxylate (DEAD) (0.61 mL, 3.3 mmol) was added and the reaction was refluxed for 
24 h. Then, the solvent was evaporated under reduced pressure and the crude was purified by 
chromatography (from hexane to hexane/ethyl acetate, 1:1) to afford protected amine 143 in 67% 
yield. Rf (hexane/ethyl acetate, 1:1) 0.25; mp 169-171 ºC; IR (ATR) 3397 (NH2), 1710 (C=O), 
1654 (C=O), 1492 (Ar); 
1
H NMR (300 MHz, acetone-d6) 4.01 (t, J = 5.7, 2H, CH2N), 4.29 (t, J = 
5.7, 2H, CH2O), 5.82 (br s, 1H, CONH2), 5.97 (br s, 1H, CONH2), 6.85 (app td, J = 9.1, 1.8, 1H, 
C5H), 7.05 (app td, J = 9.0, 5.1, 1H, C4H), 7.74 (dd, J = 5.4, 3.0, 2H, 2CHpht.), 7.87 (dd, J = 5.5, 2.9, 
2H, 2CHpht.); 
13
C NMR (75 MHz, acetone-d6)  37.9 (CH2N), 67.7 (OCH2), 111.6 (dd, J = 23.5, 3.9, 
C5H), 116.9 (t, J = 23.5, C1), 117.1 (d, J = 7.1, C4H), 123.9 (2CHpht.), 133.0 (2Cpht.), 135.2 (2CHpht.), 
144.0 (dd, J = 10.8, 3.2, C3), 150.6 (dd, J = 251.0, 8.9, CF), 153.0 (dd, J = 242.0, 6.5, CF), 162.0 
(d, J = 6.7, CONH2), 168.6 (2COpht.); ESI-MS 347.1 (M+H)
+
. 
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3-(2-Aminoethoxy)-2,6-difluorobenzamide (144). To a solution of phthalimide 143 (180 mg, 
0.52 mmol) in EtOH (15 mL), hydrazine monohydrate (51 µL, 1.0 mmol) was added and the 
reaction was refluxed for 2 h. Then, the solvent was evaporated under reduced pressure and the 
crude was purified by chromatography (from DCM to DCM/MeOH, 95:5) to afford amine 144 in 67% 
yield. Rf (ethyl acetate/EtOH, 1:1) 0.01; mp 98-100 ºC; IR (ATR) 3310 (NH2), 1675 (C=O), 1489 
(Ar);
 1
H NMR (500 MHz, methanol-d4)  3.22 (t, J = 5.1, 2H, CH2NH2), 4.20 (t, J = 5.1, 2H, CH2O), 
6.99 (app td, J = 8.9, 1.9, 1H, C5H), 7.23 (app td, J = 9.2, 5.2, 1H, C4H); 
13
C NMR (125 MHz, 
methanol-d4)  40.8 (CH2NH2), 70.1 (OCH2), 112.1 (dd, J = 22.4, 4.5, C5H), 117.1 (t, J = 23.8, C1), 
118.3 (dd, J = 9.4, 2.4, C4H), 144.1 (dd, J = 11.0, 3.3, C3), 150.7 (dd, J = 252.8, 9.0, CF), 154.6 (dd, 
J = 244.0, 5.8, CF), 165.1 (CONH2); ESI-MS 216.9 (M+H)
+
. 
 
3-[2-({[5-(Dimethylamino)-1-naphthyl]sulfonyl}amino)ethoxy]-2,6-difluorobenzamide 
(123). To a solution of amine 144 (98 mg, 0.45 mmol) and triethylamine (0.19 mL, 1.4 mmol) in a 
6:1 mixture of anhydrous DCM and DMF (3.5 mL) under an argon atmosphere, a solution of dansyl 
chloride (183 mg, 0.68 mmol) in anhydrous DCM (1 mL) was added. The reaction was stirred at 
room temperature for 24 h. Afterward, the solvent was evaporated under reduced pressure and the 
crude was purified by chromatography (DCM) to afford final compound 123 in 8% yield. Rf 
(DCM/ethyl acetate, 95:5) 0.67; mp 130-132 ºC; IR (ATR) 3316 (NH2), 1744 (C=O), 1581, 1502, 
1459 (Ar);
 1
H NMR (300 MHz, CDCl3)  2.89 (s, 6H, 2CH3), 3.38 (app q, J = 5.5, 2H, CH2N), 3.85 (t, 
J = 5.0, 2H, CH2O), 5.25 (t, J = 6.0, 1H, NH), 6.77-6.85 (m, 2H, C4H, C5H), 7.17 (d, J = 7.2, 1H, 
C6’H), 7.52 (t, J = 7.9, 1H, C3’H/C7’H), 7.57 (t, J = 8.0, 1H, C3’H/C7’H), 8.24-8.27 (m, 2H, C4’H, C8’H), 
8.54 (d, J = 7.2, 1H, C2’H); 
13
C NMR (125 MHz, CDCl3)  43.2 (CH2N), 45.6 (2CH3), 68.9 (OCH2), 
111.3 (dd, J = 20.6, 4.5, C5H), 115.5 (CHDS), 118.6 (br s, C1), 120.4 (dd, J = 9.1, 3.5, C4H), 128.8 
(2CHDS), 129.5 (2CDS), 129.6 (2CHDS), 129.1 (CDS), 130.8 (CHDS), 135.1 (CDS), 142.9 (dd, J = 9.3, 
3.5, C3), 153.0 (dd, J = 262.9, 4.6, CF), 156.7 (dd, J = 255.0, 2.9, CF), 164.7 (CONH2); ESI-MS 
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432.1 (M+H)
+
; elemental analysis (calcd., found for C21H21F2N3O4S): C (56.12, 56.17), H, (4.71, 
5.16), N (9.35, 9.29), S (7.13, 6.83). 
 
N-{2-[3-(Aminocarbonyl)-2,4-difluorophenoxy]ethyl}-7-(diethylamino)-2-oxo-2H-
chromene-3-carboxamide (124). To a solution of amine 144 (80 mg, 0.37 mmol), PyBroP® (311 
mg, 0.66 mmol) and DIPEA (0.13 mL, 0.74 mmol) in anhydrous DMF (4 mL) under an argon 
atmosphere, a solution of 7-diethylaminocoumarin-3-carboxylic acid (100 mg, 0.38 mmol) in 
anhydrous DMF (1 mL) was added. The reaction was stirred at room temperature for 4 h. 
Afterward, the solvent was evaporated under reduced pressure and the crude was purified by 
chromatography (from DCM to DCM/ethyl acetate, 1:1) to afford final compound 124 in 27% yield. 
Rf (ethyl acetate) 0.4; mp 155-158 ºC; IR (ATR) 3366 (NH2), 1709, 1663 (C=O), 1618, 1583, 1537 
(Ar);
 1
H NMR (700 MHz, DMSO-d6)  1.14 (t, J = 7.0, 6H, 2CH3), 3.48 (q, J = 7.0, 4H, 2CH2), 3.70 
(app q, J = 5.7, 2H, CH2NH), 4.18 (t, J = 5.7, 2H, CH2O), 6.61 (d, J = 2.0, 1H, CHcoum.), 6.81 (dd, J = 
9.0, 2.2, 1H, CHcoum.), 7.07 (app t, J = 8.8, 1H, C5H), 7.29 (app td, J = 9.3, 5.3, 1H, C4H), 7.69 (d, J 
= 9.0, 1H, CHcoum.), 7.85 (br s, 1H, CONH2), 8.13 (br s, 1H, CONH2), 8.69 (s, 1H, CHcoum.), 8.93 (t, J 
= 5.7, 1H, NH); 
13
C NMR (175 MHz, DMSO-d6)  12.3 (2CH3), 38.3 (CH2NH), 44.3 (2CH2), 68.3 
(OCH2), 95.9 (CHcoum.), 107.7, 109.0 (2Ccoum.), 110.2 (CHcoum.), 111.0 (dd, J = 22.6, 4.0, C5H), 115.6 
(d, J = 9.4, C4H), 116.7 (dd, J = 25.1, 20.3, C1), 131.7 (CHcoum.), 142.8 (dd, J = 10.6, 2.7, C3), 147.9 
(CHcoum.), 148.0 (dd, J = 248.5, 9.0, CF), 152.0 (dd, J = 241.7, 7.2, CF), 152.5, 157.3 (2Ccoum.), 
161.3, 161.8, 162.6 (3CO); ESI-MS 459.6 (M+H)
+
; elemental analysis (calcd., found for 
C23H23F2N3O5): C (60.13, 60.23), H, (5.05, 5.41), N (9.15, 9.44). 
 
2,6-Difluoro-3-{2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethoxy}benzamide (125). To a 
solution of amine 144 (101 mg, 0.47 mmol) and triethylamine (71 µL, 0.51 mmol) in anhydrous 
DMF (3 mL) under an argon atmosphere, a solution of Cl-NBD (93 mg, 0.47 mmol) in anhydrous 
DMF (1 mL) was added. The reaction was stirred at room temperature for 20 h. Afterward, the 
solvent was evaporated under reduced pressure and the crude was purified by chromatography 
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(from DCM to DCM/ethyl acetate, 1:1) to afford final compound 125 in 13% yield. Rf (DCM/ethyl 
acetate, 8:2) 0.16; mp 169-172 ºC; IR (ATR) 3354 (NH2), 1676 (C=O), 1586, 1491 (Ar);
 1
H NMR 
(500 MHz, acetone-d6)  4.15 (m, 2H, CH2N), 4.52 (t, J = 5.2, 2H, CH2O), 6.65 (d, J = 8.7, 1H, 
CHNBD), 6.96 (app td, J = 8.9, 2.1, 1H, C5H), 7.15 (br s, 1H, CONH2), 7.24 (app td, J = 9.1, 5.1, 1H, 
C4H), 7.39 (br s, 1H, CONH2), 8.44 (br s, 1H, NH), 8.56 (d, J = 8.7, 1H, CHNBD); 
13
C NMR (125 
MHz, acetone-d6)  43.8 (br s, CH2N), 68.5 (OCH2), 100.0 (br s, CHNBD), 111.1 (dd, J = 23.2, 4.1, 
C5H), 116.3 (d, J = 9.6, C4H), 116.9 (t, J = 25.7, C1), 123.5 (CNBD), 137.2 (CHNBD), 143.6 (dd, J = 
11.2, 3.4, C3), 144.7, 145.1, 145.4 (3CNBD), 149.3 (dd, J = 248.6, 8.3, CF), 153.3 (dd, J = 242.4, 6.3, 
CF), 161.6 (CONH2); ESI-MS 379.7 (M+H)
+
; elemental analysis (calcd., found for C15H11F2N5O5): C 
(47.50, 47.40), H, (2.92, 3.29), N (18.47, 18.13). 
General Procedure for the Synthesis of Final Compounds 149 and 150. To a solution of 
amine 144 (1 equiv) and Et3N (5 equiv) in anhydrous DMF (50 mL/mmol) under an argon 
atmosphere, a solution of the succinimidyl ester of the corresponding fluorophore (1 equiv) in 
anhydrous DMF (25 mL/mmol) was added and the reaction was stirred for 4 h at room temperature 
protected from light. Then, the solvent was evaporated under reduced pressure and the crude was 
purified by chromatography (from ethyl acetate to ethyl acetate/MeOH/NH3, 8:2:0.01) to afford the 
corresponding final compound 149 or 150. 
 
Mixture of 4- and 5-[({2-[3-(aminocarbonyl)-2,4-difluorophenoxy]ethyl}amino)carbonyl]-
2-[6-(dimethylamino)-3-(dimethyliminio)-3H-xanthen-9-yl]benzoate (149). Obtained from amine 
144 (4.1 mg, 19 µmol) and 4- and 5-TAMRA succinimidyl ester (mixed isomers, 10 mg, 19 µmol) in 
99% yield as a 1:0.5 mixture of 4- and 5-TAMRA regioisomers. Rf (DCM/MeOH/NH3, 8:2:0.01) 0.29; 
IR (ATR) 3321 (NH, NH2), 1596 (N=C), 1365, 1348 (Ar);
 1
H NMR (700 MHz, MeOD)  3.27 (s, 
18H, 4CH3(5-TAMRA), 4x0.5CH3(6-TAMRA)), 3.76 (t, J = 5.5, 1H, 0.5CH2NH(6-TAMRA)), 3.85 (t, J = 5.5, 2H, 
CH2NH(5-TAMRA)), 4.22 (t, J = 5.5, 1H, 0.5CH2O(6-TAMRA)), 4.31 (t, J = 5.5, 2H, CH2O(5-TAMRA)), 6.90-
6.91 (m, 2.5H, 2CHAr, 0.5C5H(6-TAMRA)), 6.97 (app td, J = 9.0, 1.6, 1H, C5H(5-TAMRA)), 6.99-7.02 (m, 
2.5H, 2.5CHAr), 7.18 (app td, J = 9.2, 5.0, 1H, C4H(5-TAMRA)), 7.23-7.28 (m, 3.5H, 3CHAr, 0.5C4H(6-
TAMRA)), 7.36 (d, J = 7.8, 1H, CHAr), 7.72 (d, J = 1.6, 1H, CHAr), 7.77 (s, 0.5H, 0.5CHAr), 8.05 (dd, J = 
7.8, 1.8, 1H, CHAr), 8.08-8.10 (m, 0.5H, 0.5CHAr), 8.13-8.14 (m, 0.5H, 0.5CHAr), 8.52 (d, J = 1.7, 1H, 
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CHAr), 8.57 (d, J = 1.7, 0.5H, 0.5CHAr). ESI-HRMS (calcd., found for C34H31F2N4O6 [M+H]
+
): 
629.2206, 629.2185. 
 
Mixture of 6-{4- and 6-{5- [({2-[3-(aminocarbonyl)-2,4-difluorophenoxy]ethyl}amino) 
carbonyl]-2-carboxyphenyl}-1,11-diethyl-1,2,3,4,9,10-hexahydro-8H-pyrano[3,2-g:5,6-
g']diquinolin-11-ium perchlorate (150). Obtained from amine 144 (3.6 mg, 16 µmol) and 4- and 5-
ATTO565 succinimidyl ester (mixed isomers, 10 mg, 16 µmol) in 66% yield as a 7:3 mixture of 4- 
and 5-ATTO565 regioisomers. Rf (DCM/MeOH/NH3 1:1:0.01) 0.18; IR (ATR) 3358 (NH, NH2), 
1602 (N=C), 11499 (Ar);
 1
H NMR (700 MHz, MeOD)  1.33 (t, J = 7.1, 6H, 2CH3), 1.94 (br s, 4H, 
2CH2), 2.68-2.72 (m, 4H, 2CH2), 3.57 (t, J = 5.3, 4H, 2CH2CH2N), 3.62-3.70 (m, 4H, 2CH3CH2N), 
3.78 (t, J = 5.5, 2H, CH2NHCO), 4.24 (t, J = 5.5, 2H, CH2O), 6.87-6.90 (m, 4H, 4CHAr), 6.93 (app td, 
J = 9.0, 1.4, 1H, C5H), 7.21 (app td, J = 9.2, 5.1, 1H, C4H), 7.70 (d, J = 1.1, 0.7H, 0.7CHAr), 7.74 (d, 
J = 1.1, 0.3H, 0.3CHAr), 8.07-8.13 (m, 2H, 2CHAr). ESI-HRMS (calcd., found for C40H40F2N4O6 
[M+H]
+
): 710.2910, 710.2826. 
4.1.7. Synthesis of 145-148 and 161 
 
tert-Butyl N,N-dibromocarbamate (157).
89
 To a solution of t-butyl carbamate (1.3 g, 11 
mmol) and K2CO3 (1.5 g, 22 mmol) in water (20 mL), bromine (1.2 mL, 22 mmol) was added 
dropwise. The reaction was stirred at room temperature for 2 h. Afterward, DCM (10 mL) was 
added and stirring was continued for 15 min. Then, the organic layer was separated and the 
aqueous phase was extracted with DCM (3 x 10 mL). The combined organic phases were washed 
with water (40 mL), dried (Na2SO4) and evaporated under reduced pressure to afford intermediate 
157 as an orange solid in 79% yield. 
1
H NMR (300 MHz, CDCl3)  1.49 (s, 9H, 3CH3). The 
spectroscopic data are in agreement with those previously described.
89
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tert-Butyl (2-bromodecyl)carbamate (158). To a solution of 1-decene (860 mg, 6.1 mmol) in 
refluxing anhydrous DCM (10 mL) under an argon atmosphere, a solution of dibromocarbamate 
157 (1.7 g, 6.1 mmol) in anhydrous DCM (10 mL) was added dropwise.The reaction was refluxed 
for 3 h and then it was stirred at room temperature overnight (during this time the solution turned 
from orange to yellow). Afterward, the reaction was cooled to 5-10 ºC and a 12% aqueous solution 
of Na2SO3 (7 mL) was slowly added and the mixture was stirred for 15 min. After this time, the 
mixture was extracted with DCM (10 mL) and the organic phase was washed with water (20 mL), 
dried (Na2SO4) and evaporated under reduced pressure. The crude was purified by 
chromatography (DCM) to afford intermediate 158 as an oil in 56 % yield. Rf (hexane/ethyl acetate, 
1:1) 0.38; IR (ATR) 3360 (NH), 1703 (C=O);
 1
H NMR (300 MHz, CDCl3)  0.87 (t, J = 6.6, 3H, 
CH3), 1.26 (br s, 10H, 5CH2), 1.44-1.48 (m, 11H, CH2, (CH3)3C), 1.75-1.83 (m, 2H, CH2CHBr), 3.29-
3.36 (m, 1H, 1/2CH2NH), 3.60-3.62 (m, 1H, 1/2CH2NH), 4.08 (br s, 1H, CHBr), 4.98 (br s, 1H, NH); 
13
C NMR (75 MHz, CDCl3)  14.2 (CH3), 22.8, 27.5 (2CH2), 28.5 ((CH3)3C), 29.1, 29.3, 29.5, 32.0 
(4CH2), 36.3 (CH2CHBr), 47.7 (CH2NH), 57.8 (CHBr), 79.9 ((CH3)3C), 155.9 (CO); ESI-MS 360.0 
(M+H)
+
. 
General Procedure for the Synthesis of Intermediates 151, 152, 155, and 159. To a 
solution of hydroxybenzamide 127 (1 equiv), K2CO3 (3 equiv) and NaI (0.2 equiv) in anhydrous 
DMF (10 mL/mmol 127) under an argon atmosphere, the corresponding commercial bromo 
derivative or intermediate 158 (1 equiv) was added dropwise. The reaction mixture was stirred at 
room temperature overnight. Then, the reaction was concentrated under reduced pressure and the 
residue was dissolved in ethyl acetate and washed with a saturated aqueous solution of NaHCO3 
and with water. The organic layer was dried (Na2SO4) and the solvent was evaporated under 
reduced pressure. The crude was purified by chromatography (from hexane to ethyl acetate) to 
afford the corresponding intermediate 151, 152, 155, or 159. 
 
3-[3-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)propoxy]-2,6-difluorobenzamide (151). 
Obtained from 127 (250 mg, 1.4 mmol) and N-(3-bromopropyl)phthalimide (387 mg, 1.4 mmol) in 
57% yield. Rf (hexane/ethyl acetate, 1:3) 0.54; mp 200-203 ºC; IR (ATR) 3404 (NH2), 1707, 1679 
(C=O), 1611, 1494 (Ar);
 1
H NMR (300 MHz, acetone-d6)  1.62 (m, 2H, CH2), 3.31 (t, J = 6.7, 2H, 
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CH2N), 3.63 (t, J = 5.9, 2H, CH2O), 6.59 (app td, J = 9.0, 1.8, 1H, C5H), 6.71 (app td, J = 9.3, 5.3, 
1H, C4H), 7.34-7.43 (m, 4H, 4CHpht.), 7.50 (br s, 1H, CONH2), 7.65 (br s, 1H, CONH2); 
13
C NMR (75 
MHz, acetone-d6)  27.7 (CH2), 34.8 (CH2N), 67.4 (OCH2), 110.8 (dd, J = 24.2, 5.4, C5H), 115.3 (d, 
J = 9.2, C4H), 117.9 (br s, C1), 122.9 (2CHpht.), 131.8 (2Cpht.), 134.3 (2CHpht.), 143.0 (dd, J = 13.9, 
3.3, C3), 148.0 (d, J = 231.6, CF), 153.7 (d, J = 224.7, CF), 161.3 (CONH2), 168.1 (2COpht.); ESI-
MS 361.0 (M+H)
+
. 
 
3-[4-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)butoxy]-2,6-difluorobenzamide (152). 
Obtained from 127 (221 mg, 1.2 mmol) and N-(4-bromobutyl)phthalimide (344 mg, 1.2 mmol) in 
87% yield. Rf (hexane/ethyl acetate, 1:1) 0.29; mp 155-157 ºC; IR (ATR) 3397 (NH2), 1710, 1654 
(C=O), 1492 (Ar);
 1
H NMR (300 MHz, acetone-d6)  1.84-1.88 (m, 4H, 2CH2), 3.74 (t, J = 6.7, 2H, 
CH2N), 4.14 (t, J = 5.9, 2H, CH2O), 6.93 (app td, J = 9.0, 2.0, 1H, C5H), 7.14-7.22 (m, 2H, CONH2, 
C4H), 7.41 (br s, 1H, CONH2), 7.83-7.87 (m, 4H, 4CHpht.); 
13
C NMR (75 MHz, acetone-d6)  25.8, 
27.3 (2CH2), 38.1 (CH2N), 70.2 (OCH2), 111.5 (dd, J = 23.2, 4.1, C5H), 116.6 (dd, J = 9.3, 2.9, 
C4H), 117.4 (br s, C1), 123.7 (2CHpht.), 133.1 (2Cpht.), 135.0 (2CHpht.), 144.6 (dd, J = 11.0, 3.1, C3), 
147.6 (d, J = 261.3, CF), 153.5 (dd, J = 243.2, CF), 162.2 (CONH2), 168.9 (2COpht.); ESI-MS 375.0 
(M+H)
+
. 
 
tert-Butyl {6-[3-(aminocarbonyl)-2,4-difluorophenoxy]hexyl}carbamate (155). Obtained 
from 127 (250 mg, 1.4 mmol) and 6-(Boc-amino)hexyl bromide (405 mg, 1.4 mmol) as an oil in 77% 
yield. Rf (hexane/ethyl acetate, 1:3) 0.66; IR (ATR) 3326 (NH2), 3193 (NH), 1669 (C=O), 1490, 
1366 (Ar);
 1
H NMR (300 MHz, CDCl3)  1.37-1.52 (m, 15H, 3CH2, (CH3)3C), 1.79 (qt, J = 6.8, 2H, 
CH2), 3.10 (m, 2H, CH2NH), 3.99 (t, J = 6.4, 2H, CH2O), 4.61 (br s, 1H, NH), 6.25 (br s, 1H, 
CONH2), 6.48 (br s, 1H, CONH2), 6.85 (app td, J = 9.1, 1.8, 1H, C5H), 6.97 (app td, J = 9.1, 5.2, 1H, 
C4H); 
13
C NMR (75 MHz, CDCl3) 25.6, 26.5 (2CH2), 28.5 ((CH3)3C), 29.1, 30.1 (2CH2), 40.5 (CH2N), 
70.4 (OCH2), 79.2 ((CH3)3C), 111.1 (dd, J = 23.5, 4.3, C5H), 114.2 (dd, J = 20.4, 16.8, C1), 117.0 
(dd, J = 9.6, 3.5, C4H), 144.0 (dd, J = 11.4, 3.3, C3), 150.1 (dd, J = 254.1, 6.8, CF), 153.4 (dd, J = 
246.1, 5.8, CF), 156.1 (NHCO), 162.5 (CONH2); ESI-MS 395.2 (M+Na)
+
. 
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tert-Butyl {2-[3-(aminocarbonyl)-2,4-difluorophenoxy]decyl}carbamate (159). Obtained 
from 127 (300 mg, 1.7 mmol) and bromo derivative 159 (344 mg, 1.2 mmol) as an oil in 23% yield. 
Rf (hexane/ethyl acetate, 6:4) 0.53; IR (ATR) 3356 (NH), 1681 (C=O), 1489, 1367 (Ar);
 1
H NMR 
(300 MHz, CDCl3)  0.85 (t, J = 6.7, 3H, CH3), 1.24 (br s, 10H, 5CH2), 1.41-1.42 (m, 11H, CH2, 
(CH3)3C), 1.54-1.69 (m, 2H, OCHCH2), 3.22-3.29 (m, 1H, 1/2CH2NH), 3.39-3.43 (m, 1H, 
1/2CH2NH), 4.25 (br s, 1H, OCH), 4.96 (br s, 1H, NH), 6.16 (br s, 1H, CONH2), 6.58 (br s, 1H, 
CONH2), 6.84 (app td, J = 9.1, 1.8, 1H, C5H), 7.38 (app td, J = 8.9, 5.3 1H, C4H); 
13
C NMR (75 
MHz, CDCl3)  14.5 (CH3), 23.0, 25.5 (2CH2), 28.7 ((CH3)3C), 29.6, 29.8, 30.0 (3CH2), 32.2 (2CH2), 
44.1 (CH2NH), 80.0 ((CH3)3C), 81.1 (OCH), 111.7 (dd, J = 23.3, 4.3, C5H), 114.6 (dd, J = 20.5, 16.8, 
C1), 120.5 (dd, J = 9.9, 2.3, C4H), 143.3 (dd, J = 11.2, 3.3, C3), 151.3 (dd, J = 253.9, 6.9, CF), 154.7 
(dd, J = 256.6, 7.1, CF), 156.5 (NHCO), 162.8 (CONH2); ESI-MS 328.2 (M+H)
+
. 
General Procedure for the Synthesis of Amines 153 and 154. To a solution of phthalimide 
151 or 152 (1 equiv) in EtOH (15 mL/mmol), hydrazine monohydrate (2 equiv) was added dropwise 
and the reaction mixture was refluxed for 2 h. Then, the solvent was evaporated under reduced 
pressure and the crude was purified by chromatography (from ethyl acetate to ethyl acetate/MeOH, 
95:5) to afford the corresponding amine 153 or 154. 
 
3-(3-Aminopropoxy)-2,6-difluorobenzamide (153). Obtained from 151 (290 mg, 0.81 mmol) 
in 64% yield. ESI-MS 231.1 (M+H)
+
. 
 
3-(4-Aminobutoxy)-2,6-difluorobenzamide (154). Obtained from 152 (350 mg, 0.93 mmol) in 
55% yield. ESI-MS 245.1 (M+H)
+
. 
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General Procedure for the Synthesis of Amines 156 and 160. To a solution of Boc 
derivative 155 or 159 (1 equiv) in anhydrous DCM (10 mL/mmol), trifluoroacetic acid (TFA) (20 
equiv) was added dropwise and the reaction mixture was stirred at room temperature for 1 h. Then, 
the mixture was concentrated under reduced pressure and the residue was redissolved in DCM and 
neutralized with a saturated aqueous solution of NaHCO3. The aqueous phase was then extracted 
with DCM and the organic layer was dried (Na2SO4) and concentrated under reduced pressure to 
afford amine 156 or 160 in quantitative yield, that was used in the next step without further 
purification. 
 
3-[(6-Aminohexyl)oxy]-2,6-difluorobenzamide (156). Obtained from 155 (350 mg, 0.94 
mmol) in 99% yield. ESI-MS 273.1 (M+H)
+
. 
 
3-{[1-(Aminomethyl)nonyl]oxy}-2,6-difluorobenzamide (160). Obtained from 159 (110 mg, 
0.26 mmol) in 99% yield. ESI-MS 329.2 (M+H)
+
. 
General Procedure for the Synthesis of Final Compounds 145-148. To a solution of amine 
153, 154, 156 or 160 (1 equiv), and Et3N (3 equiv) or DIPEA (1.2 equiv) in anhydrous DMF (15 
mL/mmol) under an argon atmosphere, a solution of Cl-NBD (1.2 equiv) in anhydrous DMF (2 
mL/mmol) was added and the reaction was stirred at room temperature overnight. Then, the solvent 
was evaporated under reduced pressure and the crude was purified by chromatography (from 
hexane to ethyl acetate) to afford final compounds 145-148. 
 
2,6-Difluoro-3-{3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]propoxy}benzamide (145). 
Obtained from amine 153 (184 mg, 0.51 mmol), Cl-NBD (123 mg, 0.62 mmol) and DIPEA (0.11 mL, 
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0.62 mmol) as an oil in 5% yield. Rf (DCM/ethyl acetate, 95:5) 0.29; IR (ATR) 3343 (NH2), 1701 
(C=O), 1378, 1364 (Ar);
 1
H NMR (700 MHz, acetone-d6)  2.35 (q, J = 6.4, 2H, CH2), 3.90 (br s, 2H, 
CH2N), 4.30 (t, J = 5.9, 2H, CH2O), 6.50 (d, J = 8.8, 1H, CHNBD), 6.96 (app td, J = 9.0, 2.0, 1H, 
C5H), 7.17-7.22 (m, 2H, CONH2, C4H), 7.43 (br s, 1H, CONH2), 8.40 (br s, 1H, NH), 8.53 (d, J = 8.7, 
1H, CHNBD); 
13
C NMR (175 MHz, acetone-d6)  32.6 (CH2), 39.7(CH2N), 68.8 (OCH2), 99.6 (br s, 
CHNBD), 111.5 (dd, J = 22.8, 4.1, C5H), 116.5 (dd, J = 9.4, 2.7, C4H), 117.4 (dd, J = 24.9, 19.5, C1), 
127.7 (CNBD), 135.7 (br s, CHNBD), 144.4 (dd, J = 10.7, 2.7, C3), 145.1, 145.6, 147.0 (3CNBD), 149.8 
(dd, J = 248.8, 7.9, CF), 153.5 (dd, J = 242.2, 6.5, CF), 162.4 (CONH2); ESI-HRMS (calcd., found 
for C16H13F2NaN5O5 [M+Na]
+
): 416.0782, 416.0777. 
 
2,6-Difluoro-3-{4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]butoxy}benzamide (146). 
Obtained from amine 154 (188 mg, 0.50 mmol), Cl-NBD (121 mg, 0.60 mmol) and DIPEA (0.11 mL, 
0.60 mmol) as an oil in 11% yield. Rf (DCM/ethyl acetate, 95:5) 0.34; IR (ATR) 3431 (NH2), 1701 
(CO), 1364 (Ar);
 1
H NMR (300 MHz, acetone-d6)  1.98-2.08 (m, 4H, 2CH2), 3.77 (br s, 2H, CH2N), 
4.17 (t, J = 5.9, 2H, CH2O), 6.50 (d, J = 8.8, 1H, CHNBD), 6.95 (app td, J = 9.0, 2.0, 1H, C5H), 7.14-
7.22 (m, 2H, CONH2, C4H), 7.45 (br s, 1H, CONH2), 8.43 (br s, 1H, NH), 8.52 (d, J = 8.8, 1H, 
CHNBD); 
13
C NMR (175 MHz, acetone-d6)  27.3, 30.2 (2CH2), 44.1 (br s, CH2N), 70.3 (OCH2), 99.5 
(br s, CHNBD), 111.5 (dd, J = 23.2, 4.0, C5H), 116.6 (br d, J = 8.7, C4H), 117.3 (dd, J = 24.3, 20.0, 
C1), 126.1 (CNBD), 137.9 (CHNBD), 144.5 (dd, J = 11.1, 3.2, C3), 145.2 (CNBD), 145.5 (2CNBD), 149.8 
(dd, J = 248.7, 8.0, CF), 153.5 (dd, J = 242.2, 6.4, CF), 162.8 (CONH2); ESI-HRMS (calcd., found 
for C17H15F2NaN5O5 [M+Na]
+
): 430.0939, 430.0934. 
 
2,6-Difluoro-3-({6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexyl}oxy)benzamide (147). 
Obtained from amine 156 (328 mg, 0.88 mmol), Cl-NBD (211 mg, 1.1 mmol) and DIPEA (0.19 mL, 
1.1 mmol) as an oil in 4% yield. Rf (ethyl acetate) 0.73; IR (ATR) 3335 (NH2), 1678 (C=O), 1491, 
1375, 1300 (Ar);
 1
H NMR (700 MHz, acetone-d6)  1.58 (qt, J = 3.6, 4H, 2CH2), 1.82 (qt, J = 6.8, 
2H, CH2), 1.89 (qt, J = 6.9, 2H, CH2), 3.67 (br s, 2H, CH2N), 4.08 (t, J = 6.4, 2H, CH2O), 6.48 (d, J = 
8.8, 1H, CHNBD), 6.94 (app td, J = 9.0, 2.0, 1H, C5H), 7.14-7.17 (m, 2H, CONH2, C4H), 7.41 (br s, 
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1H, CONH2), 8.32 (br s, 1H, NH), 8.52 (d, J = 8.7, 1H, CHNBD); 
13
C NMR (175 MHz, acetone-d6)  
26.3, 27.3, 29.5, 30.2 (4CH2), 44.5 (br s, CH2N), 70.5 (OCH2), 99.4 (br s, CHNBD), 111.4 (dd, J = 
23.2, 3.9, C5H), 116.4 (dd, J = 9.3, 2.5, C4H), 117.4 (dd, J = 24.4, 19.9, C1), 123.3 (br s, CNBD), 
138.0 (CHNBD), 144.7 (dd, J = 11.1, 3.1, C3), 145.2, 145.6, 145.8 (3CNBD), 149.8 (dd, J = 249.8, 8.0, 
CF), 153.4 (dd, J = 241.5, 6.6, CF), 162.3 (CONH2); ESI-HRMS (calcd., found for C19H18F2N5O5 
[M−H]
−
): 434.1289, 434,1276. 
 
2,6-Difluoro-3-[(1-{[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]methyl}nonyl)oxy] 
benzamide (148). Obtained from amine 160 (110 mg, 0.26 mmol), Cl-NBD (62 mg, 0.31 mmol) and 
triethylamine (0.11 mL, 0.78 mmol) as an oil in 11% yield. Rf (hexane/ethyl acetate, 1:1) 0.42; IR 
(ATR) 3426 (NH, NH2), 1700 (C=O), 1378, 1364 (Ar);
 1
H NMR (700 MHz, acetone-d6)  0.86 (t, J 
= 7.1, 3H, CH3), 1.20-1.33 (m, 10H, 5CH2), 1.50-1.59 (m, 2H, CH2), 1.86 (dt, J = 7.6, 6.4, 2H, 
OCHCH2), 4.01 (m, 2H, CH2NH), 4.82 (qt, J = 5.7, 2H, OCH), 6.61 (d, J = 8.8, 1H, CHNBD), 6.90 
(app td, J = 9.0, 1.8, 1H, C5H), 7.15 (br s, 1H, CONH2), 7.26 (app td, J = 9.2, 5.2, 1H, C4H), 7.37 (br 
s, 1H, CONH2), 8.31 (br s, 1H, NH), 8.53 (d, J = 8.7, 1H, CHNBD).; 
13
C NMR (175 MHz, acetone-d6) 
 14.3 (CH3), 23.3, 25.6, 29.5, 30.2, 30.3, 32.5, 32.8 (7CH2), 47.8 (br s, CH2NH), 80.1 (OCH), 100.2 
(br s, CHNBD), 111.7 (dd, J = 23.4, 3.9, C5H), 116.7 (dd, J = 24.3, 20.4, C1), 118.4 (dd, J = 9.0, 1.7, 
C4H), 123.9 (br s, CNBD), 137.7 (br s, CHNBD), 143.4 (dd, J = 11.1, 3.2, C3), 144.1 (CNBD), 145.6 
(2CNBD), 150.7 (dd, J = 249.7, 8.6, CF), 153.9 (dd, J = 243.2, 6.5, CF), 161.1 (CONH2); ESI-HRMS 
(calcd., found for C23H26F2N5O5 [M−H]
−
): 490.1902, 490.1891. 
 
N-Methyl-7-nitro-2,1,3-benzoxadiazol-4-amine (161).
90
 To a solution of Cl-NBD (200 mg, 1.0 
mmol) in MeOH (6 mL) under an argon atmosphere, methylamine hydrochloride (102 mg, 1.5 
mmol) was added and the reaction was refluxed for 30 min protected from light. Then, a 0.75 M 
aqueous solution of sodium bicarbonate (4 mL) was added dropwise under stirring. The mixture 
was allowed to stand at 0 ºC for 1 h and the resulting red bright crystals were collected by filtration 
and dried under vacuum to afford pure compound 161 in 66% yield. Rf (DCM) 0.44; mp 259-261 ºC 
IR (ATR) 3307 (NH), 1618, 1597, 1482 (Ar);
 1
H NMR (300 MHz, DMSO-d6)  3.06 (d, J = 4.8, 3H, 
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CH3), 6.30 (d, J = 8.9, 1H CHNBD), 8.52 (d, J = 8.9, 1H, CHNBD), 9.49 (s, 1H, NH); 
13
C NMR (75 
MHz, DMSO-d6)  30.2 (CH3), 99.1 (CHNBD), 120.8 (CNBD), 138.0 (CHNBD), 144.4, 145.7, 145.8 
(3CNBD); ESI-MS 194.9 (M+H)
+
; elemental analysis (calcd., found for C7H6N4O3): C (43.30, 43.29), 
H, (3.11, 3.19), N (28.83, 29.13). The spectroscopic data are in agreement with those previously 
described.
90
 
4.2. Biological Experiments 
The biological evaluation of the compounds synthesized in this thesis was carried out in 
collaboration with the research group of Dr. José Manuel Andreu at the Centro de Investigaciones 
Biológicas (CIB-CSIC), Spain. In addition, the antibacterial activity in pathogenic bacteria was 
assessed in the Prof. Sieber’s laboratory at the Technische Universität München (TUM), Germany. 
4.2.1. Protein Purification. FtsZ from B. subtilis was overproduced and purified as 
described.
84
 Untagged, full length FtsZ from Bs-FtsZ was overproduced in E. coli C41(DE3) cells, 
purified and its concentration measured as described.
105
 Bs-FtsZ was eluted from the hydrophobic 
chromatography at 99% electrophoretic purity and the gel-filtration chromatography was omitted. 
Instead, Bs-FtsZ was equilibrated in 50 mM Tris–HCl, 50 mM KCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 10% glycerol at pH 7.5, employing a 5 mL HiTrap 
desalting column. It was concentrated to < 0.5 mL (about 1 mM Bs-FtsZ) and stored at -80 ºC. Bs-
FtsZ preparations contained only 0.047 ± 0.044 guanine nucleotide bound per FtsZ, 
spectrophotometrically determined after perchloric acid extraction.
106
 The Bs-FtsZ concentration 
was determined after subtracting the nucleotide contribution, employing a calculated extinction 
coefficient 2560 M
-1
 cm
-1
 at 280 nm (2 Tyr, 0 Trp residues) in 6 M guanidinium chloride. 
Tubulin was purified from calf brain as described.
107
 Prior to use, tubulin was equilibrated by 
gel chromatography in cold GAB buffer (3.4 M glycerol, 10 mM sodium phosphate, 1 mM EGTA, 
and 0.1 mM GTP, pH 6.8).  
4.2.2. FtsZ Affinity Measurements: Ligand Competition with mant-GTP. The 
fluorescence anisotropy of mant-GTP was measured with a Fluoromax-4 (Horiba Jobin Yvon) 
photon-counting spectrofluorometer, with excitation at 357 nm (5 nm band pass) and emission at 
445 nm (10 nm band pass) using 2x10 mm cells at 25 ºC. Ligand competition with mant-GTP for 
binding to FtsZ from B. subtilis was performed as described for M. jannaschii FtsZ
82
 with 
modifications.
84
 The binding of mant-GTP to FtsZ causes a significant increase in its fluorescence 
that if not taken into account can lead to the calculation of erroneous Kd values when employing 
anisotropy measurements. To avoid this error, the ratio between the fluorescence intensities of Bs-
FtsZ-bound and free mant-GTP was determined R = 2.78 and used to correct all anisotropy-based 
binding calculations. To measure the equilibrium binding constant, mant-GTP (200 nM) was titrated 
with varying concentrations of Bs-FtsZ in experimental buffer at 25 ºC, which gave a reference 
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binding constant Kb of (9.85 ±1.05)·10
5
 M
-1
, an anisotropy value of free mant-GTP r = 0.025 ± 0.005 
and the anisotropy of bound mant-GTP r = 0.213 ± 0.002. For the competition measurements, 
samples (0.5 mL) were prepared by mixing 0.25 mL of mant-GTP (1 μM) and binding sites (0.6 μM) 
with 0.25 mL buffer without or with competing ligand at varying concentrations, and measurements 
started 4 min after. The fractional of bound of mant-GTP and the affinity of the competing ligand 
were then determined from the fluorescence anisotropy values.
82
 Controls include samples with 
GTP, without FtsZ, mant-GTP alone and test compound alone. 
4.2.3. Antibacterial Activity: Minimum Inhibitory Concentration Determination. MIC 
values for each compound against B. subtilis 168 were determined in cation-adjusted Mueller-
Hinton II broth (CAMHB) (Becton Dickinson) at 37 ºC with shaking, by the broth macrodilution 
method according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) 
for which the MIC was defined as the lowest concentration inhibiting growth determined by 
absorbance at 600 nm.
103
 
MIC on a panel of bacterial pathogens measurements: overnight cultures of the bacteria were 
diluted in fresh brain-heart broth (BHB) medium or Luria Bertani broth (LB) to optical density at 600 
nm, (OD600) = 0.01, and 100 μL were taken to in Nunclon 96-well plates with round-shaped bottoms 
with 1 μL of the corresponding DMSO stock solutions of each compound at dilution ranges from 0.4 
to 45 mg/L with 2% final concentration of DMSO. The samples were incubated for 12 h at 37 °C 
and the OD600 were obtained for MIC calculation. All experiments were conducted at least in 
triplicates, and DMSO served as control. Bacterial Strains: S.aureus strains: Mu50/ATCC 700699, 
USA300/ATCC Nr: BAA-1556 (both from Institute Pasteur, France); L. monocytogenes EGD-e and 
E. faecalis V583 ATCC700802 (both sequenced strains) were maintained in BHB medium at 37 °C, 
and Escherichia coli UTI89 and Pseudomonas aeruginosa PAO1 (both sequenced strains) were 
maintained in LB medium at 37 ºC. 
4.2.4. Stability of Compounds 40, 47 and 48 in Bacterial Culture. Compounds 40, 47 (5 
µM), and 48 (25 µM) were incubated in bacterial culture of Bacillus subtilis SU570. Samples of 0.75 
mL were taken from the culture at different times (1, 2, 4 and 18 h) and bacteria were pelleted in 
Eppendorf tubes with a microcentrifuge (Hettich Mikro 120, 12000 rpm, 10 min). Taxol (100 µM) 
was added as internal standard to 0.5 mL of the supernatant and the compounds were extracted 
with 0.75 mL of acetonitrile and dried under an argon stream. Samples were reconstituted in 
methanol, centrifuged and analyzed by HPLC-MS (see section 2.1 for analytical conditions). HPLC-
MS measurements were made by selected ion monitoring (SIM), and fractions were quantified by 
measuring the area under the peak, relative to the internal standard. 
4.2.5. FtsZ and Tubulin Polymerization Measured by Sedimentation. FtsZ polymerization 
was measured in Hepes/KOH (50 mM), KCl (50 mM), EDTA (1 mM), pH 6.8 at 25 ºC, to which the 
Experimental part 
- 168 - 
compound or DMSO vehicle, MgCl2 (10 mM) and GTP (1 mM) or GMPCPP (0.1 mM) were added. 
For the study of the compounds targeting the GTP-binding site, a GTP regeneration system was 
employed, consisting of acetyl phosphate (15 mM) and 1 unit/mL acetate kinase from E. coli, to 
which GTP (50 µM) was added. In the case of fluorescent derivatives, the slowly hydrolyzable GTP 
analogue GMPCPP (0.1 mM) was used. After incubation of 100 µL FtsZ (10 µM) in polycarbonate 
tubes, they were centrifuged at 386000g for 20 min in a TLA100 rotor (100000 rpm), at 25 ºC in a 
TLX ultracentrifuge (Beckman).  
For tubulin polymerization, samples containing 100 µL of tubulin (15 µM), MgCl2 (6 mM), GTP 
(1 mM) and compound or DMSO vehicle, were incubated for 30 min at 37 ºC, and centrifuged at 
90000g for 10 min in a TLA100 rotor (50000 rpm) at 37 ºC. 
Pellets were resuspended with 50 µL of SDS-containing electrophoresis sample solution plus 
50 µL buffer, and supernatants were diluted with 50 µL sample solution. Pellet and supernatant 
aliquots were loaded with an electrophoretic shift between them into the same lanes of 12%-
polyacrylamide gels with 0.1% SDS. Gels were stained with Coomassie blue, scanned with a CS-
800 calibrated densitometer (BioRad) and analyzed with Quantity One software (BioRad). The 
inhibition of polymerization by each compound was calculated relative to polymerization with GTP 
alone (0% inhibition) and with GDP inhibitor (100% inhibition). 
4.2.6. Bacterial Division Phenotype. B. subtilis 168 cells were grown in cation adjusted 
Mueller-Hinton broth (CAMHB) at 37 °C to an absorbance 0.1-0.2 at 600 nm and then the culture 
was divided into new flasks containing the compound at the desired concentration. Small aliquots 
(10 µL) were harvested at appropriate time intervals and bacterial cells visualized by phase-
contrast light microscopy. 
4.2.7. Fluorescent Microscopy. Experiments for cell visualization with the synthesized 
compounds targeting the GTP- binding site: A colony of B. subtilis strain SU570 (168 trpC2 
ftsZ:ftsZ-gfp-Spec),
108,109
 kindly donated by Dr. Elisabeth J. Harry, was resuspended in antibiotic 
medium no. 3 (Pennassay broth, Becton Dickinson) with 50 µg/mL spectinomycin and grown at 30 
°C to an absorbance of 0.2 at 600 nm. Samples of the culture were mixed with an equal volume of 
medium containing twice the final desired concentration of compound. Aliquots (10 µL) were 
harvested at appropriate time intervals, combined with an equal volume of prewarmed Pennassay 
broth containing ~1% w/v agarose, and 10 µL of these samples were pipetted onto microscope 
slides, covered, and visualized through a 100X PlanApochromatic objective with a Zeiss Axioplan 
fluorescence microscope equipped with a Hamamatsu 4742-95 CCD camera. Nucleoids were 
stained with 4,6-diamino-2-phenylindole (DAPI, 0.25 µg/mL) and membranes with FM4-64 (1 
µg/mL), which were added to the cells prior to visualization. 
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Experiments for cell visualization with the fluorescent probes targeting the PC- binding site: 
B. subtilis 168 cells were grown in cation adjusted Mueller-Hinton broth (CAMHB) at 37 °C to an 
absorbance 0.1-0.2 at 600 nm then the fluorescent probe (50 µM or 200 µM) was added and after 1 
hour of incubation, 10 µL of the sample was pipetted onto microscope slides, covered, and 
visualized through the previously described fluorescence microscope. Membranes were stained 
with FM4-64 (1 µg/mL), which were added to the cells prior to visualization. 
4.2.8. Fluorescence and Anisotropy Properties of Compounds 119-125 and 145-150. A 
Horiba-Jovin-Yvon Fluoromax-4 was used to measure the fluorescence intensity and the 
fluorescence anisotropy (r) values in different conditions, employing a solution of 500 µL in a 10 x 2 
mm cuvette. Fluorescence emission spectra and anisotropy of fluorescent compounds (10 µM) 
were registered employing an excitation wavelength corresponding to the maximum absortion 
wavelength of each compound in Hepes buffer at pH 6.8 and 25 ºC. Then, Bs-FtsZ (10 µM), the 
slowly hydrozable GTP analogue GMPCPP (0.1 mM), MgCl2 (10 mM) and PC190723 or 8j (10 µM) 
were subsequently added. As negative controls, fluorescence emission spectra and anisotropy 
were registered with each compound and GMPCPP, MgCl2 or PC190723 in the absence of FtsZ 
protein. 
4.3. Docking and Virtual Screening 
The virtual screening and molecular dynamics of this thesis were carried out in collaboration 
with the research group of Dr. Pablo Chacón of the Instituto de Química Física Rocasolano (IQFR-
CSIC), Spain.  
The ICM package
110
 has been employed to give computational insights into the recognition of 
FtsZ sites by small molecules. Two slightly different ICM protocols were employed for virtual 
screening and for docking. For screening the large database compounds default parameters and 
procedures were used. Multiple receptor conformers as an extra dimension for the docking search 
as described
111
 was considered for docking and for refinement of the best virtual screening poses. 
In either case, the ICM methodology utilizes internal coordinates to optimize flexible ligands in a 
grid-based receptor field. Energies are computed using MMFF partial charges with the ECEPP/3
112
 
force field. The ligand docking was also complemented by local energy minimization using a Biased 
Probability Monte Carlo method.
113
 
- Preparation of receptor structures and binding pocket definition: For virtual screening we 
employed the same apo-FtsZ structure used for MD studies. For 4D docking, the conformational 
variability of the nucleotide-binding site was represented with seven conformers extracted from 
different snapshots of a long MD of the FtsZ unbound structure. All conformations were regularized 
using ICM standard procedures. The boundaries of the binding box of nucleotide site were derived 
from the GDP-crystallized ligand coordinate (PDB ID 2rhl). 
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- Preparation of ligand structures: Virtual screening was performed against a non-redundant 
collection of vendor compound database formed by 4 million of compounds. A small database was 
built with available compounds from UCM Medicinal Chemistry Laboratory. 3D atomic coordinates, 
tautomeric forms, stereochemistry, hydrogen atoms, and protonation states were assigned using 
standard procedures. Ligand molecules were prepared for docking by rotational search followed by 
a Cartesian minimization using MMFF
114
 force field in the absence of the receptor. These free 
molecules were optimized with global energy in the internal coordinate space and the lowest-
energy conformations were used for further studies. During docking, the ligand torsional or roto-
translational variables are randomly changed. 
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5. RESUMEN 
5.1. Introducción y objetivos 
El descubrimiento y desarrollo de antibióticos puede considerarse como uno de los avances 
médicos más significativos del siglo XX. Sin embargo, la Organización Mundial de la Salud advierte 
de la gran amenaza que supone la resistencia a antibióticos para la salud pública mundial en el 
siglo XXI y de la extrema necesidad de nuevos tratamientos para combatir las cepas 
multiresistentes.
15,20
 Una de las primeras causas del gran aumento de cepas multiresistentes es el 
hecho de que la mayoría de los antibióticos actuales están dirigidos a un número concreto de 
dianas terapéuticas, como las implicadas en la síntesis de proteínas, de ácidos nucleicos, de folato 
y de la pared bacteriana. Además, la mayoría de los nuevos antibióticos comercializados son 
simples variantes de fármacos anteriores, por lo que las bacterias pueden adquirir rápidamente 
resistencia a los tratamientos actuales. Estas limitaciones ponen de manifiesto la necesidad de 
nuevos agentes antibacterianos que posean un mecanismo de acción diferente.
3,30
 En este 
sentido, el bloqueo de la división bacteriana impediría la proliferación descontrolada de bacterias y 
con ello, las septicemias letales en el caso de numerosos patógenos.
31,32
 Sin embargo, no existe 
hasta la fecha ningún agente antibacteriano aprobado para su uso clínico por la Administración de 
Alimentos y Fármacos (Food and Drug Administration, FDA) que esté dirigido a la inhibición directa 
de la división bacteriana. 
 Recientemente, la proteína FtsZ ha sido propuesta como una diana terapéutica prometedora 
para el descubrimiento y desarrollo de nuevos antibióticos.
2,31-33 
Esta proteína está presente en la 
mayoría de las bacterias conocidas y tiene un papel fundamental en la viabilidad de las bacterias 
debido a que es el primer eslabón dentro de una cascada de proteínas implicadas en el proceso de 
división bacteriana. Durante la división bacteriana, FtsZ sufre una polimerización reversible 
dependiente de GTP que da lugar a la formación del denominado anillo Z en la parte central de la 
bacteria. A continuación, el anillo Z actúa como plataforma para el ensamblaje de otras proteínas 
esenciales para el proceso de división, provocando la invaginación de la pared bacteriana y 
generando las dos células hijas.
35,36
 Por tanto, teniendo en cuenta el mecanismo descrito para la 
división bacteriana, aquellos compuestos que sean capaces de interferir selectivamente en la 
polimerización de FtsZ, impedirán la proliferación y viabilidad de las bacterias. 
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En los últimos años se han identificado compuestos con una gran diversidad estructural que 
tienen algún efecto sobre la polimerización de FtsZ. En concreto, el compuesto PC190723, 
derivado de la 3-metoxibenzamida, ha sido descrito como el inhibidor más prometedor de FtsZ.
71,77
 
Este compuesto presenta una potente actividad antibacteriana [e.g. concentración mínima 
inhibitoria (CMI) (MRSA) = 2.8 µM] y es el primer inhibidor de FtsZ que ha demostrado eficacia en 
un modelo in vivo de infección.
71 
La estructura de rayos X del complejo FtsZ-PC190723 ha 
revelado determinar que este inhibidor se une a la proteína en una región diferente a la del dominio 
de unión del GTP. Este hecho ha permitido identificar dos zonas en la proteína para la unión de 
moléculas pequeñas capaces de inhibir su función: el sitio de unión al nucleótido y el bolsillo al que 
se une PC190723. 
Teniendo en cuenta estas consideraciones, el objetivo principal de esta tesis doctoral es el 
desarrollo de nuevos inhibidores de FtsZ con buenas propiedades antibacterianas. Para ello, 
hemos iniciado un proyecto dirigido a la identificación de nuevos compuestos capaces de inhibir 
FtsZ dirigidos a los dos sitios de unión de la proteína: (i) el sitio de unión de GTP y (ii) el bolsillo 
alostérico de PC (Figura 1). 
Sitio de unión de GTP Sitio de unión de PC
Programa de
Química Médica
Desarrollo de sondas fluorescentes 
basadas en PC190723
Nuevos inhibidores de FtsZ como agentes antibacterianos
(i) (ii)
 
Figura 1. Estrategia dual para la búsqueda de nuevos inhibidores de FtsZ. 
El desarrollo de moléculas pequeñas capaces de reemplazar al GTP e inhibir FtsZ de forma 
específica con el fin de bloquear la división bacteriana implica las siguientes etapas: 
 Identificación de hits. 
 Diseño, síntesis y evaluación biológica de una nueva serie de compuestos. La evaluación de 
cada compuesto consistirá en la determinación de su constante de afinidad por FtsZ, su 
actividad antibacteriana y la selectividad frente a tubilina. 
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 Caracterización más exhaustiva de los inhibidores optimizados en cuanto a propiedades 
antibacterianas frente a cepas patógenas Gram-positivas y -negativas, perfil citológico y 
mecanismo de acción. 
Respecto al sitio de unión de PC, las interesantes propiedades antibacterianas que presentan 
los derivados de PC190723 y la falta de metodologías adecuadas para determinar la afinidad de 
posibles ligandos frente a este nuevo sitio de unión, nos llevó a desarrollar sondas fluorescentes 
basadas en este compuesto que permitan identificar nuevos inhibidores en este sitio de unión 
mediante un ensayo de afinidad basado en fluorescencia. Además, estas sondas podrían contribuir 
al estudio de este bolsillo alostérico que parece tener un papel fundamental en el ensamblaje de 
FtsZ. Por lo tanto, el segundo objetivo conlleva las siguientes etapas: 
 Diseño y síntesis de derivados fluorescentes basado en PC190723. 
 Evaluación biológica y caracterización de las propiedades fluorescentes de los compuestos 
sintetizados. 
 Empleo de las mejores sondas fluorescentes identificadas como herramientas biológicas 
tanto para el estudio del proceso de division bacteriana como para el desarrollo de un 
ensayo de desplazamiento basado en fluorescencia que nos permita la identificación de 
nuevos inhibidores alostéricos de FtsZ. 
5.2. Resultados y discusión 
5.2.1. Desarrollo de inhibidores de FtsZ dirigidos al sitio de unión de GTP 
La búsqueda de nuevos inhibidores de FtsZ se inició a partir de un cribado virtual de la 
quimioteca del Laboratorio de Química Médica de la Universidad Complutense de Madrid en el sitio 
de unión de GTP de FtsZ de B. subtilis.
84
 A continuación, los hits obtenidos se confirmaron 
mediante un ensayo de competición con mant-GTP.
82
 Los mejores inhibidores identificados poseen 
una estructura general definida por dos subunidades de ácido gálico unidas a un esqueleto central 
de naftaleno, bifenilo, benceno, ciclohexano o etileno. Entre ellos, los hits 1 y 2 presentaron las 
mejores constantes de afinidad (Kd = 2.3 y 0.8 µM, respectivamente) así como una moderada 
actividad antibacteriana en B. subtilis (CMI = 100 y 40 µM, respectivamente), y constituyen el 
primer ejemplo de inhibidores no-nucleótidos que compiten por el sitio de unión a GTP de FtsZ 
(Figura 2).
84
 
Con el objetivo de llevar a cabo un estudio de estructura-afinidad-actividad a partir de los hits 1 
y 2, nos centramos en las dos subunidades susceptibles de modificaciones estructurales: los 
sistemas de polihidroxifenilo y los espaciadores entre dichos anillos y el esqueleto central (Figura 
2). Así, se comenzó estudiando la influencia de los anillos de polihidroxifenilo y para ello se 
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consideró tanto la reducción en el número de grupos hidroxilo como la sustitución de estos grupos 
por átomos de cloro o grupos metoxi (3-30). Además, se propusieron los correspondientes 
monoésteres del hit 1 (31 y 32) para estudiar la influencia de las dos subunidades de 
polihidroxifenilo en la unión a FtsZ. Asimismo, se sintetizaron compuestos en los que los grupos 
éster de 1 fueron sustituidos por espaciadores tipo amida, sulfonamida o alqueno (33-36). 
Posteriormente, las mejores modificaciones obtenidas para el hit 1 fueron aplicadas al hit 2 y se 
sintetizaron derivados con un menor número de hidroxilos (37-42), monoésteres (43-46) y 
derivados con otros espaciadores (47-50). 
 
Figura 2. Compuestos 3-50 dirigidos al sitio de unión de GTP. 
Los compuestos diseñados se sintetizaron mediante las rutas sintéticas optimizadas en el 
desarrollo de esta investigación (Esquemas 1-8). 
 
Esquema 1. Reactivos y condiciones: (a) (i) TBS-Cl, DIPEA, DMF, MW 100 ºC, 20 min or TBS-Cl, imidazol, 
DMF, t.a., 18 h; (ii) CH3CO2H, THF, t.a., 3 h, 74-81%; (b) cloruro de oxalilo, DMF, tolueno, 50 ºC, 1 h, 
cuantitativo. 
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Esquema 2. Reactivos y condiciones: (a) Et3N, DCM, t.a., 18 h, 54-71%; (b) HF·piridina, piridina, THF, t.a., 15 
min, 26-88%.
 
 
Esquema 3. Reactivos y condiciones: (a) 52a,c, o d (0.25 equiv), Et3N, DCM, t.a., 18 h, 22-38%; (b) 52b-h (2 
equiv), Et3N, DCM, t.a., 18 h, 24-92%; (c) HF·piridina, piridina, THF, t.a., 15 min, 15-92%. 
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Esquema 4. Reactivos y condiciones: (a) HF·piridina, piridina, THF, t.a., 15 min, 78 y 93%. 
 
Esquema 5. Reactivos y condiciones: (a) H2, 10% Pd/C, MeOH, t.a., 3.5 h, 60%; (b) 52a o f (4 equiv), Et3N, 
DCM, t.a., 18 h, 33-36%; (c) HF·piridina, piridina, THF, t.a., 15 min, 75-78%; (d) ClSO3H, CHCl3, 0 ºC a t.a., 16 
h, 61%; (e) piridina, DCM, t.a., 18 h, 48%; (f) BBr3, DCM, t.a., 18 h, 38%. 
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Esquema 6. Reativos y condiciones: (a) NBS, AIBN, CCl4, 90 ºC, 16 h, 73%; (b) Ph3P, xileno, reflujo, 72 h, 
96%; (c) CH2=CHCH2Br, K2CO3, DMF, 65 ºC, 4 h, 99%; (d) Red-Al®, KOt-Bu, pirrolidina, THF, 0 ºC, 10 min, 
78%; (e) n-BuLi, THF, -78 ºC a t.a., 18 h, 30% (1E,3E) y 18% (1E,3Z); (f) DMBA, Pd(PPh3)4, DCM/MeOH, t.a., 
1 h, 19%. 
 
Esquema 7. Reactivos y condiciones: (a) (i) PhB(OH)2, Pd(PPh3)4, Na2CO3, tolueno/H2O, MW, 150 ºC, 30 
min, 75%; (ii) BBr3, DCM, t.a., 18 h, 97%; (b) 52a,d o e (4 equiv), Et3N, DCM, t.a., 18 h, 64-87%; (c) 
HF·piridina, piridina, THF, t.a., 15 min, 28-96%; (d) 52b-e (0.25 equiv), Et3N, DCM, t.a., 18 h, 46-69%; (e) 52c 
o d (2 equiv), Et3N, DCM, t.a., 18 h, 34-89%. 
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Esquema 8. Reactivos y condiciones: (a) anhídrido trifluorometanosulfónico, Et3N, DCM, t.a., 2.5 h, 99%; (b) 
ácido 3-metoxifenilborónico, Pd(PPh3)4, Na2CO3, tolueno/EtOH/H2O, MW, 150 ºC, 15 min, 75%; (c) BBr3, 
DCM, t.a., 3 h, 21-94%; (d) PhB(OH)2, Pd(PPh3)4, Na2CO3, tolueno/H2O, MW, 150 ºC, 30 min, 83-90%; (e) H2, 
10% Pd/C (H-Cube), THF, t.a., 99%; (f) 52d o cloruro de 3-metoxibencenosulfonilo, Et3N, THF, t.a., 18 h, 20-
45%; (g) HF·piridina, piridina, THF, t.a., 15 min, 66-89%; (h) NaOH, H2O, THF, reflujo, 1.5 h, 85%; (i) SOCl2, 
THF, reflujo, 3 h, 99%; (j) TBS-Cl, imidazol, 18 h, t.a., 48%; (k) Et3N, THF, t.a., 18 h, 89%. 
A continuación, se llevó a cabo la evaluación de la afinidad de los compuestos sintetizados 3-50 
por la proteína FtsZ de B. subtilis mediante un ensayo de desplazamiento del ligando fluorescente 
mant-GTP. La mayoría de los compuestos sintetizados fueron capaces de desplazar mant-GTP en 
el rango micromolar (Kd = 0.5-2.2 µM). En general, la reducción en el número de grupos hidroxilo 
de las dos subunidades aromáticas aumenta la afinidad por FtsZ y los mejores resultados se 
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obtuvieron en aquellos compuestos con un hidroxilo en cada anillo (e.g. 29, 40 y 41 Kd = 0.5-0.8 
µM) (Figura 3). En cuanto a la actividad antibacteriana, todos los compuestos fueron activos en B. 
subtilis y MRSA USA 300 (como ejemplo representativo de cepa Gram-positiva patógena). La 
reducción en el número de hidroxilos parece ser también favorable para la actividad antibacteriana, 
lo que corrobora que estos compuestos ejercen su acción mediante la inhibición de FtsZ. De 
hecho, los mejores derivados fueron aquellos con dos grupos hidroxilo [e.g. 29 y 42: CMI (MRSA) 
= 5 µM]. Otro patrón que parece ser importante en cuanto a la afinidad por FtsZ y la actividad 
antibacteriana es la introducción de átomos de cloro, como se puede observar en el compuesto 7 
[Kd = 0.8 µM; CMI (MRSA) = 10 µM]. Además, se observó que en el caso de los monoésteres, la 
afinidad por FtsZ y la actividad antibacteriana se ven reducidas con respecto a los diésteres 
análogos, sugiriendo que ambas subunidades de polihidroxifenilo son necesarias para la unión a la 
proteína [e.g. 40: Kd = 0.5 µM; CMI (MRSA) = 7 µM vs 45: Kd = 3.8 µM; CMI (MRSA) = 50 µM]. En 
cuanto a los espaciadores entre la subunidad central y los anillos de polihidroxifenilo, la eliminación 
del espaciador dio lugar al compuesto 47, que presentó la mayor afinidad obtenida hasta el 
momento (Kd = 0.5 µM) y una excelente actividad antibacteriana en MRSA (CMI = 3 µM). Sin 
embargo, la sustitución del éster por otros espaciadores produjo una disminución tanto en la 
afinidad como en la actividad antibacteriana [e.g. amida 48: Kd = 4.3 µM; CMI (MRSA) = 50 µM]. 
 
Figura 3. Inhibidores de FtsZ representativos dirigidos al sitio de unión de GTP en FtsZ. 
La selectividad frente a tubulina −la homóloga eucariota de FtsZ− de los mejores compuestos 
se determinó mediante un estudio comparativo de la inhibición del ensamblaje de estas dos 
proteínas. Así, según se muestra en la Figura 4, los resultados de estos ensayos indicaron que la 
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introducción de átomos de cloro es perjudicial en cuanto a la selectividad, puesto que el 
compuesto 7 resultó ser el inhibidor más potente de tubulina. Además, la serie de bifenilos mostró 
en general una mayor inhibición de la polimerización de FtsZ y una mejor selectividad frente a 
tubulina, con excepción del monoéster 45. 
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Figura 4. Porcentaje de inhibición de FtsZ (compuestos a 25 µM) y tubulina (compuestos a 100 µM). 
A continuación, se estudió el perfil antibacteriano de los compuestos sintetizados en un panel 
de bacterias patógenas resistentes Gram-positivas y Gram-negativas. En general, todos los 
compuestos inhibieron el crecimiento de bacterias Gram-positivas, como por ejemplo MRSA (CMI 
= 3-50 µM) y Listeria monocytogenes (L. monoc., CMI = 5-50 µM); mientras que los derivados 29, 
40-42 y 45 también fueron capaces de inhibir el crecimiento de Enterococcus faecalis (E. faecalis) 
a 50 µM. En cuanto a las cepas Gram-negativas, a pesar de que el hit 2 fue activo en 
Pseudomonas aeruginosa y Escherichia coli resistentes (P. aerug. y E. coli, CMI = 50 µM), ninguno 
de sus derivados afectó al crecimiento de bacterias patógenas Gram-negativas a la concentración 
ensayada (100 µM), lo que parece indicar que la reducción en el número de hidroxilos en estos 
compuestos es perjudicial en términos de actividad antibacteriana frente a dichas cepas. 
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Tabla 1. Actividad antibacteriana de los compuestos seleccionados frente a bacterias patógenas resistentes. 
Compuesto 
Kd
a 
FtsZ 
(µM) 
CMI (μM) 
MRSA E. 
faecalis
d
 
L. 
monoc.
e
 
P. 
aerug.
f E. coli
g 
USA 300
b
 Mu50
c
 
1 2.3 ± 0.1 60 80 >100 50 100 >100 
2 0.8 ± 0.1 50 50 >100 50 50 50 
29 0.8 ± 0.2 5 5 50 5 >100 >100 
40 0.5 ± 0.1 7 7 50 7 >50 >100 
41 0.6 ± 0.3 5 5 50 5 >50 >100 
42 0.4 ± 0.1 5 5 50 5 >50 >100 
45 3.8 ± 0.8 50 50 50 50 >50 >100 
47 0.5 ± 0.1 3 3 >100 5 >50 >100 
48 4.3 ± 1.0 50 50 >100 50 >50 >100 
a
Los valores son la media ± EEM. Cepas clínicamente aisladas de S. aureus provenientes del Instituto 
Pasteur de Francia 
b
resistentes a meticilina (ATCC Nr: BAA-1556) o 
c
resistentes a meticilina, kanamicina 
y ampicilina (ATCC 700699). 
d
Cepas secuenciadas de Enterococcus faecalis resistente a gentamicina y 
vancomicina (V583 ATCC 700802). 
e
Cepas secuenciadas de Listeria monocytogenes (EGDe). 
f
Cepas 
secuenciadas de Pseudomonas aeruginosa resistente a imipenem (PAO1). 
g
Cepas clínicamente aisladas 
de Escherichia coli proveniente de una infección de cistitis (UTI89). 
Con el fin de identificar el inhibidor de la división bacteriana más efectivo entre los compuestos 
descritos, se llevó a cabo un estudio de sus efectos en la división celular de la bacteria B. subtilis 
168 natural y en la localización subcelular de FtsZ en B. subtilis SU570. Estas últimas células 
expresan FtsZ fusionada a la proteína fluorescente verde (FtsZ-GFP) como única proteína FtsZ. 
Así, se caracterizaron los efectos celulares de los inhibidores más efectivos frente a FtsZ (29, 40, 
41, 45, 47 y 48), observándose que las células de B. subtilis 168 tratadas con cada uno de estos 
compuestos exprimentaron un aumento de longitud respecto a las células control (Figura 5). Entre 
los compuestos ensayados, el derivado 40 mostró el efecto más claro en la división bacteriana y 
las bacterias tratadas con este inhibidor consistieron en células filamentosas sin dividir mucho más 
alargadas. 
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Figura 5. Efecto en la división celular de los inhibidores de FtsZ. (A) Células de B. subtilis 168 incubadas 
durante 3 h con los inhibidores de FtsZ 29 (5 µM), 40 (4 µM), 41 (5 µM), 45 (25 µM) y 48 (12 µM) y 
observadas mediante microscopía de contraste de fases. (B) Longitud de las células B. subtilis 168. La barra 
de la imagen se corresponde a una escala de 10 µm. 
La visualización intracelular de FtsZ en células de B. subtilis SU570 indica que los compuestos 
29, 40 y 48 producen la deslocalización de la proteína, evitando la formación del anillo Z en la zona 
central y provocan la aparición de numerosos foci de FtsZ distribuidos aletoriamente en la célula. 
Dicha situación origina un defecto en la formación del anillo Z, lo que provoca la aparición de 
células alargadas incapaces de dividirse (Figura 6, fila FtsZ-GFP). Además, cuando se visualizó el 
nucleoide, se observó que éste tenía una apariencia fragmentada, por lo que estos compuestos 
parecen inducir la descondensación del ADN bacteriano (Figura 6, fila DAPI). Asimismo, la 
visualización de la membrana de las mismas células de B. subtilis SU570 con el colorante FM4-64 
también permitió apreciar que los inhibidores tienen un efecto sobre la membrana celular, ya que 
se distinguen algunos agregados intracelulares. 
En resumen, la mayoría de los compuestos descritos en esta primera parte del trabajo son 
capaces de inhibir la división bacteriana bloqueando el ensamblaje de la proteína FtsZ y por tanto 
la formación del anillo Z. Entre los compuestos desarrollados, el derivado 40 destaca como el 
inhibidor más efectivo de la división bacteriana. Este compuesto junto con 29 y 48 bloquea la 
polimerización de FtsZ, dando lugar a células filamentosas que no se dividen, impidiendo la 
viabilidad de la bacteria. 
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Figure 6. Localización subcelular de FtsZ en células de B. subtilis SU570 (FtsZ-GFP) incubadas durante 1 h 
con los compuestos 29 (5 µM), 40 (3 µM), y 48 (12 µM). El marcaje FtsZ-GFP y la tinción del nucleoide con 
colorante DAPI y de la membrana con colorante FM4-64 se visualizaron en el canal de fluorescencia 
correspondiente. La barra de la imagen se corresponde a una escala de 10 µm. 
5.2.2. Desarrollo de sondas fluorescentes dirigidas al sitio de unión de PC 
La falta de un ensayo de unión a FtsZ que permita medir la afinidad de moléculas pequeñas en 
el sitio de unión alostérico identificado para el inhibidor PC190723, dificulta el desarrollo de nuevos 
inhibidores alostéricos de FtsZ. De hecho, para identificar inhibidores que se unan al sitio de unión 
de PC sólo se han empleado hasta el momento experimentos fenotípicos como el ensayo de 
sedimentación de polímeros de FtsZ. Por lo tanto, el empleo de derivados fluorescentes de PC o 
de su análogo 8j permitiría desarrollar un ensayo de desplazamiento basado en fluorescencia para 
el cribado de librerías de compuestos y la consiguiente identificación de inhibidores de FtsZ que se 
unan a este nuevo sitio alostérico. 
En este contexto, hemos desarrollado un proyecto de investigación enfocado al diseño y 
síntesis de derivados de PC/8j fluorescentes siguiendo dos aproximaciones: (i) el anclaje de un 
fluoróforo a la estructura de 8j mediante un espaciador rígido, como por ejemplo un alquino, o una 
cadena alifática flexible (119-122), y (ii) la substitución de la subunidad heterocíclica de PC/8j por 
un fluoróforo (123-125). Respecto a los fluoróforos empleados, inicialmente se seleccionaron 
Resumen 
- 186 - 
estructuras pequeñas como nitrobenzoxadiazol (NBD), un derivado de cumarina y dansilo (Figura 
7).  
 
Figura 7. Diseño incial de derivados fluorescentes de PC190723/8j. 
En primer lugar, se sintetizó PC190723 para su empleo como control positivo en la puesta a 
punto del ensayo de desplazamiento basado en fluorescencia. La síntesis se llevó a cabo 
siguiendo la metodología previamente descrita en la bibliografía (Esquema 9).
71
  
 
Esquema 9. Reactivos y condiciones: (a) i) SOCl2, tolueno, reflujo, 5 h, cuantitativo; ii) NH4OH, THF, t.a., 16 
h, 80%; (b) BBr3, DCM, t.a., 3 días, 79 %; (c) PBr3, tolueno/DMF, 130 ºC, 3 h, 42%; (d) SnCl2·H2O, HCl, Et2O, 
50 ºC, 30 min, 98%; (e) cloruro de benciloxiacetilo, Et3N, DCM, t.a., 14 h, 80 %; (f) reactivo de Lawesson, 
tolueno, 120 ºC, 3 h, 79%; (g) BBr3, DCM, t.a., 2 h, 88%; (h) NBS, Ph3P, DCM, t.a., 2.5 h, 68%; (i) K2CO3, NaI, 
DMF, t.a., 16 h, 33%. 
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Los derivados fluorescentes 119-125 se sintetizaron mediante las secuencias de reacciones 
recogidas en los Esquemas 10-13 a partir de transformaciones que se pusieron a punto a lo largo 
de la tesis. 
 
Esquema 10. Reactivos y condiciones: (a) NBS, AIBN, CCl4, 90 ºC, 3 h, 13%; (b) 127, K2CO3, DMF, t.a., 16 h, 
82%; (c) Pd(PPh3)4, CuI, Et3N, DMF, MW, 100 ºC, 45 min, 86%; (d) NH4OH, MeOH, t.a., 17 h, 99%; (e) Et3N, 
DCM/DMF, t.a., 24 h, 28%; (f) PyBroP®, DIPEA, DMF, t.a., 4 h, 5%. 
Resumen 
- 188 - 
 
Esquema 11. Reactivos y condiciones: (a) DIPEA, MeOH, t.a., 15 h, 77%; (b) Pd(PPh3)4, CuI, Et3N, DMF, 
MW, 100 ºC, 1 h, 41%. 
Esquema 12. Reactivos y condiciones: (a) H2, Ni-Ra, THF/MeOH, t.a., 3 h, 22%; (b) NH4OH, MeOH, t.a., 17 
h, 99%; (c) Et3N, DCM/DMF, t.a., 24 h, 26%. 
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Esquema 13. Reactivos y condiciones: (a) N-(2-hidroxietil)ftalimida, DEAD, Ph3P, THF, reflujo, 24 h, 67%; (b) 
N2H4·H2O, EtOH, reflujo, 2 h, 67%; (c) Et3N, DCM/DMF, t.a., 24 h, 8%; (d) PyBroP®, DIPEA, DMF, t.a., 4 h, 
27%; (e) Et3N, DMF, t.a., 20 h, 13%. 
A continuación, se estudiaron las propiedades fluorescentes de los compuestos 119-125 con el 
fin de evaluar su potencial como sondas fluorescentes. En teoría un buen candidato a sonda 
fluorescente de FtsZ debería mostrar un cambio significativo en el espectro de emisión de 
fluorescencia [longitud de onda (λ) y/o intensidad de emisión (Iem)], o en los valores de anisotropía 
(r) en presencia de la proteína. Dicho cambio debería poderse revertir a los valores iniciales 
mediante la adición del inhibidor PC190723 y consiguiente desplazamiento de la sonda del sitio de 
unión alostérico. Por tanto, para determinar si la fluorescencia de estos ligandos cambia al unirse a 
los monómeros o a los polímeros de FtsZ se registraron espectros de emisión de fluorescencia de 
cada compuesto (10 μM) en las condiciones de polimerización, excitando a la longitud de onda 
correspondiente al máximo de absorción de cada compuesto fluorescente. Los espectros de 
emisión y la anisotropía de fluorescencia se registraron en varias condiciones partiendo de una 
disolución del compuesto de interés en tampón Hepes pH 6.8 a 25 ºC a la que se le fueron 
añadiendo consecutivamente la proteína Bs-FtsZ (10 μM), GMPCPP (0.1 mM), MgCl2 (10 mM), y 
PC190723 o 8j (10 μM) para revertir finalmente el efecto. 
En general, ninguno de los compuestos sintetizados mostró cambios significativos en la longitud 
de onda o intensidad de emisión de fluorescencia. En cambio, se observó que la anisotropía de 
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fluorescencia del derivado de NBD 125 aumenta en las condiciones de polimerización; es decir, en 
presencia de FtsZ (10 μM), GMPCPP (0.1 mM) y MgCl2 (10 mM) (basal: r = 0.035; polimerización: r 
= 0.086). La adición de PC190723 produce una disminución de la anisotropía (r = 0.036), 
demostrando que es posible desplazar el ligando fluorescente (Tabla 2). Considerando los buenos 
resultados obtenidos con el derivado 125, dicho compuesto fue seleccionado para estudiar el 
espaciador entre la difluorobenzamida y el fluoróforo NBD (145-147, Figura 8). Además, teniendo 
en cuenta la actividad frente a FtsZ de los compuestos derivados de 3-metoxibenzamida descritos 
en la bibliografía, consideramos interesante la introducción de una cadena de octilo en el 
espaciador (148, Figura 8). Llegados a este punto, también contemplamos la posibilidad de 
introducir fluoróforos adecuados para microscopía de super-resolución, como por ejemplo 4-(y-5)-
carboxitetrametilrodamina (TAMRA) y ATTO 565, con el fin de obtener sondas con mejores 
propiedades fluorescentes para estudiar los procesos dinámicos de la división bacteriana (149 y 
150, Figura 8). 
 
Figura 8. Diseño de nuevos derivados fluorescentes basados en el compuesto 125. 
La síntesis de los compuestos 145-150 se llevó a cabo siguiendo las rutas sintéticas 
representadas en los Esquemas 14-16.  
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Esquema 14. Reactivos y condiciones: (a) N-(3-bromopropil)-, N-(4-bromobutil)ftalimida, o 6-bromo-N-Boc-1-
hexanamina, K2CO3, NaI, DMF, t.a., 16 h, 57-87%; (b) N2H4·H2O, EtOH, reflujo, 2 h, 55-64%; (c) Cl-NBD, 
DIPEA, DMF, t.a., 16 h, 4-11%; (d) TFA, DCM, t.a., 1 h, 99%. 
 
Esquema 15. Reactivos y condiciones: (a) Br2, K2CO3, H2O, t.a., 2 h, 79%; (b) i) 1-deceno, DCM, reflujo, 3 h; 
ii) Na2SO3, 5-10 ºC, 15 min, 56%; (c) K2CO3, NaI, DMF, t.a., 16 h, 23%; (d) TFA, DCM, t.a., 1 h, 99%; (e) Cl-
NBD, Et3N, DMF, t.a., 16 h, 11%. 
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Esquema 16. Reactivos y condiciones: (a) Et3N, DMF, t.a., 4 h, 66, 99%. 
Una vez más, los derivados de NBD 145-148 experimentaron un incremento de anisotropía con 
la adición de MgCl2, volviendo a los valores iniciales por desplazamiento de PC190723, excepto en 
el caso de 148 en el que no fue posible revertir el aumento de anisotropía (Tabla 2). En cuanto a 
los compuestos funcionalizados con TAMRA y ATTO 565, no se observaron cambios en la 
fluorescencia ni en la anisotropía en las condiciones de polimerización. 
Tabla 2. Valores de anisotropía (r) de los derivados fluorescentes 125 y 145-150. 
 125 145 146 147 148 149 150  
Compuesto (10 µM) 0.026  0.038 0.032 0.030 0.045 0.030  0.019  
+ Bs-FtsZ (10 µM) 0.034 0.042 0.035 0.042 0.130 0.031  0.025  
+ GMPCPP (0.1 mM) 0.035 0.040 0.039 0.042 0.186 0.030  0.022  
+ MgCl2 (10 mM) 0.086 0.078 0.078 0.127 0.317 0.032  0.025  
+ PC190723 (10 µM) 0.036 0.057 0.046 0.067 0.324 0.030  0.023  
+ PC190723 (10 µM)* 0.026 0.046 0.032 0.046 0.322 0.030 0.019  
Compuesto + GMPCPP 0.034 0.038 0.028 0.038 0.053 0.029 0.019  
Compuesto + MgCl2 0.035 0.033 0.027 0.033 0.054 0.030 0.020  
Compuesto + PC190723 0.038 0.032 0.028 0.032 0.052 0.030 0.020  
Mezcla sin Bs-FtsZ 0.026 0.035 0.027 0.035 0.052 - -  
* Se añadió más PC190723 (10 µM), concentración final 20 µM. 
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Por tanto, se seleccionaron los derivados de NBD 125 y 145-147 como los mejores candidatos 
a sondas fluorescentes de la proteína FtsZ, estudiándose a continuación su efecto en la 
polimerización de FtsZ. El ensayo de sedimentación de polímeros de FtsZ indica que estos 
compuestos alteran la polimerización en función de la concentración. Así, los derivados 125, 145 y 
146 aumentaron el porcentaje de sedimento siguiendo el mismo patrón que PC190723, que actúa 
como un estabilizador de los protofilamentos de FtsZ. Por el contrario, el derivado 147 produjo una 
disminución del porcentaje de sedimento con respecto al control, actuando como un inhibidor de la 
polimerización de FtsZ (Figura 9).  
C
125 146 147
63 89 91 95 94 75 75 7973 27% sedimento: 28 22 22
Control (C) :
Bs-FtsZ 10 mM + GMPCPP 0.1 mM + MgCl2 10 mM
Compuestos:
125, 146 y 147 a 25, 50, 100 y 200 mM  
Figura 9. Ensayo de sedimentación de polímeros de FtsZ con los derivados 125, 146 y 147. 
A continuación, se determinaron las curvas de desplazamiento de los compuestos 125 y 145-
147 con PC190723 con el objetivo de evaluar el potencial de estas sondas fluorescentes en un 
ensayo que permita identificar nuevos inhibidores de FtsZ dirigidos al sitio alostérico de PC. Para 
ello, a partir de una disolución de FtsZ polimerizada (5 µM) en presencia de GMPCPP (0.1 mM), 
MgCl2 (10 mM) y el correspondiente derivado fluorescente (5 µM), se fueron añadiendo 
concentraciones crecientes de PC190723 hasta recuperar los valores de anisotropía basales 
correspondientes a la sonda libre (Figura 10). Como se puede observar en la gráfica, los valores 
de anisotropía disminuyen a concentraciones crecientes de PC190723, lo que indica que estos 
derivados de NBD pueden utilizarse como sondas fluorescentes. Así, los derivados 125 y 146 han 
sido seleccionados para llevar a cabo un ensayo de desplazamiento basado en fluorescencia en el 
que se evaluarán compuestos descritos como inhibidores de FtsZ que no actúan sobre el sitio de 
unión de GTP junto con una librería de compuestos comerciales que ha sido previamente 
seleccionada por cribado virtual. Este ensayo se está llevando a cabo actualmente y permitirá la 
determinación de las constantes de afinidad por el sitio de unión de PC y la consiguiente 
identificación de nuevos inhibidores alostéricos de FtsZ. 
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Figura 10. Curvas de desplazamiento de las sondas fluorescentes 125 y 145-147 con PC190723. 
Finalmente, se realizaron experimentos in vivo en células de B. subtilis utilizando las sondas 
fluorescentes a distintas concentraciones con el fin de marcar FtsZ y visualizar el proceso de 
división bacteriana. Así, los derivados 125 y 145-147 fueron capaces de marcar FtsZ sin afectar a 
la división bacteriana a una concentración igual o menor de 50 µM (Figura 11A). La fluorescencia 
desaparece con la adición de PC190723 (25 µM), lo que indica que la sonda está siendo 
desplazada y demuestra la especificidad del marcaje (Figura 11B). Además, se observó que las 
sondas son capaces de afectar a la polimerización de FtsZ a una concentración de 200 µM, dando 
lugar a células filamentosas, efecto característico que también se observa con el inhibidor 
PC190723. Por lo tanto, estos experimentos confirman el potencial de las sondas fluorescentes 
descritas para la visualización de la proteína FtsZ y el estudio de su papel principal en el proceso 
de división bacteriana. 
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Figura 11. Estudios in vivo con las sondas fluorescentes 125 y 145-147 en células B. subtilis 168. (A) Marcaje 
de FtsZ con las sondas a 50 µM y visualización mediante microscopía de fluorescencia. (B) Para determinar 
la especificidad del marcaje, las células se marcaron en las condiciones anteriores en presencia de PC190723 
(25 µM). (C) Células fluorescentes filamentosas observadas con las sondas a 200 µM. 
5.3. Conclusiones 
En el presente trabajo se ha llevado a cabo la identificación de agentes antibacterianos con un 
nuevo mecanismo de acción mediante el desarrollo de compuestos dirigidos a los dos sitios de 
unión descritos para la proteína de la división bacteriana FtsZ. Con respecto al sitio de unión de 
GTP, se han identificado los primeros derivados sintéticos no-nucleótidos que inhiben de manera 
específica la polimerización de FtsZ y bloquean la citoquinesis bacteriana. Estos compuestos 
presentan una buena actividad antibacteriana en bacterias Gram-positivas patógenas. Entre ellos, 
el derivado 40 destaca como un prometedor agente antibacteriano con buena afinidad (Kd = 0.5 
µM) y actividad antibacteriana [CMI (MRSA) = 7 μM]. Este inhibidor, junto con 29, 45 y 48 actúa 
como un agente que bloquea la polimerización de FtsZ y da lugar a células filamentosas que no 
son capaces de dividirse y finalmente mueren. En conclusión, estos compuestos contribuyen a 
ampliar el escaso número de miméticos de GTP que inhiben FtsZ y proporcionan la base para el 
desarrollo de agentes antibacterianos con un nuevo mecanismo de acción. 
En cuanto al sitio de unión de PC, hemos desarrollado derivados fluorescentes de PC190723 
como sondas para el marcaje de FtsZ que contribuyan al estudio in vivo de la función de FtsZ en la 
división bacteriana. En concreto, los derivados de NBD 125 y 145-147 han demostrado tener un 
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gran potencial para la visualización del anillo Z durante la división bacteriana. Asimismo, el empleo 
de estas sondas en ensayos de desplazamiento permitirá la identificación de nuevos inhibidores 
alostéricos de FtsZ, experimento que se está poniendo a punto actualmente. 
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6. SUMMARY 
6.1.  Introduction and Objectives 
Antibacterial resistance is one of the biggest threat of the health system in the 21
st
 century and 
new treatments to fight against multi-drug resistant infections are desperately necessary.
15,20
 In 
this sense, FtsZ has been proposed as an attractive target for the identification of novel mode of 
action (MoA) agents, which could contribute to fight against the virulence and the speed in which 
bacteria adquire resistance to recently approved antibiotics.
33
 FtsZ is a tubulin-like GTPase 
almost universally conserved throughout bacteria that plays a key role in the cell division process. 
This protein polymerizes into different shaped filaments leading to a highly dynamic structure 
known as the Z-ring, which together with other accessory proteins regulate and form the 
divisome.
39
 This complex finally constricts and generates two daughter cells. Therefore, FtsZ 
could be an interesting therapeutic target to fight against bacterial infections since small 
molecules able to inhibit its activity will eventually disrupt bacterial viability. 
Among the FtsZ inhibitors described so far, PC190723 is the most studied compound and its 
co-crystalization with FtsZ has allowed the identification of a long cleft as a new allosteric 
druggable site in the protein, known as the PC-binding site. This compound exhibits potent 
antibacterial activity [e.g. MIC (MRSA) = 2.8 µM] and is the first inhibitor shown to be efficacious in 
an in vivo model of bacterial infection. 
In this context, the main objective of this thesis is the development of new FtsZ inhibitors with 
good antibacterial properties. For this purpose we have focused our efforts on the identification of 
new compounds targeting the two druggable binding sites of FtsZ: (i) the GTP- and (ii) the 
allosteric PC-binding pocket (Figure 1). 
Summary 
- 200 - 
GTP-binding site PC-binding site
Medicinal 
Chemistry Program
Development of PC190723-Based
Fluorescent Probes
New Inhibitors of FtsZ as Antibacterial Agents
(i) (ii)
 
Figure 1. Dual strategy on the search for FtsZ inhibitors. 
The development of new small molecules able to replace the natural regulator GTP and to 
specifically inhibit FtsZ in order to block the bacterial cell division process involves the following 
steps: 
 Identification of hits. 
 Design, synthesis, and biological evaluation of a new series of compounds. In this 
evaluation we will consider the assessment of the FtsZ binding affinity, the antibacterial 
activity and selectivity against tubulin. 
 Further characterization of optimized inhibitors in terms of antibacterial properties against 
Gram-positive and Gram-negative pathogens, cytological profile, and mechanism of action. 
Regarding the PC-binding pocket, the interesting antibacterial properties of PC190723 and the 
lack of a methodology to assess the binding affinity against this newly reported binding site in 
FtsZ, prompted us to develop fluorescent probes based on this inhibitor to set up a fluorescence-
based binding assay for the identification of new inhibitors. In addition, these probes could 
contribute to study this allosteric site that seems to play a key role in the FtsZ assembly, in order 
to get a better understanding about this dynamic process. Therefore, the second goal of this 
project implies the following steps: 
 Design and synthesis of fluorescent derivatives based on PC190723. 
 Biological evaluation and fluorescent characterization of the synthesized compounds. 
 Use of the best fluorescent probes as biological tools for the study of the bacterial cell 
division process and for the identification of new FtsZ inhibitors by a fluorescence-based 
displacement assay. 
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6.2. Results and Discussion 
6.2.1. Development of FtsZ Inhibitors Targeting the GTP-Binding Site 
In the search of new FtsZ inhibitors of the GTP-binding site, we docked our in-house library 
into the GTP-binding pocket of B. subtilis FtsZ and tested the hits with the highest scores in the 
mant-GTP fluorescence anisotropy competitive assay.
84
 The best molecules obtained from this 
screening shared a general structure of two gallate subunits bound to a central core of differently 
substituted naphthalene, benzene, biphenyl and cyclohexane rings as well as an ethylene spacer. 
Among them, hits 1 and 2 showed the highest affinities for Bs-FtsZ (Kd = 2.3 and 0.8 µM, 
respectively), and moderate antibacterial activity in B. subtilis (MIC = 100 and 40 µM, 
respectively), being the first non-nucleotide synthetic molecules that effectively compete with GTP 
for binding to FtsZ (Figure 2).
84
 
In order to carry out a structure-affinity-activity analysis around hits 1 and 2, we focused our 
attention on two subunits susceptible to structural modifications: the galloyl rings and the ester 
bonds used as spacers (Figure 2). Variations in the central core were discarded since derivatives 
of our in-house library bearing other scaffolds displayed less affinity and/or antibacterial activity 
than the 1,3-naphthyl or 3,5-biphenyl counterparts. The structure of compound 1 was used as a 
starting point for chemical modifications. Thus, to study the influence of the hydroxy groups of the 
phenyl rings, we first considered the reduction of the number of these groups as well as their 
substitution pattern and their replacement by other substituents such as methoxy or chlorine, 
while keeping constant other parts of hit 1 (3-30). In addition, monoester derivatives 31 and 32 
were synthesized in order to study the influence of both polyhydroxyphenyl rings in the binding to 
FtsZ. Furthermore, compounds in which the ester groups of 1 were replaced by other spacers 
such as amides, sulfonamides and double bonds were contemplated (33-36). After the biological 
evaluation of this series, the best modifications obtained for hit 1 were applied to biphenyl 
derivative 2 and compounds having a lower number of hydroxy groups (37-42), monoesters (43-
46) and non-ester derivatives (47-50) were synthesized. 
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Figure 2. Synthesized compounds 3-50 targeting the GTP-binding site. 
The synthesized compounds 3-50 were then evaluated using the mant-GTP fluorescence 
anisotropy competitive assay
82
 to measure their binding affinities (dissociation constant, Kd) for 
FtsZ of B. subtilis. Most of the tested compounds were able to displace mant-GTP in the 
micromolar range (Kd = 0.5-2.2 µM). In general, the reduction in the number of hydroxy groups on 
both phenyl rings improves the binding affinity, and the best Kd values were obtained for those 
derivatives having only two hydroxy groups (e.g. 29, 40 and 41 Kd = 0.5-0.8 µM) (Figure 3). 
Assesment of antibacterial activity of compounds 3-50 indicates that, in general, all compounds 
are active against B. subtilis and MRSA USA 300 (as a representative example of Gram-positive 
pathogenic bacteria). The reduction in the number of hydroxy groups seems to be favorable in 
terms of potency, which supports that these compounds exert their antibacterial activity through 
inhibition of FtsZ. In fact, the most potent derivatives were those with only two hydroxy groups 
[e.g. 29 and 42: MIC (MRSA) = 5 µM]. Another structure-affinity-activity relationship that can be 
drawn for this series is that the introduction of chlorine atoms proved to be important for FtsZ 
affinity and antibacterial activity, as can be shown for compound 7 [Kd = 0.8 µM; MIC (MRSA) = 
10 µM]. Moreover, FtsZ affinity and antibacterial activity of monoesters were reduced when 
compared with their corresponding diesters, suggesting that both polyhydroxyphenyl subunits are 
required for FtsZ binding and antibacterial activity [e.g. 40: Kd = 0.5 µM; MIC (MRSA) = 7 µM vs 
45: Kd = 3.8 µM; MIC (MRSA) = 50 µM]. Regarding the influence of the spacer between the 
central core and the polyhydroxyphenyl rings, the replacement of the ester groups by 
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sulfonamides or alkenes did not provide higher FtsZ affinity nor good antibacterial activity [e.g. 
amide 48: Kd = 4.3 µM; MIC (MRSA) = 50 µM]. However, submicromolar affinity (Kd = 0.5 µM) and 
excellent antibacterial activity against MRSA (MIC = 3 µM) were obtained when the linker 
between the biphenhyl central core and the phenyl subunits was removed in compound 47. 
 
Figure 3. Representative FtsZ inhibitors targeting the GTP-binding site. 
Afterward, tubulin and FtsZ assembly inhibition was determined as an assessment of FtsZ 
selectivity. As shown in Figure 4, the introduction of chlorine atoms was detrimental for selectivity, 
being compound 7 among the most potent tubulin inhibitors. In addition, most biphenyl derivatives 
exerted stronger FtsZ inhibition as well as good tubulin selectivity, with the exception of 
monoester 45. 
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Figure 4. Percentage of FtsZ (25 µM of compound) and tubulin (100 µM of compound) inhibition. 
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Microbiological profile of selected compounds on a broader panel of antibiotic-resistant Gram-
positive and Gram-negative pathogenic bacteria was also determined (Table 1). In general, all 
tested compounds inhibited the growth of Gram-positive resistant pathogenic bacteria such as 
MRSA (MIC = 3-50 µM) and Listeria monocytogenes (L. monoc., MIC = 5-50 µM), being 29, 40-42 
and 45 also able to inhibit Enterococcus faecalis (E. faecalis) growth at 50 µM. Regarding Gram-
negative bacteria, although initial biphenyl hit 2 showed moderate activity in resistant 
Pseudomonas aeruginosa and Escherichia coli (P. aerug. and E. coli, MIC = 50 µM), none of its 
derivatives affected the growth of Gram-negative pathogens at the assayed concentration (100 
µM), which indicates that removal of hydroxy groups was detrimental for the antibacterial activity 
against these strains. 
Table 1. Antibacterial activity against pathogenic bacteria of selected compounds. 
Compuesto 
Kd
a 
FtsZ 
(µM) 
MIC (μM) 
MRSA E. 
faecalis
d
 
L. 
monoc.
e
 
P. 
aerug.
f E. coli
g 
USA 300
b
 Mu50
c
 
1 2.3 ± 0.1 60 80 >100 50 100 >100 
2 0.8 ± 0.1 50 50 >100 50 50 50 
29 0.8 ± 0.2 5 5 50 5 >100 >100 
40 0.5 ± 0.1 7 7 50 7 >50 >100 
41 0.6 ± 0.3 5 5 50 5 >50 >100 
42 0.4 ± 0.1 5 5 50 5 >50 >100 
45 3.8 ± 0.8 50 50 50 50 >50 >100 
47 0.5 ± 0.1 3 3 >100 5 >50 >100 
48 4.3 ± 1.0 50 50 >100 50 >50 >100 
a
The values are the mean ± SEM. 
b
S. aureus community acquired, methicillin resistant ATCC Nr: BAA-
1556 (Institute Pasteur, France) and 
c
Methicillin, ampicillin and kanamycin resistant Mu50/ATCC 700699 
(Institute Pasteur, France). 
c
Enterococcus faecalis, gentamicin and vancomycin resistant V583 
ATCC700802 (sequenced strain). 
d
Listeria monocytogenes, EGDe (sequenced strain). 
e
Pseudomonas 
aeruginosa, imipenem resistant PAO1 (sequenced strain). 
f 
Escherichia coli, UTI89 from cystitis infection 
(sequenced strain). 
In order to identify the most effective bacterial division blockers among the selected 
compounds, we examined their effects on the cell division of wild type B. subtilis 168 and on FtsZ 
subcellular localization in B. subtilis SU570, a strain that has FtsZ fused to green fluorescent 
protein (FtsZ-GFP) as the only FtsZ protein. First, we characterized the cellular effects of our most 
effective FtsZ inhibitors (29, 40, 41, 45, 47, and 48). Cells of wild type B. subtilis 168 exposed to 
each of these compounds were longer than control cells (Figure 5). Among them, derivative 40 
exhibited the clearest effect as bacterial division blocker. The phenotype of cells treated with 
biphenyl 40 (4 µM) consisted of long filamentous undivided cells. This effect was also observed 
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when the cells were incubated with the amide analogue 48 (12 µM) and weaker effects were 
found with 41 (5 µM) and fragment 45 (25 µM) as well as with the naphthyl compound 29 (5 µM). 
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Figure 5. Cell division effect of FtsZ inhibitors. (A) B. subtilis 168 incubated during 3 h with FtsZ inhibitors 29 
(5 µM), 40 (4 µM), 41 (5 µM), 45 (25 µM), and 48 (12 µM) and observed by phase contrast microscopy. 
Scale bar: 10 µm. (B) B. subtilis 168 cell length. 
Moreover, these compounds impaired the normal assembly of FtsZ-GFP into the mid-cell Z-
ring prior to division of B. subtilis SU570 at concentrations near their MIC values, further 
supporting FtsZ targeting. The observed effects consisted of a reduction in the proportion of cells 
with normal Z-rings at division sites with respect to controls and FtsZ delocalization into 
characteristic punctuate foci along the bacterial cells (Figure 6, FtsZ-GFP row). Z-rings along the 
filamented cells were very frequently observed abnormally close to each other with compounds 
29, 40, and 48, whereas FtsZ-GFP foci were more abundant in cells treated with compounds 29 
and 40. The impairment of the cell division ring is also reflected by abnormal nucleoid 
morphology. In contrast with the control cells, nucleoids frequently had a fragmenting appearance 
in cells treated with the FtsZ inhibitors (Figure 6, DAPI row). Membranes were visualized in the 
same B. subtilis SU570 treated cells with the vital stain FM4-64, and frequent extra membrane 
accumulations and patches were observed. 
Therefore, the majority of the GTP-replacing compounds under study inhibited bacterial cell 
division by disrupting FtsZ assembly and impairment of the Z-ring. Among them, biphenyl 
derivative 40 stands out as the most effective bacterial cell division inhibitor. This compound 
together with compounds 29 and 48 acts as an effective FtsZ modifier and leads to filamentous 
undivided cells, finally disrupting bacterial viability. 
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Figure 6. Effect of FtsZ inhibitors on FtsZ subcellular localization. Cells of B. subtilis SU570 (FtsZ-GFP) were 
incubated during 1 h with 29 (5 µM), 40 (3 µM), and 48 (12 µM). FtsZ-GFP, membrane stained with FM4-64, 
and DNA stained with DAPI were visualized through their corresponding channels with a fluorescence 
microscope. Scale bar: 10 µm. 
6.2.2. Development of Fluorescent Probes for the PC190723 Binding Site of FtsZ 
The lack of a binding assay to assess the affinity of small molecules for the new druggable 
pocket of FtsZ, known as the PC190723-binding site, hampers the development of new FtsZ 
inhibitors addressing this allosteric site as antibacterial agents. Indeed, only phenotypic 
experiments such as polymer pelleting assays have been used in order to identify new inhibitors. 
Therefore, fluorescent derivatives of PC or its analogue 8j could be used as valuable tools to set 
up a fluorescence-based assay for the identification of FtsZ inhibitors by screening a library of 
compounds against this newly identified binding site. 
This fact prompted us to carry out a project aimed at the design and synthesis of fluorescent 
probes based on PC/8j following two different approaches: (i) attachment of a fluorophore to the 
structure of 8j through a rigid linker, such as an alkyne moiety, or a flexible aliphatic chain (119-
122), and (ii) substitution of the heterocyclic subunit of PC/8j by a fluorescent tag (123-125). With 
respect to the fluorescent tag, we selected small fluorophores such as nitrobenzoxadiazole 
(NBD), a coumarin derivative, and dansyl (Figure 7). 
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Figure 7. Initial design of PC190723/8j fluorescent derivatives. 
Once fluorescent compounds 119-125 were synthesized, we assessed their fluorescent 
properties in order to evaluate their potential as chemical probes. In theory, a good candidate for 
a FtsZ fluorescent probe based on PC190723 should show a significant modification in the 
emission fluorescence spectrum [wavelength (λ) and/or emission intensity (Iem)] or in the 
fluorescence anisotropy values (r) in the presence of the protein, that could be then reverted to 
the initial values by addition and displacement of the parent compound PC190723. Therefore, 
fluorescence emission spectra and anisotropy of compounds 119-125 (10 µM) were registered 
employing an excitation wavelength corresponding to the maximum absortion of each compound 
in Hepes buffer at pH 6.8 and 25 ºC. Then, Bs-FtsZ (10 µM) in Hepes buffer, the slowly 
hydrozable GTP analogue GMPCPP (0.1 mM) and MgCl2 (10 mM) were subsequently added to 
set up the polymerization conditions. Finally, PC190723 or 8j (10 µM) was added in order to 
displace and revert the possible effect of the fluorescent probes.  
In general, the fluorescence emission spectra of the compounds did not show significant 
changes. However, fluorescence anisotropy of NBD derivative 125 (Table 2) increased when 
MgCl2 was added and the polymerization was initiated (basal: r = 0.035; polymerization: r = 
0.086), being then restored by displacement with PC190723 (r = 0.036), which indicates that this 
fluorescent compound binds to the protein at the same binding site than PC190723. Taking into 
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account the positive results obtained with 125, we selected this compound to study the influence 
of the spacer between the difluorobenzamide and the NBD moiety by increasing the length of the 
alkyl chain (145-147, Figure 8). Moreover, based on the activity data of 3-methoxybenzamide 
derivatives in FtsZ previously reported, we also considered the introduction of an octyl chain in the 
linker (148). At this point, fluorophores for super-resolution microscopy such as 4-(and-5)-
carboxytetramethylrhodamine (TAMRA) and ATTO 565 were also taken into account in order to 
obtain probes with optimized fluorescent properties for the study of the bacterial division process 
(149 and 150, Figure 8). 
 
Figure 8. Design of new fluorescent derivatives based on compound 125. 
Once again, NBD derivatives displayed an increase in anisotropy when MgCl2 was added and 
their basal values were restored by displacement with inhibitor PC190723, with exception of probe 
148 (Table 2). Regarding TAMRA and ATTO-565 derivatives 149 and 150, no anisotropy changes 
were observed under polymerization conditions. 
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Table 2. Anisotropy values (r) of fluorescent derivatives 125 and 145-150. 
 125 145 146 147 148 149 150  
Compound (10 µM) 0.026  0.038 0.032 0.030 0.045 0.030  0.019  
+ Bs-FtsZ (10 µM) 0.034 0.042 0.035 0.042 0.130 0.031  0.025  
+ GMPCPP (0.1 mM) 0.035 0.040 0.039 0.042 0.186 0.030  0.022  
+ MgCl2 (10 mM) 0.086 0.078 0.078 0.127 0.317 0.032  0.025  
+ PC190723 (10 µM) 0.036 0.057 0.046 0.067 0.324 0.030  0.023  
+ PC190723* 0.026 0.046 0.032 0.046 0.322 0.030 0.019  
Compound + GMPCPP 0.034 0.038 0.028 0.038 0.053 0.029 0.019  
Compound + MgCl2 0.035 0.033 0.027 0.033 0.054 0.030 0.020  
Compound + PC190723 0.038 0.032 0.028 0.032 0.052 0.030 0.020  
Mixture without Bs-FtsZ 0.026 0.035 0.027 0.035 0.052 - -  
* Additional 10 µM of PC190723 was added. Final 20 µM concentration. 
Therefore, the best candidates to be used as fluorescent probes to set up a displacement 
binding assay against the PC-binding site seem to be NBD derivatives 125 and 145-147. The 
study of the effect of these probes in FtsZ polymerization by polymer pelleting assay showed that 
they alter the polymerization in a concentration depending manner. Thus, compounds 125, 145, 
and 146 increased the pellet percentage of FtsZ protofilaments as their parent compound -
PC190723- acting as FtsZ stabilizing agents, whereas derivative 147 reduced FtsZ polymerization 
as shown by the decrease in the pellet percentage with repect to the control (Figure 9). Hence, 
this latter inhibitor showed a different activity pattern, acting as an inhibitor of FtsZ polymerization 
instead of stabilizing the protofilaments. 
C
125 146 147
63 89 91 95 94 75 75 7973 27% Pellet: 28 22 22
Control (C) :
Bs-FtsZ 10 mM + GMPCPP 0.1 mM + MgCl2 10 mM
Compounds:
125, 146, and 147 at 25, 50, 100 and 200 mM  
Figure 9. Effects of NBD derivatives 125, 146, and 147 in FtsZ polymerization. 
In order to evaluate the potential of these probes, displacement anisotropy curves were carried 
out. Starting from a solution of polymerized FtsZ (5 µM) in the presence of GMPCPP (0.1 mM), 
MgCl2 (10 mM) and the corresponding fluorescent probe (5 µM), increasing concentrations of the 
Summary 
- 210 - 
inhibitor PC190723 were subsequently added until the anisotropy was restored to the basal value 
of the free compound (Figure 10). As it is shown in the graph, anisotropy values decrease with 
increasing concentrations of PC, which indicates that all these NBD derivatives can be used as 
fluorescent probes. Among them, 125 and 146 were selected to carry out a fluorescence-based 
displacement assay to screen a library of already described FtsZ inhibitors that do not target the 
GTP-binding site and a series of hits obtained by virtual screening of a commercial library against 
the PC-binding pocket. This assay, which is currently on going, will allow the assessment of 
affinity constants for the PC binding site and therefore, the possibility of performing a high-
throughput screening in order to identify new FtsZ inhibitors targeting this allosteric binding site. 
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Figure 10. Displacement curves of fluorescent probes 125 and 145-147 by PC190723. 
Finally, in order to confirm whether selected fluorescent probes would enable to stain FtsZ in 
cells allowing the monitorization of the division process, we carried out in vivo studies of the 
probes at different concentrations with B. subtilis cells. Thus, probes 125 and 145-147 were able 
to label FtsZ in the cells without affecting bacterial cell division at concentrations lower than 50 µM 
(Figure 11A). This fluorescence disappeared by addition of PC190723 (25 µM) and consequent 
displacement of the probe, which demonstrate the specificity of the labeling (Figure 11B). 
Moreover, at higher concentration (200 µM) the probes were able not only to stain the cells but 
also to alter FtsZ polymerization (Figure 11C).
87
 These results show that fluorescent probes 125 
and 145-147 can be used at 50 µM to visualize FtsZ protein in vivo, which demonstrates its ability 
to study the role of FtsZ in the bacterial division process. 
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Figure 11. In vivo studies of fluorescent probes 125 and 145-147 in B. subtilis. (A) Labeling of FtsZ with the 
probes at 50 µM and visualization by fluorescent microscopy. (B) To assess specificity, cells were labeled 
under previous conditions and PC190723 (25 µM) was then added. (C) Fluorescent filamentous cells were 
observed at 200 µM of compound. 
6.3. Conclusions 
In this thesis we have addressed the development of antibacterial agents with a novel mode of 
action targeting FtsZ protein. We report the first series of synthetic non-nucleotide small 
molecules able to replace the natural regulator GTP. These inhibitors specifically perturb protein 
assembly rather than tubulin polymerization and block bacterial cytokinesis. Furthermore, they 
display high antibacterial activity against multidrug-resistant Gram-positive pathogenic bacteria. 
Among them, biphenyl 40 stands out as the most promising FtsZ inhibitor, with good affinity (Kd = 
0.5 µM) and antibacterial activity [MIC (MRSA) = 7 μM]. This compound together with 29, 45, and 
48, acts as an effective FtsZ assembly modifier and leads to filamentous undivided cells, finally 
disrupting bacterial viability. Overall, these inhibitors contribute to expand the scarce number of 
GTP mimetics available and provide a compelling rationale for the development of antibacterial 
agents with novel modes of action. 
Regarding the recently identified PC-binding site, we have developed fluorescent derivatives of 
PC190723 as chemical probes to label FtsZ, which will contribute to the in vivo study of the FtsZ 
role in bacterial division process. Among the synthesized fluorescent compounds, NBD 
derivatives 125 and 145-147 have demonstrated to be valuable tools for the visualization of the Z-
ring during bacterial division process, and can be used as fluorescent probes in a displacement 
assay. This assay, which is currently on going, will allow the identification of new allosteric 
inhibitors of FtsZ as antibacterial agents. 
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